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ABSTRACT
Murine gammaherpesvirus 68 (MHV-68) is a B cell tropic pathogen of small rodents
which shares genetic and pathobiological similarities with Epstein-Barr virus (EBV)
and Kaposi's sarcoma associated herpesvirus (KSHV). Unlike EBV and KSHV,
MHV-68 replicates well in vitro and infects inbred mice making it a valuable and
amenable model for the study of gammaherpesvirus replication and their interaction
with the host. Glycoprotein 150 (gpl50) is a virion membrane glycoprotein of
MHV-68 that shares similarities with gp340/220 a membrane glycoprotein of EBV
which facilitates EBV attachment to B cells. Antibodies against gpl50 have been
reported to neutralise MHV-68 infection. The aim of this study was to determine the
function of gpl50 and latterly to assess the potential of gpl50 as a vaccine antigen to
prime and protect inbred mice against MHV-68 infection. For functional studies of
gpl50 two main strategies were adopted; (i) the production of a recombinant virus in
which the gene encoding gpl50 is made dysfunctional resulting in a gpl50
'knockout' (KO) virus and (ii) generation and use of purified gpl50 in cell binding
studies to determine if gpl50 can bind to cells. Recombinant viruses were generated;
virus induced plaques expressing the green fluorescent protein, used as a marker
gene for identification of recombinant viruses, were observed. However, no viruses
in which the required deletion of the gpl50 gene had occurred were isolated. A
gpl50-His fusion protein (gpl50-His) consisting of the extracellular domain of
gpl50 attached to a hexahistidine residue was successfully cloned, expressed in
bacteria and purified. Similarly, a glutathione-S-transferase-His (GST-His) fusion
protein was generated to be used as a control in binding studies. No significant
binding of gpl50-His to murine epithelial cells was detected in an enzyme linked
immunosorbent assay (ELISA) or by fluorescent associated cell sorting (FACS)
analysis. In contrast, significant binding of gpl50-His to primary splenocytes was
shown by FACS analysis. Gpl50-His also bound to purified splenic B cells and both
CD19+ (B cells) and CD 19" splenocytes. Antibodies against gpl50 failed to block
binding ofMHV-68 to murine epithelial cells. Results indicate that gpl50-His binds
the heterogeneous splenic cell population as a whole i.e. not a particular subset of
lymphocytes. This suggests gpl50 may interact with a ubiquitous cell surface
protein or perhaps a protein specific to leukocytes and could be involved in MHV-68
iv
attachment to these cells. Gene gun nucleic acid immunisation of inbred mice with a
plasmid encoding gpl50 under the control of a constitutive promoter, alone or in
combination with a recombinant vaccinia virus expressing gpl50 (VVgpl5°) was
undertaken followed by intranasal challenge with MHV-68. Virus specific antibody
appeared earlier in the group that received gpl50 DNA plus VVgpl5°. The groups
that received gpl50 DNA in conjunction with either Wgpl5° or a control vaccinia
virus (VVgpt) appeared to have reduced levels of latently infected cells in the spleen
day 15 post infection and reduced splenomegaly (a phenomenon of MHV-68
infection) in comparison with control mice. This could indicate that vaccinia virus,
in a non-specific manner, boosts the specific immune response to previously
administered DNA and in this case was able to limit the level of MHV-68 reaching
the spleen. However, this vaccine regimen failed to significantly alter the level of
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1.1.1 An Introduction to Herpesviruses
Herpesviruses are large double stranded deoxyribonucleic acid (DNA) viruses
widespread throughout nature, attempts to isolate them for most animals; including
fish, amphibians, reptiles, birds and mammals, have been successful. To date, eight
human herpesviruses have been identified. Herpes simplex virus 1 and 2 (HSV 1 and
HSV2) and varicella-zoster virus (VZV) are human alphaherpesviruses. These
viruses undergo acute and recurrent infections of the epidermal skin tissue resulting
in the development of cold sores and genital herpes (HSV), chicken pox and shingles
(VZV) (Whitley, 1996, Arvin, 1996). Complications of alphaherpesvirus infections
can result in encephalitis, meningitis and keritinitis (Whitley, 1996). Human
cytomegalovirus (HCMV), Human herpesvirus 6 (HHV6), Human herpesvirus 7
(HHV7) are betaherpesviruses their infection of man is largely asymptomatic
infections (Britt & Alford, 1996, Pellet & Black, 1996, Frenkel & Roffman, 1996).
There is on going debate as to whether HHV6 is the etiology of a number of human
diseases including multiple sclerosis. Primary betaherpesvirus infection can result in
mononucleosis like syndromes and mild skin rashes. Vertical transmission to the
foetus can result in a variety of deformities such as blindness, hearing loss and
mental retardation. Infected individuals who are immunocompromised either
through receiving immunosuppressive therapies or who have acquired
immunodeficiency syndrome (AIDS) can develop lethal disseminated infections
(Britt & Alford, 1996, Pellet & Black, 1996). Epstein-Barr virus (EBV) and
Kaposi's sarcoma virus (KSHV) also known as human herpesvirus 4 (HHV4) and
human herpesvirus 8 (HHV8) respectively, are gammaherpesviruses.
Gammaherpesvirus infections are largely asymptomatic. However, EBV is
associated with the syndrome infectious mononucleosis and a number of
malignancies such as nasopharyngeal carcinoma (NPC), endemic Burkitt's
lymphoma, post transplant lymphoproliferative disease and Hodgkin's lymphoma
(Rickinson & Kieff, 1996). The relatively recently discovered HHV8 has been
shown to be associated with Kaposi's sarcoma and body-cavity based B cell
lymphomas (Chang et al., 1994, Cesarman et al., 1995a, Soulier et al., 1995). The
prevalence of these conditions is greatly increased in immunocompromised
individuals.
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An important common biological property of herpesviruses is their ability to
establish latent infection; the viral genome becomes episomal and a restricted set of
viral genes is expressed. This property of herpesviruses enables their lifelong
persistence within the host. The limited number of viral proteins expressed enables
the virus to evade immune detection. The latent infection may subsequently be
reactivated resulting in the production of infectious virions (Roizman, 1996).
1.1.2 Herpesvirus Composition
A common morphology determines herpesvirus designation. Typically, herpesvirus
virions consist of a core containing linear double stranded DNA in a toroid form
enclosed by an icosahedral capsid, approximately lOOnm in diameter, formed from
162 capsomeres with a channel running through the centre. A 'tegument' consisting
of amorphous material surrounds the capsid. A lipid envelope forms the outer
covering of the virion which contains many glycoproteins that protrude, in a spike
like fashion, from the virion surface (refer to figure 1). Among studied herpesviruses
the DNA varies in size from approximately 125 -235 kbp and commonly encodes
around 80 open reading frames (Gompels et al., 1988, Roizman, 1996). The
genomic organisation of the 80 plus vertebrate herpesviruses differs between types in
the number and positioning of repeat sequences interspersed by unique regions
(Roizman, 1996).
1.1.3 Herpesvirus Subfamilies
Despite common properties displayed by the family, herpesviruses vary widely with
respect to host range, replication rate, efficiency of cell destruction, cell specificity
and clinical manifestations. Based on biological properties and, more recently,
genetic conservation three herpesvirus subfamilies have been defined;
alphaherpesvirinae, betaherpesvirinae and gammaherpesvirinae (Roizman, 1996).
Table 1.1 displays examples of herpesviruses from each subfamily.
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A. A schematic representation of the herpesvirus virion (Adapted from
Roizman, 1996). B. An electron micrograph of a section through a herpes
simplex virion (Adapted from Levy et al., 1994). C. An electron
micrograph of extracellular Epstein-Barr virus (EBV) virions budded from
EBV-infected lymphocytes, the black dots are 5nm-diameter gold particles
staining the membrane glycoprotein gp340/220 (From Gong & Kieff,
1990).
CHAPTER 1 INTRODUCTION
Alphaherpesvirus characteristics include a variable host range, short replication
cycle, rapid spread in cell culture and their primary site of latency in sensory ganglia.
Betaherpesviruses have a restricted host range, a longer replication cycle and spread
slowly in culture. A notable characteristic of betaherpesvirus infection is the
enlarged phenotype of infected cells with intranuclear inclusions. Latency is
established in secretory glands, lymphoreticular cells, kidneys and other tissues.
Gammaherpesviruses have a very restricted host range, limited to the family or order
of the natural host. In vitro some gammaherpesviruses can cause lytic infection in
types of epithelial and fibroblastic cells, all members are able to replicate in
lymphoblastoid cells. They are either T or B cell specific and characteristically
establish latency in these lymphocytes commonly within lymphoid tissues. There are
two genera the Lymphocryptovirus, also called gamma 1 herpesvirus, for which EBV
is the prototype, and Rhadinovirus, alternatively named gamma2herpesvirus, the
protoypical member being herpesvirus saimiri (HVS). Other gammaherpesviruses
include KSHV/HHV8, bovine herpesvirus 4 (BHV-4), ovineherpesvirus 2 (OHV-2),
alcelaphine herpesvirus 1 (AHV-1) equine herpesviruses 2 and 5 (EHV2 and EHV5)
and murine gammaherpesvirus 68 (MHV-68) (Roizman, 1996).
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Name Host Size Disease association
ALPHAHERPESVIRUS subfamily
Herpes simplex subgroup
Herpes Simplex 1 (HSV-1/HHV1) Human 152 Cold sores, keratitis, ocular disease
Herpes Simplex 2 (HSV-2/HHV2) Human 152 Genital herpes
Bovineherpes virus 2 (BHV-2) Cow 133 Rhinotracheitis
Marek's Disease Virus (MDV) Chicken 180 T cell lymphomas in chickens
Varicellovirus subgroup
Varicella zoster (VZV/ HHV3) Human 125 Chicken pox, shingles
Pseudorabies virus Pig 140 Aujeszky's disease
Equine herpesvirus 1 Horse Respiratory disease, abortion





Human 229 Foetal deformatities
Lymphoproliferation in
immunocompromised





Human herpesvirus 6 (HHV6) Human 162
Human herpesvirus 7 (HHV7) Human
GAMMAHERPESVIRUS subfamily
yl; Lymphocryptovirus subgroup
Epstein-Barr virus (EBV)/ (HHV-
4)




Herpesvirus pan Chimpanzee 170
Herpesvirus papio Baboon 170
y2; Rhadinovirus subgroup
Herpesvirus saimiri Squirrel monkey 155 Fatal lymphoproliferations in cotton tail




Human herpesvirus 8 (HHV-8)
Human 140 Kaposi's sarcoma
Body cavity based lymphoma
Multicentric Castlemans disease
Herpesvirus ateles Spider monkey 135
Equine herpesvirus 2 Horse 184 Respiratory disease
Equine herpesvirus 5 Horse 150 Respiratory disease
Herpesvirus sylvilagus Cotton tail
rabbit
Lymphomas & lymphoproliferations
Woodchuck herpesvirus Woodchuck 160
Murine gammaherpesvirus 68/
Murid herpesvirus 4
Murid rodents 118 Lymphomas
Bovine herpesvirus 4 Cow 145 Respiratory disease
Wildebeest herpesvirus/
Alcelaphine herpesvirus 1
Wildebeest 160 Malignant Catarrhal fever in cattle
Ovine herpesvirus 2 Sheep Malignant catarrhal fever in cattle
Table 1.1. Examples of members of each herpesvirus family. Size; approximate size of genome in
kbp. Note, this represents only a limited number of herpesviruses and is in no way proportional to the
number of members known for each subfamily, more gammaherpesviruses are displayed due to
greater relevance to this document. HHV; Human herpesvirus. (Adapted from Roizman, 1996).
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1.1.4 Genomic Content - Conserved Gene Blocks
Within the unique DNA of herpesvirus genomes the reading frames are closely
arranged and they frequently overlap. There are both leftward and rightward
orientated genes and genes containing splice sites. A set of conserved genes is
carried by most herpesviruses and these encode products required for productive
viral replication. These range from enzymes required for nucleic acid metabolism,
(such as thymidine kinase, alkaline exonuclease, dUTPase and the large subunit of
ribonucleotide reductase), enzymes for DNA synthesis (for example DNA
polymerase and helicase-primase), transcriptional activators, glycoproteins and
structural capsid proteins. Initially three conserved gene blocks were defined
(Davison & Taylor, 1987), this has now been expanded to seven regions of
conserved genes (Chee et al., 1990). Table 1.2 displays the blocks of conserved and
semiconserved genes of the herpesviruses. The blocks of conserved genes are
interspersed with blocks of genes specific to a viral family or the specific virus.
1.1.5 Unique Genes
Out with the conserved herpesvirus genes there are a variety of types of unique genes
encoded by individual herpesviruses which have evolved within viruses for
adaptation to particular environments or confer a particular advantage on the virus.
Some unique genes are specific to one particular virus whereas others appear to be
pertained by a few different herpesviruses. There are many examples of viral genes
which have cellular homologues these encode proteins with roles in modulation of
cell cycle and signal tranduction e.g. cyclin D, bcl-2 and G-protein coupled receptor
(IL-8r); cytokines, chemokines and modulators of host immune response e.g. IL-10,
IL-17 and complement control proteins. Although there is a set of highly conserved
herpesvirus glycoproteins specific viruses also encode unique glycoproteins of which
gpl50 of MHV-68 is considered to be one (discussed further in section 1.7.7).
Although all studied herpesviruses have genes associated with latency between
different viruses these genes are very diverse and lack conservation (Virgin et al.,
1997, Albrecht et al., 1992, Russo et al., 1996, Baer et al., 1984).
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Table 1.2 Conserved gene blocks of herpesviruses
Gene Block Gene Function a-Herpesviruses 3-Herpesviruses y-Herpesviruses
HSV-1 I VZV HCMV | HHV7 HVS | EBV
1 DNA replication protein UL42 ORF16 UL44 UL27 ORF59 BMRF1
1 RR (small) UL40 ORF18 ORF60 BARF1
1 RR (large) UL39 ORF19 UL45 UL28 ORF61 BORF2
1 Capsid assembly/DNA UL38 ORF20 UL46 UL29 ORF62 BORF1
maturation protein
1 Myosin, Tegument protein UL37 ORF21 UL47 UL30 ORF63 BOLF1
1 Tegument protein UL36 ORF22 UL48 UL31 ORF64 BPLF1
1 Capsid protein UL35 ORF23 UL49 UL33 ORF66 BFRF2
1 Tegument protein UL34 ORF24 UL50 UL34 ORF67 BFRF1
1 UL33 ORF25 UL51 UL35
1 Glycoprotein UL32 ORF26 UL52 UL36 ORF68 BFLF1
1 UL31 ORF27 UL53 UL37 ORF69 BFLF2
2 DNA polymerase UL30 ORF28 UL54 UL38 ORF9 BALF5
2 Glycoprotein B UL27 ORF31 UL55 UL39 ORF8 BALF4
2 Transport protein UL28 ORF30 UL56 UL40 ORF7 BALF3
2 ssDNA binding protein UL29 ORF29 UL57 UL41 ORF6 BALF2
3 IE transactivator UL54 ORF4 UL69 UL42 ORF57 BMLF1
3 Helicase/primase UL52 ORF6 UL70 UL43 ORF56 BSLF1
3 UL51 ORF7 UL71 UL44 ORF55 BSRF1
3 dUTPase UL50 ORF8 UL72 UL45 ORF54 BLLF2





UL22 ORF37 UL75 UL48 ORF22 BXLF2
UL23 ORF36 ORF21 BXLF1
4 Fusion protein UL24 ORF35 UL76 UL49 ORF20 BXRF1
4 Tegument protein UL25 ORF34 UL77 UL50 ORF19 BVRF1
4 UL79 UL52 ORF18 BVRF1.5
4 Capsid/assembly protein UL26 ORF33 UL80 UL53 ORF17 BVRF2
5 Capsid protein UL18 ORF41 UL85 UL56 ORF26 BDLF1
5 Major capsid protein UL19 ORF40 UL86 UL57 ORF25 BcLFl
5 UL87 UL58 ORF24 BcRFl
6 DNA packaging protein UL15 ORF42 UL89c2 UL60 ORF29b BDRF1
6 UL92 UL63 ORF31 BDLF
6 UL17 ORF43 UL93 UL64 ORF32 BGLF1
6 UL16 ORF44 UL94 UL65 ORF33 BGLF2
6 DNA packaging protein UL15 ORF45 UL89el UL66 ORF29a BGRF1
6 UL14 ORF46 UL95 UL67 ORF34 BGLF3
6 UL96 UL68 ORF35 BGLF3.5
6 Kinase UL13 ORF47 UL97 UL69 ORF36 BGLF4
6 Alkaline exonuclease UL12 ORF48 UL98 UL70 ORF37 BGLF5
6 Glycoprotein M UL10 ORF50 UL100 UL72 ORF39 BBRF3
6 Helicase/primase UL8 ORF52 UL102 UL74 ORF41 BBLF3
6 UL7 ORF53 UL103 UL75 ORF42 BBRJF2
6 Capsid protein UL6 ORF54 UL104 UL76 ORF43 BBRF1
6 Helicase/primase UL5 ORF55 UL105 UL77 ORF44 BBLF4
7 Uracil DNA glucosidase UL2 ORF59 UL114 UL81 ORF46 BKRF3
7 Glycoprotein L UL1 ORF60 UL115 UL82 ORF47 BKRF2
Conserved gene blocks of alpha, beta and gammaherpesviruses. Grey shading indicates partially
conserved genes. Note that the order of the gene blocks follows the betaherpesvirus arrangement. RR
- ribonucleotide reductase, IE - immediate early. HSV-1 - Herpes simplex virus 1, VZV - varicella
zoster virus, HCMV - human cytomegalovirus, HHV7 - human herpesvirus 7, HVS - herpesvirus
saimiri, EBV - Epstein-Barr virus.
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1.1.6 Features of Herpesvirus Lytic Replication
Much of the information on herpesvirus lytic replication has been established from
the study of herpes simplex virus. The course of herpesvirus lytic replication follows
a general pattern of events; initial attachment to target cell, entry, uncoating of virus
capsid, trafficking of viral DNA to the nucleus, viral gene expression, viral DNA
replication, assembly of capsid and packaging ofDNA, envelopment of the capsid in
a membrane studded with viral proteins, egress and budding from cell (Roizman &
Sears, 1996).
The viral envelope enables entry of the virus into cells, glycoproteins within the
envelope membrane facilitate the attachment to the target cell and the post
attachment entry process. The herpesvirus envelope either fuses, in a pH-
independent manner, directly with the cellular membrane or with the vesicular
membrane following capping of the virion into the cell. The capsid acts as a vector
for the viral DNA trafficking it to the cell nucleus. For all herpesviruses DNA
synthesis and capsid construction occurs in the nucleus of infected cells. When the
viral genome is released by the capsid into the nucleus it immediately circularises. It
is then replicated by a rolling circle mechanism which yields head to tail concatemers
of unit length (Jacob & Roizman, 1977, Jacob et al., 1979). Sequential expression
of immediate early, early and late genes occurs (described in section 1.1.7). Several
proteins required for DNA synthesis e.g. DNA polymerase, alkaline exonuclease,
dUTPase and ribonucleotide reductase large are virally encoded and their genes are
conserved across the herpesviruses (Davison & Taylor, 1987). Herpesvirus genomes
contain origins of replication, HSV has three, these are sites from which DNA
replication is initiated and they are essential for the herpesvirus genome to be
amplified. Unit lengths of DNA are cleaved from the concatemers and packaged
according to sites coded for by consensus sequences upstream of the cleavage site.
Homologous sequences exist in HSV 1 and 2, EBV, HVS, BHV1, HCMV and VZV
(Davison, 1984, Deiss et al, 1986, Matsuo et al, 1984 and Spaete & Mocarski, 1985).
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Late viral gene expression results in the production of viral glycoproteins which
localise to the nuclear membrane. Following packaging of the viral genome into the
capsid the capsid undergoes a conformational change and buds from the nucleus
(Deiss et al., 1986). The exact process by which herpesviruses gain their final
envelope membrane is not entirely clear. The body of evidence suggests that in the
case of HSV, immature glycoproteins embed into the nuclear membrane, and the
mature capsids bud through the membrane acquiring both envelope and
glycoproteins (Vlazny et al., 1982). The immature virus particles, then pass through
the Golgi apparatus, on route to the plasma membrane, where viral glycoproteins
become processed to maturity (Desai et al, 1988, Kousoulas et al, 1983 a & b). The
mature viruses travel to the plasma membrane, via a Golgi derived vesicle and are
released into the extra-cellular space by a process of reverse phagocytosis (Johnson
& Spear, 1982). Alternatively, the virus may acquire its final envelope at the plasma
membrane where glycoproteins have been trafficked to. There is data suggesting that
HSV-1 acquires it's final membrane from a post-ER compartment i.e. the Golgi and
implies that the virus undergoes de-envelopment and re-envelopment steps during
virus egress (Whiteley et al., 1999). Figure 1.2. depicts the lytic replication cycle of
EBV, in this case the capsid is thought to acquire it's envelope by budding at the
plasma membrane or following envelopment by post-Golgi vesicles (Gong & Kieff,
1990). Electron micrographs have shown HHV-8 acquiring a viral glycoprotein




Virion is internalised into a vesicle
gH/gL complex facilitates fusion
gp41 is required to bind to MHCII



















Figure 1.2. Schematic representation of the process of lytic replication
of EBV. Description on following page.
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Figure 1.2. Schematic representation of the process of lytic replication of EBV.
1. The virus attaches to the target cell by interaction of a virion membrane
glycoprotein with a cell surface receptor, in the case of EBV to the complement
receptor CR2/CD21. 2. Following attachment the virion is internalised into a vesicle
derived from the plasma membrane, the virion membrane fuses with the vesicle
membrane in a pH independent manner, membrane glycoproteins are required for
this event, fusion effects the release of the viral capsid into the cytoplasm. 3. The
uncoated capsid traffics to the nuclear membrane and releases the linear double
stranded viral DNA into the nucleus. 4. The linear viral genome immediately
circularises. 5. Sequential viral protein expression ensues, initially immediate early
proteins (IE) are generated these include transcriptional activators that act to initiate
synthesis of the early viral proteins (E) which include enzymes involved in DNA
synthesis (e.g. DNA polymerase) and nucleotide metabolism (e.g. thymidine kinase).
Subsequently, late proteins (L) are expressed these include structural capsid proteins
and viral glycoproteins. 6. The viral genome is replicated via a rolling circle
mechanism. Lengths of genome are cleaved and directed into newly formed
nucleocapsids. Complete capsids with packaged DNA enter the endoplasmic
reticulum (ER). 7. Newly synthesized proteins enter the ER and receive
modifications such as N-linked glycosylation. 8. The majority of glycoproteins
travel through the Golgi receiving further processing to newly acquired N-linked
glycosylation and addition of O-linked glycosylation on their way to the cell
membrane. 9. Vesicles release nucleocapsids into the cytoplasm 10. It is proposed
that the nucleocapsid acquires a definitive envelope either by 11. budding through
the plasma membrane containing the Golgi-processed viral glycoproteins or 12. by
budding into post -Golgi derived vesicles containing viral glycoproteins followed by




1.1.7 Herpesvirus Gene Expression & Transcription Pattern
During a productive infection, herpesvirus gene expression is tightly regulated and
occurs in a sequential fashion. The primary viral genes expressed following
infection and arrival of the viral DNA in the nucleus are termed immediate early
genes that are transcribed prior to viral protein synthesis. These include transcription
activators that turn on other viral genes. The next set of genes expressed are termed
early genes which are transcribed in the absence of viral DNA synthesis and are
required to facilitate replication of the viral genome. These genes encode proteins
such as additional transcriptional activators and those genes involved in nucleic acid
metabolism, genome replication and capsid assembly e.g. helicase-primase, TK,
DNA polymerase, dUTPase etc. Subsequently the late genes are expressed following
transcriptional activation via the early expressed transcription activators e.g. the R
transactivator of EBV (Ragoczy & Miller, 1999). The late genes encode structural
proteins that are expressed only after viral DNA synthesis e.g. tegument proteins and
glycoproteins required for the assembly of virions (Roizman & Sears, 1996).
During latent infection viral gene expression is very restricted and is initiated from
promoters separate from those used during productive viral infection. When
classifying genes according to their pattern of expression the herpesvirus groupings
consist of latent and lytic, lytic genes being subdivided into immediate early, early
and late. Herpesvirus genes are transcribed predominantly by host cell RNA
polymerase II, RNA polymerase III transcribes a small proportion of genes which
commonly encode non-translated RNAs.
1.1.8 Gammaherpesviruses
Of the gammaherpesviruses, most interest has been directed at those causing disease
in humans (EBV & HHV8) and domestic cattle (OHV 2 and AHV 1). OHV2 and
AHV1 have a causal association with malignant catarrhal fever (MCF), a fatal
lymphoproliferation of domestic ruminants and are therefore economically important
(Bridgen et al., 1991 & 1989, Plowright et al., 1972). In addition, herpesvirus
saimiri has received significant research interest due to its ability to transform T
lymphocytes in vitro (Mittrucker et al., 1993) and its oncogenic effects in animals
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(New World primates e.g. marmosets and the cotton tail rabbit) other than the
squirrel monkey, its natural host (Medveczky et al., 1989, Wright et al., 1977).
Gammaherpesviruses share the ability to establish latent infection in lymphocytes.
Most gammaherpesviruses are B cell tropic e.g. EBV and MHV-68 however there
are exceptions such as HVS which is T cell tropic.
1.1.9 Epstein-Barr Virus
EBV, the prototype gamma 1 herpesvirus originally isolated from an endemic
Burkitt's lymphoma tumour biopsy (Epstein et al., 1964) was the first herpesvirus to
be fully cloned and sequenced (Dambaugh et al, 1980, Baer et al, 1984, Elatfull et al,
1988 & Parker et al, 1990). The EBV genome consists of approximately 172kb
linear double stranded DNA with a GC content of 60%. At each end of the genome
there are multiple direct terminal repeats of about 0.5kb forming large terminal
repeats (LTRs) that flank the so called unique region of the genome. Two types of
EBV - type 1 and type 2 have been defined, also known as type A and B
respectively. EBV-1 is more prevalent in western societies whereas both types are
isolated with an equal frequency in African countries (Zimber et al., 1986). The
genome of type 1 and type 2 are almost identical except for the genes which encode
the latency associated nuclear proteins. Type 2 is less transforming than type 1.
The difference is based on variations in two latency associated genes i.e. EBV
nuclear antigens (EBNAs) 2 and 3 (Rickinson et al., 1987, Rowe et al., 1989).
The EBV genome encodes genes for over 90 proteins these include the full
contingent of conserved and partially conserved herpesvirus genes (refer to table
1.2). There are 18 gammaherpesvirus specific genes accompanied by
gamma 1 herpesvirus specific and EBV unique genes. The ORFs are named by their
location and coding orientation within a BamHl restriction digest fragment of the
EBV genome (e.g. BZLF1 meaning BamHl Z fragment first leftward ORF) rather
than being numbered by order as other gammaherpesvirus ORFs have been labelled.
The gammaherpesvirus specific genes include a bcl-2 homologue encoded by
BHRF1 which is functionally active as an early expressed gene and the EBV R
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transactivator (encoded by BRLF1) (Henderson et al, 1993 & Tarodi et al, 1994).
EBV encodes a second functional bcl-2 (BALF4), which inhibits apoptosis and
associates with Bax and Bak as does the product of BHRF1 (Marshall et al., 1999).
The EBV R transactivator is a lytic gene responsible for regulating the expression of
other lytically expressed viral proteins (Ragoczy & Miller, 1999).
ZEBRA (Z fragment EBV reactivation antigen) encoded by BZLF1 is also a
gammaherpesvirus specific gene, a homologue has been identified in KSHV.
ZEBRA is associated with reactivation from latency acting as a key immediate early
transactivator for lytic virus replication and is thought to be closely related to the
cellular fos/jun family of proteins (Packham et al, 1990). As well as inducing the
reactivation of the latent EBV genome, ZEBRA also causes the induction of cellular
genes such as tumour growh factor (TGF-P), a powerful immunosuppressive
cytokine (Cayrol & Flemington, 1995).
The latency associated proteins, described later in section 1.2.4, are encoded by EBV
unique genes, no homologues have been described for any other herpesviruses. EBV
encodes an interleukin 10 (IL-10) homologue expressed during lytic EBV replication
(Stewart & Rooney, 1992 and Stewart et al., 1994b) which has been shown to
enhance the efficiency by which EBV can infect/transform B cells in vitro (Stuart et
al., 1995). The EBV IL-10 is a lymphokine able to dampen local cellular immune
responses as an antagonist to natural killer (NK) cell and T cell mediated responses
(Moore et al., 1990). IL-10 also promotes B cell proliferation and so may act as part
of the virus induced B cell activation (Rousset et al., 1992).
Unlike many of the gamma2herpesviruses, EBV does not code for a G protein
coupled receptor (GCR), cyclin D or a complement regulatory protein (CRP)
homologue. However, EBV does specifically up regulate two cellular GCR proteins
(Birkenbach et al, 1993), cyclin D2 (Sinclair et al, 1994) and complement receptors
CD23 and CR 2 (also termed CD21) (Wang et al., 1990, Calender et al., 1987).
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With greatest relevance to this document EBV encodes a unique virion membrane
glycoprotein called gp340/220 (also known as gp350/220). Gp340/220 is encoded
by the BamWl L fragment which is located in the centre of the genome. Gp340/220
is a heavily glycosylated protein abundant on the surface of the EBV virion envelope
and facilitates attachment of EBV to cells by binding to CD21 (also known as CR2)
the complement receptor predominantly expressed on B cells (Nemerow et al., 1987,
1989, 1990a & 1990b). MHV-68 is the only herpesvirus to encode a gene that
exhibits any significant sequence homology to gp340/220 i.e. gpl50 of MHV-68
displays some limited sequence similarity (Stewart et al., 1996). Gp340/220 has been
shown to be identical between the two types of EBV (Lees et al., 1993). Further
discussion of gp340/220 is present in section 1.7.3.
1.2.1 EBV Infection of Immunocompetent Hosts
In the majority of people EBV infection is subclinical, primary infection occurring
during the first three years of life. The virus is thought to be orally transmitted and
approximately 90% of the human population are asymptomatic carriers. EBV
specific cytotoxic T cells generated during the primary infection function to keep the
life long EBV infection in check as the virus persists in a few circulating B
lymphocytes (Gavioli et al., 1993, Murray et al., 1992, Apolloni et al., 1992).
Complications arise when primary EBV infection occurs in early adulthood,
approximately 50% of cases result in infectious mononucleosis syndrome
characterised by acute enlargement of lymphoid tissue, particularly in the cervical
region. As the virus replicates in the oropharynx there is a strong antibody response
to the lytic antigens of EBV, however it is not clear how important this humoral
immune response is in the control of the infection. The strong cell mediated immune
response that occurs is thought to be the principal means of acute infection control
predominantly effected by CD8 positive T cells (Reinherz et al., 1980, Tomkinson et
al., 1987, Lynne et al., 1998).
Following resolution of primary infection all infected individuals continue to shed
the virus into the saliva intermittently for life (Yao et al., 1985, Sixbey et al., 1984).
Bone marrow and B lymphocytes in the circulating blood and lymphoid tissues are
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major reservoirs for EBV (Decker et al., 1996, Khan et al., 1996,). These resting B
cells are latently infected with EBV i.e. EBV gene expression is extremely restricted,
there is no productive replication to form infectious virus rather the EBV genome is
maintained within the cell in a manner designed to limit immunogenicity and
therefore identification by host immune surveillance. In asymptomatic carriers there
is approximately one EBV positive B cell per 106 B cells (Lewin et al., 1987, Yao et
al., 1991, Khan et al., 1996, Miyashita et al., 1995). The sporadic reactivation of
EBV and proliferation of EBV infected cells that occurs is limited by the continuous
presence and immune surveillance by viral specific cytotoxic T cells (Moss et al.,
1979, Rickinson et al., 1979, Rickinson et al., 1980). The importance of this
immune control is well demonstrated when transplant patients under T cell
immunosuppression frequently succumb to EBV infected B cell proliferation
resulting in malignant lymphomas (Hanto et al., 1983).
1.2.2 EBV Tropism
EBV is B cell tropic and is known to attach via the interaction of gp340/220 with the
complement receptor CR2/CD21 predominantly expressed on B cells (Nemerrow et
al., 1987, 1990a & 1990b, Fingeroth et al., 1984). CD21 is a 145 kDa membrane
glycoprotein containing 8-11 N-linked oligosaccharides which binds the C3d
component of complement (Tedder et al., 1984, Weis et al., 1984). B lymphocyte
infectability correlates with CD21 expression (Jondal et al., 1976). CD21 is thought
to be involved in B cell activation and may be a mediator of transmembrane signal
transduction (Changelian & Fearon, 1986). Binding of EBV to CD21 on resting B
cells is thought to result in B cell activation and subsequent proliferation (Sinclair et
al., 1994).
EBV also infects epithelial cells (Sixbey et al., 1984 & 1987, Greenspan et al.,
1985). There is uncertainty as to what receptor the virus uses to enter epithelial cells,
the CD21 epitope may be expressed very weakly on normal epithelial cells (Young et
al., 1986) and CD21 has been detected on some human epithelial tumour cell lines in
vitro (Birkenbach., et al 1992, Billaud et al., 1989, Fingeroth et al., 1999)
alternatively EBV perhaps uses an alternative unidentified receptor (Kim et al.,
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1998). EBV has been detected in gastric carcinomas not expressing CD21
(Yoshiyama et al., 1997). The virus may also enter epithelial cells as the result of
EBV infected B cells fusing with epithelial cells (Bayliss & Wolf, 1980), direct cell
to cell spread (Imai et al., 1998) or as a complex with IgA (Sixbey & Yao, 1992).
EBV infection of T cells is uncommon however it does occur (Kikuta et al., 1988,
Anagnostopoulos et al., 1992), T cells have been shown to express CD21 (Fischer et
al., 1991). An alternative EBV receptor to CD21 present on a T cell line has also
been identified (Hedrick et al., 1992 & 1994).
There has been some controversy as to whether the virus shed into the saliva of
infected individuals is derived from squamous epithelial cells or intraepithelial B
cells (Allday & Crawford, 1988, Niedobitek & Young, 1994, Karajannis et al.,
1997). In the more recent studies of EBV infected cell types, detection of EBV
infected epithelial cells in the tonsils or exfoliated in saliva of acutely infected
individuals was not possible whereas EBV infected B cells were commonly
identified in the same locations (Anagnostopoulos et al., 1995, Tao et al., 1995,
Karajannis et al., 1997). It is clear however, that in vivo EBV can and does infect
epithelial cells. Debate surrounds whether epithelial cells are important for the life
cycle of the virus.
The study ofEBV has been frustrated by the fact that EBV replicates inefficiently in
epithelial cells in vitro. By manipulating epithelial cells to express the B cell
receptor, CD21, on their surface more cells are infected but the infection continues to
be poor (Li et al., 1992, Chodosh et al., 2000). This shows that post entry
requirements contribute towards viral cell tropism i.e. despite the presence of the
receptor, post attachment and entry the virus needs other cell specific factors,




Despite EBV infection being asymptomatic in the majority of individuals the
association of EBV with a number of human malignancies has fuelled the interest in
research into EBV. EBV was first isolated from and is closely associated to endemic
Burkitt's lymphoma (eBL) a B cell tumour localised to the jaw principally found in
equatorial Africa and Papua New Guinea (Burkitt 1970). In these areas eBL occurs
at approximately 10 cases per 100,000 individuals a year, accounting for half of all
childhood lymphomas. Predominantly affecting children, 98% eBL are EBV
positive (zur Hausen et al., 1970) and EBV is considered a necessary feature with
other cofactors in the chain of events to effect malignancy. An important cofactor of
eBL is hyperendemic falciparum malaria infection thought to promote the
chromosomal rearrangements found in eBL B cells, which result in deregulating the
expression of c-myc, an oncogene. Chromosomal translocation results in the
oncogene c-myc moving from chromosome (chr) 8 to either chrl4, 2 or 22 where it
is positioned under the control of an immunoglobulin promoter (Leder et al., 1983,
Klein & Klein, 1985, Lenoir & Bornkamm, 1987).
It should be noted that besides eBL there are two other forms of this lymphoma -
sporadic and AIDS-associated BL which both display pathological and cytological
features of endemic BL but are frequently EBV negative (Ziegler et al., 1976,
Magrath, 1990, Hamilton-Dutoit et al, 1991b). A number ofEBV positive and EBV
negative B cell lines have been derived from BL tumors which are used in the study
ofEBV (Epstein et al., 1966, Pizzo et al., 1978)
The presence of EBV DNA and protein expression in nasopharyngeal carcinoma
(NPC) is well documented (Niedobitek et al., 1991, Wolf et al., 1973, Desgranges et
al., 1982). NPC consists of proliferation of the squamous epithelial cells in the
postnasal space. The virus DNA is associated with the malignant epithelial cells and
not the infiltrating lymphocytes characteristic of the EBV associated tumours (Wolf
et al., 1973). Although tumour incidence is infrequent across the world in general,
there are areas of significantly high incidence, particularly in south east Asia. NPC
is the most common tumour in Southern Chinese males and the second most
18
CHAPTER 1 INTRODUCTION
common tumour of Southern Chinese females (Simons & Shanmugaratnam, 1982).
World wide there are approximately 80,000 cases annually (Parkin et al., 1984)
resulting in death within 5 years for a high percentage of cases. It is thought that
cofactors are required for the development of NPC because the time between
infection and onset of the tumour is approximately 50 years. Existence of genetic
predisposition to NPC is suggested by an association of the risk of development of
NPC with certain HLA haplotypes (Simons et al., 1975) and the high predisposition
to NPC retained by first generation offspring of Southern Chinese immigrants in the
USA (Ho, 1975). Environmental cofactors have been implicated in tumour
development such as tumour promoting chemicals e.g. phorbol esters and
nitrosamines detected in Chinese salted fish and other food products in areas of high
NPC incidence (Poirier et al., 1987).
EBV is also the cause of lymphoproliferative disease to which immunosuppressed
individuals are susceptible. This is particularly a problem for transplant recipients
due to the use of immunosuppressive drugs inhibiting T cell activity, post transplant
lymphoproliferative disease (PTLD) develops as a result of uncontrolled proliferation
of EBV positive B cells (Crawford et al., 1980, Nalesnik et al., 1988, Thomas et
al., 1991). In lung transplant patients the incidence of PTLD has been reported to be
between 6.4 - 20% (Levine et al., 1999). AIDS patients frequently develop large-
cell lymphomas and Burkitt's lymphoma with which EBV is associated (Beral et al.,
1991b, Neri et al., 1991, MacMahon et al., 1991).
Many AIDS patients and HIV carriers develop oral hairy leukoplakia, a wart like
lesion on the lateral borders of the tongue with an epithelial focus of EBV
replication. Viral causation appears clear as treatment with the antiviral drug
acyclovir, which inhibits EBV replication, results in regression of the lesions, lesions




Individuals with a rare genetically determined, X-linked immunodeficiency are
predisposed to EBV associated disease, and commonly develop X-linked
lymphoproliferative syndrome also known as Duncan syndrome (Purtilo et al., 1975,
Harada et al., 1982,, Sayos et al., 1998). After acute EBV infection, the majority of
males with Duncan syndrome develop fatal infectious mononucleosis, those that
survive frequently develop lymphoma and/or hypogammaglobulinemia (Tatsumi &
Purtilo, 1986, Purtilo et al., 1989).
Detection of EBV presence in up to 50% of cases has suggested EBV may play a
role in Hodgkin's disease (HD) although the evidence as yet is not sufficient to
implicate EBV in the aetiology of HD (Weiss et al., 1989, Herbst et al., 1991,
Rickinson and Kieff, 1996). Hodgkin's disease is characteried by the presence of
malignant multinucleate Reed-Sternberg and mononucleate Hodgkin cells within the
affected lymph node. The HD tumour is thought to be of immature lymphoid origin.
Within five years of infectious mononucleosis there is approximately a 5 fold
increase in the likelihood of developing HD (Mueller et al., 1989).
Varying frequencies of the presence of EBV DNA have been detected in different
types of T cell lymphoma such as angioimmunoblastic lymphadenopathy (Ott et al.,
1992) nasal lymphoma (Harabuchi et al., 1990) and peripheral T cell lymphoma
(Jones et al., 1988) however, the role of the virus in disease development remains to
be elucidated. EBV has also been detected in gastric carcinomas, investigations are
currently underway to elucidate if EBV has a causal role in these malignancies
(Takano et al., 1999, Shibata & Weiss, 1992).
Although the majority of the world population experience an asymptomatic EBV
infection the occurrence of the diseases described above, particularly the syndromes
closely associated with EBV such as eBL, and NPC call for a strategy to prevent
EBV induced disease. As yet there is no licensed EBV vaccine, however work in
this direction has been pursued for over twenty years. Sections 1.8.6-1.9.1 describe





The ability to form a latent infection in lymphocytes is a feature common to all
gammaherpesviruses and pivotal for their life long persistence within the host. To
understand how this is achieved investigation into the genes expressed in latency
have been undertaken. Several different states of EBV latency have been identified
i.e. different patterns of gene expression in different circumstances of latent
infection. Table 1.3 illustrates the different situations and which latent genes are
expressed.
1.2.5 Latency Type III
Within EBV positive lymphoblastoid cell lines (LCLs), generated in vitro by
culturing peripheral B lymphocytes from EBV positive individuals, the whole
contingent of known latency genes is expressed this includes the six EBV nuclear
antigens (EBNAs) named EBNA1, 2, 3A, 3B, 3C and LP (leader protein), three
latent membrane proteins (LMP) LMP 1, 2A and 2B and the two EBV infected cell
RNAs otherwise known as EBERs. In addition a family of transcripts of unclear
function from the BamHl A region of the genome, known as BARTs are expressed
(Brooks et al., 1993). An alternative nomenclature where the EBNAs are numbered
from 1 to 6 (respectively) is used by some. This pattern of latent gene expression,
with the full array of EBV latent proteins expressed, is described as latency type III
(Rickinson & Kieff, 1996). As well as characteristic of LCLs this form of expression
occurs in infectious mononucleosis and in EBV positive lymphomas in transplant
patients (Tierney et al., 1994, Laytragoon-Lewin et al., 1997). EBV immortalised
LCLs display high levels of B-cell activation markers (CD23, CD30, CD39 and
CD70) and cellular adhesion molecules (ICAMI, LFA1 and LFA3) (Rooney et al.,
1986, Gregory et al., 1988).
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Type of Latency EBV Genes Circumstance Detected
Expressed
I EBNA 1 EBV infected resting B cells in
EBERs immunocompetent host (Chen et al., 1999)
BARTs Endemic Burkitt's Lymphoma (Rowe et
al., 1987)
II EBNA1 NPC (Brooks et al., 1992)
LMP1 (some) Hodgkin's Lymphoma (Deacon et al.,
LMP 2A/LMP 2B 1993)
EBERs
BARTs
III EBNA 1 EBV infected lymphoblastoid cell lines
EBNA 2 (LCLs)
EBNA 3A Post transplant lymphoproliferative disease
EBNA 3B (PTLD) (Young et al., 1989)
EBNA 3C Lymphoproliferative disease in AIDS
EBNA LP patients (Hamilton-Dutoit et al., 1993,
LMP 1 Brink et al., 1997)




Table 1.3. The EBV latency genes and the circumstances in which they are
expressed.
1.2.6 Latency Type 1
Endemic Burkitt's lymphoma biopsies display EBV latency type I which is
characterised by the expression of EBNA1 and the EBERs (Rowe et al., 1987). The
BARTs are also detected in latency type I (Brooks et al., 1993). EBNA1 is required
for the maintenance of the genome by ensuring equal partitioning of viral DNA to
the daughter cells as cells divide. EBNA1 has a glycine-alanine repeat region which
confers upon it the ability to evade degradation by the host cellular proteosome and
subsequent MHCI presentation to cytotoxic T cells (Levitskaya et al., 1995 & 1997).
After prolonged culture of BL tumour explants in vitro some BL cell lines drift
towards latency type III phenotype suggesting that in vivo host factors (immune
surveillance) dictate the necessity of restricted EBV gene expression to enable
persistence of the lymphoma (Rowe et al., 1986).
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1.2.7 Latency Type II
NPC and HD are two classic examples of latency II disease lymphomas (Deacon et
al, 1993, Brooks et al, 1992 & Hamilton-Dutoit et al, 1993, Young et al., 1988). In
latency II the EBV gene expression is limited to EBNA1, LMP1 (in some cases), 2A,
2B and the BARTs (Hitt et al., 1989, Gilligan et al., 1991). LMP1 is thought to play
a role in the development of these malignancies given that LMP-1 can induce
morphological transformation in human keratinocytes (Hu et al., 1993). LMP1 can
transform immortal rodent fibroblast lines (Baichwal & Sugden, 1988).
In resting B cells of the persistently infected immunocompetent individual latent
EBV gene expression includes only the EBERs and LMP2A (Miyashita et al., 1995,
Decker et al., 1996, Miyashita et al., 1997). LMP2A is thought to prevent the virus
from reactivating by exerting negative effects on stimulatory cellular transduction
pathway signalling (Miller et al., 1995). As the cells are not dividing EBNA1 is not
required for genome maintenance.
1.2.8 Herpesvirus Saimiri
The T lymphotrophic herpesvirus saimiri (HVS) is the prototypical
gamma2herpesvirus which can be consistently isolated from the blood of the squirrel
monkey (Saimiri sciureus) it's natural host. Infection of the squirrel monkey is
asymptomatic, however in other species of New World primate and the cotton tail
rabbit HVS infection results in fulminant T cell lymphomas (Wright et al., 1977,
Medveczky et al, 1989). Three strains, types A, B and C have been defined for HVS
according to high variability in the leftmost 7 kilobases of the long unique region of
the viral genome which are responsible for the oncogenicity of the virus (Medveczky
etal., 1984).
In vitro, HVS can transform human and New world monkey T cells to continuous
growth (Schirm et al, 1984 & Biesinger et al, 1992), they grow independent of
antigen presenting cells and antigen stimulation. Some (but not all) HVS
transformed T cells require the presence of interleukin 2 (IL-2) (Szomolanyi et al.,
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1987, Medveczky et al., 1993). The T cell transforming ability of HVS has been
viewed as a powerful culture system for studying T cell biology. HVS transformed T
cells do not require antigen and accessory cell stimulation to grow continuously,
previously unavailable features that inhibited studies of T cell function. The T cell
subtypes HVS can transform in vitro include CD4+, CD8+ and y/5 T cells (Berend et
al, 1993 & De Carli et al, 1993, Yasukawa et al, 1995). Importantly the HVS
transformed T cells retain their cytokine production profile and CD8+ T cells retain
their antigen specificity and cytotoxicity (Weber et al., 1993, De Carli et al, 1993,
Berend et al, 1993 & Mackewicz et al, 1997). Additional to the transforming
properties of HVS, HVS has been considered as an experimental model to study
gammaherpesviruses and also for use as a viral vector e.g. in human gene therapy
(Stevenson et al., 1999a & 2000).
1.2.9 HVS Genome
HVS has a 112.9kbp unique DNA region of low GC content (34.5%) flanked by
approximately 35 noncoding 1.444kbp repeats of high GC content (70.8%) and
encodes at least 76 open reading frames. Of the ORFs, 60 have counterparts in other
herpesviruses, the majority of which are the conserved and semiconserved
herpesvirus genes (refer to table 1.2). In addition there are gammaherpesvirus, type
2 gammaherpesvirus and HVS specific genes. HVS demonstrates that
gamma2herpesviruses seem to be particularly prone to sequestering cellular genes,
HVS encodes at least 15 genes with homology to cellular genes including D-type
cyclins, human interleukin 8 receptor (IL8R), CD59, complement control proteins,
thymidylate synthase and dihydrofolate reductase, this is on the high side in
comparison to other herpesviruses (Albrecht et al., 1992).
HVS encodes the herpesvirus conserved glycoprotein genes displayed in table 1.2.
However, ORF 51, located at the site of gp340/220 of EBV and gp!50 of MHV-68
shares no significant homology with its counterparts.
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1.3.1 Kaposi's Sarcoma Associated Herpesvirus
KSHV, the eighth human herpesvirus, was discovered only six years ago, following
detection of portions of the genome in Kaposi's sarcoma tissue (Chang et al., 1994,
Moore & Chang, 1995). Intense investigation has determined KSHV to be
associated with three human malignancies, Kaposi's sarcoma (KS), primary effusion
lymphoma (PEL) and multicentric Castleman's disease (MCD). There are reports of
detection of the KSHV genome in all the epidemiological forms of KS, which
include 'classic' (presenting in elderly Mediterranean men), endemic (localised to
Central Africa), human immunodeficiency virus (HlV)-associated and post-
transplant. Not only does epidemiological evidence support KSHV as an aetiological
cofactor of KS but also, patients treated with foscarnet (an antiviral agent known to
inhibit KSHV replication) experienced regression of KS lesions (Morfeldt &
Torssander, 1994). KSHV genome has been consistently detected in primary
effusion lymphomas (PEL), also known as 'body-cavity-based lymphomas' (BCBL),
this is a rare form of AIDS-related B-cell lymphoma which presents as malignant
lymphomas in the pleural or abdominal cavity. Usually EBV and KSHV are both
present in PEL (Cesarman et al., 1995a & b, Gessain et al., 1997) but there are cases
where KSHV has been detected in the absence of EBV (Carbone et al., 1996, Renne
et al., 1996a, Cesarman et al., 1996) and of PEL sufferers that are HIV negative
(Carbone et al., 1996, Nador er al., 1995). KSHV is also present in a large proportion
of cases of multicentric Castleman's disease, an angiolymphoproliferative lesion,
particularly those associated with HIV-infection (Soulier et al., 1995; Gessain et al.,
1996). KSHV is considered to be very closely associated with KS and PEL, but less
closely with MCD. As with EBV the occurrence of KSHV associated disease is
greatly enhanced in the immunosupressed e.g. AIDS patients and post transplant
patients.
1.3.2 KSHV Epidemiology
Unlike many other herpesviruses KSHV does not appear to be ubiquitous i.e. it may
have a more limited presence among the human population. KS occurs in a cluster
of well defined populations (e.g. Mediterranean men, central African populations,
AIDS sufferers and post transplant patients) (Beral, 1991a). KSHV is thought to be
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predominantly sexually transmitted, epidemiological studies show a high prevalence
in AIDS patients with KS (83-88%) and also in KS-negative homosexual men (35%),
in comparison the KSHV seroprevalence of women with no sexual exposure and
HIV negative blood donors is very low (0-1%) (Kedes et al., 1996, Gao et al., 1996,
Blackbourn et al., 1999). There is also grounds to suggest vertical transmission of
KSHV occurs due to the incidence of childhood KS. KSHV is thought to be
transmitted via infected mothers breast milk as childhood KS commonly presents in
a distribution likely to have arisen from virus entry of the gastrointestinal mucosa
(Ziegler et al, 1996). KSHV has been detected in saliva (Boldogh et al., 1996,
Koelle et al., 1997, Veira et al., 1997, Blackbourn et al., 1998) and may be the route
of horizontal KSHV transmission. The detection of seroconversion to KSHV is a
useful indication of exposure to KSHV and preempts the onset ofKS.
1.3.3 KSHV Tropism
KSHV displays tropism for spindle-like cells, thought to be of endothelial origin that
dominate the varied cell types present in KS lesions (Staskus et al., 1997, Davis et
al., 1997, Rainbow et al., 1997). KSHV has also been detected in circulating
endothelial cells, B cells, CD8+ T cells, macrophages and prostatic glandular
epithelium (Boshoff et al., 1995, Ambroziak et al., 1995, Li et al., 1996; Corbellino
et al., 1996b, Harrington et al., 1996, Staskus et al., 1997; Sturzl et al., 1997;
Sirianni et al., 1997). Like EBV, KSHV is difficult to culture in vitro with only very
limited replication achieved in fibroblastoid cells (Foreman et al., 1997, Renne et al.,
1996a & 1998). KSHV establishes a latent infection characterised by expression of a
restricted set of viral genes and the presence of circular KSHV genome (Russo et al.,
1996, Renne et al., 1996b). Latently infected B cell lines have been established from
PEL and the peripheral blood mononuclear cells (PBMCs) of individuals suffering
from PEL e.g. BCBL-1 (Cesarman et al., 1995b, Arvanitkis et al., 1996, Renne et
al., 1996a, Said et al., 1996, Boshoff et al., 1998). In order to study virus
ultrastructure and lytic virus gene expression, lytic replication can be induced by the
addition of phorbol esters and sodium butyrate (Miller et al., 1996 & 1997). As
with EBV, some low level spontaneous lytic replication does occur in the KSHV
infected B lymphoma cell lines. Although difficult, KSHV has been cultured
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directly from KS lesions (Foreman et al., 1997) and saliva (Viera et al., 1997). The
range of cells that will support productive infection of HVS and KSHV in vitro is
very limited (Renne et al., 1998) there is essentially no information on what these
primate rhadinoviruses may use as a receptor for entry to cells.
1.3.4 KSHV Genome
Initially sequence analysis of a large genomic region (21kb) containing blocks of
structural genes was done and showed that KSHV was most closely related to HVS
(Moore et al., 1996). Subsequently full sequence analysis was performed on KSHV
from a PEL cell line (BC-1) (Russo et al., 1996). The KSHV genome consists of a
140.5kbp long unique region (LUR) flanked by multiple GC rich (85%) terminal
repeats of 801 bp units. There are five internal repeat regions within the LUR. At
least 81 ORFs have been identified, of these 66 have homology to ORFs of HVS.
These HVS homologous genes include the full complement of herpesvirus conserved
and semi-conserved genes (see table 1.2) and further gammaherpesvirus and
rhadinovirus specific genes. KSHV has a number of KSHV specific genes and
overall, in comparison to other herpesviruses, has a particularly extensive number of
genes sharing homology with mammalian counterparts e.g. bcl-2, cyclin D,
macrophage inflammatory protein (vMIP), OX-2 an NCAM-like adhesion molecule
(vOX), IL-6 and interferon regulatory factors (vIRF).
The existence of open reading frame K8.1 was confirmed experimentally (Chandran
et al., 1998), it was not identified following initial sequence analysis (Russo et al.,
1996). K8.1 encodes a small (37kDa) virion surface membrane glycoprotein, a
positional and possibly functional homologue of gp340/220 of EBV and gpl50 of
MHV-68 (described in more detail in section 1.7.8).
1.3.5 Animal Models
Analysis of the biology and pathogenicity of EBV and KSHV has been limited by
their inherent species specificity and restricted growth in vitro. Before the analysis
of MHV-68, animal models for the study of gammaherpesviruses were limited to
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HVS infection of primates or rabbits and EBV infection of rhesus macaques
(Moghaddam et al., 1997) common marmosets (Callithrix jacchus) and cotton top
tamarins (Saguinus oedipus oedipus) (Finerty et al., 1992). Following EBV infection
common marmosets suffer a poorly defined IM like syndrome (Emini et al., 1986,
Wedderburn et al., 1984) however they have not been suitable to study secondary
diseases associated with EBV. Cottontop tamarins receiving large doses of EBV
experience lethal lymphomas (Cleary et al., 1985). Persistent infection is less clear,
low level latent infection of the tamarin has been reported however this was achieved
when animals were immunised with an EBV vaccine prior to EBV challenge
(Niedobitek et al., 1994). Chimpanzees can be infected by human EBV and this has
occurred by unintentional transfer from humans to chimps in play units however
their limited availability impedes their use (Levine et al., 1980). Infection of rabbits
with an EBV related herpesvirus isolated from the baboon (Macaca arctoides) has
also been proposed as an animal model for the investigation of antiviral drugs and
vaccines against EBV (Wutzler et al., 1995, Hayashi & Akagi, 2000). A
'humanised' severely combined immunodeficient (SCID)/hu-PBL-SCID mouse
model has been used in development of therapies to treat EBV induced malignancies
(Johannessen & Crawford, 1999, Mosier et al, 1992, Buchsbaum et al, 1996). The
SCID mice lack mature B or T cells but have parts of immune function reconstituted,
at least transiently, by infusions of human lymphocytes. The use of humanised SCID
mice suffers from the inherent cross species differences that may hinder the outcome
and interpretation of results.
MHV-68 closely parallels the genetic and pathobiological characteristics of EBV
however, MHV-68 replicates relatively well in vitro and so is an invaluable tool to
study gammaherpesvirus gene expression during the lytic virus cycle. Furthermore,
because MHV-68 is a pathogen of mice it is also a good model to study the roles of
specific gammaherpesvirus genes in vivo and the immune response employed by the
host to control gammaherpesvirus infections. Use of MHV-68 as a model system




1.3.6 Murine Gammaherpesvirus 68
The discovery of murine gammaherpesvirus 68, (MHV-68) was reported in 1980,
following isolation from the brain of a bank vole, Clethrionomys glareolus, in
Slovakia (Blaskovic et al., 1980). Based on genomic analysis, revealing similarities
in structure, content and organisation, MHV-68 was classified a gammaherpesvirus
(Efstathiou et al., 1990a & b, Mackett et al., 1997). MHV-68 has been fully
sequenced and approximately 80 open reading frames (ORFs) have been determined
for the genome which consists of 118.2kbp unique DNA flanked by variable copies
of 1.23kb repeat sequences (Virgin et al., 1997. Davison, unpublished observations).
The GC content of the unique region and the terminal repeats is 46% and 78%
respectively. The GC content of the unique region is low compared to EBV (GC
content 60%) and consistent with other gamma 2 herpesviruses unique region e.g
HVS and KSHV which have a GC content of 34.5% and 53.5% respectively
(Albrecht et al., 1992, Russo et al., 1996). The unique region of the genome has
large blocks of conserved genes, with high colinearity to equivalent gene blocks of
the genomes of KSHV, HVS and EBV, interspersed by regions containing virus
specific ORFs. As many as 63 ORFs with homology to those of HVS and KSHV
have been identified. The overall identity of MHV-68 ORFs to their homologues in
the other gammaherpesviruses indicates that MHV-68 is more closely related to HVS
and KSHV than to EBV and has been therefore been classified a gamma2herpesvirus
(Virgin et al., 1997). Refer to figure 1.3 showing the genomic organisation ofMHV-
68.
The conserved herpesvirus family genes present include structural proteins such as
capsid proteins and the glycoproteins gB, gH, gM and gL, genes encoding proteins
for virus assembly e.g. packaging proteins, proteins involved in nucleic acid
metabolism; uracil DNA glycosylase, deoxyuracil triphoshatase and ribonucleotide
reductase large and proteins involved in genome replication e.g. DNA polymerase
and helicase-primase. The semi-conserved herpesvirus genes encoded by MHV-68
include thymidine kinase and the small subunit of ribonucleotide reductase. In
summary, all the conserved and semiconserved genes displayed for
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gammaherpesviruses in table 1.2 are present in MHV-68 except for a homologue to
ORF41 of HVS.
On following page:
Figure 1.3 Organisation of the MHV-68 genome. The unique region of the
genome is represented by a single black line with co-ordinates marked off in kilobase
pairs. Terminal repeat (TR) and internal repeat (IR) regions are marked by green
boxes. The open reading frames (ORFs) are indicated by arrows, the direction of the
arrow indicates the direction of transcription. ORFs which are unique to MHV-68
are indicated by yellow arrows. The gene number is shown except where the
function of the gene is known. Functions are abbreviated as follows: crp\
complement regulatory protein; gB, glycoprotein B; K3, homologue of the
immediate early gene of HHV-8; TK, thymidine kinase; gH, glycoprotein H; gM,
glycoprotein M; ung, uracil DNA glycosylase; gL, glycoprotein L; rta, R
(immediate-early) transcriptional transactivator; gpl50, glycoprotein with homology
to gp340/220; dut, dUTPase; mta, M (immediate-early) transcriptional transactivator,
rr2, small subunit ribonucleotide reductase; rrl, large subunit ribonucleotide
reductase; eye D, homologue of mammalian cyclin D; bcl-2, homologue of
mammalian bcl-2; IL-8R, homologue of mammalian interleukin-8 receptor. The red
ring marks the position of gpl50, ORFs encoding glycoproteins are denoted by blue






























ORF 51, also known as M7, is specific to MHV-68 and encodes glycoprotein 150
(gpl50). As mentioned earlier sequence comparisons have shown gpl50 to share
significant homology with gp340/220 and there is a potential homologue at the same
location ofKSHV. Gpl50 is described in detail in section 1.7.7.
Overall the MHV-68 genes associated with lytic virus replication are well conserved
however those involved in latency and transformation seem to have diverged and to
be encoded by virus specific genes. There are no sequence homologues of the EBV
EBNA and LMP genes or the transforming genes ofHVS. At the point of individual
ORFs there is great variability in the level of viral and cellular homology, there are
several ORFs such as those encoding bcl-2 and TK, for which the MHV-68 encoded
protein is more closely related to the EBV gene product than to that of HVS and
KSHV (Virgin et al., 1997).
1.3.7 MHV-68 Katencv
Gene expression during latent MHV-68 infection is not clear, the questioned
sensitivity ofmRNA detection systems hinder these type of analyses. However, it is
clear that MHV-68 does not encode obvious homologues of the EBV, KSHV and
HVS tumour- or latency-associated genes (Virgin et al., 1997).
1.3.8 Pathogenesis ofMHV-68
Following intranasal (i.n.) inoculation ofMHV-68 into mice, three to four weeks of
age, an acute infection of the lung develops. The acute infection of the lung lasts for
approximately ten days and is associated with inflammatory infiltrates. Infectious
virus titre in the lung peaks around 5 days post infection and is cleared by day 14.
Viral antigen is predominantly located in lung epithelial and mononuclear cells
(Sunil-Chandra et al., 1992a). Virus spreads from the lung to the spleen (and
sometimes is detectable in other organs such as the heart, kidney, adrenal glands) but
productive viral replication is limited at this site. The acute infection gives way to
the establishment of a life long persistent/latent infection. Viral latency is
predominantly located to the spleen in which the B lymphocytes have been shown to
specifically harbour the latent virus (Sunil-Chandra et al., 1992b & Usherwood et al,
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1996b). Latent virus first becomes detectable in the spleen at seven days post
infection. The latent virus titre steadily increases peaking fifteen days post infection.
Peak latent virus titre is associated with a marked CD4+ T cell driven splenomegaly
(Ehtisham et al., 1993 & Usherwood et al., 1996a) a phenomenon similar to the
Epstein-Barr virus induced infectious mononucleosis. During splenomegaly B cell,
CD4+ T cell and CD8+ T cell numbers all increase by 2 - 3 fold. Of the CD8+ T cells
there is a predominance expressing a V(34 positive phenotype which suggests the
presence of a superantigen expressed by MHV-68 (Tripp et al., 1997). After the
peak, latent virus titres decrease to a low but detectable level, never being completely
eliminated. The lung has also proven to be a major site of MHV-68 latency. Viable
episomal DNA has been detected in the lungs of MHV-68 infected pMT mice,
lacking B cells, and intact mice, with and without antiviral drug treatment inhibiting
productive viral replication, months post infection (Stewart et al., 1998, Usherwood
etal., 1996b).
CD8+ T cells play a critical role in control of the acute infection of the lung.
Intranasal inoculation ofMHV-68 into mice depleted of CD8+ T cells gives rise to a
lethal infection. Productive virus titres were highly elevated in both the lungs and
spleens of the CD8+ T cell depleted mice. The CD4+ T cell depleted mice however,
were largely unaffected, though did fail to develop a splenomegaly (Ehtisham et al.,
1993). Not only are CD4+ T cells essential for the development of splenomegaly,
they are also required for the elevated levels of splenic viral latency seen at day
fifteen post infection (Usherwood et al., 1996a). Humoral responses do not become
detectable until after the acute infection has been resolved but once established
remain high throughout the animals life (Stevenson et al., 1998). The mechanism by
which CD8+ T cells effect killing has yet to be established. MHV-68 infection and
response of mice deficient in perforin, one of the main methods of killing used by
CD8+ T cells and natural killer cells, does not appear to differ significantly from




As outlined, the spleen and lungs are sites of viral persistence in a latent form. Viral
latency is characterised by limited viral gene expression and viral genome present in
a closed circular form i.e. episomal DNA. Current evidence for EBV suggests that
latently infected B lymphocytes are an essential feature for EBV persistence. There
are conflicting theories as to whether epithelial cells are secondary or not for the
maintenance ofEBV in the host.
The bone marrow is considered the major site of EBV latency. The suggested theory
is that mucosa is not essential for EBV persistence and EBV is only present in the
mucosa due to reseeding form the lymphoid compartment. Little evidence exists for
the presence of latent EBV in the mucosal epithelium, however low levels may have
been missed and it is difficult to examine this question in humans due to difficulties
in obtaining biopsy material. MHV-68 provides an opportunity to examine possible
sites of latency undetected previously. The revelation of MHV-68 latently
occupying the lungs long term, highlights the possible association of
gammaherpesviruses with lung pathologies. EBV has been detected in cells
exfoliated from the lung (Lung et al., 1985) and in the lung tissue of cryptogenic
fibrosing alveolitis (CFA) (Egan et al., 1995, Stewart et al., 1999b) suggesting that
the lung may be a reservoir of EBV and sometimes associated with lung pathology.
Fibrosis of the lungs has been detected in interferon gamma receptor knock out mice
infected with MHV-68 (E. Ebrahini, unpublished observations). Lung arteritis has
also been attributed to MHV-68 when observed in mice following long term MHV-
68 infection (Week et al., 1997).
1.4.1 Cytokine Profile
In response to intranasal infection of MHV-68 into mice high levels of interferon
gamma (IFN-y) and interleukin 6 (IL-6) are produced in the lymphoid tissues, levels
peaking at day ten post i.n. infection. Interleukin 2 (IL-2) and interlekin 10 (IL-10)
are present but at much lower levels (Sarawar et al., 1996). IFN-y does not appear
essential for recovery from acute infection. In mice deficient of IFN-y there is little
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difference in the phenotype of MHV-68 infection compared to wild type mice
(Sarawar et al., 1997). However, following intranasal inoculation of MHV-68 into
IFN-y receptor knockout mice, the spleens showed atrophy with a reduction in
splenic B cells, CD4+ and CD8+ T cells (Dutia et al., 1997). Alpha and beta
interferon (IFN-a and IFN-P respectively) appear to be of great importance in the
control of acute MHV-68 infection. Shortly after intranasal inoculation ofMHV-68,
transgenic mice negative for IFN-a/p receptors suffer from a lethal infection (Dutia
etal., 1999b).
1.4.2 Lvmphoproliferative Disease
MHV-68 is associated with the development of lymphoproliferative disease in mice
during long term infection. 9% of inbred mice, infected intranasally with MHV-68,
developed lymphomas over a period between nine months to three years post
infection. Fifty percent of these mice displayed high grade lymphomas. In mice
immunosuppressed by treatment with cyclosporin A before and during infection the
incidence of lymphomas increased to 60%. The lymphomas were associated with
lymphoid, liver, lung and kidney tissue. The lymphomas consist of B cells,
predominantly light chain restricted, suggesting a clonal origin, and CD3 positive T
cells. No lytic antigen positive cells were detected, however cells positive for viral
DNA were detected in and at the periphery of lymphomas (Sunil-Chandra et al.,
1994). The Sll cell line which is positive for episomal MHV68 genome was
generated from an infected B cell lymphoma (Usherwood et al., 1996c).
1.4.3 MHV-68 Cellular Tropism & Latency
Unlike HVS, MHV-68 is B cell tropic with respect to latency. MHV-68 establishes
latency in splenic B cells in vivo (Sunil-Chandra et al. 1992b, Usherwood et al.,
1996b). In situ hybridization and immunostaining has indicated epithelial cells and
monocytes in the lung tissue harbour latent virus. There is also evidence, resulting
from intra peritoneal infection, demonstrating MHV-68 can establish latency in
peritoneal macrophages (Week et al., 1999). Furthermore, MHV-68 will also
persistently infect transformed cell lines of B-cell origin, such as the NSO mouse
myeloma cell line and the Sll B cell lymphoma line, but not those of T cell origin.
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Persistently infected NSO B cells were shown to contain episomal DNA (Sunil-
Chandra et al., 1993).
As yet, the receptor MHV-68 uses to attach to cells is unknown. Unlike EBV,
MHV-68 can infect and replicate productively in many different cell types in vitro,
including epithelial and fibroblastoid cell lines originating from rodents and primates
(Rajcani et al., 1985), suggesting it may use a ubiquitous cellular receptor to enter
cells. Following gastric instillation of MHV-68 gastrointestinal epithelial cells have
been shown to undergo lytic MHV-68 infection (Peacock & Bost, 2000). In an
investigation into the interaction of MHV-68 with murine splenocytes CD43+ cells
(T lymphocytes, macrophages and activated B cells) were shown to be readily
susceptible to MHV-68 infection in addition to resting B cells (Dutia et al., 1999a).
1.4.4 Glycoproteins
Glycoproteins consist of proteins that have been modified by the covalent attachment
of an oligosaccharide group or groups to specific amino acids. In general eukaryotic
cells produce glycoproteins with N- and/or O-linked glycosylation. N-linked
glycosylation refers to oligosaccharides that are covalently attached to the amino
group of asparagine residues present in the consensus N-linked glycosylation motif
of Asn-X- Ser/Thr. O-linked glycosylation describes oligosaccharides that are linked
via the hydroxyl group of a serine or threonine residue.
1.4.5 Glycoproteins - General Location & Roles
Glycoproteins are abundant in plasma membranes of eukaryotic cells, they perform
assorted functions such as acting as receptors, ligands, ion channels, intercellular
adhesion molecules etc. Many secreted proteins are glycoproteins including
hormones, cytokines and immunoglobulins. The hydrophillic nature of the
oligosaccharide chains increase the solubility of glycoproteins, a desirable property
for proteins exposed to the extracellular environment. The sugar component of
membrane glycoproteins is mainly attached to the extracellular domain of the
protein. Most enveloped animal viruses, including all herpesviruses, encode genes
for glycoproteins. With respect to herpesvirus replication glycoproteins can have
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roles in attachment and entry into cells, virion structure, egress, cell to cell fusion,
receptor formation and immune modulation (Vanderplasschen et al., 1993, Foster et
al., 1999, Haddad et al., 1989, Johnson et al., 1988, Tanner & Alfieri, 1999). Virus
encoded glycoproteins are generated by and undergo the same modification
processes as those of the cellular host (Campadelli-Fiume & Serafini-Cessi., 1985).
1.4.6 N-linked Glvcosvlation
1.4.7 Generation ofa lipid linked-oligosaccharide precursor
Of the two main types of glycosylation the process of N-linked glycosylation has
been studied the most extensively. The first step of N-linked glycosylation is the
synthesis of an oligosaccharide precursor that is linked to a lipid called dolichol
(Dol) (see figure 1.4). This oligosaccharide precursor is transferred en bloc to
nascent proteins in the endoplasmic reticulum (ER). The structure of the dolichol-
oligosaccharide is conserved among eukaryotes and consists of dolichol linked via a
pyrophosphate linkage to an oligosaccharide comprised of 14 monosaccharide units.
The monosaccharide units include N-acetyl glucosamine (GlcNAc), glucose (Glc)
and mannose (Man). The monosaccharide units are present as precursors also known
as monosaccharide donors in the cytosol, ER and Golgi. The monosaccharide donors
include phosphorylated intermediates GDP-Man, UDP-GlcNAc, Dol-P-Man (Dol-P
= dolichol phosphate) and Dol-P-Glc . Initial attachment of monosaccharide units to
dolichol occurs in the cytosol. First GlcNAc is added to dolichol by GlcNAc-1-
phosphotransferase and a second GlcNAc is added by a GlcNAc-transferase both
from UDP-GlcNAc donors. Tunicamycin is an analogue of UDP-GlcNAc a reagent
often used to inhibit N-linked glycosylation by blocking GlcNAc-1-
phosphotransferase activity in order to determine if a protein has N-linked
glycosylation. Subsequent to the attachment of the two N-acetyl glucosamine
residues five mannose residues are added from GDP-Man precursors. The
Man5GlcNAc2-Dol formation then flips from the cytosol to the lumen of the ER by
an unknown mechanism. Four mannoses are then attached from Dol-P-Man donors.
Finally, three glucose residues donated by Dol-P-Glc are attached and the precursor








Figure 1.4. The biosynthesis of the dolichol lipid linked
oligosaccharide precursor; the first step in IN-linked glycosylation of
proteins. Glycosyltransferases in the cytosol and endoplasmic reticulum
(ER) sequentially transfer precursor sugars to the lipid dolichol. The
formation of the oligosaccharide begins in the cytosol, however following
the attachment of the first four mannose residues the complex flips across
the ER membrane into the ER lumen where synthesis is completed. The
oligosaccharide precursor is ready for transfer to nascent proteins after the
attachment of the three glucose residues. Tunicamycin is an analogue of
UDP-N-acetylglucosamine that blocks N-linked glycosylation by
inhibiting the attachment of UDP-N-acetylglucosamine to dolichol
catalysed by N-acetylglucosamine-1 -phosphotransferase. Adapted from
Varki et al., 1999.
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1.4.8 Transfer ofthe oligosaccharide to nascent protein
Most potential glycoproteins have a signal sequence called a signal peptide or leader
sequence at the amino terminal which directs newly synthesised proteins from the
ribosome to the ER lumen (von Heijne, 1986). The signal sequences found in viral
glycoproteins all share a central region of uncharged hydrophobic residues often
bounded by a positively charged residue on the amino terminal end. There does not
appear to be any specific sequence requirement other than that the largely
hydrophobic stretch be at least 11 amino acids long (von Heijne, 1986). The dolichol
lipid linked oligosaccharide precursor is transferred to newly synthesised proteins
rapidly as they enter the ER by a protein complex called the
oligosaccharyltransferase complex (OST) which resides in the ER membrane (see
figure 1.5). The OST cleaves the high energy GlcNAc-P bond and the
oligosaccharide is attached via the amino group of an asparagine residue positioned
in the defined N-linked glycosylation sequence of Asn-X-Ser/Thr (where X can be
any amino acid except proline). Not all potential glycosylation sites are used.
Studies of a rabies glycoprotein have suggested that the amino acid following the
Ser/Thr residue can influence the efficiency of glycosylation (Mellquist et al., 1998).
1.4.9 Cleavage ofGlucose & Protein Folding
Having been attached to the nascent protein sequential processing of the
oligosaccharide occurs mediated by enzymes present in the ER and Golgi. Enzymes
trim and add sugars (including monosaccharides such as sialic acid, fucose and
galactose in addition to the types already described in the oligosaccharide precursor)
as the protein encounters them in transit through the ER. Initially glucosidase I acts
to remove the terminal al-2-linked terminal glucose. Subsequently the remaining
two glucose residues are cleaved off by glucosidase II (Moremen et al., 1994). The





Figure 1.5. Transfer of the dolichol linked oligosaccharide precursor
to a newly emerging protein in the ER. This is performed by the
'oligosaccharide transfer complex' (OST) that resides in the endoplasmic
reticulum (ER) membrane. The oligosaccharide is transferred
specifically to arginine in the motif Asn-X-serine/threonine (where X is
any amino acid except proline) accomplishing N-linked glycosylation.
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1.5.1 Importance of Glycosvlation For Protein Structure Formation
Chaperones have been identified that bind to nascent proteins which appear to be
involved in regulating correct protein folding. Calnexin is described as one such
chaperone, this is a lectin that specifically binds to glycoproteins displaying N-linked
glycans (Hammond et al., 1994). The innermost glucose-linked to mannose has been
found to be crucial and calnexin binds via this residue independent of the protein
conformation (Herbert et al, 1995, Zapun et al., 1997). The proposed model is that
calnexin acts as a 'docking' protein retaining the polypeptide in the ER and promotes
protein folding (Labriola et al., 1995, Ou et al., 1993). It has been reported that
when calnexin is unable to associate with the glucose residue, for example in cells
deficient in glucosidase I and II or when cells are treated with inhibitors of
glucosidase (1-deoxynojirimycin, castanospermine), increased misfolding of
glycoproteins occurs (Ora & Helenius, 1995, Saunier et al., 1982). Alph-
glucosyltransferase reglycosylates incorrectly folded proteins which are then either
refolded or degraded (Sousa & Parodi, 1985). This shows that early in generation
the presence of N-linked glycosylation influences protein structure. The mechanism
for detection of incorrectly folded proteins is not fully known.
1.5.2 N-glvcan Processing Pathways
The N-glycan group existing as Man8GlcNAc2-Asn following the removal of the
three glucose residues is called the high mannose subtype and can now undergo
further processing. There are two processing pathways that the high mannose
glycans may undergo. In one pathway two of the mannose residues are
phosphorylated by a series of enzyme activities which targets the glycoprotein to the
lysosome. However, most glycoproteins undergo the other form of processing
whereby specific a-mannosidase enzymes located in the ER and Golgi sequentially
process the high mannose N-glycans (see figure 1.6) . In general the mannosidases
trim off four mannose residues and the resulting Man5GlcNAc2 sugar is then subject
to diverse modification in the Golgi by glycosyltransferases e.g. GlcNAcT-I and
GlcNAcT-II adding sugars and glycosidases cleaving sugars e.g a-mannosidase II
(Tulsiani et al., 1982). A model exists where different processing enzymes are
located in different cisternae of the Golgi stack and act as the glycoprotein passes
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through their domain in a highly ordered sequence similar to a manufacturing
assembly line (Hirschberg & Snider, 1987). The final N-linked glycan can be one of
three types i.e. high mannose, hybrid or complex N-linked glycosylation. High
mannose N-linked oligosaccharides have no new sugars added to them in the Golgi
and are characteristic of immature glycoproteins. Most extracellular N-linked
glycosylation is of the complex type where both the a3 and a6 mannose residues are
substituted with GlcNAc residues. Where both substituted and unsubstitued
mannose residues are present the glycan is termed a hybrid (refer to figure 1.6).
Many different sugars can be attached in various degrees of branching complexity.
The presence of fucose attached by the action of fucosyltransferase to the primary
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Figure 1.6. Processing of N-linked oligosaccharides in the endoplasmic reticulum (KK) and Golgi.
The processing pathway occurs in a highly ordered sequence, each step is dependent on the previous
one. Initially the glucose residues are cleaved off, it appears likely that only when correct protein
folding has occurred is the last glucose trimmed. A mannose is removed and the protein is transferred
to the Golgi where mannosidase I cleaves an additional three mannoses and N-acetylglucosamine
transferase adds N-acetylglucosamine. Following the cleavage of a mannose by mannosidase II the
oligosaccharide is resistant to Endo H, an enzyme which cleaves the bond between the first two N-
acetylglucosamines. Endo II is a reagent commonly used to distinguish between complex and high
mannose oligosaccharides. Addition and cleavage of sugars continues for complex and hybrid
oligosaccharides, the star symbols indicate where branches of sugar chains can form. Adapted from
Varki et al., 1999 & Stryer el al., 1995.
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1.5.3 O-Linked Oligosaccharides
O-linked glycosylation refers to the linkage of oligosaccharides to proteins via the
hydroxyl group of serine and threonine residues (small oligosaccharides can also be
linked to the side chain of hydroxyproline or hydroxylysine). O-linked glycans are
generally shorter and more variable than N-linked oligosaccharides. In contrast to
the formation of N-linked glycosylation a lipid-linked oligosaccharide precursor is
not required, the first step of glycosylation involves the direct attachment ofGalNAc
(from UDP-GalNAc) to serine and threonine residues by GalNAc transferase (see
figure 1.7). It is thought that O-linked glycosylation occurs relatively late in the
biosynthetic pathway i.e. in the Golgi (Jenkins & Curling, 1994, Johnson & Spear,
1983). There appear to be at least eight different isozymes of GalNActransferase in
mammalian cells that are possibly differentially expressed among different tissues
and cell types (Clausen & Bennet, 1996). No consensus sequence has been identified
for O-linked glycosylation. Patterns are emerging from study of sites of O-linked
glycosylation for example alanine, serine and threonine are commonly found
adjacent to the glycosylated residue (O'Connell et al., 1992, Wang et al., 1993,
Wilson et al., 1991). Proline residues are frequently located around the site of O-
linked glycosylation which fits in well with the common presence of O-linked
glycosylation at p turns in proteins, structures that proline residues promote. O-
glycans tend to be less branched than N-linked glycosylation, however the two types
of glycosylation do tend to have similar terminal patterns of sugar structures. The
enzyme O-glycosidase cleaves O-linked glycosylation.
There are four main core subtypes of O-linked sugars determined by the specific
modification to GlcNAc and attachment of secondary monosaccharides in particular
linkages (e.g. pi-3 linkage etc.) by an appropriate glycosyltransferase (see figure
1.7). Core 2 linkages are the most common linkages followed by core 1 linkages
(core 3 and 4 linkages occur much less). There are further types of rarer core
glycosylation. The attachment of further sugars to the O-linked glycan is thought to
depend on the expression levels and subcellular distributions of glycosyltransferases
as with N-linked glycosylation. The default pathway for glycoproteins (with N-
linked and/or O-linked glycosylation) lacking specific retention signals involves
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envelopment into membranous vesicles which transport the mature glycoproteins
from the Golgi to the plasma membrane (Stryer, 1995).
1.5.4 Influences on Presence and Form ofGlvcosvlation
There are a variety of factors that determine whether a protein becomes glycosylated
or not and the diversity of oligosaccharides attached to the same protein. Protein
sequence, as mentioned is key in directing the site of glycan attachment where the
specific N-linked glycosylation motif is required for N-linked glycosylation and
serine and threonine residues are required in a, as yet, less well defined context for
O-linked glycosylation. In addition, the accessibility of potential glycosylation sites
is an important factor and depends on protein conformation. Potential glycosylation
sites near the N terminus are more likely to be occupied, this is possibly due to the
fact that this end of the protein emerges into the ER first (Gavel & von Heijne,
1990). The transport rate of the protein through the ER and Golgi and the expression
and location of glycosyltransferases dictating which enzymes a growing sugar
encounters first is thought to be a factor. Also, different host cell types can produce
a specific protein with different glycosylation profiles. Studies of glycoproteins
produced in in vitro cell cultures have shown that the culture environment e.g.
presence of growth factors affecting glycosyltransferases, availability of sugars etc.
influences the extent of glycosylation (Jenkins & Curling, 1994). So too can the
growth rate of the cells i.e. activation state. The method of cell culture can affect
glycosylation and is exemplified by the different glycosylation profiles of
immunoglobulins produced in ascites tumours compared to hybridomas grown in
serum-based media (Patel et al., 1992). In this situation the content of the
oligosaccharides can vary with regard to different sugar residues incorporated which
appears to influence the half life of the antibodies when injected into animals
(Maiorella et al., 1993). This variability is of concern in the manufacture of vaccines















Figure 1.7. A. O-linked protein glycosylation. This begins in the Golgi
and is initiated by N-acetyl galactosamine transferase attaching a N-
acetylgalactosamine to serine and threonine residues of proteins. B. Core
structures; patterns of sugar units have been identified which are formed
following the attachment of the initial N-acetylgalactosamine to which
further sugars are added commonly in long chains, the four main core
structures are shown as an examples (Varki et al., 1999). C. An example
of an O-linked oligosaccharide.
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1.5.5 Function of Protein Bound Glvcans
The properties of a glycoprotein commonly influenced by protein bound glycans
include: solubility, stability, quarternary structure, activity, antigenicity and half-life
of the protein. Sugar groups can physically shield the protein they are bound to from
proteases. Glycans also contribute to directing intracellular traffic e.g. the
phosphorylation ofmannose early in the ER directs proteins to the lysosome (Dahms
& Kornfeld, 1989). The hormone P-human chorionic gonadotrophin (P-HCG)
exemplifies the importance of glycosylation for protein function, deglycosylated P-
HCG is able to bind to its receptor but fails to stimulate adenylate cyclase in contrast
to the glycosylated form. Glycosylation is necessary for proteolytic processing and
transport of the measle glycoprotein F (Sato et al., 1988). The F2 subunit has three
predicted N-linked glycosylation sites, mutation of any of these asparagines results in
decreased transport to the cell surface (Alkhatib et al., 1994b) and impaired
proteolytic cleavage, stability and fusion capacity presumably by altering the
conformation of F2 (Alkhatib et al., 1994a).
Fine tuning of the activity of growth factors has been attributed to the type and extent
of their glycosylation. N-CAM, the neural cell adhesion molecule mediates
homophilic binding between neuronal cells. During growth development the length
of polysialic acid chains commonly found at the outermost ends ofN- and O-linked
oligosaccharides decrease markedly. It is thought that these sugar chains are
involved in maintaining developmental plasticity by regulating intercellular
interactions of neuronal cells, the lengthy oligosaccharide chains physically
distancing the cells (Rutishauser et al., 1985, Rutishauser, 1998). The activities of
erythropoietin and plasminogen activator are modulated by the type of glycans
present (Takeuchi et al., 1989, Goldwasser et al., 1974, Wittwer & Howard, 1990).
Glycosylation can affect antigenicity, either masking antigenic sites or being part of
the epitope itself. Masking peptide epitopes with carbohydrates is a method
sometimes used by viruses such as HIV for immune evasion from neutralising
antibodies (Bosch et al., 1994). By forming a new glycosylation site the H3 of
influenza virus can escape monoclonal antibody recognition (Skehel et al., 1984).
Poor immunogenicity of the Ebola glycoprotein GP is thought to be due to the high
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level of glycosylation it has causing GP to be less antigenic (Feldmann et al., 1994,
Geyer et al., 1992). The N-linked glycan structure of the hormones lutropin, thyroid-
stimulating hormone and pro-opiomelanocortin controls their half life. A receptor
for sulfated GalNAc is located in the liver endothelium and rapidly removes these
hormones specifically bearing this glycan. An example where a glycan structure
functions to allow identification and clearance of a protein. Lymphocyte homing and
inflammatory responses involving leukocyte intravasion are regulated by glycans that
function as ligands for lectins. The selectin cell adhesion molecules provide an
example where oligosaccaharide modifications act as recognition molecules (Varki
et al., 1992).
1.5.6 Study of Glycosylation
There are a variety of methods to determine if a viral protein is glycosylated. A
preliminary indication that a protein is glycosylated is provided by the typical
appearance a glycoprotein has as diffuse bands in SDS-PAGE gels due to the
heterogeneity of each oligosaccharide present. The periodic acid-Schiff (PAS)
reaction enables the identification of glycoproteins in gels this employs the
susceptibility of glycans to periodate oxidation (Gerard, 1990). Enzymes such as
endoglycosidases and exoglycosylases can be employed to determine the presence
and extent of glycosylation. In practice, shifts in protein mobility may be seen in
SDS-PAGE gels following the treatment of glycoproteins with enzymes such as
endoglycosidase H (endo H), peptide-N-glycosidase F (PNGaseF) and
endoglycosidease F2 that cleave glycan groups. Specific enzymes can indicate not
only the presence of glycosylation but also the type and bonding of some sugar units
present e.g. neuraminidase from Arthobacter hydrolyses terminal a2,3-, a2,6- and
a.2,8- ketosidic bonds that join sialic acid residues to oligosaccharides.
Neuraminidase derived from Newcastle disease virus cleaves a2,3- and a.2,8- but not
a2,6- ketosidic bonds, of the two neuraminidases only the Arthobacter
neuraminidase altered the mobility of glycoprotein N of EBV, no further shift was
seen when O glycosidase was added, indicating that the majority of the sugars on the
molecule were a2,6-linked sialic acid residues (Lake et al., 1998). High mannose N-
linked oligosaccharides are specifically sensitive to endo H which gives an indication
48
CHAPTER I INTRODUCTION
of the maturity and/or localisation of a protein i.e. high mannose glycoproteins tend
to remain in the ER and nuclear regions and do not undergo processing to complex
N-linked glycans in the Golgi and localise to the plasma membrane. Changes in size
and antigenic conformation of a protein when produced in the presence of inhibitors
ofN-linked glycosylation such as tunicamycin is a tool used to identify glycoproteins
e.g. as used by Li et al., 1999 in analysis of the KSHV membrane glycoprotein K8.1.
Chemical treatments e.g. hydrogen fluoride, P-elimination (alkaline borohydride
treatment - under carefully controlled conditions cleaves only O-linked glycans) and
hydrazinolysis (Ashford, 1992), are available that effect complete removal ofN- and
O-linked oligosaccharides. Lectins, which are proteins that bind carbohydrates,
and glycan specific antibodies enable detection of oligosaccharide groups. Western
blots can be overlayed with lectin to identify glycoproteins. Metabolic radioactive
labelling using radioactive sugar precursors such as [3H] or [14C] labelled
glucosamine is another method to detect glycosylated proteins. Other strategies to
study glycoproteins include genetic manipulation of glycosylation i.e. site directed
mutagenesis of potential glycosylation sites. Cell free in vitro synthesis of proteins
and comparison with the native form can give indications about the contribution of
post translational modifications which do not occur in the cell free system e.g.
glycosylation to protein size, structure and function. Expression of the gene
encoding the protein in alternative hosts to mammalian cells such as yeast and
bacteria where glycosylation is different or does not occur also provides opportunity
to assess the extent and structural/functional importance of glycosylation to a protein.
1.5.7 Contribution ofOligosaccharides to Protein Function
Many proteins produced by recombinant DNA technology and/or following
expression in a heterologous host where they carry no or altered glycosylation do not
appear to be affected in their function. Human derived interferon gamma produced
in E. coli has full antiviral and antiproliferaive activity in vitro (Rinderknecht et al.,
1984). The exact nature of the carbohydrates added may not always be important, for
example baculovirus-expressed haemagglutinin glycoprotein of measles virus
functions in haemagglutination and fusion (Vialard et al., 1990). In the absence of
glycosylation glycoprotein D of herpes simplex virus is still able to function as a
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binding protein (Sodora et al., 199la & b). Some but not all N-linked glycosylation
of glycoprotein gpl20 of human immunodeficiency virus (HIV) is essential for virus
replication (Lee et al., 1993). The consequences of altered glycosylation are very
unpredictable and can range from no effect to complete loss of function. Absence of
glycosylation may have an indirect effect on function due to conformational changes
in the protein.
1.5.8 In Depth Analysis of Glycoprotein Structure
The study of the exact make up of attached oligosaccharides is difficult due to the
complex nature of their structure which commonly branch and have various
modifications made from the initial backbone attached in the ER. Mass spectrometry
(MS) and nuclear magnetic resonance (NMR) are used along with chromatography
based separation to analyse the sequence of oligosaccharides. Mass spectrometery
involves the determination of mass and composition by ionisation of the
oligosaccharide, the resulting particles are accelerated (put under vacuum) and
subject to a magnetic field, the different ions present are differentiated by their
different deflection patterns i.e. according to their mass to charge ratio. NMR is
based on the fact that electrons in a molecule shield the nucleus to some extent from
electromagnetic radiation causing different atoms to absorb at slightly different
frequencies.
The overall structure of a glycoprotein can be determined by X ray crystallography.
For this the protein must be soluble and readily crystallize, high concentrations of
protein are necessary. X-ray crystallography has been used extensively for
elucidation of the structure of the glycoprotein haemagglutinin of influenza (Weis et
al., 1990, Wiley et al., 1981, Wilson, 1981).
1.5.9 Study OfViral Glycoprotein Function
Following identification of a viral glycoprotein and basic structural analysis e.g.
confirming size, presence of glycosylation, localisation, time and level of expression
functional studies are often undertaken. Data from basic analysis of a glycoprotein
can provide initial insights into the potential role of a glycoprotein for example - if a
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glycoprotein is located on the virion membrane surface it may be involved directly in
initial infection of cells i.e. attachment and entry whereas a glycoprotein that is not
represented on the viral membrane but resides in the nuclear membrane and ER of
infected cells is likely to be involved in other processes such as virion formation.
The generation and isolation of mutant viruses that are unable to express a specific
glycoprotein is a common method used to elucidate the function of the glycoprotein
in virus replication. The principal method in the determination of the function of
HSV glycoproteins described in sections 1.6.9-1.7.1 has been the study of mutant
and recombinant viruses deficient in specific glycoproteins. In addition, binding
studies of the purified glycoprotein and the generation of recombinant viruses
expressing a foreign glycoprotein to see if the tropism of the virus is altered are done
to determine glycoprotein function. For the study of glycoproteins of particularly
hazardous viruses such as HIV and Ebola pseudotyped viruses have been employed
where for example vesicular stomatis virus (VSV) or Moloney leukemia virus are
engineered to express HIV and Ebola glycoproteins respectively (Pauza, 1991, Yang
et al., 1998). Expression of the glycoprotein of interest in cells independent of other
viral proteins can provide information on whether the glycoprotein requires other
viral proteins to localise and function correctly. The effect of antibodies against the
glycoprotein of interest on virus replication can provide indications of whether the
glycoprotein is involved in binding and/or entry of the virus into target cells.
1.6.1 Viral Membrane Proteins - Structural Classes
The majority of herpesvirus glycoproteins belong to the type I group of membrane
glycoproteins. Type I proteins have a single transmembrane spanning domain
usually comprised of 18-27 primarily hydrophobic amino acid residues, the bulk of
the protein is extracellular with a relatively small cytoplasmic region. The N
terminus of the protein is extracellular with a cytoplasmic carboxy terminus. Type II
viral membrane proteins are orientated in the opposite direction whereby the carboxy
terminus is extracellular, neuraminidase of influenza is a type II glycoprotein
(Varghese et al., 1988). Type III glycoproteins, such as gM of pseudorabies virus
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(Dijkstra et al., 1996) have multiple membrane spanning domains with both the
amino and carboxy terminus located in the cytoplasm. There are some exceptions
such as gL of HSV-1 which is entirely extracellular and is anchored to the virion
membrane by forming a complex with gH (Hutchinson et al., 1992).
1.6.2 Virus-Receptor Interactions
There are numerous examples of enveloped viruses that employ virally encoded
glycoproteins to bind to cellular receptors which facilitate virion attachment to host
cells. For some viruses a single membrane glycoprotein protein is responsible for
both receptor binding and membrane fusion e.g. rhabdoviruses, whereas others such
as the herpesviruses express multiple different glycoproteins to effect cell entry.
1.6.3 Influenza - Haemagglutinin
The glycoprotein of influenza called haemagglutinin (HA) has been studied in great
depth and provides a good example of common glycoprotein roles; functioning in
attachment and fusion. HA facilitates the attachment of influenza to cells by binding
sialic acid residues linked to cellular membrane proteins. HA is a type I integral
membrane glycoprotein it has an ectodomain of 512 amino acids, a transmembrane
domain of 27 amino acids, and a 10 amino acid cytoplasmic tail (Verhoeyen et al.,
1980) which forms a homotrimer of non-covalently linked monomers (Wiley &
Skehel, 1977 & 1987, Wilson et al., 1981). X ray crystallography has been used to
determine the 3D structure of the HA trimer (Weis et al., 1990, Wiley et al., 1981,
Wilson et al., 1981). The three repeated HA monomers form a rod like structure
with a knob at the end which protrudes from the viral membrane. Alpha helices form
the spike and the knob is mainly composed of beta sheets. The haemagglutinin has
three sialic acid binding sites at the knob region. The interaction between influenza
HA and sialic acid is considered weak but stable virus attachment is enabled due to
the multiple number of interactions. HA mediates fusion of the membrane of the
endocytosed virus particles with the endosomal membrane.
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HA is a good example where structure of a glycoprotein is closely linked with
function. Three distinct forms of haemagglutinin have been identified. The HAO
form, as it is known, is as the molecule exists on the surface of the virus prior to
infection. The HA form ready for fusion results from protease cleavage at a site near
the base of the spike at a particular arginine residue. The cleavage results in two
polypeptide chains - HAi(47kDa) and HA2 (29kDa) that are linked by a disulphide
bond. Cleavage is essential for infectivity and is directed by the existence of a
specific cleavage signal of about 16 amino acids near the extracellular base of the
HA protein. The third form of haemagglutinin, fusogenic HA, occurs at acidic pH i.e.
approximately pH 5 (Stegmann et al., 1987). The transition of the glycoprotein to the
fusogenic form is produced by a conformational change in the protein that exposes
previously concealed amino acid domains - fusion peptides. The influenza
haemagglutinin has an uncharged fusion peptide sequence ofwhich other viral fusion
glycoproteins have analogous peptides e.g. those of Sendai virus, respiratory
syncytial virus (RSV), HIV gp41 and the Ebola glycoprotein (Lamb et al., 1999).
1.6.4 Influenza - Neuraminidase
Influenza also encodes a second virion membrane glycoprotein called neuraminidase.
Neuraminidase (NA) is a homotetrameric glycoprotein(~220kDa) composed of four
453 amino acid proteins with cytoplasmic N termini (class II membrane proteins).
NA functions to remove sialic acid from the surface of cells (catalysing the cleavage
of the aketosidic linkage between the sialic acid and an adjacent D-galactose or D-
galactosamine) (Palese et al., 1974). By electron microscopy the complex appears
mushroom shaped with a stalk and head. The tetrameric complex of neuraminidase
has four active sites located at the head of the mushroom structure (Lentz et al.,
1987, Colman et al., 1983). In addition to influenza, HIV, Ebola, Sendai virus also
have glycoproteins that function to cleave receptors on the cell surface on the way




1.6.5 HIV - Env Proteins Interaction with CD4 & Coreceptors
For retroviruses the best studied virus-receptor interaction is that of HIV with the T
cell surface molecule CD4. CD4 is a member of the immunoglobulin superfamily
which functions as a coreceptor in the antigen and class II MHC-dependent
interactions that initiates T cell activation, it is also expressed on macrophages,
monocytes and dendritic cells. HIV has two envelope glycoproteins gp41 and gpl20
which are formed by the cleavage (performed by a cellular protease) of a precursor
called gpl60. Gpl20 binds to CD4 on the target cell surface to initiate infection, it is
a good example of a glycoprotein determining viral tropism (Dalgleish et al., 1984,
McDougal et al., 1991). Distinct but overlapping binding sites on gpl20 have been
identified for macrophages and T cells (Shioda et al., 1991). Gpl20 has five loops
formed by disulphide bonds of highly variable domains called V1-V5. The V3 loop
domain governs several properties of the virus i.e. cell tropism and cell entry
efficiency. Variations in the V3 loop correlate with differences of tropism of HIV
isolates for macrophages and T cells (Fouchier et al., 1992, Ebenbichler et al., 1993,
Milich et al., 1993, Shioda et al., 1992).
The gpl20-CD4 interaction results in a conformational change of gp41 exposing it's
hydrophobic domains, required for membrane fusion, to the cell surface. Fusion of
the viral and plasma membrane follows in a pH independent manner. CD4 has been
identified as the receptor for HIV however in addition HIV requires a coreceptor for
entry into target cells. Two main coreceptors have been identified for HIV which are
G protein coupled receptors (GCRs) the chemokine receptors CXCR4 and CCR5.
Coexpression of the a-chemokine receptor CXCR4 or the P-chemokine receptor
CCR5 with CD4 confer susceptibility of cells to T cell tropic HIV or macrophage
tropic HIV respectively (Feng et al., 1996, Deng et al., 1996). There is an increasing
number of chemokine receptors being identified that are able to act as coreceptors for
retroviruses most of which are seven transmembrane spanning GCRs (Deng et al.,
1997, Owen et al. 1998, Doranz et al., 1996). Gp41 is thought to be analogous to




Viruses of the paramyxovirus family, including Sendai virus and measles, in general
have two virion envelope glycoproteins - haemmagglutinin (H) and a fusion protein
(F). In some cases the haemagglutinin also displays neuraminidiase activity. H
appears to have an analogous binding function to that of influenza HA. The measles
H is a homodimer (Sato et al., 1995) that has been shown to bind to CD46 (Dorig et
al., 1993, Naniche et al., 1993). CD46 is a complement-regulatory protein widely
distributed throughout human tissue which normally binds complement components
C3b and C4b and acts as a cofactor in the proteolytic inactivation of C3b/C4b by
factor I (Liszewski et al., 1991).
Glycoprotein F is formed by the cleavage of a precursor Fo (60 kDA) into two
subunits Fi(41kDa) and F2 (18kDa) these are linked by a disulphide bond. (Dorig et
al., 1993, Naniche et al., 1993). The new amino terminus of F1 has a stretch of
hydrophobic amino acid residues and it is thought that this may play and important
role in fusion (Richardson et al., 1986, Richardson et al., 1983, Richardson et al.,
1980).
1.6.7 Filovirus Glycoprotein - GP
Ebola and Marburg, enveloped negative ssRNA filoviruses which cause highly lethal
haemorrhagic disease in humans, have a sole glycoprotein that in a homotrimeric
fashion forms spikes which protrude from the virus membrane (Elliot et al., 1985).
The glycoprotein known as GP exists in two forms - a transmembrane form of 120-
170 kDa (Will et al., 1992) and a secreted form (SGP) of 60kDa. GP is a type I
transmembrane glycoprotein that mediates viral entry (Sanchez et al., 1996). GP
binds to endothelial cells and is thought to determine the tropism of Ebola for
vascular endothelial cells (Yang et al., 1998). The SGP is thought to have an
immune mediated role, it may inhibit early neutrophil activation and possibly
diminish any inflammatory response that might provide innate immunity to the virus.
This is based on evidence that Ebola SGP has been shown to interact with
neutrophils by binding CD 16b which is the neutrophil-specific form of the Fc
gamma receptor III (Yang et al., 1998). GP is encoded by two ORFs, the primary
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gene product is SGP and GP is expressed following transcriptional editing or
translational frame shifting (Sanchez et al., 1996). GP is highly glycosylated, N and
O-linked glycosylation accounting for 1/3 to Vi of the GP mass (Feldmann et al.,
1994, Feldmann et al., 1991).
1.6.8 Glycoproteins of HSV
Of the herpesviruses the glycoproteins of HSV-1 have been the most extensively
studied. HSV-1 is known to code for at least eleven glycoproteins, gB, gC, gD, gE,
gG, gH, gl, gK, gL, gM and gN (these are the abbreviated names i.e. g stands for
glycoprotein) (Roizman & Sears, 1996). Four of which, gB, gH, gL, and gM, are
considered core herpesvirus genes, with all sequenced herpesviruses containing
homologous genes (Gompels et al., 1995, Russo et al., 1996, Virgin et al., 1997). gB,
gH, gL, gD and gK are essential for propagation of HSV-1 in vitro (Cai et al., 1988,
Roizman & Sears, 1996). Glycoproteins that are dispensable for in vitro replication
ofHSV may be very important in vivo, gG has been implicated in virus replication of
the CNS (Weber et al., 1987) and gE-gl form a hetero-oligomer Fc receptor that may
act to shield virus infected cells from the host immune response (Johnson &
Feenstra, 1987, Johnson et al., 1988, Balan et al., 1994)
1.6.9 Attachment of HSV
For HSV-1, work suggests that cell receptors for viral entry may be highly conserved
or are multiple in number as many different cell types from different species are
susceptible to infection in vitro. However, cells vary in their susceptibility to HSV
infection. The sequential steps of HSV infection and glycoproteins involved in
attachment and entry of target cells have been intensely studied. Initial attachment of
herpes simplex viruses is mediated by gB (predominantly for HSV-2) or gC
(predominantly for HSV-1) or both, these have been shown to attach to cell surface
proteoglycans, namely the ubiquitous heparan sulphate (HS) (Cai et al., 1988,
Wudunn & Spear 1989, Spear et al., 1992, Shieh et al., 1992, Trybala et al., 1993,
Laquerre et al., 1998)
56
CHAPTER 1 INTRODUCTION
Glycoprotein B exists as a homodimer and is located on the virion surface (Claesson-
Welsh & Spear, 1986). Glycoprotein B negative viruses can bind to but are unable to
penetrate cells (Manservigi et al., 1977, Sarmiento et al., 1979, Sarmiento & Spear
1979). Considered the most conserved herpesvirus glycoprotein the sequence of gB
from a herpesvirus is often analysed to determine how closely the virus is related to
other herpesviruses (Auerbach et al., 2000).
Glycoprotein C also binds heparan sulphate but unlike gB it is dispensible for in vitro
replication of HSV-1 (Herold et al., 1991). Glycoprotein C also has an immune
modulatory role, it has been shown to bind the complement component 3b and
accelerate the decay of C3bBb and in vivo acts to mediate HSV evasion of
complement attack (Fries et al., 1986, Friedman et al., 1984, Lubinski et al., 1998 )
Glycoprotein D and gH-gL also have roles in attachment/entry into the cell (Ligas &
Johnson, 1988, Turner et al., 1998). The interaction with HS is labile until other
glycoproteins such as gD begin to participate in the entry process. By studying
insertion and deletion protein variants four functional regions (I to IV) have been
defined for gD that are important for virus entry (Chiang et al., 1994, Muggeridge et
al., 1990, Rux et al., 1998). Glycoprotein D provides a stable attachment to cells and
has been shown to bind to several different cellular receptors which have been
termed herpesvirus entry mediators (Hve) and include HveA, HveB and HveC
(Whitbeck et al., 1997, Willis et al., 1998, Rux et al., 1998). HveA (formerly
HVEM) is a novel member of the tumour necrosis factor/nerve growth factor
(TNF/NGF) receptor family, initially identified by screening a human cDNA library
for genes that could mediate HSV-1 entry into resistant cells. It is found
predominantly on T cells and other cells of the immune system (Montgomery et al.,
1996,Whitbeck et al., 1997). HSV can bind to but not enter cells negative for HveA
(Montgomery et al., 1996). HveC and B are poliovirus receptor related proteins
(previously named PRR1 and PRR2 respectively) belonging to the immunoglobulin
superfamily. Glycoprotein D binding to HveC is dependent on the native
conformation of gD but independent of it's N-linked glycosylation (Whitbeck et al.,
1997). Complex formation between soluble gD and HveC appears to involve one or
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two gD molecules for one HveC protein. (Krummenacher et al., 1998). In summary,
HSV entry can be mediated by two structurally unrelated types of gD receptors
through related but not identical binding to gD i.e. different domains of gD are
involved for binding members of the immunoglobulin superfamily compared to the
novel TNF/NGF receptor (Krummenacher et al., 1998). GD is essential for HSV
entry, gD negative mutants can bind but are unable to penetrate target cells (Ligas &
Johnson, 1988).
HveB, HveC and the 'herpesvirus Ig-like receptor' (HIgR), a splice variant of HveC,
are likely to be employed by HSV-1 and -2 for entry into the human cell lines most
frequently used in HSV studies (Cocchi et al., 1998a). The use of these proteins in
vivo by HSV seems likely as a relatively high level of expression of these
immunoglobulin superfamily members was detected in human tissue samples from
the nervous system (Cocchi et al., 1998b).
1.7.1 HSV Post Attachment/Entry
Post attachment, the gH-gL complex facilitates pH independent fusion of the virion
envelope to either the plasma membrane directly or the membrane of virus
containing internalised vesicle, allowing entry of the virus into the cytoplasm of the
cell (Forrester et al., 1992, Hutchinson et al., 1992). A notable characteristic of
HSV-1 gH is that it requires the presence of gL to be processed correctly and locate
to the plasma and virion membrane (Hutchinson et al., 1992, Roop et al., 1993). GL
may affect the processing of gH by masking N-glycans as suggested from evidence
from gH of pseudorabies, although gH localises to the virion membrane in the
absence of gL the N-glycans on the pseudorabies gH are processed to a greater extent
than in the presence of gL (Klupp et al., 1997).
As described, the process of HSV attachment and entry occurs via multiple
glycoproteins some of which form associations with each other and can exist in
different oligomeric forms e.g. dimers and trimers of gD have been identified
(Handler et al., 1996). Individual glycoproteins function at distinct and different
points in entry in a sequential, cascade-like mechanism (Fuller & Lee, 1992). The
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lack of a single glycoprotein-cell surface receptor interaction reflects the normal life
cycle ofHSV where, in principal, it infects 2 different cell types - epithelial cells and
neurons.
Following entry, uncoating occurs and the virus genome migrates to the cell nucleus.
Late viral gene expression results in the production of viral glycoproteins which
localise to the nuclear membrane. Virion formation and egress is thought to occur as
described in section 1.1.6. Unlike some glycoproteins that are not required for the
production of enveloped virus particles but are critical for virion infectivity (e.g. GD
and GB), gK is not present in the virion but is essential for assembly and egress of
infectious virus (Hutchinson & Johnson, 1995, Jayachandra et al., 1997). GK has
immature N-linked glycans and locates to the nuclear and perinuclear membranes
(Hutchinson & Johnson, 1995). GK is thought to indirectly regulate the fusion of
infected cells (gK negative viruses cause extensive fusion of infected cells in culture)
(Hutchinson & Johnson, 1995).
1.7.2 Glycoproteins of Epstein-Barr Virus
EBV contains homologues for gB (gpl 10), gL (gp25), gH (gp85), gM and gN (Gong
et al., 1987, Heineman et al., 1988, Lake et al., 1998). The roles of these have been
studied to varying extents. Further glycoproteins expressed by EBV include gp42
(BZLF2), gp340/220 and gpl50 (BDLF3).
1.7.3 EBV Gp340/220
Of great interest is the unique glycoprotein gp340/220 possessed by EBV, the most
abundant protein present on the surface of virions and a major neutralising
determinant. Gp340/220 is also known as gp350/220 due to a difference in the
interpretation of the resolving size of the protein observed by SDS-PAGE (i.e
lOkDa). Gp340/220 can be identified as two forms either the full protein with a
molecular weight of 340, 000 or a smaller version of 220,000 produced from a
spliced transcript from the gp340/220 encoding gene (Beisel et al., 1985). O-linked
and N-linked types of glycosylation constitute about 50% of the molecular mass of
gp340/220 (Morgan et al., 1984b). A limited region of gp340/220 has distant
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homology to HSV-1 gC (Beisel et al. 1985) however gp340/220 appears to be unique
to EBV. Gp340/220 facilitates attachment to B cells via binding the complement
receptor CD21 (also known as CR2/C3dg receptor) (Nemerow et al., 1987). A
nonapeptide located at the N-terminal region of gp340/220 has been identified that
corresponds to a similar amino acid sequence in the complement C3dg protein, this
mediates the binding to CD21 (Nemerow et al., 1989). Gp340/220 may also have
an immune modulatory role by promoting Fas mediated T cell apoptosis (Tanner &
Alfieri, 1999). In addition to facilitating virus attachment to cells the interaction of
gp340/220 to CD21 may lead to the activation of a signal transduction pathway
resulting in increased CD19 tyrosine phosphorylation level which may ultimately
enable efficient expression of viral genes following infection (Nemerrow et al., 1989,
Sinclair et al., 1994). With respect to entry, the cross linking of CD21 by binding
gp340/220 can result in capping (Tanner et al, 1987) after which the gH-gL complex
is thought to induce fusion of the virion envelope to the vesicle membrane (Miller &
Hutt-Fletcher, 1988). Direct fusion of EBV with the cell membrane of B
lymphoblastoid cells has been observed as opposed to uptake into and fusion with a
vesicle membrane seen with normal B lymphocytes (Nemerow & Cooper, 1984).
Besides the direct association with a cellular receptor, EBV can gain access to cells
as a complex with IgA and it has been suggested that this may be how EBV spreads
to epithelial cells (Sixbey & Yao, 1992).
1.7.4 EBV Post Attachment/Entry Facilitating Glycoproteins
As is the case for gH of HSV, gL of EBV (also known as gp25) is required to enable
plasma localisation of EBV gFI (also known as gp85) and together they form a
complex involved in virus penetration. (Yaswen et al., 1993). Gp42 has been shown
to complex with gH-gL and is essential for fusion but not absorbtion of EBV to B
lymphocytes (Wang & Hutt-Fletcher, 1998). The extracellular domain of gp42 binds
the HLA-DR beta chain (MHCII) and can inhibit antigen presentation (Spriggs et al.,
1996). A model has been devised where two different types of complex mediate
EBV infection of epithelial cells and B cells i.e. gH-gL can enable infection of
epithelial cells and gH-gL plus gp42 is required for infection of B cells (Wang et al.,
1998, Li et al., 1995). Gp42 is poorly conserved with no predicted homologue in any
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other human herpesvirus (Li et al., 1995), however there is a homologue in ORF51
of EHV-2 (Telford et al., 1995) and there may be a functionally similar protein in
HCMV (Huber & Compton, 1997, Li et al, 1997).
GM appears to have a role in penetration but is not essential for EBY replication
(Lake et al., 1998). GM is predicted to be a highly hydrophobic type 3 membrane
protein with 8 putative transmembrane domains (Baer et al., 1984) as are all studied
herpesvirus gM homologues i.e. pseudorabies virus, HSV-1, HCMV, EHV1
(Dijkstra et al., 1996, Baines & Roizman, 1993, Lehner et al., 1989, Osterreider et al.,
1996). Similar to the scenario for gH and gL, the presence of gM is required for
authentic processing of gN a small (15kDa) type I membrane protein (Lake et al.,
1998). GN and gM can be detected in the plasma membrane on infected cells,
although their presence has not been shown on the virion membrane they are likely
to be present. The role of gM and GN has not been fully elucidated. The function of
EBV gpl50 (BDLF3) is unknown, a gpl50 negative virus had no detectable
replication defect in vitro (Borza & Hutt-Fletcher, 1998).
1.7.5 EBV gB
Unlike HSV-1 gB, EBV gB is not present on the viral surface and plays no role in
attachment or entry (Gong & Kieff, 1990). However, gB is essential for productive
infection of cells (Herrold et al., 1996, Lee & Longnecker, 1997). This is
reminiscent of HSV-1 gK, which is also an essential gene but is not a virion
component (Hutchinson & Johnson, 1995). GpllO is detained in the ER, has N-
linked glycosylation of the pre-golgi, high mannose type and localises to the nuclear
membrane (Gong & Kieff, 1990, Papworth et al., 1997, Lee, 1999). GB of KSHV
has been shown to have a similar localisation pattern to gB of EBV, demonstrating
the close relationship of these viruses, however there is not sufficient functional
homology to allow efficient complementation of an EBV mutant lacking gB with gB
of KSHV (Pertel et al., 1998). Localisation of gB homologues at the nuclear
membrane, from where herpesviruses bud, suggests they may be involved in the
egress of the virus from the nucleus.
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1.7.6 Glycoproteins of MHV-68
From the genetic analysis of MHV-68 homologues for the genes encoding the four
glycoproteins gB, gH, gL and gM have been identified (Virgin et al., 1997). Of
these only gB has been characterised for MHV-68. Investigation into the nature of
the MHV-68 gB was considered important as it provides a good reflection on the
similarity of MHV-68 with gammaherpesviruses such as EBV. Gpl 10 of EBV is
unusual compared to the HSV gB prototype (Gong & Kieff, 1990). The gene
encoding gB ofMHV-68 is located to the left end of the genome (ORF 8) similar to
the position of gl 10 in EBV (BALF4). MHV-68 gB has 42%, 49% and 26% codon
identity with gB of EBV, HVS and HSV-1 respectively. As with gpl 10 and gB of
KSHV, gB of MHV-68 has N-linked glycosylation of the high mannose type, is
retained in the ER; localising to the nuclear membrane and is not detected in mature
virions (Stewart et al., 1994a).
1.7.7 MHV-68 Glycoprotein 150 (gp!501
Glycoprotein 150 (gpl50) is the only other MHV-68 glycoprotein to have been
characterised, selected for study as a potential homologue of gp340/220 of EBV.
Like gp340/220, the gene encoding gpl50 is in a central genomic position.
Comparison of FASTA1 scores of positionally analogous glycoprotein amino acid
sequences for other gammaherpesviruses, relative to 2,087 ofMHV-68 showed only
gp340/220 to have significant homology (FASTA score 278). Gpl50 has 25%
identity and 40% similarity at the amino acid level with gp340. The gene encoding
gpl50, M7, is not spliced and the predicted protein consists of 483 amino acids.
Gpl50 is a type one transmembrane glycoprotein with a long hydrophilic domain
flanked by a hydrophobic signal peptidase cleavage site at the amino terminus and a
hydrophobic transmembrane domain near the carboxy terminus (refer to figure 1.8).
Gpl 50 has a high content of serine and threonine (24%) and there are three potential
sites for N-linked glycosylation, only one ofwhich appears to be used (deduced from
enzymatic digestion analysis, plus two of the potential sites contain a proline).
Gpl50 has an unusually high proline content (23%) predominantly contained in a
1 FASTA is an option of the UW GCG package which allows comparisons of protein sequences (Devereux et al., 1984)
62
CHAPTER 1 INTRODUCTION
domain of proline rich repeats, 22 amino acids in length. This repeat region is
similar to a domain of gp340/220, and is thought to effect the large apparent
molecular weight of 150,000, observed for gpl50 on SDS-PAGE gels (the predicted
molecular weight of the core unglycosylated protein is 48,000). A precursor to
gpl50, with a molecular weight (MW) of 130,000 and high mannose N-linked
glycans, is formed but only the mature 150,000 MW gpl50 is expressed on the
surface of infected cells and virion particles. An additional minor unglycosylated
protein with a MW of 110,000 can be identified on blots probed for gpl50, it is not a
precursor of gpl50 and is thought to arise from a downstream translational initiation
site in the gpl50 mRNA. Antibodies to gpl50 have been reported to neutralise
MHV-68 infection in vitro in the absence of complement (Stewart et al., 1996).
Similarly antibodies to Gp340/220 neutralise EBV infection in vitro. Gp340/220
determines the B cell specificity of EBV through binding CD21, predominantly a B
cell marker and complement receptor (Nemerow et al., 1989). It is thought that
gpl50 could have a similar function to gp340/220 i.e. in facilitating virus binding to
cells, possibly determining the B cell specificity of MHV-68, however gpl50 does
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CCAGCTGACCCTTCAACCCCAGAGTCAACACCCCCCGCGGATCCCCCAGCTCCTCAACCA
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GCTGGACCTGGAGCCGAAACAGAGACGCCAGATGGGGATACCACCACTCAACCAGCATCC
70720 + + + + + + 70779
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CCCCAGACTACAGCGCCCATGCACCCCGTTCCAGACATTTCTACCCTGCTTTGGATACGA
70780 + + + + + + 70839
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CCCACGATCGCCATAATATTGATATTTCTCCTTATGACTATCTTTCATATCATGTACTGT
70840 + + + + + + 70899
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70900 + + + + -70931
V C L H E stop
B.





Signal peptide . ,& ' 1 repeat region transmembrane
domain
Figure 1.8. A. The sequence of the MHV-68 open reading frame 51 encoding
gpl50. The DNA sequence is numbered according to the complete MHV-68
genome numbering described by Virgin et al., 1997. The end of the sequence
represents the end of the cDNA obtained by RT-PCR (Stewart et al., 1996). The
predicted amino acid sequence is shown below the DNA sequence. The sites of
consensus promoter and polyadenylation signal sequences upstream and downstream
of the ORF (boldface and underlined), the extent of the two hydrophobic domains
(highlighted in yellow), the sites of potential N-linked glycosylation (bold face and
marked with an asterix), and the extent of a proline-rich 22-amino-acid repeat unit
(highlighted in grey) are indicated (adapted from Stewart et al., 1996). The location
of the Acc\ restriction enzyme sites are shown and the consensus polyadenylation
signal for ORF50 is marked by the dotted line above the nucleic acid sequence. B. A
schematic representation of the gpl50 encoding gene, lollipop symbols represent
potential sites ofN-linked glycosylation.
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1.7.8 KSHV K8.1
KSHV encodes K8.1 which has the same genetic locus and orientation as gpl50 and
gp340/220 of MHV-68 and EBV respectively (Raab et al., 1998). K8.1 is spliced,
encodes a glycoprotein of 228 amino acids (201 amino acids when mature after
cleavage of the signal sequence), that resolves at the relatively small size of 37kDa.
A transcript encoding a smaller 167 amino acid product designated K8.1.B, derived
from ORF K8.1, has been identified that shares similar amino and carboxyl termini
with ORF K8.1 but with an in-frame deletion (Chandran et al., 1998). K8.1 is
similar to gpl50 being a type I transmembrane glycoprotein with 4 potential N linked
glycosylation sites and a high content of serine and threonine residues (21%). Like
gpl50 and gp340/220, K8.1 localises to the surface of virions and infected cells
(Chandran et al., 1998, Li et al., 1999). Antibodies to K8.1 are detected regularly in
individuals with KS and have the potential to be used as contributory serological
markers (e.g. together with anti-latency-associated nuclear antigen (LANA)
antibodies) for infection by KSHV (Li et al., 1999, Zhu et al., 1999). Studies into
the function of K8.1 and whether antibodies against K8.1 are neutralising have not
yet been published however it is very possible that K8.1 shares a similar role to
gpl50.
As yet, other than K8.1, limited attention has been directed to the glycoproteins of
KSHV which include the conserved herpesvirus glycoproteins. Like gpllO of EBV,
gB encoded by KSHV has been shown to lack Golgi processing and localise to the
endoplasmic reticulum and nuclear membrane. Although gB of KSHV can interact
with EBV gpllO there is not sufficient functional homology to enable efficient
complementation of gpl 10 negative EBV mutants (Pertel et al., 1998).
1.7.9 Immune Response to Glycoproteins
For most enveloped viruses antibodies against one or more of the membrane
glycoproteins neutralises infectivity. Neutralisation of infection can occur by
physically inhibiting virus attachment to cells or at a further entry step of infection
(i.e. post attachment) depending on the function and location of the recognised
glycoprotein. Glycoprotein specific antibodies can reduce virus infectivity by
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aggregating virus particles and target virions for phagocytosis and complement
induced destruction. In addition these antibodies can identify productively infected
cells, expressing viral glycoproteins, for destruction by antibody dependent cellular
cytotoxicity and complement lysis. The significant response and protective effects of
antibodies against viral glycoproteins have been demonstrated for a wide range of
viruses e.g. antibodies to the envelope glycoprotein of rabies (Rhabdovirus) blocked
infection in vitro and in vivo prevented rats from undergoing lethal disease,
(Dietzschold et al., 1992). Monoclonal antibodies to the H glycoprotein of measles
exerted a therapeutic effect in virus infected cells in culture (Schneider-Schaulies et
al., 1992). Antibodies against glycoproteins of respiratory syncytial virus (RSV)
administered parenterally or direct to the lungs in cotton rats had a therapeutic effect
against RSV infection (Crowe et al., 1994, Crowe et al., 1998). Antibodies against
HA and NA are associated with resistance to influenza infection (Clements et al.,
1986, Couch & Kasel, 1983). Essentially all of the neutralising antibody activity to
HIV-1 in infected hosts is directed against the envelope glycoproteins gpl20 and
gp41. B and T cell responses are directed to the V3 loop of gpl20 (Parker et al.,
1988, Robert-Guroff et al., 1994, Takahashi et al., 1988, Carrow et al., 1991, Emini
et al., 1992, Javaherian et al., 1989). Single amino acid substitutions in gpl20 within
the V3 region have been identified which confer the resistance of immune escape
mutants of HIV-1 to neutralising antiserum (Watkins et al., 1993). The
glycoproteins of HSV are highly immunogenic, gD and gB are particularly effective
at inducing neutralising antibodies (Blacklaws et al., 1990). In animal models the
levels of neutralising antibodies against glycoproteins gB and gD of HSV have been
shown to correlate with the degree of protection (Meignier et al., 1987, Stanberry et
al., 1987).
Although much emphasis is placed on the ability of glycoproteins to generate
neutralising antibodies glycoproteins are also recognised by T cells and glycoprotein
specific CTLs can effect protection against virus infections. For example, in
experimental guinea pigs protection from Ebola virus infection has been achieved by
immunisation with plasmids encoding GP and SGP prior to challenge (Xu et al.,
1998). The antibody response was weak and non-neutralising and it appears that
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cytotoxic T cells to epitopes of GP played an important role in control of virus
infection.
1.8.1 Viral Vaccines Based on Glycoproteins
Among the varying strategies for vaccination, glycoproteins have received much
attention as potential vaccine immunogens for a wide range of viruses. Glycoprotein
based vaccines can take many forms including - purified native protein, recombinant
proteins expressed independently of other viral components, protein subunit
vaccines, glycoproteins combined into immune stimulating complexes (ISCOMs)
and liposomes, peptide epitope vaccines, recombinant viral vectors (incorporation of
the glycoprotein encoding gene into viral vector such as vaccinia virus) and DNA
vaccines (the glycoprotein encoding gene is introduced directly into an individual to
be expressed by recipients own cells). The different vaccine forms have their
inherent advantages and disadvantages. Currently there is no licensed vaccine
available for human use based on a glycoprotein however, viral glycoproteins are the
focus ofmuch research and have the potential to emerge in the future.
For HSV gD and gB have been manipulated and tested in a number of vaccine forms
e.g. a gD vaccinia recombinant (Straus et al., 1994, Straus et al., 1993), GD and GB
have been formed into a protein subunit vaccine (Straus et al., 1997) and a gD DNA
vaccine has been developed (Kriesel et al., 1996). The success of these have been
limited and is thought to reflect their restricted immunogenicity. GB of CMV is the
major surface antigen and important target of neutralising antibodies (Britt et al.,
1988) and cellular immune responses. A subunit vaccine consisting of gB coupled
with a lipid emulsion adjuvant induced high titres of CMV specific neutralising
antibodies and is a serious candidate for human clinical trials (Pass et al., 1995).
Expression of CMV gB in canarypox was achieved in order to improve CTL
responses to gB (Gonczol et al., 1995). DNA vaccination of glycoprotein genes of
pseudorabies virus have been tested for protection against pseudorabiesvirus
infection in pigs (Haagmans et al., 1999). Table 1.4 provides a very limited number
of examples of different experimental viral vaccines that have been developed based
on glycoproteins. The vaccine forms generated and potential of gp340/220 as an
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immunogen to provide protection against EBV infection are discussed in sections
1.8.7-1.8.9.
As well as glycoproteins being the direct object of a vaccination strategy -
generation of attenuated viruses for vaccination has been approached by making
viruses deficient in a glycoprotein known to be important for virus replication and
virulence - for example a gH HSV deletion mutant (Boursnell et al., 1997).
When selected for use as an immunogen the amount of variation of a glycoprotein
between isolates of a virus must be appreciated. Fortunately, herpesvirus
glycoproteins are very stable between isolates in comparison to glycoproteins such as
gpl20 of HIV and haemagglutinin of influenza. The antigenic variation of the
influenza HA is the basis of the emergence of 'flu epidemics and pandemics.
Virus Immunogen Vaccine Form Reference
HIV Gpl60 DNA vaccine Kaneko et al., 2000
HSV gB & gD Protein subunit Straus et al., 1997
HSV gD DNA vaccine Manickan et al., 1995
Pseudorabies virus gD DNA vaccine Haagmans et al., 1999
EBV Gp340/220 Vaccinia recombinant Mackett et al., 1996
EHV-1 gc DNA vaccine &
Vaccinia recombinant
Huemer et al., 2000
CMV gB Protein subunit Pass et al., 1995 & 1999
CMV gB DNA vaccine Endresz et al., 1999





Babai et al., 1999
RSV Glycoprotein G Synthetic peptide Trudel et al., 1991
Table 1.4. Examples of experimental viral vaccines based on glycoproteins.
1.8.2 EBV Vaccine Development
When considering vaccine development the beneficial potential to human health has
to be evaluated. With this in mind, there are currently three main areas where a
vaccine against EBV could make a significant impact these include the prevention of
infectious mononucleosis, eBL and NPC. In western societies the focus is on
combating IM, although perhaps less worthy, this is likely to be the most
commercially attractive target being a problem of more financially buoyant
countries. IM has been reported to be the second most frequent disease in
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adolescents in the US (Wedderburn et al., 1984), and although death is a rare
outcome, IM can be fatal (Bailey, 1994). The prevention of endemic Burkitt's
lymphoma in Africa and Papua New Guinea has long been goal however the lack of
profitability has impeded progress. Populations with a high risk of NPC would
greatly benefit from an effective vaccine against NPC, small human trials testing an
EBV vaccine have been done in China (Gu et al., 1995).
1.8.3 Potential EBV Vaccine Beneficiaries
EBV naive individuals
The question of who would benefit from receiving a vaccine against EBV must take
into consideration that currently 95% of the world human population is EBV
positive. Young children, naive to EBV are obvious candidates to be vaccinated
against EBV in an effort to prevent primary infection and so avoid IM, NPC and
eBL. Lifelong protection may not be achieved but a delay in EBV infection would
possibly limit the potential development of NPC by enabling the individual to
contain reactivating virus more efficiently. To prevent eBL ideally a vaccine would
prevent establishment of latency in lymphocytes. If total protection is not possible,
reducing the pool of latently infected B cells may reduce the incidence of BL.
Reduction of lytic replication during primary EBV infection may subsequently result
in less latently infected B cells. Infectious mononucleosis may be avoided or
delayed in individuals primed against EBV able to limit the proliferation of virus
carrying B cells. In summary, if a vaccine that is completely effective at preventing
EBV infection is unlikely the next best scenario is a vaccine that would reduce the
pool of latently-infected B cells, the ability of EBV to reactivate and so the
development ofEBV clinical disorders.
EB V infected individuals
Vaccinating individuals that are already infected with EBV offers potential benefits,
this approach may positively modify the immune response to EBV limiting the
development of late complications of EBV infection. In NPC a marker prior to
disease development is the presence of serum IgA antibodies to lytic antigens of
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EBV (Zeng et al., 1985). It has been suggested that excessive replication of EBV
may be part of the process of NPC occurrence. A vaccine that modified the
individuals immune response in a way that would subdue EBV lytic replication could
possibly prevent NPC from developing. In China NPC commonly occurs in adults of
about 40 years of age and may be due to a waning immunity to EBV. A vaccine that
boosted the immunity of an individual already infected with EBV to lytic EBV
antigens may help to maintain life long immunity against EBV reactivation. An
alternative vaccine that targets EBV latent antigens could stimulate cell mediated
immunity to eliminate infected B cells post primary infection and reduce the pool of
potential reactivatable and eBL cells.
Individuals with EB V associated disease
Therapeutic vaccination is another possibility i.e. an EBV vaccine administered to
individuals actually presenting with EBV positive neoplasms would aim to
specifically target the immune response to the tumours via EBV antigens expressed
in the malignant cells e.g. EBNAs, LMP1 and LMP2a/2b and possibly also genes
such as BZLF-1 (Cochet et al., 1993). Regression of EBV induced human B cell
lymphoproliferation and protection against LPD has been observed in SCID mice
following the introduction of CTLs primed against EBV antigens (Buchsbaum et al.,
1996, Johannessen et al., 1999). This work was directed at the development of T cell
therapy to treat lymphoproliferative disorders primarily in the immunosuppressed
transplant patient however it has implications for vaccine development suggesting if
the CTLs present in immune intact individuals could be focused towards EBV
antigens the EBV induced proliferation could be eliminated.
1.8.4 Immune Response to EBV
Primary infection of EBV induces a humoral immune response of antibodies specific
to an array of EBV encoded proteins. During acute IM the initial antibody response
consisting of IgM is directed specifically against lytic viral proteins including early
antigens, viral capsid antigens and viral membrane antigens. Antibodies to EBNA 1
and EBNA 2 develop later. In acute IM the humoral response is considered
ineffective as the antibody response to gp340, the most potent source of neutralising
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antibodies, is lacking (Khanna et ah, 1995a). Gp85 the gH homologue of EBV is the
focus of the antimembrane antigen antibody response rather than gp340 (Henle &
Henle, 1979). The majority of the neutralising antibody response to EBV is directed
to gp340/220 (Thorley-Lawson & Poodry, 1982). The antibody directed to EBNA
and viral capsid antigens is thought to have no or little role in protection although
remaining for life (Khanna et al., 1995a).
After acute infection the IgM levels to EBV subside and EBV specific IgG is
produced. Complement dependent neutralising antibody occurs early in acute IM and
is followed by the development of complement independent neutralising antibody
(Sairenji et al., 1984). EBV production can be controlled by EBV antibodies,
antisera against membrane antigens from IM patients correlates with inhibition of
EBV replication in vitro (Sairenji et al., 1991). Monoclonal antibodies against
different epitopes of EBV gp340 have been shown to neutralise EBV infection and
inhibit EBV release from infected cells (Thorley-Lawson & Geilinger, 1980).
Cell mediated immunity plays a major role in the control of primary and persistent
EBV infection (Rickinson & Moss, 1997). During primary infection approximately
90% of the EBV specific CTLs are directed against lytic antigens (Tan et al., 1999).
The levels of latently infected B cells are regulated by cell mediated immune
recognition of EBV immediate early and latent antigens expressed (Bogedain et al.,
1995 & Khanna et al., 1995b). The importance of this cell mediated control is
clearly demonstrated when immunosuppression of CTLs in transplant patients results
in EBV induced lymphoproliferative disease. EBV specific CTLs that have been
isolated from patients with post transplant lymphoproliferative disease, expanded in
vitro and infused back into the sufferer have successfully suppressed the
development of PTLD (Rooney et al., 1995). CTLs can inhibit EBV induced B cell
transformation following recognition of MHC I processed viral antigens on the
surface of infected B cells (Bejarano et al., 1988 & 1990). In EBV seropositive
individuals EBV specific CTLs can readily be isolated which are thought to persist
for life suppressing the potential development of EBV associated disorders by
constant immune surveillance (Moss et ah, 1979, Rickinson et ah, 1979).
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Most of the information on the cell mediated immune response to EBV surrounds the
CTLs directed against EBV latent antigens there is a deficit of information of those
to the lytic cycle antigens due to the lack of a cell line permissive for lytic EBV
replication. CD4+ T cells specific for gp340 have been identified (Wallace et al.,
1991). It is possible that CD4+ T cells activated by viral antigens are involved in
the control of infection by modulating a local inflammatory response through
cytokine release. In vitro lytically infected cells have been shown to be more
sensitive to NK induced cell lysis (Blazar et al., 1980). Also, cells expressing gp340
at their surface are targets of EBV specific antibody dependent cellular cytotoxicity
(Khyatti et al., 1991).
1.8.5 Desired Immune Response Generated by a Vaccine to EBV
The two specific facets of immunity to EBV are the humoral and CTL response. In
designing a vaccine the type and specificity of immunity against the virus desired
must be identified. In view of the oral route of EBV transmission a vaccine that
produced protective immunity at the mucosal surfaces may be especially beneficial
aiming to prevent initial EBV infection. The humoral immune response to EBV
could be modified to prevent initial infection of cells by antibody neutralisation of
virus blocking attachment and entry of the virus. The cytotoxic T cell response could
be primed to more effectively clear infected cells.
1.8.6 EBV Vaccine Development
With regard to EBV vaccine development, two main directions have been taken.
One area has targeted the immunogenicity of the lytic antigen gp340/220
concentrating principally on the ability of this membrane glycoprotein to induce
neutralising antibodies. Strategies based on gp340 in general aim to limit lytic
replication, preferably for the prevention of primary infection of EBV. The other
focus of EBV vaccine design has been on a vaccine that generates an efficient EBV
specific CTL response targeting the destruction of cells infected with EBV as
opposed to preventing initial infection of cells. Latently expressed EBV antigens
have been subject to most investigation in this area in an attempt to generate CTLs in
the individual that will recognise and eliminate latently infected B cells in the host.
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1.8.7 Gp340/220 Based Vaccines
Due to the potential oncogenic nature of EBV an attenuated virus vaccine is not
favoured therefore alternative strategies have been considered. As gp340 includes
the major neutralising determinants for EBV it is an obvious candidate for
exploitation as a vaccine immunogen and importantly gp340/220 is highly conserved
between EBV types 1 and 2 (Lees et al., 1993). In this vein many different methods
have been employed to express and generate purified and viral vector incorporated
gp340 including purification from the membranes of the EBV infected LCL B95.8
(Morgan et al., 1984a & 1988a, Randle et al., 1985, Epstein et al., 1985) expression
from mammalian expression vectors in different mammalian cell types (Conway et
al., 1989, Madej et al., 1992, Motz et al., 1986 & 1987, Whang et al., 1987),
baculovirus (Zhang et al., 1993, Nuebling et al., 1992) and yeast expression systems
(Emini et al., 1988). The different expression methods have their inherent pros and
cons. Expression of fragments of gp340 in bacteria produced peptides that were
unable to induce neutralising antibodies (Pither et al., 1992, Zhang et al., 1991) The
purification of gp340 from infected cells was inefficient, resulting in very small
quantities of protein which would not ultimately be suitable for human use due to the
use of phorbol esters and sodium butyrate to stimulate productive replication of
EBV. Similarly, a bovine papilloma expression system used to generate gp340 may
encounter resistance for human use the vector being based in a virus with oncogenic
potential. Activity continues in analysing the production and potential of gp340
protein based vaccines (Jackman et al., 1999). Recombinant viruses such as
adenovirus 5 and vaccinia virus engineered to express gp340 have also been
generated (Ragot et al., 1993, Mackett et al., 1985). In general the forms of gp340
produced in recombinant expression systems in mammalian cells have proved to be
the most desirable being indistinguishable by monoclonal antibodies from the wild
type form of gp340 (Whang et al., 1987, Madej et al., 1992).
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1.8.8 Gp340 Based Vaccination Trials
A number of vaccination trials to assess protection against EBV induced disease
have been done with gp340 based vaccines in several animal models. Promisingly a
gp340 vaccinia recombinant (strain WR) was successful at protecting cotton top
tamarins (Saguinus oedipus oedipus) from a lethal lymphomagenic dose of EBV.
Likewise a gp340 expressing adenovirus 5 recombinant induced protective immunity
against EBV induced lymphomas in cotton top tamarins. However, the mechanism
of protection is not fully understood as gp340 specific antibody levels did not
correlate with protection in these studies (Morgan et al., 1988b, Ragot et al., 1993).
Decreased EBV replication was observed in common marmosets immunised with the
same vaccinia virus expressing EBV gp340 (Mackett et al., 1996). Reduced viral
shedding was achieved following EBV challenge of common marmosets that had
been immunised with purified gp340 derived from a bovine papilloma virus
expression system (Cox et al., 1998). These studies show promise however the
mechanism of protection has not been clearly defined and does not appear to be due
to neutralising antibodies against gp340, cell mediated immunity has been implicated
in providing the protection.
Over the past years a vaccine based on gp340, or a surface glycoprotein of any
herpesvirus for that matter, has aimed to induce immunity to prevent preliminary
infection usually by the induction of neutralising antibodies. The potential of gp340
as a useful CTL target is gaining more attention. Gp340 has been shown to prime
cytotoxic T cells also (Wilson et al., 1999). T cells that prevent EBV transformation
in vitro have been generated by gp340 iscom stimulation (Bejarano et al., 1990).
Plus, prior immunization ofHLA A2/Kb transgenic mice with gp340 and gp85 CTL
epitopes induced a strong epitope-specific CTL response and afforded protection
against gp85- or gp340-expressing vaccinia virus challenge (Khanna et al., 1999). In
addition, T helper cells specific for gp340 have been detected in EBV seropositive




Human trials using a recombinant vaccinia virus (Chinese strain Tien Tan)
expressing gp340 have been done in China (Gu et al., 1991 & 1995). The gp340
vaccinia recombinant was initially tested for toxicity in mice and rabbits and then
administered to adults. The individuals had a weak or undetectable response with no
change in neutralising antibodies. Subsequently the vaccine was administered to
children of about 10 years old who did show a clear specific antibody response. The
lack of response in the adults may have been due to previous exposure to vaccinia
virus. As very young children are likely to be the ultimate target of a vaccine to
prevent infection being naive to EBV a trial involving 19 infants aged 9-12months
was performed. Prior to the trial all the participants tested seronegative for EBV and
vaccinia virus. The gp340 vaccinia virus recombinant did appear to provide
protection to 6/9 children who remained EBV negative a year post vaccination unlike
the 10 control individuals, whether this is long term immunity is not clear. Three
years post vaccination 5/9 were EBV negative, those that had been infected with
EBV had lower sera titres than infected controls suggesting lower EBV lytic
replication and therefore partial protection against EBV. These results are promising
however they must be viewed with caution due to the limited numbers involved in
the trials.
1.9.1 EBV T Cell Epitope Based Vaccines
An alternative approach to the development of a vaccine strategy against EBV is that
based on CTL epitopes. The aim is to immunise the CD8+ T cell repertoire using
formulations of synthetic peptides which mimic immunodominant epitopes known to
be recognised by the EBV induced CTL response. This approach to vaccination has
mainly aimed to target latently infected B lymphocytes rather than virions and
lytically infected cells at the primary site of infection. This would in theory reduce
virus-induced B cell proliferation but not prevent initial infection of cells and
therefore latency could be established albeit in a reduced number ofB lymphocytes.
For EBV, the CTL epitopes focused upon for the incorporation into a vaccine are
those of latency associated proteins. The low levels of EBV infected cells in healthy
76
CHAPTER 1 INTRODUCTION
EBV carriers are thought to be regulated in the main by CTLs for EBNA 3 and LMP.
EBNA3 has particularly immunodominant epitopes that are commonly recognised by
EBV specific CTLs in healthy EBV carriers (Murray et al., 1992, Burrows et al.,
1994). The tumour cells of PTLD express all of the EBV latent genes of which
EBNA 3 proteins are the main CTL targets (Khanna et al., 1995a).
As different ME1C class I alleles present different peptides the diversity of HLA
MHC class I restriction within the human population increases the difficulty of
developing a peptide vaccine. A peptide vaccine that is effective for the majority of
the human population is likely to need a variety of epitopes incorporated. There are
reports of investigations into the EBV epitopes recognised by CD8+ T cells in
particular MHC backgrounds. There is also evidence that recombinant vectors
expressing the epitopes in a chain is feasible i.e. the epitopes are processed and
presented effectively able to reactive memory specific CTLs in vitro (Thomson et al.,
1995). Reports also suggest that allelic variation in the repertoires of T-cell receptors
could limit the CTL reactivity to a particular epitope, another obstacle for peptide
vaccinology (Schmidt et al., 1991). Analysis of the conservation of any chosen
epitope among strains of EBV must also be done. Vaccines based on latent antigen
CTL epitopes have been designed (Khanna et al., 1995a). Reduction in the numbers
of latently infected cells may be sufficient to reduce the incidence of EBV associated
diseases however sterile immunity would be preferable.
1.9.2 AIMS
The aim of this project was to characterise the function of the virion membrane
glycoprotein gpl50 with respect to MHV-68 replication. Approaches taken were to
make a MHV-68 recombinant virus unable to express gpl50 and to assay the
potential binding function of gpl50 in isolation as a purified protein. In addition, the
potential of gpl50, administered in the form of a DNA vaccine in conjunction with a
gpl50 expressing recombinant vaccinia virus, to protect inbred mice against MHV-
68 challenge was subject to a preliminary investigation.
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2. MATERIALS & METHODS
Unless otherwise stated all standard laboratory reagents were purchased from Sigma
or BDH- Merck.
Unless otherwise stated reagents were made up in water (H2O) prepared using a 18 Q
Millipore water filter unit.
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MOLECULAR BIOLOGY
2.1.1 Plasmids
Plasmid Size Description Selection
E. coli Mam
pSP72/gpl50 4 kb Vector pSP72 (Promega) with the gene for gpl50 inserted
between restriction sites fiindill and EcoBl (Stewart et al.,
1996). Supplied by Dr. J P Stewart.
Amp NA
pBluescript 11 KS 2.96kb Cloning vector (Promega) Amp
pBabe/puro 5.1 kb Mammalian expression vector based on Moloney murine
leukemia virus (Morgenstern & Land 1990)
Amp Puro
pIND/Hygro 5.2kb Ecdysone inducible mammalian expression vector
(Invitrogen).
Amp Hygro
pIND/Hygro/TacZ 8.2kb Positive control vector, encoding the p-galactosidase gene,
for mammalian transfection and expression in the ecdysone
inducible expression system (Invitrogen).
Amp Hygro
pIND(SPl)/Hygro 5.2kb A version of pIND/Hygro with three binding sites for the
transcription factor SP1 to increase expression levels five




8.2kb Positive control vector, encoding the P-galactosidase gene,
for mammalian transfection and expression in the ecdysone
inducible expression system (Invitrogen).
Amp Hygro
pVgRXR 8.7kb Invitrogen vector encodes the heterodimeric ecdysone
receptor, under the constitutive CMVIE promoter, for the
ecdysone inducible mammalian expression system.
Zeocin Zeocin
pEGFP-Cl 4.7 kb Clontech plasmid encoding green fluorescent protein (GFP)
gene cassette gfp-Cl; the gfp gene with a CMV immediate
early promoter and a SV40 polyadenylation signal.
Kan Neo
pGEX-2T 4.9kb Vector for the inducible prokarytic expression of
recombinant proteins fused to glutathione-S-transferase
derived from Schistosoma japonicum.
Amp NA
pET-22b(+) 5.5kb Vector for the inducible prokaryotic expression of
recombinant hexahistidine tagged proteins under the control




pMVIO 4.7kb Cloning vector, encodes P-galactosidase under the
constitutive CMVIE promoter. Supplied by Dr. J.P. Stewart
Amp
pcDNA3 5.4kb Invitrogen mammalian expression vector containing CMVIE
promoter for constitutive expression of cloned gene.
Amp Neo
pcDNA3.1(+) 5.4kb Invitrogen mammalian expression derived from pcDNA3. Amp Neo
pVR1255/gpl50 6.4kb pVR1255 (Hartikka et al., 1996) with the gpl50 encoding
gene inserted between Sail and BamHl sites replacing the
luciferase reporter gene. Supplied by Dr. F. Belardelli.
Kan
pVR1255/IFN-aI 5.5kb pVR1255 (Hartikka et al., 1996) with the interferon alpha I
(IFN-al) encoding gene inserted between Notl and BamHl
sites replacing the luciferase reporter gene. Supplied by Dr.
F. Belardelli.
Kan
pAC8 4.5kb Vector pCR2.1-TOPO (Invitrogen) containing the green
fluorescent protein (GFP) expression cassette with the gfp




Table 2.1. Cloning and expression plasmid vectors. Drug selection used in E.coli
and in mammalian cells (Mam) - Amp- ampicillin, Carb- carbenicillin, Kan-
kanamycin, Hygro- hygromycin, Neo- neomycin, Puro- puromycin, Zeo- zeocin.
NA - not applicable. CMVIE - cytomegalovirus immediate early promoter.
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2.1.2 Computer Assisted Analysis of DNA
For analysis of DNA sequences with regard to restriction mapping, sequence
homology and protein translation the University of Wisconsin Genetics Computer
Group (UWGCG) suite of programmes was accessed (Devereux et al., 1984).
2.1.3 Quantification ofDNA
DNA concentration was quantified by fluorometry using a DyNA Quant 200
fluorometer (Hoefer Pharmacia Biotech Inc.) following the manufacturers
instructions. Commercial DNA (Hoefer Pharmacia Biotech Inc.) of known
concentration was used to calibrate the machine. DNA, 2pl, was added to 2ml of
solution A (lOpl Hoechst 33258 stock solution lmg/ml and 10ml lOx TNE (lOOmM
Tris, 10 mM EDTA Na2.2H20, 2M NaCl, pH7.4) in 90 ml H2O in a glass cuvette
for quantification.
2.1.4 Polymerase Chain Reaction tPCRl
Hot start PCR reactions were performed using either Taq DNA polymerase
(Boehringer Mannheim) or Pfu DNA polymerase (Stratagene). Reactions using Taq
DNA polymerase were performed in a final volume of lOOpl made up with H2O
containing lpl dNTP mix (25mM for each nucleotide - dATP, dGTP, dCTP and
dTTP), 1OjllI reaction buffer (Boehringer Mannheim), 1.5mM MgCf (Boehringer
Mannheim), lpl of each of a sense and antisense primer (20 pM solution), lpl target
DNA (amounts varied from lng to lOOng) and lpl Taq DNA polymerase
(lunit/lpl). Reactions with Pfu DNA polymerase contained lOpl of Pfu buffer
(Stratagene), 1 pi dNTP mix (25mM for each nucleotide as above), 1 pi of each of a
sense and antisense primer, lpl Pfu DNA polymerase (lunit/pl) and lpl of target
DNA (amounts varied from lng to lOOng) made up to a final volume of lOOpl with
H20.
An Omnigene PCR machine (Hybaid) was used for the temperature cycles. The
standard PCR cycling programme consisted of an initial stage of 95°C for 5 minutes
and then the calculated primer annealing temperature for 1 minute at which point the
temperature was held for the addition of the DNA polymerase. The temperature
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programme continued with a sequence consisting of primer extension at 72°C, for the
calculated duration required for the predicted product length, 95°C for 30 seconds for
DNA denaturation and the primer annealing temperature for 1 minute. This
sequence represented one cycle, routinely cycles were repeated 25 times followed by
a final stage of extension at 72°C for 5 minutes. The resulting products of all PCR
reactions were checked by agarose gel electrophoresis as described in section 2.2.5.
For nested PCR lOpl of the product from the first round of PCR was used as the
target for the second round of PCR.
2.1.5 RT-PCR
Following extraction of mRNA from cells in six well plates using the Boehringer
Mannheim mRNA Capture Kit, as described in section 2.3.5., reverse transcription
(RT) was performed in one of the two 0.2ml tubes used to capture the mRNA for
each sample. To the 0.2ml tube, 50pl of reverse transcription mix consisting of
50mM Tris-HCl, 40mM KC1, 6mM MgCl, lOmM dithioerythrithol, pH8.3, 20nM of
each of dATP, dCTP, dGTP and dTTP and 40 units of Moloney murine leukemia
virus (M-MuLV) reverse transcriptase (Boehringer Mannheim) was added. Tubes
were incubated at 37°C for 60 minutes on an Omnigene PCR machine (Hybaid). To
remove the reverse transcription mix tubes were washed with the wash buffer
provided as part of the mRNA capture kit. A 50pl PCR mix containing 0.5pl dNTP
mix (25mM for each nucleotide - dATP, dGTP, dCTP and dTTP), 5pi reaction
buffer (Boehringer Mannheim Ltd), 1.5mM MgCL (Boehringer Mannheim Ltd),
0.5pi of each of a sense and antisense primer (20 pM solution) and lpl Taq DNA
polymerase (1 unit/lpl) made up in FLO, was then added to the tubes. The
temperature cycles, as described in section 2.1.4 were performed using an Omnigene
PCR machine (Hybaid). As a control for intact RNA and efficient reverse
transcription primers for murine P-actin (intron spanning) shown in section 2.1.8
were used. To ensure the product detected was from cDNA and not from
contaminating DNA one half of the samples was subjected to PCR without prior
reverse transcription.
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2.1.6 Calculation of Primer Annealing Temperature
For PCR with Taq DNA polymerase the annealing temperature for primers was
calculated using the following formula:
4 x (Na + Nc) + 2 x (Na + Nj) - 5 = Primer annealing temperature (°C)
N equals the numbers of G, C, A and T nucleic acid bases in the primer
complementary to the target in the first round of PCR. When using Pfu DNA
polymerase the annealing temperature was reduced by 10°C from that calculated by
the formula above. If a PCR failed to yield a product the PCR was repeated with
annealing temperatures reduced by one or two degrees, the annealing temperatures
displayed for primer pairs are those which successfully yielded a product.
2.1.7 Calculation of PCR Extension Time
Extension times were calculated on the basis of 1 kb/minute when using Taq DNA
polymerase. In cases using Pfu DNA polymerase extension times based on
2kb/minute were used.
2.1.8 Primers
Oligonucleotides were purchased from MWG biotech. For primers in which not all
of the sequence is complementary to the target sequence the bases complementary
during the first cycle of PCR are underlined with a dashed line.
L50 - Left of gpl50 (sense)
Xhol
5 '-CGCGCTCGAGCIGACAGTGACACATGTTCC-3'
5' Location on MHV-68 genome: 69,236
L51 - In gpl50 (antisense)
BglU Accl EcoRI
5 '-AGATCTGTCGACGAATTCTGC_GGGCG_TCT_TTGJ_GT-3'
Location on MHV-68 genome: 69,743
L50 & L51 product size: 533bp
Target: MHV-68 genome




A52 - In gpl50(sense)
EcoRl AccI Bglll
5'-GAATTCGTCGACAGATCTTTATTCATGATCATGTCTGIG-3'
5' location on MHV-68 genome: 70,956
B52 - Right of gpl50 (antisense)
Hindlll
5 '-cgcgaagctjattctccctgagcgatggc-3 '
5' location on MHV-68 genome: 71,380
A52 & B52 product size: 449bp
Target: MHV-68 genome
PCR conditions with Taq DNA polymerase: annealing temperature: 53°C, extension
time: 45 seconds.
L50 & B52 product size: 965bp
Target: PCR products of A52 & B52 plus L50 & L51
PCR conditions with Taq DNA polymerase: annealing temperature: 59°C, extension




Feature (denoted by dotted line): Kozak translational initiation sequence




5' location on MHV-68 genome: 70,917
IElgpl50 & IE2gpl50 product: 1481 bp
Target: mhv-68 genome









5' location on mhv-68 genome: 70,994
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IA3 & IA4 product: 1560bp
Target: MHV-68 genome









5' location on pGEX-2T: 926
GSTln & GST2e product: 689bp
Target: pGEX-2T









5' location on MHV-68 genome:70,826
Restriction site 5' end: Xhol
MAI & MA2 product size: 1324bp
Target: MHV-68 genome





5' location on MHV-68 genome:70,824
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IElgpl50 & MA2stop product size: 1391bp
Target: MHV-68 genome









5' location on pEGFP-Cl plasmid (Clontech): 1646
CMV1 & SV40 product size: 1631 bp
Target: pEGFP-Cl (Clontech)
PCR conditions using Pfu DNA polymersase: annealing temperature: 45°C,
extension time: 4 minutes.
RCVd (sense)
5 '-GGACGCGTTCATCGATGATG-3'
5' location on MHV-68 genome: 69,165
SV40d (antisense)
5 '-GCATTCTAGTTGTTGTCC-3'
5' Location on pEGFP-Cl: 1598
RCVd & SV40d product size:626bp
Target: MHV-68 pRCVII generated recombinant virus genome
PCR conditions using Taq DNA polymerase: annealing temperature: 57°C,
extension time 1 minute, 40 cycles.
PAG1 (sense)
5'-GTAGGATCCGTGA_GAGTGTACACAAAGACGC-3' (sense)
5' location on MHV-68 genome:69,698
PAG2 (antisense)
5 '-GGAGAATTCTCCTJTGGTICAGC-3' (antisense)
5' location on MHV-68 genome:70,199
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PAG1 & PAG2 product: 501bp
Target: MHV-68 genome (gpl50)




5' location on MHV-68 genome: 69,765
PAG12 (antisense)
5' -GTATCTGATGTGTCAGCAG-3'
5' location on MHV-68 genome: 70,130
PAG11 & PAG12 product: 367bp
PCR conditions using Taq DNA polymerase: anneal temperature: 49°C, extension
time: 1 minute.
PAG11 & MA2
Product size: (a) 1059bp or (b) 2.68kbp
Target: (a) wild type MHV-68 or (b) recombinant virus I respectively.









5' location on MHV-68 genome: 16,505
PGB1 & PGB2 product size: 286bp
Target: MHV-68 genome
PCR conditions using Taq DNA polymerase: annealing temperature: 53°C, extension
time: 30 seconds.
PGB1 & IA4 product size: 1.8kbp
Target: pBabe/PgBgpl50
PCR conditions using Taq DNA polymerase: annealing temperature 53°C, extension
time: 2 minutes and 15 seconds.
Murine P-actin forward primer (P-AC1)
5 '-TGTGATGGTGGGAATGGGTCAG-3'
Murine P-actin reverse primer (P-AC2)
5 '-TTTGATGTCACGCACGATTTCC-3'
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P-AC1 & P-AC2 product size: 514bp











II (antisense) - 5' location on MHV-68 genome: 69,601
5 '-CTCTACTTGTAATACCCTC-3'
Annealing temperature: 49°C
31 (sense) - 5' location on MHV-68 genome: 69,767
5 '-CCTCAGAACCAACTTCCC-3'
Annealing temperature: 51°C
61 (sense) - 5' location on MHV-68 genome: 70,069
5 '-CAGGAAGATGAACCCACC-3'
Annealing temperature: 51°C
91 (sense) - 5' location on MHV-68 genome: 70,324
5' -GTTCCTCAACCAACTGCC-3'
Annealing temperature: 51°C



















Sequencing of plasmid DNA was performed by Ian Bennet within the Department of
Veterinary Pathology using an LI-COR DNA sequencer 4000 (MWG-Biotech).
2.2.1 Restriction Enzyme Digestion of DNA
The restriction enzymes BamHl, Bglll, EcoKl, Kpnl, Hindlll, Ncol, Xhol and Accl
were purchased from Gibco BRL and were used according to the manufacturers
instructions in the supplied buffers. The standard reaction mix consisted of 1 unit of
a restriction enzyme to lpg of target DNA in the appropriate buffer (total volume
ranging from 20 -50 pi) this was contained in 1.5ml microfuge tube and incubated in
a 37°C water bath for 2 hours. Dnase free RNase, (lpl of lOmg/ml) was added to
the reaction mix, prior to incubation, when the DNA target had significant RNA
contamination.
2.2.2 Dephosphorvlation of Exposed DNA Termini
The 5' phosphate of the cut ends of plasmid DNA following restriction digestion
were dephosphorylated by the direct addition of 10 units of calf intestinal alkaline
phosphatase (Boehringer) to the restriction digest reaction mix for a further 20
minute incubation at 37°C. The reaction was stopped by phenol/chloroform
extraction as described in section 2.2.7.
2.2.3 Generation of Blunt Ended DNA
T4 DNA polymerase (Gibco BRL) was used to fill in the 3'-overhangs of
pSP72/gpl50 generated by^ccl digestion. Following restriction digestion DNA was
extracted with phenol/chloroform and precipitated with ethanol as described in
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section 2.2.7. pSP72/gpl50 DNA was then resuspended in a lOOp.1 solution
containing 10 units of T4 DNA polymerase, lpl dNTP mix (Gibco BRL) (25mM of
each nucleotide), 20pl T4 DNA polymerase buffer (Gibco BRL), 78pl H2O and then
incubated for 30mins at 37°C in a water bath.
2.2.4 DNA Ligation
Ligation of DNA fragments was carried out using T4 DNA ligase (Gibco BRL).
Purified DNA fragments were mixed with the cleaved vector DNA at an approximate
ratio of 5:1 respectively in ligase buffer (50mM Tris-HCl, pH7.6, lOmM MgCh, 1
mM dithiothreitol, 5% (w/v) polyethylene glycol-8000, Gibco BRL), 1 unit of T4
DNA ligase and ImM ATP at a final volume of 20pl. This reaction mix was
incubated at 4°C overnight.
2.2.5 Agarose Gel Electrophoresis
DNA samples, restriction enzyme digests and PCR products were mixed with 1/6
volume of gel loading buffer (H2O containing 15% ficoll type 400, 0.25%
bromophenol blue, 0.25% xylene cyanol and 0.25% orange G). A lkbp DNA ladder
(Gibco BRL), was used as a marker to determine the size of bands in kilobase pairs.
Samples were loaded into a horizontal agarose gel made from 0.7% SeaKem LE
agarose (Flowgen) dissolved in TAE buffer (40mM Tris-acetate, pH 7.8 and ImM
EDTA) with 2.5pg/ml ethidium bromide. The gel was submerged in a Bio-Rad mini
sub tank containing TAE buffer and samples electrophoresed at a constant 50 volts.
DNA bands were visualised using a UV transilluminator.
2.2.6 Isolation of DNA Fragments from Agarose Gels
The DNA for isolation was visualised in an agarose gel on a UV transilluminator and
a sterile scalpel blade was used to cut the required band from the gel. Dialysis
tubing, pore size of a 12,000 MW cut off point (BDH), was prepared by boiling in
H20 plus 1 mM EDTA for 10 minutes. The tubing was rinsed with H2O and the
piece of gel placed into the tubing with 200pl elution buffer (lOmM Tris-HCl pH
7.9, ImM EDTA plus 1% gelatin). The dialysis tubing was clamped at each end and
placed in an electrophoresis tank with TAE buffer, the DNA was electrophoresed
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from the gel into the elution buffer for 1 hour at 70 volts. The elution buffer,
containing the DNA was transferred to a microfuge tube and phenol/chloroform
extraction followed by ethanol precipitation was done as described in section 2.2.7.
2.2.7 Phenol/Chloroform Extraction and Ethanol Precipitation of DNA
To remove protein contaminants from DNA solutions phenol/chloroform extraction
was performed. To a DNA solution an equal volume of phenol/chloroform solution
(phenol, chloroform and isoamyl alcohol, ratio of 25:24:1 respectively, pH7.5) was
added, mixed and then centrifuged for 30 seconds at 10,000 a g. The upper phase
containing the DNA was removed and transferred to a new tube containing an equal
volume of chloroform. The tube was mixed and then centrifuged for 30 seconds at
10,000 x g. The upper phase was removed and added to a new tube containing 'A
volume of 7.5M ammonium acetate and then 3 volumes of ethanol were added. The
tube was incubated at -20°C for 1 hour to allow the DNA to precipitate. The tube
was spun for 10 minutes at 10,000 x g to pellet the DNA. The supernatant was
discarded and the pellet washed with 200pl of 70% ethanol. The tube was spun as
before and then the pelleted DNA was resuspended in TE buffer (lOmM Tris-HCl
pH 7.9, ImM EDTA).
2.2.8 Purification of DNA Fragments Generated by PCR
To purify PCR cloned DNA fragments a wizard column PCR prep kit (Promega) was
used according to manufacturers instructions.
2.2.9 Extraction of Viral DNA
For the extraction of viral/cellular DNA from mammalian cells, ~5xl07 cells in a
T175 Nunc culture flask 5 days following infection with MHV-68 at 0.01 MOI were
washed twice in PBS. Cells were resuspended at 5 x 107 cells/ml in TE and
transferred to a 15ml polypropylene tube (Falcon). To the cell suspension, 10
volumes of extraction buffer (0.1M EDTA, 0.5% SDS, 0.2M Tris pH 8.0), containing
20pg/ml RNase (Sigma) was added. Following incubation of the tube for 1 hour at
37°C, proteinase K (Sigma) was added at a final concentration of 100pg/ml and
incubation was done overnight at 56°C. Phenol/Chloroform extraction was done
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three times followed by one chloroform extraction. For each extraction the tube was
rotated for 15 minutes at RT and spun at 2500 x g for 15 minutes each time. Ethanol
precipitation of the DNA was done at room temperature.
For small scale preparations of DNA from wells of 96 well plates up to T25 Nunc
tissue culture flasks of cell cultures a Qiamp DNA extraction kit (Qiagen) was used.
2.3.1 Radioactive Labelling of DNA fragments
DNA radiolabeled with the isotope P was used to probe Southern and northern
blots. A random primed DNA labelling kit (Boehringer Mannheim) was used to
generate probes as follows. To denature target DNA (either PCR products or DNA
fragments eluted from agarose gels), 25ng in 9pl H2O was heated at 95° C for 10
minutes and then cooled on ice. Subsequently, lpl of each dNTP; dATP, dGTP and
•3 <2
dTTP, 2pl hexanucleotide reaction mix (Boehringer Mannheim), 5 pi [a P] dCTP
(50pCi) (Amersham) and lpl/2units Klenow enzyme (Boehringer Mannheim) was
added to the DNA and the tube incubated in a 37°C water bath for 35 minutes. TE
buffer was then added to increase the volume of the mix to lOOpl. The radiolabelled
probe was then purified from the unincorporated dNTPs using a sephadex g-50
NICKtm column (Pharmacia Biotech) resulting in 500pl final probe.
2.3.2 Southern Blotting
For Southern blotting, 5pg of each DNA sample was electrophoresed in a standard
0.7% TAE/agarose gel as above. Subsequently, the gel was immersed in gel soak 1
(0.5 M NaOH, 1 M NaCl) for 20 minutes two times, to denature the DNA. The gel
was then soaked 2 times in a neutralisation buffer (0.5M Tris HC1, pH7.5, 1.5 M
NaCl) for 20 minutes. The gel was rinsed in E^O and transferred to a tank for
capillary transfer of the DNA onto a nylon membrane (Micron Separations Inc). The
gel was placed on a platform directly on top of three sheets of 3mm paper with ends
immersed in lOx SSC (1.5M NaCl, 0.15M NaCitrate, pH 7.0) in wells. A nylon
membrane was placed on top of the gel followed by 2 sheets of 3mm paper, many
layers of absorbent paper towels and a heavy weight. The gel was blotted overnight.
To cross link the transferred DNA to the nylon, the membrane was placed in a UV
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Stratalinker™ 1800 (Stratagene) and pulsed with UV light for 30 seconds. To stain
the markers, the marker lane was cut off and immersed in 1M acetic acid for 10
minutes followed by 10 minutes in methylene blue (0.2% methylene blue, 0.4M
acetic acid, 0.4M sodium acetate) and rinsed in H2O. Blots were stored at -70°C.
2.3.3 Probing Southern Blots
Prior to probing, Southern blots were incubated in hybridisation solution (6 x SSC
plus 5% non fat dried milk) at 68°C for 2 hours. The required radiolabeled probe
generated as in section 2.3.1 was denatured by the addition 0.1 volume of 1 M NaOH
and incubated at 37°C for 5 minutes. The blot was then incubated at 68°C, overnight,
in fresh hybridisation solution, to which the denatured probe had been added. Excess
probe was washed from the blot by a series of increasingly stringent washes i.e. 2 x
15 minutes in 5 x SSC plus 0.5% SDS (sodium dodecyl sulphate) at RT, 2 x 15
minutes in 1 x SSC plus 0.5% SDS at 37°C and 3x15 minutes in 0.1 x SSC plus 1%
SDS at 55 - 65°C. Between each wash the radioactivity level on the blot was
monitored using a Geiger counter. After the final wash the nylon membrane was
wrapped in Saran wrap (Dow, USA) and loaded into a film cassette with X-OMAT
XAR-5 Kodak film and a DuPont Cronex Lightning Plus intensifying screen
(Sigma). Film cassettes were placed at -70°C. Exposure times varied from 2 hours
to two weeks. Prior to developing the film, cassettes were fully thawed. To remove
bound probe from blots in order to re-probe the blot with different probes the blots
were subject to stringent washes in boiling water plus 1% sodium dodecyl sulphate.
Stripped blots were exposed to film overnight to monitor removal of radioactive
probe.
2.3.4 Cytoplasmic RNA Extraction
For the extraction of cytoplasmic RNA from mammalian cells, cells were harvested
from a confluent T175 Nunc tissue culture flask and then washed twice in PBS.
Following this, cells were resuspended in 1 ml of ice cold Tris saline (25mM Tris,
pFI 7.4, 130mM NaCl and 5mM KC1). The suspension was transferred to a 1.5 ml
microfuge tube, spun at 3,000 x g for 30 seconds and the cells resuspended in 400pl
ice cold Tris saline. To this, 1 OOjul of Igepal buffer (1% Igepal CA-630, 0.5%
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sodium deoxycholate and 0.01% dextran sulphate in Tris saline) was added and the
tube inverted ten times followed by centrifugation at 3000 x g for 30 seconds. The
supernatant was transferred to a microfuge tube containing 500pl phenol/chloroform
(1:1), then 25pl 20% SDS and 15pl 5M NaCl was added and the tube vortexed for 30
seconds. Following centrifugation at 10,000 x g for 2 minutes the aqueous phase was
transferred to a new tube with 500 pi phenol/chloroform and then vortexed and spun
as before. This phenol extraction was repeated 3 times until the interface was clear.
An equal volume of chloroform/isoamyl alcohol (24:1) was added to the recovered
aqueous phase and the tube was vortexed and spun as before in order to extract the
phenol. The aqueous phase was transferred to a tube containing 1ml of ethanol
which was then incubated at -20°C from 30 minutes to overnight. Following
centrifugation at 10,000 x g for 20 minutes at 4°C the RNA pellet was washed in
80% ethanol and spun at 10,000 x g for 20 minutes. The pellet was allowed to dry
and then resuspended in 50pl diE^O. To quantify the RNA the optical density of lpl
diluted in 500pl H2O was measured at 260/280nm. To check the quality of the
RNA, l-3pg RNA was mixed with 1/6 volume of gel loading buffer (50% glycerol,
ImM EDTA [pH8.0] and 0.25% bromophenol blue) and loaded in an electrophoresis
gel consisting of 0.8% SeaKem LE agarose (Flowgen) dissolved in TBE (89mM
Tris-borate, pFI7.5, and 2mM EDTA) containing 2.5pg/ml ethidium bromide. The
gel was submerged in a Bio-Rad mini sub tank containing TBE buffer and the
samples electrophoresed at a constant 50 volts. Ribosomal RNA bands were
visualised using a UV transilluminator.
2.3.5 mRNA extraction for RT-PCR
For extraction of RNA from monolayers in six well plates, media was removed and
wells were washed once with ice cold PBS. Using the plunger of a 1 ml syringe the
cells (~106/well) were scraped into 1 ml PBS and transferred to a 1.5 ml microfuge
tube. To extract the mRNA a mRNA capture kit (Boehringer Mannheim) was used
according 0 manufacturers instructions. Cells were pelleted by centrifugation at 250
x g and resuspended in 200pl of ice cold lysis buffer. The DNA was sheared by
passing the sample through a 21 gauge needle six times. A solution containing 0.25
nmol of biotin-labeled oligo(dT)2o, 4pl, was added to the sample and the mix was
93
CHAPTER 2 MATERIALS & METHODS
incubated for 5 minutes at 37°C. For immobilisation of the poly(A+) RNA, 50pi of
the mix was added to a strepavidin-coated 0.2 ml PCR tube and incubated for 3
minutes at 37°C. The mix was removed from the tube and washed three times using
200pl of washing buffer. The captured mRNA was then used directly for reverse
transcription and amplification by PCR in the tube as described in section 2.1.5.
2.3.6 Northern Blotting
For northern blotting, RNA samples were prepared by mixing 5.5pl (5pg) of RNA
with lpl 10 x MOPS (0.2M 3-[N-Morpholino] propanesulphonic acid [pH7.0],
80mM sodium acetate and lOmM EDTA [pH 8.0] ), 3.5pl formaldehyde and lOpl
formamide). For denaturation of the RNA, the RNA solution was heated at 65°C for
15 minutes and then cooled on ice. Following the addition of 2pl of RNA loading
buffer (50% glycerol, ImM EDTA [pH8.0] and 0.25% bromophenol blue) lOpl was
loaded onto a 1.2% agarose gel (1.2% 'SeaKem' agar, 2.2M formaldehyde, 1 x
MOPS, lpg/ml ethidium bromide). The gel was electrophoresed overnight at 35
volts in a Biorad electrophoresis gel tank in which the running buffer (lx MOPS)
was continuously recirculated.
The gel was then blotted by capillary transfer onto a nylon membrane (Micro
Separations Inc.). To cross link the RNA to membrane, the membrane was placed in
a UV Stratalinker™ 1800 (Stratagene) and pulsed with UV light for 30 seconds. To
stain the markers, the marker lane was cut off and immersed in 1M acetic acid for 10
minutes followed by 10 minutes in methylene blue (0.2% methylene blue, 0.4M
acetic acid, 0.4M sodium acetate) and rinsed in H2O. Blots were stored at -70°C.
2.3.7 Probing Northern Blots
Reagents;
50x Denhardt's Solution: 5% Ficoll (MW 400), 5% polyvinylpyrrolidone (MW
360,000) and 5% BSA in H20




(Sigma): 5mg/ml DNA, boiled for 5 minutes and sheared by
passing through a 21-gauge needle
Prehybridisation buffer: 5 x SSPE, 5 x Denhardt's, 50% formamide, 0.5% SDS
and 100p.g/ml salmon sperm DNA.
Hybridisation buffer: 5 x SSPE, 5 x Denhardt's, 50% formamide, 10%
dextran sulphate. 0.5% SDS and 200pg/ml salmon
sperm DNA.
Prior to probing with radiolabeled DNA probes, northern blots were incubated in
prehybridisation buffer for 2 hours at 45°C. The required radiolabeled probe
generated as in section 2.3.1 was denatured by the addition of 0.1 volume of 1 M
NaOH and incubated at 37°C for 5 minutes. The blot was then incubated overnight,
at 45°C, in hybridisation solution, to which the denatured probe had been added. To
remove excess probe the blot was subjected to a series of increasingly stringent
washes i.e. 2 x 15 minutes in 5 x SSPE, 0.5% SDS at RT, 2 x 15 minutes in 1 x
SSPE, 0.5% SDS at 37°C and 3x15 minutes 0.1% SSPE, 1% SDS at 55-65°C. The
blot was then wrapped in saran wrap and placed in a film cassette with X-OMAT
Kodak film and a DuPont Cronex Lightning Plus intensifying screen (Sigma).
BACTERIAL WORK
2.3.8 Bacterial Strains
Commercial competent Escherichia coli (E. coli) (Epicurian Coli XL 1-Blue cloning-
grade competent cells, Stratagene) were used for plasmid cloning and for protein
expression from vector pGEX-2T. BL21 (DE3) E. coli (Novagen), containing the
gene for T7 RNA polymerase under the control of the lacUV5 promoter which is
inducible by isopropyl-P-D-thiogalactopyranoside (IPTG), were used for protein
expression from pET22b based vectors.
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2.3.9 Heat Shock Transformation of Bacteria with Plasmid DNA
Frozen competent bacteria were thawed on ice. Competent cells, lOOpl were
transferred into a prechilled Falcon 2059 polypropylene tube, p-mercaptoethanol
(Invitrogen), 1.7pl, was added to the lOOpl bacteria (giving a 25mM final
concentration) and the tube was incubated on ice for 10 minutes swirling every two
minutes. Ligation mix (amount of DNA ranging between 0.1 - 50ng), lpl, was
added to the cells which were incubated on ice for a further 30mins. The tube was
then placed in a 42°C water bath for 45 seconds and returned to ice for 2 minutes.
LB medium (Luria Bertani medium: lOg bacto-tryptone, 5g bacto-yeast extract, lOg
NaCl per litre at pH 7.0), 900pl, was then added to the tube and the bacteria were
incubated at 37°C shaking for 1 hour. Transformed bacteria, 100 - 900pl were
removed and spread onto bacterial plates. Bacterial agar plates were made by the
addition of bacto-tryptone agar at 15g/L to LB medium prior to autoclaving, before
pouring plates the selection agent consisting of either 100p.g/ml ampicillin (LB
amp+) or 50pg/ml carbenicillin was added to the LB. The LB agar plates were
incubated at 37°C overnight following application of bacterial samples.
When growing and selecting bacteria transformed with pVgRXR the selective
antibiotic Zeocin™ was used at 25pg/ml in low salt LB medium. Low salt LB
medium consisted of lOg Tryptone, 5g NaCl and 5g yeast extract made up to a litre
with FI2O.
2.4.1 Colony Transformation of BL2HDE31 Bacteria
From freshly streaked BL21(DE3) bacteria, 2-4 colonies were picked from an LB
agar plate containing lOmM MgCl2. The colonies were dispersed in 200pl of
transformation buffer; TFB (H2O containing lOOmM KC1, 45 mM MnCIAFbO,
lOmM CaCl2.2H20, 3mM HAC0CI3 and 10 mM K-MES ( 2fmorpholino]ethone
sulphonic acid plus KOH to pH to 6.3) in a Falcon 2059 polypropylene tube. The
tube was incubated on ice for 15-30 minutes. DND solution, 7pl, consisting of 90%
(v/v) dimethyl sulfoxide (DMSO), lOmM potassium acetate and 1M dithiothreitol
(DTT) was added to the tube. The tube was swirled and then incubated on ice for
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10-15 minutes. Another 7jal of DND was added to the tube which was then swirled
and incubated on ice for 10-20 minutes. Plasmid DNA solution, 2pl (~50ng), was
added to the tube and then incubated on ice for 30 minutes. To heat shock the cells
the tube was placed in a 42°C water bath for 90 seconds and then chilled on ice for 2
minutes. SOC medium (LB containing lOmM MgCb, lOmM MgSCL and 20mM
glucose), 800pl, was added to the tube and incubated at 37°C with shaking for 1
hour. Transformed bacteria, 100-900pl were plated onto LB amp+ agar plates and
incubated at 37°C overnight.
2.4.2 Glycerol Stocks
For long term storage of plasmid containing bacteria, glycerol stocks were made.
Glycerol, 0.15 volumes was added to 0.85 volumes of a growing liquid culture.
Aliquots of 1ml of this mix in 1.5 ml microfuge tubes were flash frozen by placing in
solid CCVethanol and stored at -70°C.
2.4.3 Small Scale Purification of Plasmid DNA from Bacteria
Small scale plasmid preparations (minipreps) to isolate plasmid DNA from
transformed bacteria were done by using an alkaline lysis method. Colonies were
picked from freshly streaked plates of transformed bacteria and each was inoculated
into individual 10ml aliquots of LB medium containing 100pg/ml ampicillin (LBA
medium) in 25ml plastic universal tube (Sterilin). The tubes were incubated
overnight at 37°C with shaking. The bacteria were pelleted by centrifugation (4000 x
g, 5 minutes), resuspended in 200pl glucose solution (50mM glucose, 25mM Tris-
HC1 (pH8.0) and lOmM EDTA) plus 5mg/ml hen egg lysozyme (Sigma), transferred
to 1.5ml microfuge tubes and incubated for 5 minutes at room temperature (RT). All
subsequent incubations were carried out on ice. Lysis solution, (0.2M NaOH, 1%
SDS), 400pl, was added to each tube and mixed gently. Following a 5 minute
incubation, cold neutralisation solution (3M potassium acetate, 2M acetic acid),
300pl, was added to each tube, mixed vigorously and incubated for 15 minutes.
After centrifugation of the tubes at 10,000 x g for 5 minutes the supernatants were
transferred to new microfuge tubes containing 500pi propan-2-ol and incubated for
15 minutes. The nucleic acid was pelleted by centrifugation of the tubes (10,000 x g,
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5 minutes). The supernatant of each tube was decanted off and the pellet was
allowed to dry before resuspending in 200pl TE buffer. lOOpl of 7.5 M ammonium
acetate was added to each tube followed by a 15 minute incubation.. The tubes were
centrifuged at 10,000 x g for 5 minutes and each supernatant was transferred to a new
microfuge tube containing 600pl ethanol and incubated for 1 hour at -20°C to
precipitate the DNA. To pellet the precipitated DNA the tubes were spun for 5
minutes at 10,000 x g. DNA pellets were each suspended in 20-50pl TE buffer.
To yield larger quantities of plasmid DNA large scale plasmid preparations
(maxipreps) were done on 400ml LBA medium bacterial cultures using either the
caesium/chloride gradient method according to Sambrook et al, 1989 as described
below or a Qiagen maxi prep column.
2.4.4 Large Scale Preparation of Plasmid DNA from E. coli
In order to grow larger volumes of bacterial cultures, 10 ml of an overnight culture
was added to 400ml LBA in a 2 litre flask which was then incubated at 37°C, shaking
overnight. The bacteria were pelleted by centrifugation at 7000 x g for 5 minutes.
The pellet was resuspended in 20ml of glucose solution, and incubated for 10
minutes at room temperature. All subsequent incubations were done on ice. Lysis
solution (as for small scale DNA preparation), 40 ml, was added to the tube, mixed
gently and incubated for 5 minutes. Following this, 20 ml of neutralisation solution
was added, and the tube incubated for 15 minutes. After centrifugation, as before,
the supernatant was passed through a gauze filter, 0.6 volumes of propan-2-ol added.
Following a 30 minute incubation the tube was spun as before, the supernatant
discarded and the pellet allowed to dry. The pellet was then resuspended in 6 ml TE
to which 3 ml 7.5 M ammonium acetate was added and then incubated for 30
minutes in a 30ml glass Corex tube. The tube was spun at 10,000 x g for 10 minutes
and the supernatant transferred to a new tube. DNA was precipitated by the addition
of 18 ml ice cold ethanol and incubation at -20°C for 1 hour. The tube was then
spun at 10,000 x g for 10 minutes and the pellet resuspended in TE/CsCl 1:1 (v/w).
This solution was then loaded into a 36ml Quick sealtm ultraclear polyallomer tube
(Beckman), and 700pl of ethidium bromide (5mg/ml) was added to a full tube i.e.
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36ml TE/CsCl. Tubes were heat sealed, placed in a Vti50 rotor and spun at 242,000
x g in a Beckman L8-M ultracentifuge for 18 hours. The resultant DNA bands in the
CsCl gradient were visualised using the UV transilluminator. The supercoiled
plasmid band was drawn off using a wide bore syringe. To remove the ethidium
bromide from the harvested DNA an equal volume ofCsCl/TE saturated butanol was
added and the tube inverted to mix. The lower layer, containing the DNA, was
drawn off to a new tube. Again, an equal volume of CsCl/TE saturated butanol was
added and the tube inverted and the lower layer pipetted off. This process was
repeated two more times until no pink colour from contaminating ethidium bromide
could be seen. The CsCl was then removed from the DNA by dialysing the solution
against several changes of TE, overnight at 4°C. The DNA was precipitated by the
addition of 0.5 volumes of 7.5 M ammonium acetate and 3 volumes of ethanol
followed by incubation for 1 hour at -20°C. The tube was spun at 10,000 x g for ten
minutes, the pellet washed with 70% ethanol, the tube spun as before and the pellet
resuspended in 500pl TE.
2.4.5 Protein Expression and Purification
For expression of fusion proteins, BL21 (DE3) bacteria containing the pET22b based
vector plasmids were grown in 100ml LB medium with 50p.g/ml carbenicillin on a
shaker at 37°C. When the culture reached an optical density (OD) of approximately
0.6 at 600nm, isopropyl (3-D-thiogalactopyranoside (IPTG) was added (ImM final
concentration) to induce fusion protein expression. The culture was incubated for a
further 2.5 hours. To purify the periplasmic fraction of the bacteria, the cells were
pelleted by centrifugation (5 minutes at 500 x g) and resuspended in 0.4 culture
volumes of 30mM Tris-HCl pH8.0, 20% sucrose, 1% (v/v) aprotinin (Sigma) and
ImM phenylmethylsulfonyl fluoride (PMSF) (Sigma). The suspension was
incubated at room temperature for 10 minutes with shaking and then centrifuged as
before. The pellet was resuspended in 0.4ml volumes of ice cold 5mM MgSCL and
incubated on ice for 10 minutes with shaking. The suspension was centrifuged as
before and the supernatant retained (the periplasmic fraction). The His tagged fusion
protein was extracted by affinity purification using Ni2+ charged resin beads
(Novagen) according to manufacturers instructions. Briefly, prior to incubation the
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HisBind resin was prepared by sequential washes in 3 volumes of deionised water, 5
volumes of charge buffer (50mM NiS04) and 3 volumes of binding buffer (5mM
imidazole, 500mM NaCl, 20mM Tris-HCl pH7.9). All steps were carried out at 4°C.
The prepared periplasmic fraction (approximately 35ml from a 100ml culture) was
mixed with 5ml 8x concentrated binding buffer (40mM imidazole, 4M NaCl,
160mM Tris-HCl pH7.9) to give a final concentration of lx binding buffer. The mix
was added to 5ml (settled bed volume) Ni2+ charged HisBind metal chelation resin
in a 50 ml Falcon tube and incubated on a rotator for 2 hours. Resin was settled by
centrifugation for 3 minutes at 500 x g, brake off. The resin was subjected to a series
of 15 minute washes on a rotator including 10 volumes binding buffer, 6 volumes
wash buffer (60mM imidazole, 50mM NaCl, 20mM Tris-HCl, pH7.9) and 6 volumes
elute buffer (1M imidazole, 500mM NaCl, 20mM Tris-HCl, pH7.9). The eluate
(elute buffer post incubation with resin) was retained and dialysed against several
changes of PBS overnight. Concentration of the fusion protein was achieved by
filter centrifugation of the eluate at 500 x g using Centriplus concentrators (Amicon)
pore size of 30 (molecular weight cut off point of 30,000). Protein samples were
stored at -20°C. Fractions from each stage of the purification process were routinely
retained and analysed by SDS-PAGE. The Ni2+ charged resin was stripped by
incubation in strip buffer (lOOmM EDTA, 500nm NaCl, 20mM Tris-HCl pH7.9).
For expression of fusion protein from XL1 blue E. Coli containing pGEX-2T based
vector plasmids bacteria were grown in 100ml LB medium containing lOOpg/ml
ampicillin. Induction was performed as above. Bacteria were pelleted by
centrifugation at 5000 x g for 5 minutes and resuspended in 4ml binding buffer. The
suspension, in a tube on ice, was probe sonicated using an ultrasonic generator at
50% power (Dawe Instruments Ltd.) in a series of three 15 second bursts. The
bacterial lysate was centrifuged at 10,000 x g for 20 minutes at 4°C. The supernatant
9+
(soluble fraction) was retained and applied to 2.5ml Ni charged HisBind resin.
Purification and concentration of the His tagged fusion protein proceeded by the
same method used for purification of His tagged fusion proteins from the periplasmic
fraction as described above.
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2.4.6 Determination of Protein Concentration
Protein concentration was measured using a Cecil CE 2041 spectrophotometer by
reading the optical density at 280nm of each protein sample diluted in PBS contained
in a glass cuvette. Protein concentration was calculated according to Beer-Lambert's
law (Stoscheck, 1990):
A280 = sCL
Where A280 is the absorbance at 280nm, 8 is the molar extinction coefficient of the
protein at 280nm, C is the molar concentration of the sample and L is the path length
in cm. For glutathione-S-transferase an absorbance of 1 at 280nm = 0.5mg/ml
(Smith & Johnson, 1988).
2.4.7 Biotinvlation of Protein
Approximately 1 mg/ml of protein was dialysed in 0.1M NaHCC>3, pH 8.3-8.4
overnight at 4°C. To every lOOpl of dialysed protein solution 50pl of biotin 1mg/ml
in H2O was added and then incubated at 4°C overnight. The protein solution was
then dialysed in phosphate buffered saline (PBS: 80mg/ml NaCl, 2mg/ml KC1,
2mg/ml KH2PO4, 11.05mg/ml Na2HP04, pH 7.2) to remove excess biotin.
2.4.8 SDS-PAGE
In preparation for sodium dodecyl sulphate- polyacrylamide gel electrophoresis
(SDS-PAGE), 2 - 3 x 107 eukaryotic cells per ml in a microfuge tube on ice were
subjected to probe sonification by a series of 5 second bursts using an ultrasonic
generator at 50% power (Dawe Instruments Ltd.). Lysates were suspended in an
equal volume of 2 x SDS-PAGE sample buffer (lOOmM Tris-HCl, pH 6.8, 4% SDS,
20% glycerol, 0.02%bromophenol blue, 200mM dithiothreitol) and samples were
heated to 95°C for 5 minutes. Cell lysate, iOpl, was loaded per well of SDS-PAGE
gel, equivalent to approximately 1.5 x 105 cells. Bacterial cells were pelleted from
10ml culture media by centrifugation (4000 x g, 5 minutes), resuspended in 500pl
PBS in a microfuge tube on ice and were subjected to probe sonification by a series
of 5 second bursts using an ultrasonic generator at 50% power (Dawe Instruments
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Ltd.). The bacterial cell lysate was mixed with an equal volume of 2x SDS-PAGE
sample buffer and heated for 5 minutes at 95°C. In order to prepare crude soluble
and insoluble fractions of the bacteria, cells were pelleted from 10ml of culture
media by centrifugation (4000 x g, 5 minutes) and resuspended in 500pi 50mM Tris-
HC1 pH8.0, 2mM EDTA in a microfuge tube. Hen egg lysozyme to a concentration
of lOOpg/ml and then Triton X -100 to a final concentration of 0.1% was added and
the tube incubated at 30°C for 15 minutes. The microfuge tube was placed on ice and
subjected to probe sonication by a series of 5 second bursts using an ultrasonic
generator at 50% power (Dawe Instruments Ltd.). The tube was then centrifuged at
12,000 x g for 15 miuntes at 4°C. The supernatant contains the soluble proteins to
which an equal volume of 2 x SDS sample buffer was added. The pellet, the
insoluble fraction was resuspended in 1 x SDS sample buffer.
Samples (10pl) were electrophoresed using a vertical slab gel system ('Dual mini
slab' Atto). The main separating gel was composed of 7.5%
acrylamide:bisacrylamide (37.5:1) (National Diagnostics), 375mM Tris-HCl, pH8.8,
0.1% SDS, 0.7mg/ml ammonium persulphate and 0.08% TEMED (Sigma). The
percentage of acrylamide:bisacrylamide in the main separating gel was varied from
5% to 14% depending on the samples analysed. The stacking gel was composed of
5% acrylamide (5% acrylamide:bisacrylamide, 125mMTris-HCl, pH 6.8, 0.1% SDS,
0.8mg/ml ammonium persulphate and 0.2% TEMED (Sigma)). The molecular
weight protein markers used were prestained 'Rainbow' markers (Amersham) or
Biorad prestained protein markers. Gels were electrophoresed at a constant current
of 15-20mA per gel for approximately 2 hours. The process was stopped once the
dye reached the bottom of the gel.
2.4.9 Staining SDS-PAGE Gels with Coomassie blue
Proteins electrophoresed through a polyacrylamide gel were visualised by incubating
the gel with Coomassie blue (0.25% Coomassie brilliant blue R250, 10% acetic acid,
45% methanol) overnight and then incubating in a series of changes of excess destain
(10% acetic acid, 20% methanol) for 2 hours to overnight until the background
cleared. Gels were dried using a Biorad gel dryer for 2 hours at 80°C.
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2.5.1 SDS-PAGE of Radiolabeled Samples
In order to enhance autoradiography, SDS-PAGE gels containing 35S labeled samples
were impregnated with Enhance (Dupont). Following electrophoresis gels were first
soaked in protein fixer solution (10% glacial acetic acid (v/v), 30% methanol (v/v))
for 1 hour and then immersed in Enhance for 1 hour. Subsequently gels were
incubated in an excess of water, for 30 minutes, to precipitate the fluorescent
material in the gel. Gels were then dried as above and exposed to X-OMAT XAR-5
autoradiographic film.
2.5.2 Western Blotting
Proteins separated in a SDS-PAGE gel were transferred to a 0.45pm pore
Immobilon-P membrane (Millipore) by electrophoresis in transfer buffer (30mM
Tris, 200mM glycine, 20% methanol) using a Bio-Rad mini transfer blotting kit at
250mA for 60 minutes. After transfer the membrane was incubated in blocking
buffer (50mM Tris, pH 7.4, 150mM NaCl (TBS) plus 5% powdered milk (Marvel)
and 5% normal pig serum) for 60 minutes at RT. The membrane was then incubated
in primary antibody diluted (dilutions used are displayed in section 2.5.4) in the
blocking buffer for 2 hours at RT or overnight at 4°C. The blot was washed 3 times
in TBS plus 0.2% Tween. The secondary antibody conjugated to alkaline
phosphatase diluted 1:1000 in blocking buffer was added to the blot and incubated
for a further hour at RT. The blot was washed 5 times with TBS, 0.2%Tween and
then once in TBS. The blot was developed by soaking with nitro blue tetrazonium
and 5-bromo-4-chloro-3-indoyl phosphate (NBT/BCIP) (1 Sigma tablet per 10ml
H2O). The reaction was stopped by the addition of excess H20.
2.5.3 Far-western/VOPBA-Virus Overlay Protein Binding Assay
To assay the binding of gpl50-His fusion protein to proteins in a western blot, the
membrane was incubated in blocking buffer (as for section 2.5.2 above) for 45
minutes at room temperature. After the initial blocking stage the fusion protein was
diluted in blocking buffer and applied to the blot for 30 minutes to 2 hours at room
RT or overnight at 4°C. The membrane was then washed and primary and secondary
antibody steps followed as above. Alternatively, if a biotinylated fusion protein was
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used an avidin conjugated to alkaline phosphatase Vectastain ABC-AP kit (Vector
Labs) was used according to manufacturers instructions to detect binding. An
alternative blocking buffer used contained 0.1% bovine serum albumin in TBS. To
assay the binding of virus to proteins in a western blot the culture supernatant of
BHK cells infected with MHV-68 (5 days post infection) was incubated with the blot
or for higher concentrations of virus preparations as prepared in section 2.6.8 were
diluted in blocking buffer and applied to blots for 30 minutes to 2 hours at room RT
or overnight at 4°C. The membrane was then washed and primary and secondary
antibody steps followed as for section 2.5.2 above.
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Polyclonal rabbit anti-gpl50-GST 1:500 WB, IS Stewart et al.,
1:250 FACS, 1996
ELISA
Polyclonal rabbit anti-MHV-68 1:500 WB Sunil-Chandra et
IS al., 1992a
Polyclonal swine anti-rabbit IgG AP 1:1000 WB Dako
Monoclonal mouse anti-His(C-term) 1:5000 WB
1:50 FACS
Invitrogen
Monoclonal rat anti-CD4 Neat FACS In House
Monoclonal rat anti-CD8 Neat FACS In House
Polyclonal goat anti-rat IgG FITC 1:500 FACS Serotec
Polyclonal goat anti-rat IgG R PE 1:10 FACS Serotec
Polyclonal goat anti-mouse IgG FITC 1: 50 FACS Serotec
Polyclonal goat anti-mouse IgM
biotinylated
1:100 FACS Serolab
Polyclonal goat anti-rabbit IgG biotinylated 1:500 Serotec
Strepavidin-FITC 1:100 FACS Serotec
Monoclonal rat-anti mouse CD 19 (B cell 1:200 FACS Pharmingen
marker)
Polyclonal rabbit anti-mouse Ig HPX 1:2000 ELISA Dako
Polyclonal rabbit-anti-mouse IgG/A/M HPX 1:2000 ELISA Serotec
Polyclonal rabbit anti-mouse IgG2a 1:1000 ELISA Serotec
Polyclonal rabbit anti-mouse IgG2b HPX 1:500 ELISA Serotec
Polyclonal rabbit anti-mouse IgG 1 1:500 ELISA Serotec
Polyclonal swine anti-rabbit IgG FITC 1:30 FACS
IF
Dako
Table 2.2. Antibodies and Immunodetection Reagents. Conjugates: FITC -
fluorescine isothiocyanate, R-PE - R-Phycoerythrin, HPX - horseradish peroxidase,
AP-alkaline phosphatase, GST - glutathione-S-transferase. FACS - fluorescence
associated cell sorting, WB - Western blots, IF - Immunofluorescence, IS -
Immunostaining, ELISA - Enzyme linked immunosorbent assay. In house normal
rabbit, pig, goat and mouse sera were also used dilutions are indicated in the text.
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Baby Hamster Kidney cell
line (BHK-21)
An immortal fibroblastoid cell line (Stoker &
Macpherson, 1961)
COS (COS-1) SV40 transformed fibroblastoid cell line (Gluzman,
1981)
Sll Mouse derived B lymphoma cell line positive for MHV-
68 episomal DNA (Usherwood et al., 1996c)
NS0 Non-immunoglobulin secreting mouse myeloma cell
line (Kholer and Milstein, 1976).
A20 Mouse B cell lymphoma cell line (Kim et al., 1979)
EL4 A C57BL/6 murine T lymphoma cell line (Ralph, 1973)
C127 (ATCC CRL 1616) Mouse epithelial cell line derived from a mammary
carcinoma (Lowy et al., 1978)
CV-1 African green monkey kidney cells, fibroblastoid
(Jensen et al., 1964)
S31 Mouse derived B lymphoma cell line (Usherwood et
al., 1996c)
Table 2.3. Cell Lines
2.5.6 Tissue culture
Baby hamster kidney cells (BHK-21) were grown in T175 flasks (Nunc) seeded at 2
X 106 cells with BHK growth medium (Glasgow modified Eagle medium (GMEM)
(Gibco BRL) supplemented with 10% (v/v) Tryptose phosphate broth (TPB) (Gibco
BRL) and 10% (v/v) new born calf serum (NBCS) (Harlan Sera Lab), 70pg/ml
penicillin (Merck BDH), 10pg/ml streptomycin (Sigma) and 2mM L-glutamine
(Merck BDH)).
CV-1, COS-1 and C127 cells were grown in T175 flasks (Nunc) seeded at 2 x 106
with Dulbecco's modified Eagle medium (DMEM) (Gibco BRL) containing 10%
Foetal calf serum (FCS) (Globepharm), 70pg/ml penicillin, lOpg/ml streptomycin
and 2mM L-glutamine.
To passage adherent cell types (BHK, C127, COS-1 and CV-1 cells) monolayers
were harvested by washing with 5 ml of versene solution (0.02% versene in sterile
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PBS containing 200pg/ml ethylenediaminetetra acetic acid (EDTA) and 1% phenol
red, pH 7.1-7.3) and then incubating with 5 ml of Trypsin/EDTA solution (tissue
culture grade, Life Technologies, Paisley) until monolayers lifted from plastic. To
dislodge cells and break up clumps flasks were tapped and cells were pipetted up and
down. Trypsinisation was stopped by the addition of 15 ml growth medium. The
cell suspension was transferred to a universal tube and the cells pelleted by
centrifugation at 500 x g for 5 minutes. The supernatant was discarded and the cells
resuspended in 10ml fresh medium ready to be seeded into flasks. Cells were
passaged when confluent (approximately every 3-4 days).
SI 1, NSO, EL4 and A20 cell lines were grown in T75 flasks (Nunc) seeded at 5 x
106 cells with supplemented RPMI 1640 (Gibco BRL) containing 10% FCS, 70pg/ml
penicillin, 10pg/ml streptomycin, 50pM (3-mercapto-ethanol (ME) (Sigma) and 2mM
L-glutamine. To passage non-/semi-adherent cells, flasks were banged to dislodge
cells, the total medium transferred to a universal tube and the cells pelleted by
centrifugation at 500 x g for 5 minutes. The supernatant was discarded and the cell
pellet resuspended in fresh medium ready to be seeded into new flasks. All cell lines
were incubated at 37°C in equilibrium with humidified 5% CO2.
2.5.7 Mammalian Cell Quantification
In order to quantify the number of viable mammalian cells in a suspension, a 1: 1
dilution was prepared with 0.1% Trypan blue (0.1% trypan blue (Gurr) in PBS).
Cells were counted using a haemacytometer, unstained viable cells differentiated
from blue stained dead cells.
2.5.8 Storage & Retrieval of Cells
For long-term storage of cell lines, cells were resuspended at 106 cells/ml in freeze
down solution (10% dimethyl sulfoxide (DMSO) in foetal calf serum). Aliquots of
lml cell suspension/cryovial were frozen gradually in a -70 °C freezer overnight.
Cryovials were then transferred to liquid nitrogen tanks, -180°C, for indefinite
storage.
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Cells retrieved from liquid nitrogen storage were thawed rapidly by placing the
cryovial in a 37°C water bath. The thawed cell suspension was transferred to a
universal tube and 9ml of media was added slowly, with constant swirling. Cells
were pelleted by centrifugation at 450 x g for 5 minutes, resuspended in 7ml fresh
media and transferred into a T25 flask (Nunc).
2.5.9 Transfection of Mammalian Cells with DNA by Electroporation
For transfection, cells were harvested from monolayers of -80% confluency. Cells,
2xl06, were resuspended in 800pl of their standard growth medium and added to an
electroporation cuvette (Equibio). As a standard, 30 pg DNA of chosen plasmid for
transfection was added to the cells and mixed by gentle pipetting. For co-
transfection with viral DNA, 4pg of viral DNA and 30pg of chosen plasmid were
added to the cells together. Using an Equibio electroporator the cells were
electroporated (260V pulse for approximately 18msec, capacity 1050pF) and then
resuspended immediately in 5ml medium. The 5ml was then split between two wells
of a six well plate (Nunc), each well made up to 5ml with medium and incubated at
37°C in equilibrium with humidified 5% CO2. The medium was changed on the
wells 24 hours later and selective agents applied if required.
2.6.1 Ecdvsone-Inducible Mammalian Expression System
Following transfection of mammalian cells with the ecdysone inducible expression
vectors, by electroporation, cells in 6 well plates were incubated for 24 hours. The
medium was then replaced with fresh medium containing the expression induction
agent, Ponasterone A (Invitrogen) at a final concentration of 5pM. Cells were
assayed for gene expression 24 hours post induction.
2.6.2 Generation of Stable Mammalian Cell lines
In order to generate a stable cell line expressing pVgRXR, 48 hours post transfection
with plasmid, cells were split and seeded at 25% confluency into fresh medium
containing Zeocin at 150pg/ml. In the same way, cells transfected with both
pVgRXR and an ecdysone system expression plasmid were split into medium
containing 150pg Zeocin and 150pg hygromycin. Cells were fed with selective
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medium every 3-4 days until foci could be identified. The antibiotic resistant cell
foci were ring cloned. Ring cloning involved removing the medium from the well
and placing a sterile ring (cut from the base of a gilson pipette tip) with a coating of
silica gel (to form a seal) on top of a focus of cells. The cells were harvested by a
versene wash followed by trypsinisation. Cells were transferred to a well of a 24
well plate and grown up in selective medium.
Generation of stable cell lines containing pBabe/puro was also performed by ring
cloning. The selection media used contained puromycin at 2pg/ml. Cells were
selected and subsequently maintained under selection continuously.
2.6.3 P-galactosidase Staining
To identify cellular expression of P-galactosidase, cell monolayers were fixed with
0.5% glutaraldehyde in PBS for 15 minutes. Following two short washes in PBS the
cells were washed twice in detergent solution (40ml PBS, ImM MgC^, 0.02%
Nonidet P40 (Fisons), 0.01% Na deoxycholate) for five minutes. The cells were
then covered in X-gal solution (20ml detergent solution plus 2ml Fe/Fe solution
(50mM potassium ferricyanide and 50mM potassium ferrocyanide), lOOpl X-gal
stock (40mg/ml X-gal (Sigma) in DMSO)). Plates were incubated at 37°C on a
shaker for 1-5 hours to allow P-galactosidase positive cells to stain blue. Wells were
rinsed with water and air dried.
2.6.4 Immunofluorescence Staining
To prepare slides of in vitro cultured mammalian cells for immunofluorescence
o
staining, 5jli1 of cells suspended at 10 cells/ml in PBS was applied to a glass slide
and allowed to air dry on. Slides were then dipped in acetone for 5 minutes to fix the
cells. The slides were allowed to dry and stored at 4°C if not used immediately. To
block the slides lOOjul of 5% normal pig serum in PBS was applied to the cells and
slides were incubated at 37°C in a moist box (as with all further incubations) for 45
minutes. Slides were washed in PBS and then the primary antibody, diluted in PBS
+ 1% BSA (antibody dilutions used are displayed in section 2.5.4) was applied to the
cells. After 2 hours incubation the slides were washed 3 times by immersing in PBS
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for 5 minutes on a shaker each time. The secondary FITC conjugated antibody,
diluted in PBS + 1% BSA, was applied to the cells and incubation was done for 1
hour. The slides were washed 5 times as before. The slides were mounted by
dispensing a drop of 'Citifluor' (Citifluor Ltd. UK) onto the cells and placing a glass
coverslip on top. Fluorescent stained cells were viewed using a UV light microscope
at a wavelength of450nm.
2.6.5 Radiolabelling Cells and Virions with [35S] Methionine
Monolayers of C127 cells, approximately 80% confluent, in six well plates were
infected with MHV-68 at a MOI of 5 pfu/cell (5xl06pfu/106cells/well) or left
uninfected and incubated at 37°C, 5% CO2. After 24 hours the media was removed
from infected and control wells and replaced with 5ml methionine free medium
(Gibco BRL) plus 2mM L-glutamine. Plates were incubated for 30 minutes at 37°C
with 5% CO2. The methionine free media was then removed and replaced with 2ml
labelling media (methionine free media plus 2mM L-glutamine with lmCi/ml 35S-
methionine (Amersham) added). The plate was incubated for 4 hours at 37°C with
5% CO2 in the presence of activated charcoal. The labelling media was then
removed and the monolayer washed with PBS. Subsequently, the monolayer was
scraped using a 1ml syringe plunger into 2 ml RIPA buffer (50mM Tris pH8.0,
150mM NaCl, 0.5% deoxycholate, 1% NP-40, 0.1% SDS) or low ionic strength
buffer (50mM Tris pH8.0, 150mM NaCl, ImM EDTA, 0.5% NP-40). If not used
immediately, radiolabelled cell samples were stored at -20°C.
2.6.6 Radioimmunoprecipitation
Radiolabelled cell samples were dispensed into 500pl aliquots in screw capped
microfuge tubes. Samples were precleared of proteins that bind to protein-A-
sepharose (PAS) by the addition of 35pl 50:50 PAS (50:50 protein-A-sepharose was
prepared by suspending 500 mg of dry PAS resin in 10ml TBS + 5% BSA +0.01%
azide in a 15ml falcon tube, this was incubated at 4°C overnight allowing the PAS to
hydrate. The PAS was washed three times by resuspending the resin in the TBS
buffer and gentle centrifugation (500 x g). Finally the beads were resuspended at
50:50 in TBS buffer (2ml resin to 2ml buffer). This stock was stored at 4°C.
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Following a 30 minute incubation at room temperature the resin was pelleted by
centrifugation, 20 seconds at 2500 x g, and the supernatant was transferred to a new
tube. Antibody; 2.5pl serum or monoclonal antibody, was then added to the
supernatant. The tube was rotated for 2.5 hours at RT. PAS (50:50), 35pl, was then
added to each tube and the incubation was continued for 30 minutes for precipitation
to occur. The tubes were centrifuged briefly (20 seconds, 2500 x g) and the
supernatant aspirated. The pellet was resuspended in 1ml wash buffer (the buffer the
samples were originally harvested in i.e. RIPA buffer) and then repelleted by
centrifugation as before. This process was repeated five times, before the final wash
and the resuspended resin was transferred to a new tube to reduce background caused
by radiolabeled protein adhered to the walls of the microfuge tubes. Following the
final wash the resin pellet was resuspended in 35pi 1 x SDS-PAGE sample buffer.
Tubes were spun to pellet the resin before removing samples of the supernatant for
loading on SDS-PAGE gels.
2.6.7 Immunostaining on Paraffin Embedded Tissues
To dewax, paraffin sections cut onto biobonded slides were placed in xylene for 15
minutes followed by immersion in 100% ethanol for 5 minutes. The slides were then
placed in 0.3% H2O2 in methanol (freshly made up) for 30 minutes. To hydrate the
sections, slides were immersed in a series of ethanol dilutions; 100%, 95%, 70%,
50% and 30% for 30 seconds each and then two times in H2O for one minute.
Followed by immersion of slides in 1% Triton X-100 in H2O for 90 seconds and
then two times in FLO for 5 minutes. Sections were digested with lOmg/ml
proteinase K in 20mM Tris, 2mM CaC^, pH 7.0 for 20 minutes at 37°C. Next, slides
were incubated in PBS plus 2g/L glycine and 5mM EDTA for 5 minutes and then
PBS for 3 minutes. To block, prior to immunostaining, slides were placed flat in a
moist chamber, 2% normal goat serum (NGS) in PBS was dispensed onto each
section and incubation was done for 30 minutes - overnight at room temperature.
Primary antibody, diluted (dilutions used for antibodies are shown in section 2.5.4) in
2% NGS, was applied to slides. Following 2 hours, incubation slides were washed in
PBS 3 times for 5 minutes each. Secondary antibody, biotinylated goat anti-rabbit
IgG diluted 1/500 with 2% NGS in Vector Laboratories solution BA1000 was
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applied to sections and incubated for 2 hours. Slides were washed 3 times as before.
Vector Laboratories solution PK4000 was applied to the sections and slides were
incubated for 30 minutes followed by 3 washes as before. Following addition of the
DAB (diaminobenzidine) substrate (Sigma Fast DAB) sections were monitored
closely for colour change. To stop exposure, slides were washed in PBS and then
H2O. Haematoxylin was used to counterstain the sections and then the slides were
dehydrated through the ethanol dilutions (in reverse order to the hydration process)
and mounted in DPX/xylene.
2.6.8 MHV-68
Murine gammaherpesvirus 68 (MHV-68) was originally isolated from Clethrionomys
glareolus, a bank vole, in Slovakia (Blaskovic et al., 1980). The G2.4 infectious
clone used in these experiments was originally derived from MHV-68 stock supplied
by Professor Blaskovic to the Department ofPathology, Cambridge University.
Working stocks of MHV-68 were prepared by infection of BHK-21 cells, in
suspension, at a multiplicity of infection (MOI) of 0.01. Suspensions were incubated
for 1 hour on a shaker at 37°C. Following infection cells were transferred to T175
Nunc tissue culture flasks containing 50 ml ETC medium and incubated for 6 to 7
days at 37°C, 5% humidified CO2. Monolayers were dislodged by tapping the flasks
and using a scraper (Sterilin), the cells were pelleted by centrifugation at 2000 x g
for 30 minutes at 4°C. The supernatant was discarded and cells were transferred to a
Dounce homogeniser (Wheaton, USA) which was used to disrupt the BHK cells.
The homogenised suspension was centrifuged at 2000 x g for 30 minutes at 4°C. The
supernatant (containing virus) was stored on ice whilst the pellet was homogenised a
second time and recentrifuged at 2000 x g for 30 minutes at 4°C. Supernatants were
pooled and dispensed into 200pl or 500pl aliquots and stored at -70°C until use.
BHK lysate was prepared in the same way omitting infection of cells.
2.6.9 Vaccinia Virus
Vaccinia virus recombinants, VVgpl5° and VVgpt, had been generated previously by
Dr. J P Stewart using vaccinia strain WR (Stewart et al., 1999). Vaccinia virus
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working stocks were prepared by infection ofCV-1 cell monolayers in T175 flasks at
a MOI of 0.01. After 3 days incubation at 37°C, 5% humidified CO2, virus was
harvested by the same method used for MHV-68 virus preparation.
2.7.1 Inbred Mice Strains
For in vivo work the mouse strains used were supplied by Bantin & Kingman aged 3
- 4 weeks of age on arrival and included:
BALB/c Haplotype H-2d
C57BL/6 Haplotype H-2b
2.7.2 Infection of Experimental Animals
Prior to intranasal infection with virus, mice were anaesthetised using halothane
(BOC Gases). For infection with MHV-68 and vaccinia virus recombinants, the
required titre of virus was diluted in 40pl and 50pl PBS, respectively, and
administered to the nose of the animal. To remove organs for analysis, animals were
killed by cervical dislocation and the lungs and spleen immediately dissected from
the cadaver. Lungs were placed in cryovials and frozen at -70°C, spleens were
deposited into 5 ml medium and stored on ice for infectious centre assays on the
same day.
2.7.3 Virus Titration
Organs to be assayed for MHV-68 titre were stored at -70°C, thawed rapidly at 37°C
and kept on ice. The organ was homogenised in a glass homogeniser (Soham
Scientific, UK) with 1ml cold BHK culture media. The homogenate was transferred
to a cryovial and frozen at -70°C. The homogenate was thawed rapidly as before
and centrifuged at 2000 a g for 5 minutes at 4°C to pellet cell debris.
Tissue homogenates or virus samples were diluted in bijoux, in duplicate, in a series
of 10 fold dilutions. To each bijoux a 200pl suspension of 106 BHK cells were
added. The dilutions, at a final volume of 2ml of BHK growth medium were
incubated at 37°C on a shaker (200 rpm) for 1 hour to allow virus adsorption.
Following absorption samples were mixed by vortexing and then each sample was
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poured into a 60mm petri dish (Falcon) containing 4ml medium. Petri dishes were
gently swirled to evenly distribute cells and incubated at 37°C, 5% CO2, for 4 days.
The medium was removed and 3ml of 4% formal saline was added to each dish to fix
the cell monolayers. Following fixation for a minimum of 15 minutes the formal
saline was removed and 0.1% toludine blue was added to stain the cells. After a
minimum of 15 minutes the toludine blue was poured off and the plates rinsed gently
in water and allowed to dry. Virus plaques were visualised and counted using a light
microscope. Virus titre was referred to as plaque forming units (pfu).
For titration of vaccinia virus, organs were prepared in the same way as for MHV-68
however, serial dilutions were applied to confluent monolayers of CV-1 cells in six
well plates. Following a 1 hour incubation at 37°C, 5% CO2, to allow for virus
adsorption the inoculum was replaced with 5ml medium. Cells were fixed and
stained following 3 days of incubation at 37°C, 5% CO2'
2.7.4 Infectious Centre Assay
To detect infectious centres, the spleen of infected animals was removed
immediately after death and placed into 5ml of ice cold supplemented RPMI (as in
section 2.5.6). The cells were teased from the spleen using sterile forceps in a 60mm
petri dish containing 5ml supplemented RPMI. The cells were transferred to a
universal tube and pelleted by centrifugation at 500 x g, 4°C for 5 minutes. The
supernatant was discarded and the cells resuspended by gently tapping the universal
tube. In order to lyse the red blood cells, 1ml of sterile H2O was added to the cells
and then immediately afterwards 9ml of PBS was added. The cells were pelleted as
before and resuspended in 10ml supplemented RPMI. Large clumps of red cell
ghosts were allowed to settle and then the cell suspension was carefully pipetted off,
transferred to a bijoux and kept on ice. Petri dishes were set up with 6ml
supplemented RPMI containing 106 fresh BHK cells in suspension. Spleen cells
were counted and then, in duplicate, a 10 fold series of cell numbers were added to
the 60 mm Petri dishes e.g. 107, 106 and 105 splenocytes/petri dish. Remaining
splenocytes, not plated out, were frozen at -70°C to lyse the cells, for subsequent
infectious virus titration. The plates were incubated for 5 days at 37°C, 5% CO2.
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Plates were fixed and stained as described for plaque assays. Numbers of plaques/
plate were counted using a light microscope and the infectious centre titre was
calculated per 10 splenocytes and per spleen.
2.7.5 Plaque Purification
Cells harbouring virus that had under gone homologous recombination with the
recombinant virus plasmid constructs formed plaques expressing the green
fluorescent protein (GFP). These were detected by fluorescence microscopy using a
UV filter (excitation at 450 ± 25nm). Plaques expressing GFP were picked, using a
pasteur pipette, from cell monolayers that had been overlayed with agar (2% low
melting point 'Seaplaque' agar (Flowgen) in PBS mixed with an equal volume of
media) 24 hours post transfection, and each transferred to 1ml ETC media in a glass
universal. The universals were sonicated for 60 seconds in a bath sonicator. The
picked plaque suspensions were serially diluted from 10"1 to 10"5 and 400pl of each
dilution was inoculated onto BHK cell monolayers in six well plates. After a 1 hour
incubation at 37°C to allow adsorption, the inoculum was removed and cell
monolayers were washed with 5ml of ETC media. An agar overlay, as above, was
applied to each well. Four days after infection green plaques were picked, serially
diluted and plated out as before. This process was repeated at least four times in
duplicates.
As an alternative to plaque picking, virus cloning was also done by inoculating a
series of 2 fold dilutions of virus samples onto BHK monolayers in 96 well plates.
Cells of wells containing one virus plaque, expressing GFP, were scraped into a
volume of 200pl of cell culture media and each transferred to a glass universal. The
universals were bath sonicated for 60 seconds to lyse the cells. The suspensions
were then used for subsequent dilutions and inoculation into BHK monolayers in 96
well plates. The same process was used when CI27 cells were used instead of BHK
cells.
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2.7.6 Virus Neutralisation Assay
To assay the ability of antisera to block MHV-68 infection a standard plaque
reduction assay was done. Sera were heat treated at 56°C for 30 minutes to destroy
complement. Virus, lOOpfu, was incubated with the heat treated antisera diluted in
phosphate buffered saline at a final volume of 50pl. After an hour incubation at
37°C the virus/antiserum mix was added to confluent monolayers of CI27 cells in 6
well plates in a final volume of 1ml standard media. Following incubation at 37°C
for one hour the virus/antiserum mix was removed, the monolayer washed with
medium and then 6 ml of medium added. Plates were incubated for 5 days at 37°C,
5% CO2 and then fixed with 4% formal saline, stained and counted as for a standard
plaque assay.
2.7.7 Analysis of Protein Blocking MHV-68 Infection
Confluent CI27 cell monolayers in six well plates were incubated with fusion
protein, 2pM in 500pl standard CI27 culture media for one hour at 4°C on a shaker.
Virus, 200 pfu was added in 200pl media and incubation was continued for one hour
at 4°C and then shifted to 37°C for one hour to allow penetration of virus into cells.
The monolayer was washed twice with an excess of low pH buffer (40mM citric
acid, lOmM KCL, 135mM NaCl, pH3.0) to inactivate and remove remaining
extracellular virus (Boyle & Compton, 1998). The standard CI27 culture media,
6ml, was added to each well. Plates were incubated for 5 days at 37°C, 5% CO2 and
then fixed with 4% formal saline, stained and counted as for a standard plaque assay.
In addition, the ability of fusion protein to block infection in suspension was done in
oredr to reduce the volumes used, 106 cells were suspended in 250pl media
containing 2pM fusion protein in a 1.5ml microfuge tube. Tubes were rotated at 4°C
for one hour. Virus, 200 pfu in lOOpl ofmedia was added and tubes were incubated
for one hour at 4°C. The temperature was shifted to 37°C for one hour. Cells were
pelleted by centrifugation at 500 x g and washed twice with 1ml of low pH buffer as
above, pelleted and resuspended in CI27 culture media. The cell suspension was
transferred to a well of a six well plate made up to 6ml with culture media.
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2.7.8 Preparation of Serum from Blood
After animals were killed by cervical dislocation blood was collected from the heart.
To prepare serum blood was incubated overnight at 4°C in 0.2ml microfuge tubes to
allow clotting to occur. The following day tubes were centrifuged at 10,000 v g for
20 minutes. The upper layer of serum was transferred to a new tube and stored at -
20°C.
2.7.9 MHV-68 Enzvme-Linked Immunosorbent Assay (ELISA)
Reagents:
Borate buffered saline (BBS): Boric acid, 61.85g, disodium tetraborate 95.4g, NaCl
43.85g made up to a final volume of 10 litres in distilled water, pH 8.2.
Blocking buffer: BBS plus 2% normal rabbit serum.
Wash buffer: BBS plus 0.05% (v/v) Tween 20.
Antigen dilution buffer: BBS plus 1% normal rabbit serum, 0.01% Tween 20.
Carbonate/bicarbonate buffer (pH 9.8): - 22ml of 0.2M sodium carbonate solution
added to 28ml 0.2M sodium bicarbonate solution.
UV inactivated MHV-68: MHV-68 stock (3.8x108 pfu/ml) was UV irradiated for 30
minutes.
HRP substrate solution: Sigma Fast™ OPD peroxidase substrate tablet set - one o-
phenylenediamine dihydrochloride (OPD) tablet and one urea hydrogen
peroxidase/buffer tablet dissolved in 20ml H20 - yields a solution of 0.4mg/ml OPD,
0.4mg/ml urea hydrogen peroxide and 0.05M citrate phosphate buffer.
The mouse MHV-68 sera conversion ELISA was carried out (in accordance with
Usherwood et al, 1996a) on mouse sera in order to determine the level of MHV-68
specific antibody. In preparation, wells of Immulon 4 96 well plates (Dynatech),
were coated with rabbit anti-MHV-68 hyper-immune serum diluted 1/1000 in
carbonate/bicarbonate buffer, lOOpl was added per well and the plate incubated
overnight at 4°C. The plate was flicked to remove the serum solution and then
blocked by the addition of lOOpl/well of blocking buffer and incubation at 37°C for
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one hour. The plate was washed six times in wash buffer and then tap water each
time. After the final wash lOOpl of UV inactivated MHV-68 antigen diluted 1/64 in
antigen dilution buffer was added per well and the plate incubated for one hour at
37°C. The plates were washed six times as before. Each mouse serum sample was
diluted 1/20 and titrated in 1/2 serial dilutions down the plate. As a positive control
MHV-68 hyperimmune mouse serum diluted at 1/400 and as a negative control
normal mouse serum diluted at 1/20 were titrated down the plate in 1/2 serial
dilutions. The total volume per well at this stage was lOOpl. The plate was
incubated for one hour a 37°C and then washed as before. Horseradish peroxidase
(HPX) conjugated rabbit anti-mouse immunoglobulin was diluted to 1/2000 in
antigen dilution buffer and lOOpl added per well. Alternatively, at this stage HPX
conjugated rabbit antisera against different mouse immunoglobulin isotypes was
used (refer to antibody dilutions in section 2.5.4). Following incubation for 1 hour at
37°C the plates were washed 6 times as before. lOOjul ofHRP substrate solution was
then added to each well. After 15 minutes incubation at room temperature the
reaction was stopped with lOOpl of 12.5% (V/V) sulphuric acid. The sample OD
value was measured at 490nm using an ELISA plate reader (DYNATECH MR5000).
To determine the relative levels of MHV-68 specific antibody OD values were
plotted on a standard curve generated from the positive control MHV-68
hyperimmune mouse serum values, calculated as 1/mean OD values per dilution.
2.8.1 Preparation of Splenic Lymphocytes for Binding Assays
For preparation of splenocytes for FACS binding assays, a fresh spleen was removed
from a Balb/c mouse and placed into a 60 mm petri dish containing 5 ml of chilled
complete RPMI medium. Using sterile forceps the spleen cells were teased out into
the medium. Spleen casing and clumps were discarded, the contents of the petri dish
was pipetted into a universal. The cells were pelleted by centrifugation at 500 x g,
4°C for 5 minutes. Cells were resuspended in 10ml medium and the clumps allowed
to settle. The medium was then transferred to a universal tube containing 10ml of a
lymphoprep reagent; histopaque (Sigma). Pipetting was done slowly to ensure the
media formed a separate layer on top of the histopaque. Following centrifugation at
2000 x g for 20 minutes, brake off, the layer of lymphocytes that formed between the
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media and the histopaque was gently pipetted off using a pasteur pipette. The
lymphocytes were transferred to a fresh universal and the volume made up to 20ml
by the addition of ~15 ml media. The cells were centrifuged at 900 x g for 10
minutes, brake off, resuspended in 20ml fresh media and centrifuged a further 10
minutes at 500 x g, brake off. The cells were resuspended in 20ml fresh media, a
sample was taken for counting and the cells pelleted as before and resuspended in
media at the required cell concentration.
2.8.2 MACS Preparation of B Cells
B cells were purified from splenic lymphocyte preparations for binding assays by
magnetic associated cell sorting (MACS). Splenic lymphocytes were resuspended
in ice cold 1% foetal calf serum in PBS (PBS/FCS) at a concentration of 108
cells/900pl. To 900pl of cell suspension lOOpl of anti-CD43 microbeads (Miltenyi
Biotec GmbH) was added. The mixture was incubated at 4°C for 15 minutes and
then made up to 15 ml with FCS/PBS. The cells and beads were pelleted by 5
minutes centrifugation at 500 x g and then resuspended in 1ml PBS/FCS, this was
then loaded onto a MACS column (type BS, capacity 108 cells, Miltenyi Biotech
GmbH) held in the magnetic cell sorter apparatus (Miltenyi Biotech GmbH). The
column was washed with 15 ml PBS/FCS and the total flow through (containing the
purified B cells) was collected. The cells were pelleted as before and resuspended in
medium as quickly as possible. To assess the purity of the B cells FACS staining
was done.
2.8.3 FACS Analysis & Binding Assay
Cells, 106per well of a 96 round bottom well plate (Nunc), were suspended in 200pl
FACS buffer (PBS, 1% bovine serum albumin (BSA), 0.2% sodium azide) for 45
minutes. Cells were pelleted by centrifugation at 500 x g, brake off, for 5 minutes
and resuspended in either a total of 50pl of fusion protein preparation, 50 pi of
MHV-68 virus preparation or 50pl of BHK cell lysate each diluted in FACS buffer
with 0.2% sodium azide present and incubated at 37°C for 1.5 hours. Cells were
washed 3 times in FACS buffer. The washing process consisted of pelleting the cells
by centrifugation at 500 x g, (brake off) for 5 minutes, pipetting off the supernatant
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gently by hand, resuspending the cells by vortexing the plate and then adding FACS
buffer. Cells were resuspended in 50pi primary antibody, either rabbit anti-gpl50
antibody or anti-His antibody diluted (1:250 and 1:50 respectively) in FACS buffer
and incubated at 4°C for 60 minutes. Cells were washed as before and then
incubated with the secondary swine anti-rabbit FITC antibody (30pl/well) for 30
minutes at 4°C. Following this, cells were washed 5 times in FACS buffer and then
resuspended in 200pl of 1% formal saline. Cells were sorted using a FACStar
(Becton Dickinson) FACS machine operated by Alan Ross, a technician within the
department. Routinely events from 10,000 cells were used for analysis. The marker
for positive cells was postioned at 1% of the events from primary and secondary
antibody alone. When splenocytes were used lymphocytes were discriminated for by
cell size and granularity.
FACS staining for cell surface markers was done as the above method (omitting the
initial protein incubation step), the anti cell surface marker antibody as the primary
antibody followed by the appropriate anti-primary Ig species secondary antibody if
required (working dilutions of antibodies in FACS buffer are shown in section 2.5.4).
If double staining was done the primary antibodies were added simultaneously.
2.8.4 ELISA Binding Assay
CI27 cells were seeded at 1 x 104cells/well of a flat bottomed 96 well plate (Nunc).
After 12 hours, wells contained confluent monolayers required for the cell binding
assay. Cells were washed with PBS and then fixed with 4% paraformaldehye in PBS
for 45 minutes. Wells were washed twice with PBS and then lOOpl of normal pig
serum diluted at 1:500 in FACS buffer was added to wells as a block. Following 30
minutes incubation at RT the block was removed and either 50pl fusion protein
preparation, 50pi MHV-68 virus preparation or BHK lysate, diluted in FACS buffer,
was added to wells and incubated for 1.5 hours at 37°C. Wells were washed 3 times
with PBS and then 50pi of primary antibody (anti-gpl50 antibody or anti-His
antibody) was added. After 1 hour at RT wells were washed 3 times with FACS
buffer. Alkaline phosphatase conjugated secondary antibody was added, 50pl, and
wells were incubated for 30 minutes at RT. The plate was then washed 5 times with
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PBS and 50pl/well of alkaline phosphatase substrate NBT/BCIP (Sigma) was added.
After a 60 minute incubation at RT the optical density of the wells was read, at
405nm wavelength, using a Dynatech MR5000 ELISA plate reader.
Gene Gun Reagents & Methods
2.8.5 Precipitation of DNA onto Microcarriers
To 49mg of 1.6pm gold microcarriers (Biorad) in a 1.5 ml microfuge tube 120pl of
0.1M spermidine (Sigma) was added. The tube was vortexed for a few seconds and
then sonicated for 5 seconds to break up clumps of gold particles. To the
gold/spermidine mix lOOjul of lmg/ml DNA was added. The tube was vortexed for
<5 seconds. While vortexing the tube at a moderate rate, 120pl of 1M CaCl was
added dropwise to the mixture. The mixture was allowed to precipitate at RT for 10
minutes. The tube was spun briefly at 2000 x g to pellet the gold. The supernatant
was discarded and the pellet resuspended by flicking the tube gently. The pellet was
washed 3 times with 1ml 100% ethanol, between each wash the gold was pelleted by
a brief spin at 2000 a g. After the final ethanol wash the pellet was resuspended in
200pl of 100% ethanol containing 0.0lmg/ml polyvinylpyrrolidone (PVP) (Biorad).
The mixture was transferred to a 15ml polypropylene Falcon tube and the volume
made up to 7ml with the ethanol /PVP solution. If not used immediately for tube
preparation the DNA/microcarrier suspension could be stored at -20°C for up to two
months.
2.8.6 Loading the DNA/Microcarrier Suspension into Gold-Coat Tubing
A 75cm length of Gold-Coat tubing (Biorad) was loaded into a Tubing Prep Station
(Biorad) and high grade nitrogen gas (99.998%) was allowed to flow through the
tubing at 0.3-0.4 litres per minute (LPM) for at least 15 minutes prior to use to ensure
the tubing was dry. The tubing was attached to a peristaltic pump and then
approximately 3 ml of microcarrier/DNA suspension, while being gently vortexed,
was drawn into the tubing. The tubing was quickly brought to a horizontal position
and slid into the Tubing Prep Station. During this procedure the microcarriers settled
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in the tube and the ethanol was immediately pumped from the tube. The tube was
then rotated 180° to allow the gold to begin coating the inside of the tubing. After 5
minutes the tubing was rotated continuously. Following the first 5 minutes of
rotation the nitrogen gas supply was turned on at 3.5 LPM to dry the Gold-Coat
tubing while rotating for a further 15 minutes. The tubing was removed from the
Tubing Prep Station and cut into 1.27cm bullets. Each bullet was examined and
those insufficiently coated with gold were discarded. The bullets were stored with
desiccant in a tube sealed with parafilm at 4°C.
To quantitate the DNA in a bullet the inside of the bullet was flushed with 500pl
H20 to elute the gold particles. The suspension was centrifuged briefly at 600 x g to
pellet the gold particle and the amount of DNA present in the supernatant was
quantified by fluorometry as described in section 2.1.3. Routinely, approximately
1 fig ofDNA was present per bullet.
2.8.7 In Vitro Particle Delivery
To test the expression of plasmid from gene gun bullets in vitro, CI27 cells at 80%
confluency in six well plates were used. The cells were washed once with DME
containing no additives. The wash was removed. The bullet for testing was loaded
into the Helios Gene Gun (Biorad) and the cells were fired on directly at a pressure
of 40 psi of high grade (99.995%) helium (BOC Gases). Standard growth medium
for CI27 cells was replaced in the wells immediately post gene gun delivery. Cells
were harvested 6 and 24 hours post firing to assay for mRNA expression (refer to
section 2.3.5).
2.8.8 In Vivo Particle Delivery
Prior to delivery of DNA into the abdominal epidermis, the abdominal fur of each
mouse was clipped as closely as possible using an electrical minishaver (Wahl). The
spacer on the nozzle of the Helios Gene Gun was held against the abdomen of the
mouse. The DNA coated gold particles were discharged into the skin at a pressure of
500 psi. One bullet was discharged per animal per immunisation with each plasmid.
Gene gun mediated immunisations were carried out without the use of anaesthesia.
122
CHAPTER 2 MATERIALS & METHODS
For tissue sections, the target animal was killed by cervical dislocation and the area
of the skin which was fired onto was excised using scissors. For fixation, the skin
sample was placed into 10% formal saline overnight and then removed to 70%
ethanol. Samples were embedded in paraffin wax and 6pm sections were cut onto
biobonded slides. Haematoxylin and eosin (H & E) staining was performed by





Genetic studies of herpesviruses have provided a considerable amount of information
on the biology and molecular biology of these viruses. An important approach used
to determine the function and importance of viral genes for the replication of
herpesviruses is the study ofmutant and recombinant viruses in which specific genes
are dysfunctional or mutated. Mutant viruses have been isolated from herpesvirus
populations on the basis of altered plaque phenotype (Ejercito et al., 1968), drug
resistance (Kit & Dubbs, 1963, Tognon et al., 1988, Pelosi et al., 1998) and host
range properties (Aurelian & Roizman, 1964). With the power ofmolecular cloning
techniques it is possible to generate recombinant viruses with specific genes of
interest made dysfunctional by insertion into, mutation and deletion of the gene of
interest. With regard to herpesvirus glycoproteins many mutant viruses, particularly
for HSV-1, have been generated and isolated with dysfunctional glycoprotein genes
(e.g. Forrester et al., 1992, Balan et al., 1994, Dijkstra et al., 1996, Wang & Hutt-
Fletcher, 1998). This has provided the opportunity to determine the function of each
individual glycoprotein in the context of the virus lifecycle by studying the
phenotype of the recombinant viruses in comparison with that of wild type virus in
vitro and in vivo.
The inability of EBV and KSFIV to grow permissively in cell culture systems has
hampered the study of the molecular biology of these gammaherpesviruses. In
contrast the relatively efficient replication ofMHV-68 in vitro indicates potential for
more amenable genetic manipulation to generate recombinant viruses. In order to
determine the function of gpl50 the aim was to generate a gpl50 'knock out' (KO)
virus, unable to express gpl50.
3.1.2 Gpl50 KO Recombinant Virus - Cloning Strategy
The preliminary strategy used to generate a gpl50 negative recombinant virus is
summarised in figure 3.1.1. The intention was to delete part of the gpl50 gene and
insert a gene cassette encoding green fluorescent protein (GFP) into the gpl50 gene
within the virus genome using homologous recombination. GFP, originally derived
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from the jelly fish Aequoria victoria, fluoresces green upon excitation by UV light
(450nm wavelength) (Zolotukhin et al., 1996). Within the gene cassette the GFP
gene is under the control of the constitutive CMV immediate early promoter
(CMVIE) and GFP would therefore be expressed during productive replication of the
virus and hence act as a fluorescent marker for the selection of recombinant viruses.
This marker is particularly advantageous as it allows early detection of recombinants
before extensive cytopathic effect is observed and visualisation of GFP by UV
microscopy avoids disruption of the continued growth of the virus. GFP is a tool
increasingly used in molecular biology detection systems including the identification
of recombinant herpesviruses (Duboise et al., 1996, Delecluse et al., 1998, Prichard
et al., 1999).
The plasmid pSP72/gpl50 encoding the entire gene for gpl50 was digested with
restriction enzyme Accl. This digest resulted in the removal of a 132bp fragment
from the gpl50 gene (for position ofAccl sites in gp!50 see figure 1.8). Following
this the Accl cut ends were blunt ended using T4 DNA polymerase. A 1.6kbp DNA
fragment containing the GFP gene, flanked by the CMV immediate early promoter
(CMVIE) and the Simian virus 40 polyadenylation signal (SV40pA) was amplified
from the plasmid pEGFP-Cl, by PCR using Pfu DNA polymerase and primers
CMV1 and SV401 (refer to section 2.1.8 for primers and PCR conditions). The PCR
product was purified and blunt end ligated into the prepared cut pSP72/gpl50. The
deletion of part of the gpl50 gene was designed to ensure that in the event that the
GFP cassette was lost from the recombinant virus genome the gpl50 gene would
remain dysfunctional and the virus would be unable to revert to wild type. The left
and right hand gpl50 sequence flanking the GFP cassette, required for homologous
recombination with complementary sequences in the viral genome, were 1023bp and
365bp in length, respectively. The ligation mix was used to transform competent E.
coli by the heat shock method. Of the 200 colonies that grew, selected using
ampicillin, 12 were picked, grown up in liquid culture and their plasmid DNA
extracted. One plasmid preparation was identified which contained the GFP cassette,
this produced the correct banding pattern (bands of 4kbp, 1.4kbp and 200bp)
following digestion of the plasmid preparations withTccI as shown in figure 3.1.2.a.
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Accl cut and then blunt ended PCR amplification of
GFP gene cassette
4. Co-transfection into BHK cells
MHV-68 genome | y
Homologous recombination
□
Recombinant gp150 negative MHV-68
n— GFP|sv4o| -a
The method designed to generate a recombinant MHV-68 virus lacking a
functional gpl50 gene and encoding the green fluorescent protein (GFP) gene
cassette. Step 1. pSP72/gpl50 is cut with AccI and blunt ended. Step 2. A 'GFP'
gene cassette containing the GFP gene flanked by a CMV immediate early
promoter (CMV) and the SV40 polyadenylation signal (SV40), is cloned by PCR
using iPfii> DNA polymerase. Step 3. The cloned gene cassette is blunt end ligated
into the Accl cut pSP72/gp 150 to create pgpl50/gfp-Cl. Step 4. Purified MHV-68
genomic DNA and the pgpl50/gfp-Cl are co-transfected into BHK cells by
electroporation. Homologous recombination between the gpl50 gene of MHV-68
and the disrupted gpl50 gene of pgpl50/gfp-Cl yield a recombinant gpl50
knockout MHV-68.
Figure 3.1.2. Analysis of pgpl50/gfp-Cl plasmid construct for the generation
of a gpl50 knock out recombinant virus
Restriction digestion and polymerase chain reaction (PCR) analysis of
pgpl50/gfp-Cl to confirm green fluorescent protein (GFP) encoding cassette
insertion and orientation, (a) Restriction digest of pgpl50/gfp-Cl using Accl,
Lane -1:1 kbp marker, 2: pgpl50/gfp-Cl, bands at ~4kbp, 1.4kbp and a faint
band at 200bp. (b) PCR to determine presence and orientation of gfp in
pgpl50/gfp-Cl. Primers for gfp\ CMV1 & SV40 1 used to determine presence of
gfp (lanes 2-5) primers PAG1 & SV40 1 were used to check orientation of gfp
(lanes 6-9). Lane -1:1 kbp DNA ladder marker, 2: pEGFP-Cl positive control, 3
& 7: pSP72/gpl50 negative control, 4 & 8: pSP72/gpl50 negative control, from
small scale DNA preparation, 5 & 9: pgpl50/gfp-Cl small scale DNA
preparation, 6: pgpl50/gfp-Cl ligation mix positive control.
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PCR was used to determine the orientation of the inserted gene cassette. PCR using
the primers PAG1 (positioned in gpl50) and SV401 produced a 2kbp product
confirming that the GFP insert was orientated in the same transcriptional orientation
as the gpl50 gene it had been inserted into as shown by figure 3.1.2.b (refer to
section 2.1.8 for primers and PCR conditions). A large scale preparation of this
plasmid, called pgpl50/gfp-Cl, was made ready using the CsCl method, for
transfection into mammalian cells. Pgpl50/gfp-Cl (30pg) was transfected into BHK
cells to check for expression of GFP, by UV microscopy green fluorescent cells
could be identified 6 hours post transfection.
Pgpl50/gpf-Cl (30pg) and purified MHV-68 genome (5pg) were co-transfected into
BHK cells by electroporation. By 24 hours post transfection cells expressing GFP,
exhibiting green fluorescence, were detected. The green fluorescent areas of cells
spread within the monolayer and green fluorescent plaques had formed by four days
post transfection. Present with the 'green' plaques were also 'white' wild type (non-
fluorescent) plaques at an approximate ratio of 1:12. Green plaques were picked and
the virus contained within was serially diluted and plated with fresh BHK cells which
also gave rise to both 'green' and 'white' plaques at an approximate ratio of 1:9
respectively. This process was repeated a further two times by which point only
'green' plaques could be observed (see figures 3.1.3. & 3.1.4.). 'Green' plaques did
not differ in morphology or development rate in comparison to wild type plaques.
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Figure 3.1.3. Plaque purification of recombinant virus expressing green
fluorescent protein
Plaque pick number
To generate a recombinant gpl50 knock out virus MHV-68 DNA (5pg) and
pgpl50/gfp-Cl (30pg) were co-transfected into BHK cells. Plaque purification
was done on BHK cells to purify virus expressing green fluorescent protein (GFP)
from wild type virus. The levels of wild type MHV-68 (squares) and GFP
expressing recombinant virus (triangles) present in sequential plaque picks is
shown. The limits of detection for plaque picks 1-4 were 10, 10, 100 and 1000 pfu
respectively. This was due to the increasing titres of GFP expressing virus. The
titres of virus expressing GFP were determined by UV microscopic examination
and wild type virus were determined by light microscopic examination, following
formal saline fixation and toluine blue staining of monolayers. Bars denote
standard deviation of duplicate samples. Pfu- plaque forming units.
Figure 3.1.4. Recombinant MHV-68 expression of green fluorescent protein
Plaques present in BHK cell monolayers three days after infection with virus
derived from 'green' plaque picks of recombinant MHV-68 virus expressing green
fluorescent protein (GFP), as viewed by phase contrast light microscopy (i) and by
UV microscopy (ii). The GFP expressing plaques were produced in the generation
of a gpl50 knockout virus following the co-transfection of MHV-68 DNA and
pgpl50/gfp-Cl into BHK cells. Initial plaque picks (A) gave rise to both 'green'
plaques (green arrows) and wild type 'white' plaques (white arrows). The later
sequential plaque picks (B) gave rise to only gpl50 KO 'green' plaques. Original
magnification: 50x
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3.1.3 DNA Analysis of 'Green' Virus
DNA analysis of the 'green' virus was performed to check that the virus was free
from wild type MHV-68 and to determine if the desired homologous recombination
with the gpl50 gene had occurred. PCR was performed on DNA extracted from
'green' virus cultures to check for the presence of wild type gpl50. At this stage
these cultures had been passaged four times, DNA was extracted from limiting
dilution cultures of the fifth passage. Primers PAG 11 and MA2 were used which
flank the region of gpl50 into which the GFP cassette was inserted (for PCR
conditions refer to section 2.1.8). The predicted product resulting from wild type
was 1059 bp, the expected product generated from the recombinant virus construct
was 2.68 kbp. As figure 3.1.5. shows, for all 'green' virus samples tested a wild type
gpl50 band was produced. The predicted recombinant virus band was detected for
one clone (a faint band is present in lane 7 of figure 3.1.5.). The absence of
recombinant gpl50 bands in other samples, despite the visible presence of green
fluorescent plaques, was likely to be due to competition from the considerably
shorter wild type DNA target. This PCR cannot be used to quantify the ratio ofwild
type to recombinant gpl50 present for this reason.
From this data it was clear wild type gpl50 DNA was present suggesting the
presence of wild type virus however, all plaques appeared to display green
fluorescence i.e. 'white' wild type plaques were not observed. Speculation included
the possibility that the green virus only produced plaques when some form of
attenuated helper virus (slow growing or unable to form plaques) was present. To
test this theory limiting dilutions of green virus at 0.4 pfuAvell were plated out on
BHK monolayers in 96 well plates. All plaques observed exhibited green
fluorescence. DNA was extracted from plaque positive and negative wells four days
post infection and PCR was done to detect wild type and recombinant gpl50. If the
recombinant virus was able to enter cells (via gpl50 supplied in trans by growth with
a helper virus), replicate, but was not able to spread without helper virus it may be
possible to detect independent recombinant virus by PCR. That is to say, wells in
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Figure 3.1.5. PCR analysis to check for the presence of wild type MHV-68
gpl50 DNA in green fluorescent 'gpl50 knockout' MHV-68 clones
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2. -ve control -BHK DNA
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To generate a recombinant gpl50 knock out (KO) virus MHV-68 genomic DNA
and pgpl50/gfp-Cl were cotransfected into BHK cells. Homologous
recombination resulted in the production of viruses expressing green fluorescent
protein (GFP). Plaque purification was done until all plaques observed exhibited
green fluorescence. In order to determine if the consistently green fluorescent
plaques were free of wild type virus, DNA was extracted five days post infection
of BHK cells. Polymerase chain reaction (PCR) analysis, 25 cycles, was done
using 0.5pg and 0.05 pg of extracted DNA with primers PAG11 and MA2 which
flank the site in gpl50 of GFP gene cassette insertion. The predicted size of
product amplified from the designed recombinant construct was 2.68kbp, and
1059bp from wild type gpl50. The arrows indicate the position of these products -
mt and wt respectively. The numbers on the left indicate the size of thelkbp DNA
ladder marker bands in bp.
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which no plaques were observed may have recombinant virus present alone which
have undergone one round of replication. This assay aimed to test the theory that
plaques occur only where helper virus with wild type gpl50 and recombinant virus
co-localise. DNA samples extracted from 16 randomly selected wells of a 96 well
plate were analysed by 25 cycles of PCR, using primer pair PAG 11 and MA2 (for
primers and PCR conditions see section 2.1.8). By PCR, the wild type and
recombinant product always co-localised and correlated precisely to the wells which
were observed to have 'green' virus present i.e. plaques expressing GFP were seen
(see figure 3.1.6.a). Only those wells which displayed green fluorescing cells were
positive by PCR. To improve sensitivity and to detect virus specific bands (the PCR
was prone to non specific products - also present using BHK DNA alone as seen in
figure 3.1.6.a) the PCR products, following agarose gel electrophoresis, were
transferred to a nylon membrane. The membrane was probed with a 32P
radiolabeled probe generated by random primed labelling using the entire gpl50
gene as a template. As figure 3.1.6.b shows consistent co-localisation of
recombinant and wild type PCR products was detected, neither product was observed
independent of the other. Lanes of the Southern blot that appeared negative after 24
and 48 hour autoradiographic film exposure were cut from the blot and exposed to
autoradiographic film independent of the positive lanes for longer periods of time (up
to two weeks), no further bands were detected.
3.1.4 Southern Blot Analysis
In order to determine if homologous recombination had occurred at the required site
restriction digestion of DNA extracted from 'green' virus cultures was carried out
using BamHl. BamHl was selected for use as there is a BamHl site within gpl50 and
the BamHl sites flanking this site produce gpl50 positive bands of a relatively small
and identifiable size, 1.3kbp and 1.8 kbp, upon digestion The digests were
separated by agarose gel electrophoresis and transferred to a nylon membrane. The
Southern blot was probed with a P radiolabelled probe generated by random primed
labelling using the whole gpl50 gene, cut from the plasmid pSP72/gpl50 using
Hindlll and EcoKl and electroeluted from an agarose gel, as a target. Figure 3.1.7.
shows the BamHl restriction maps of the gpl50 encoding region within the MHV-68
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Figure 3.1.6. PCR analysis to check for the presence of wild type MHV-68
gpl50 DNA in green fluorescent 'gpl50 knockout' MHV-68 clones
In order to determine if wild type and recombinant virus gpl50 DNA were
consistently co-located in wells containing plaques expressing green fluorescent
protein and if any gpl50 DNA was present in wells negative for plaques in a 96
well plate of limiting dilutions (0.4pfu/well) of 'green fluorescent' recombinant
virus a polymerase chain reaction (PCR) analysis was done. DNA was extracted
from 16 random wells, PCR, 25 cycles, was done using primers PAG11 and MA2
which flank the site in gpl50 of GFP gene cassette insertion. The predicted size of
product amplified from the designed recombinant construct was 2.68kbp (mt), and
1059bp from wild type (wt) gpl50. (a) Products were separated by electrophoresis
through a 0.7% agarose gel containing ethidium bromide and visualised using a UV
transilluminator. (b) In addition, products were transferred from the agarose gel to
a nylon membrane by capillary transfer. The nylon membrane was probed with a
32P labelled gpl50 DNA probe in order to distinguish gpl50 specific products. The
probe was generated by random primed labelling using the entire gpl50 gene as a
target. The membrane was exposed to autoradiographic film for 24 hours. Lanes: 1
& 22 - 1 kb DNA ladder, 2 & 3 - BHK DNA, negative control, 4 - wild type MHV-
68 DNA, 5 - pgpl50-gfp-Cl, 6 to 21 - wells 1-16. The arrows indicate the
position of the gpl50 products mt and wt. The numbers on the left indicate the size
of thelkbp DNA ladder marker bands in bp.
Figure 3.1.7. Predicted BamYW restriction maps of the gp!50 encoding region









(b) Recombinant virus structure














Predicted BamHI restriction site maps of the gpl50 encoding region of the MHV-
68 genome for (a) wild type and (b) gpl50 'knock out' recombinant virus. Letter
designation of BamHI fragments in the wild type MHV-68 genome are in
accordance with Efstathiou et al., 1990. (c) Schematic representation of the
predicted bands detected when probing BamHI restriction digests of wild type
MHV-68 (WT) and gpl50 'knock out' recombinant virus (RV), separated by
agarose gel electrophoresis and transferred to a nylon membrane, using a gpl50
specific random primed 32P radiolabeled probe.
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wild type and predicted recombinant genome indicating the sizes of bands predicted
to be observed following the required double crossover homologous recombination
event.
The Southern analysis of BamWl digests in figure 3.1.8. shows the presence ofwild
type BarnWl restriction fragments (1.3kbp and 1.8kbp) in the 'green' virus samples.
In addition, there are bands of ~0.3kbp, 3kbp and 4kbp, from the banding pattern it
appears that the whole plasmid may have integrated into the genome adjacent to the
5' end of gpl50 most likely via a single recombination event. The inserted plasmid
could most probably loop out of the recombinant MHV-68 genome returning the
genome to wild type. The relative intensity of the 1.3kbp band for recombinant virus
lanes is high in comparison to larger bands. This may be explained by the theory that
both the wild type genome and recombinant genome with the whole plasmid
integrated are predicted to produce a 1.3kbp fragment positive for gpl50 DNA
following digestion with BamHl. Figure 3.1.9. illustrates the integration event which
could explain this out come.
In summary recombinant viruses, expressing GFP were generated however the
targeted gpl50 gene had not been disrupted. The entire plasmid appears to have
integrated into the genome which would explain the co-localisation of wild type and
recombinant gpl50 detected by PCR. This is unlikely to be a useful reagent as a
GFP tagged 'wild type' virus because the plasmid insertion is likely to be unstable.
The plasmid insert may loop out and the virus resort back to complete wild type virus
- the detection of wild type Bamlil digestion fragments suggests this may be
occurring. After five passages of the 'green' viruses no wild type plaques were
observed however, on further passage wild type virus may re-emerge at a level
detectable by plaque assay.
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Figure 3.1.8. Restriction digestion, using BamYll, of DNA from three different
clones of 'green fluorescent' recombinant virus
DNA was extracted from BHK cells infected with 'green fluorescent' recombinant
virus (RV) clones (generated by homologous recombination ofMHV-68 DNA and
vector pgpl50/gfp-Cl) and digested with BamHl. All plaques induced by these
viruses expressed green fluorescent protein i.e. no wild type plaques were
observed. Restriction digests of DNA were electrophoresed through a 0.7%
agarose gel and transferred to a nylon membrane by capillary transfer. The
membrane was probed using a gpl50 specific 32P radiolabeled probe. The probe
was generated by random prime labelling using the whole gpl50 gene as a target.
The membrane was exposed to autoradiographic film for 7 days. Lane: 1- lkb
DNA ladder, 2 - wild type MHV-68 BamHl digested DNA, 3 - BHK DNA, 4 -
gpl50 RV 4E, 5 - gpl50 RV 6B, 6 - gpl50 RV 6F, 7 - pSP72/gpl50 BamHl
digested (4kbp), 8 - pgpl50/gfp-Cl BamHl digested, dashes indicate blank lanes.
The numbers on the left indicate the size in bp of the lkb DNA ladder marker
bands. Numbers on the right indicate the approximate size of predominant bands
in kbp.
Figure 3.1.9. Schematic representation of a single recombination event
resulting in integration of the vector pgpl50/gfp-Cl into the MHV-68 genome
Single recombination
Resulting structure
SamHI BamHI BamHI BamHI BamHI
The diagram shows the homologous recombination event and resulting
arrangement of the gpl50 region of the MHV-68 genome which is likely to have
occurred - determined from the size ofBam\\\ restriction digest fragments, positive
for gp 150 sequence, for 'green' recombinant virus DNA (bands of 4.0, 3.0, 1.8, 1.3
and 0.3kbp). It appears that the whole plasmid may have inserted into the MHV-
68 genome via a single homologous recombination event. The detection of a 1.8kb
fragment is likely to be produced from digestion of wild type MHV-68 which
occurs when the plasmid loops out of the genome. This may explain why the
1.3kbp is more intense relative to larger bands for 'green' recombinant viruses in
figure 3.1.8. as both wild type and recombinant genomes produce a 1.3kbp (Q)
fragment upon BamW\ digestion.
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3.1.5 Recombinant Virus II
In order to produce a gpl50 'knock out' recombinant virus a new plasmid construct
was generated. This new construct was designed to be compatible with a gpl50
complementary cell line i.e. the possibility of the knock out virus reverting to wild
type by recombining with the gpl50 DNA pertained by the cell line was minimised.
As yet it was not known if gpl50 was essential to virus replication however, the
absence of gpl50 could have adverse effects on virus growth therefore it was
considered worthwhile to take this precautionary measure. This was done by
limiting, as far as possible, sequences in the recombinant vector that were
complementary to the gpl50 gene which would be carried by a complementary cell
line.
Figure 3.2.1. illustrates the strategy, described here, used to generate the recombinant
virus construct, named pRCVII. Initially the sequences flanking gpl50 were
amplified by PCR. The left hand flanking sequence, of approximately 500bp, was
obtained using primers L50 and L51 (for primers and PCR conditions refer to section
2.1.8). Primer L51 is positioned within the N terminal region of gpl50, ideally the
sequences used for targeting homologous recombination would be out with the
gpl50 gene so that propagation of the recombinant virus in a gpl50 complementary
cell line would not allow wild type revertants to form via recombination of the
recombinant virus genome with the gpl50 gene encoded by the cell line. However,
at the 5' end of the gpl50 gene there is a polyadenylation consensus sequence for
ORF 50 (Mackett et al., 1997) (refer to figures 3.2.1. and 1.8 for location),
elimination of this may alter the viral phenotype in addition to any effects caused by
the absence of gpl50 and so this region was included in the recombinant construct.
Primers A52 and B52 were used in a PCR to generate the right hand flanking
sequence of approximately 400bp (for primers and PCR conditions refer to section
2.1.8). The 5' primer, A52 is located just downstream of the gpl50 gene (refer to
figure 3.2.1.).
Primers L51 (antisense) and A52 (sense) as shown in section 2.1.8 were designed
with three complementary restriction enzyme sites at their 5' ends. In the conditions
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Figure 3.2.1. Strategy used to generate pRCVII, the construct for generation
of a gpl50 negative recombinant MHV-68 virus
ORF50 poly A
Section of viral genome
ORF50 gp150 ORF52
Primers: L50




533bp -EcoRI, Acc\, BglII EcoRI, Accl, BglII-














Step 4b: Cut pFlanks with Accl &








Step 3: Ligate PCR product into
^^7 (2.9kbp) to generate 'pFlanks'
KI SI LTS
of a PCR, the products of L50/L51 and A52/B52 could anneal to each other via
these complementary sequences and act as a target for generation of a product
consisting of the two flanks joined (see figure 3.2.1). Therefore, the initial PCR
products were purified and then 1 pi of each product was used as the combined target
in a subsequent PCR using primers L50 and B52 resulting in a product of 965bp (for
primers and PCR conditions refer to section 2.1.8). The product was purified and
then digested using Xhol and Hindlll. The cut product was ligated into the cloning
vector pSK (2.9kbp) which had been prepared by digestion with Hindlll and Xhol
followed by dephosporylation to prevent self ligation. XL 1-Blue E. coli were
transformed with the ligation mix using the heat shock method. Of 78 transformants
which grew, selected using ampicillin, 12 were picked, grown up and their DNA
extracted. Digestion of the DNA using EcoRA indicated that one colony contained
pSK with the insert (two bands of approximately 3.4kbp and 400bp were generated,
pSK alone only has one EcoRl site). A small scale DNA preparation, named
pFlanks, of this clone was cut with Accl and then dephosphorylated in preparation to
insert a gene cassette encoding green fluorescent protein (GFP). The GFP gene
cassette consisting of gfp flanked by the CMVIE promoter and the SV40pA was cut
from vector pAC8 using Accl. The cassette differed slightly from the same cassette
in pEGFP-Cl, used for the previous recombinant construct in that the multiple
cloning site between gfp and the SV40 poly A signal in the pAC8 construct had been
removed. The cassette was electroeluted from an electrophoresed agarose gel of the
Accl digestion of pAC8, purified and ligated into the Accl cut pFlanks. The ligation
mix was used to transform XL 1-Blue E. coli by the heat shock method. Of 36
transformants, selected using ampicillin, 12 were picked, grown up and their DNA
extracted. From restriction digestion of the DNA samples, using Ncol and EcoBA, 1
clones appeared to have the plasmid plus insert, producing bands of approximately
3.4kbp, lkbp, 700bp and 251bp. This banding pattern indicated the GFP gene
cassette was orientated in the opposite transcriptional direction to gpl50.
Preferentially the GFP cassette would be orientated in the same transcriptional
direction as gpl50 therefore the rest of the transformants (24 more) were picked and
analysed as before to determine if any contained the GFP insert in this direction. The
GFP cassette was orientated in the same direction as all the previous clones.
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Rightwards transcriptional orientation of GFP was not essential therefore a large
DNA preparation of one transformant was generated using the CsCl gradient method
ready for production of the recombinant virus. This plasmid was named pRCVII.
In order to check that the GFP cassette was functional BHK cells were transfected
with 30pg of either uncut pRCVII or Kpnl and Hindlll digested pRCVII (this
digestion cuts the GFP cassette plus flanking sequences from the plasmid, described
as the recombinant cassette). Cells expressing green fluorescent protein were
observed using UV microscopy 24 hours post transfection.
Subsequently, Kpnl/Hindlll digested pRCVII was co-transfected with MHV-68
genomic DNA into CI27 cells. CI27 cells were used as opposed to BHK cells as
they form more uniform monolayers, show greater contact inhibition of growth and
the MHV-68 plaques are more discrete. The sequence for recombination with the
viral genome, known as the 'recombinant cassette', was excised entirely from the
vector by restriction enzyme digestion prior to transfection in order to prevent the
whole plasmid integrating into the genome. Circularised plasmids are used for the
production of recombinant viruses (Mackett et al., 1984) however, linearised
sequences were considered to be less prone to single recombination events resulting
in insertion of the vector and failure to displace the targeted gene. Fully formed
'green fluorescent' plaques expressing GFP were observed 7 days post transfection,
as were wild type 'white' plaques. Plaque morphology of 'green fluorescent'
plaques did not differ in their appearance, i.e. in size and development rate, to wild
type plaques. 'Green fluorescent' plaques were picked through the agar overlay of
these cultures. Plaque purification of 'green fluorescent' virus was performed by
passage of sequential plaque picks. Despite selection of 'green' plaques physically
isolated from other plaques in monolayers wild type plaques were consistently
observed at level of 1:15 to 1:5 of total plaques. Limiting dilutions of plaques
(0.4pfu/well) were plated on cell monolayers in 96 well plates in order to isolate
'green' plaques. Upon subsequent plating of green plaques harvested from wells of
limiting dilutions which appeared to have green plaques present in the absence of
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wild type plaques -green virus was observed however wild type plaques also
developed albeit at a lower level i.e. 1:100.
Although a low level presence of wild type plaques (approximately 1:100) was
present after six passages DNA was extracted for analysis to determine if the 'green'
virus present had been generated by the required recombination event. The DNA
from four green virus samples, each derived from the initial transfection, which had
undergone plaque picking and limiting dilution, was extracted from T175 flasks of
virus grown on CI27 cells. BamHl digests of the DNA were subjected to agarose gel
electrophoresis followed by Southern analysis. The Southern blot was probed with a
32P radiolabeled probe generated by random prime labelling using the whole gpl50
gene as a target. In addition, a P radiolabeled probe generated by random prime
labelling using the GFP gene cassette DNA as a target was used. Figure 3.2.2 shows
the predicted products resulting from a BamHl digest of the designed recombinant
virus.
As figure 3.2.3 shows BamHl digested wild type MHV-68 DNA probed with the
gpl50 specific probe produced the expected bands of 1.3kbp and 1.8kbp, with longer
exposure times (>24 hours) of the probed blot to autoradiographic film two larger
bands were observed of approximately 4kbp and 5kbp - these sizes correlate with
BamHl partial digestion products. These bands were seen for each of the four
'green' virus DNA samples, in addition there was a high molecular weight smear of
approximately 14-18kbp for the 'green' virus DNA alone. When probing the same
digests with the GFP specific probe the large smear alone was detected for the
'green' virus DNA (refer to figure 3.2.4). This suggested the recombinant cassette
may have inserted into a region within one of the large BamHl fragments of the
MHV-68 genome. Two regions of the genome are known to produce large DNA
restriction fragments when digested with BamHl, these are described as fragment Ai
of approximately 18kbp and A2 of approximately 14kbp (Efstathiou et al., 1990b).
As shown in figure 3.2.5a Ai is located at the left hand end of the genome and A2 is
located to the right of the centre of the genome beginning at ~77kbp from the left of
the genome. Insertion of the recombinant cassette into Ai did not seem unreasonable
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Figure 3.2.2. Predicted BamVW restriction maps of the gpl50 encoding region









(b) Recombinant virus structure - generated using pRCVII
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Predicted BamHI restriction maps of the gp 150 encoding region of the MHV-68
genome for (a) wild type (WT) virus and (b) a gpl50 recombinant virus generated
using pRCVII. Letter designation of the BamHI fragments in the wild type MHV-
68 genome are in accordance with Efstathiou et al., 1990b.
Figure 3.2.3. Southern analysis of restriction digests of DNA from wild type
MHV-68 and 'green fluorescent' recombinant virus generated using pRCVII
'Green' Virus






Representative Southern analysis. DNA was extracted from CI27 cells infected with
either wild type (WT) MHV-68 or 'green' virus generated using pRCVII. DNA
samples were digested with BamHl (B), EcoRI (E), Hindlll (H) or Ncol (N) and
electrophoresed through a 0.7% agarose gel and transferred to a nylon membrane. The
Southern blot was probed with a 32P radiolabeled gpl50 specific probe generated by
random primed labelling using the whole gpl50 gene as a target. The probed blot was
exposed to autoradiographic film for 24 hours. The numbers on the left indicate the size
of lkb DNA ladder marker (M) bands in bp. The far left lane contains the vector
pRCVII (5.4kbp) partially digested with Kpnl and Xhol (this cuts the recombinant
cassette (~ 2.5kbp) from the plasmid (2.9kbp)). Note: the large patches at >12kbp for
WT and 'Green' virus lanes E, H and N appeared as single bands, similar for those
seen in figure 3.2.5., with a shorter autoradiographic film exposure time of 6 hours
however a longer exposure time is shown here in order to achieve better resolution of
the smaller bands in the 'Green' virus lanes E and N.
Figure 3.2.4. Southern analysis of restriction digests of DNA from wild type
MHV-68 and 'green fluorescent' recombinant virus generated using pRCVII
WT 'Green' Virus
B | E | H IN
pRCVII
Probe: GFP gene cassette specific
DNA was extracted from CI27 cells infected with either wild type (WT) MHV-68
or 'green' virus generated using pRCVII. DNA samples were digested with
BamHl (B), EcoRl (E), Hindlll (H) or Ncol (N) and electrophoresed through a
0.7% agarose gel and transferred to a nylon membrane. The Southern blot was
probed with a 32P radiolabelled green fluorescent protein (GFP) gene cassette
specific probe generated by random primed labeling using the whole GFP gene
cassette as a target. The probed blot was exposed to autoradiographic film for 24
hours. The numbers on the left indicate the size of the lkb DNA ladder marker
(M) bands in bp. The far left lane contains the vector pRCVII (5.4kbp) digested
with Kpnl and Xhol (this cuts the recombinant cassette (~ 2.5kbp) from the
plasmid (2.9kbp)).
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due to the experience of laboratory co-workers who were making MHV-68
recombinant viruses in the same manner, targeting other genes i.e. the bcl-2 and Ik¬
s'1 homologues (for genomic positions see figure 1.3). Their recombinant constructs
commonly integrated into the left hand end of the viral genome rather than the
targeted site.
To investigate if insertion into the left hand end of the genome was the case further
digests of the 'green' virus DNA were done using Hindlll, EcoRi and Ncol. Hindlll
and Ncol were selected as these have several sites at the left hand end of the genome
across the region of the Ai BamHl fragment, if the insert was positioned in this
region smaller bands, of a size easier to determine, should be detected. An EcoRl
digest was also done as the recombinant cassette has an EcoRl site and so
introduction into the genome would result in an extra EcoRl fragment being
generated. vVcoI was also chosen for this reason, within the recombinant cassette
there are two Ncol sites.
Figure 3.2.3 shows the bands observed when digests were probed with the gpl50
specific probe. For Hindlll the appearance of the digest of 'green' virus DNA did
not appear significantly different to that of wild type DNA. A large band was
detected of ~14kbp, this indicated that the insert was not likely to be in the left hand
end of the genome as the sizes of Hindlll fragments range between 5 - 7kbp across
the Ai BamHl fragment region (see figure 3.2.5a). The fainter smaller bands in the
Hindlll digests shown in figure 3.2.3 were only observed at long exposure times
(>24 hours) of the blot to autoradiograhic film and are likely to be background. For
the iscoRI 'green' virus digest two bands were observed one very large band of
~13kbp and another of ~2.8kbp suggesting insertion of the recombinant cassette into
an end of one of the large EcoRl restriction fragments of MHV-68. For wild type
virus, just one large gpl50 positive band was seen upon FicoRI digestion.
Furthermore, two bands were detected in a Ncol digestion of 'green' virus DNA -
one very large band of ~ 14kbp and another of ~ 1.5kbp. As figure 3.2.4 shows this
was also observed when the same digest was probed using the GFP specific probe
indicating that the recombinant cassette had integrated into a large Ncol fragment of
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the viral genome, close to one end of the fragment. This resulted in the generation of
a still large Ncol fragment and a smaller fragment produced from the cleavage of the
new Ncol site and the Ncol site at the insertion end of the fragment. Restriction
digest maps of the genome were compared to locate where large fragments produced
by each restriction enzyme overlapped. To the right of the centre of the genome an
area of 801 bp was identified across which large digest fragments (>12kbp) for each
of the four restriction enzymes used overlap. Refer to figures 3.2.5a. and 3.2.5b. this
is the area in which the insert may be located. Figure 3.2.6 provides a schematic
representation to explain how the bands detected by Southern analysis correlate to
this proposed location of recombinant cassette integration. The smaller EcoBA
fragment detected using the gpl50 specific probe on the 'green' virus digest is
slightly smaller (~2.8kb compared to 3.2kb) than the predicted band this could be
due to a deletion of a portion of sequence. Figure 3.2.7 shows the genes located in
this region i.e. ORF57 and ORF58. The data suggest the recombinant cassette has
inserted into ORF58 and it is possible that a portion of ORF58 or a region upstream
up to the next EcoBA restriction site may have been deleted. The function of ORF58
is not known, ORF57 encodes an immediate early transcriptional activator.
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Figure 3.2.7. Arrangement of ORFs in the region of the MHV-68 genome
where the RCVII cassette may have integrated
Possible insertion region of RCVII cassette
J
BamHI A/col
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Based on the restriction fragments, from digests of 'green' viral DNA using
different restriction enzymes, that were detected in Southern analysis using probes
for gpl50 and the green fluorescent protein encoding cassette, the recombinant
virus cassette is thought to have inserted into the viral genome within the region
between the BamUl and Ncol restriction sites indicated. Numbers indicate the
region of the MHV-68 unique DNA in base pairs according to Virgin et al., 1997.
Open reading frames (ORFs): mta - M immediate early transcriptional activator,
ORF58 - unknown function, ORF59 - DNA replication proten, rr2 - small
ribonucleotide reductase, rrl - large ribonucleotide reductase.
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3.1.6 Earlier Analysis of Recombination by PCR
In view of the time taken to purify and analyse recombinant viruses a system using
PCR was designed to determine if the desired recombination event had occurred
soon after the initial transfection stage. Following co-transfection ofMHV-68 DNA
and Kprl and Xhol cut pRCVII BHK cells were plated into wells of a 24 well plate
following co-transfection with. DNA was extracted from each well five days post
transfection and PCR analysis was done to determine if the required recombination
event had occurred. For this, diagnostic primers were used i.e. one primer within the
GFP cassette, SV40d and another out with the recombinant cassette RCVd,
positioned upstream of the recombination site (for primers and PCR conditions refer
to section 2.1.8). Using this primer pair a product of 626bp should be observed if the
specific recombination event has occurred. Control PCRs for the detection of viral
DNA in the samples using primers L50 and L51 for the left hand region of gpl50
were positive, producing the predicted product of approximately 533bp. In contrast,
a product was not detected by a 40 cycle PCR using the diagnostic primers. This
suggested the desired homologous recombination had not occurred using these
conditions.
3.1.7 Mammalian Expression of Gpl50
Attention was directed to generating a mammalian cell line able to express gpl50. In
the event that gpl50 is essential for MHV-68 replication a cell line able to express
gpl50 would be an invaluable tool as a complementary cell line in which to grow a
gpl50 negative recombinant virus. Initial data suggested the first recombinant virus
engineered may require a helper virus for replication and so a cell line able to supply
gpl50 in trans would allow propagation and purification of the recombinant virus.
3.1.8 pBabePuro for Mammalian Expression of Gpl50
The design of the gpl50 complementary cell line aimed to avoid potential problems
of toxicity of glycoprotein expression and so gpl50 was placed under the control of
the putative MHV-68 gB promoter PgB. Toxicity is a property of glycoproteins
known to hinder the generation of constitutively expressing cell lines (Whang et al.,
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1987, Conway et al., 1989, Motz et al., 1987, Gompels & Minson, 1989). For
example Whang et al., 1987, experienced rapid loss of cells expressing gp340/220
consistent with the theory that high expression of glycoproteins is detrimental to cell
growth. In theory, cells containing gpl50 under the control of PgB would express
gpl50 upon infection with MHV-68, which would provide the necessary viral
transactivation signals to act on PgB and induce gpl50 expression. In the absence of
virus infection gpl50 expression should be minimal and present in substantial
amounts only when required following virus infection. A similar system was used to
successfully propagate a gH negative HSV-1 mutant in Vero cells carrying the HSV-
1 gH gene under the control of the HSV-1 gD promoter (Forrester et al., 1992).
Primers PGB1 and PGB2 were used in a PCR to amplify a 265bp region directly
upstream from the translation initiation site of gB on the MHV-68 genome (Stewart
et al., 1994) (for primers and conditions see section 2.1.8). This is the putative gB
promoter (PgB). The PCR product was cut with Xhol and Hindlll and ligated into
pSP72 (previously cut with Xhol and Hindlll and dephosphorylated ready for
ligation). The ligation mix was used to transform XL 1-Blue E. coli by the heat shock
method. Of 350 colonies selected using ampicillin 12 were picked, grown up and
their plasmid DNA extracted. Extracted DNA was analysed by restriction digestion
with Xhol and Hindlll, 8 samples appeared to have the insert (two bands, one of
~2.4kbp and another of ~265bp correlating to the plasmid and insert respectively).
The plasmid DNA from one sample, named pSP72/PgB was cut with Hindlll and
EcoKl and then dephosphorylated in preparation to receive a gpl50 DNA insert.
The entire gene encoding gpl50 was amplified by PCR using primers IA3 and IA4
(see section 2.1.8 for primers and PCR conditions). The product, ~1.5kbp was cut
with Hindlll and fscoRI and then ligated into pSP72/PgB. A lpl sample of the
ligation mix was used as the target in a PCR with primers PGB 1 and IA4 in order to
amplify a product consisting of gpl50 downstream of PgB i.e. PgBgpl50 (for
primers and conditions see section 2.1.8). The identity of the 1.8kbp product was
checked by digestion with Hindlll which correctly produced two bands of ~1.5kbp
and ~265bp correlating to gpl50 and PgB, respectively. PgBgpl50 was cut with
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Bglll and EcoRl and ligated into the Moloney murine leukemia virus based
mammalian expression vector pBabePuro (Morgenstern & Land, 1990) (previously
cut with BamHl and EcoRl and dephosphorylated ready to receive the insert). The
ligation mix was used to transform XL 1-Blue E. coli using the heat shock method.
All 21 colonies that grew, selected using ampicillin, were picked, grown up and their
plasmid DNA extracted. Plasmid DNA was digested using Hindlll to test for the
presence of the insert, only one clone produced the correct banding pattern (two
bands, one of 5kbp and another of 1.9kbp). A large scale plasmid preparation was
made from this clone, the plasmid was named pBabe/PgBgpl50. Figure 3.2.8 shows
the structure of pBabe/PgBgpl50. Complete integrity of the PgBgpl50 region of
the plasmid was confirmed by sequence analysis using the gpl50 spanning
sequencing primers and primer PGBseq (refer to section 2.1.8 for primers).
3.1.9 Generation of a Cell Line Carrying pBabe/PgBgp!50
The vector pBabe/PgBgpl50 was transfected into CI27 cells by electroporation. In
addition the vector pBabePuro was transfected into cells in order to generate a
control cell line i.e. vector without PgBgpl50 cassette. Following transfection, cells
were plated into wells of a six well plate. The culture media was removed 24 hours
post transfection and selective media containing puromycin was added. After three
days under puromycin selection resistant colonies of cells emerged. After a week
post transfection resistant colonies were harvested by ring cloning and transferred to
wells of a 24 well plate. Eleven different pBabe/PgBgpl50 clones were grown up by
transferring cells into sequentially larger culture vessels at each passage. After four
passages the DNA was extracted from a confluent cell monolayer in a T75 flask for
each clone to check for the presence of gpl50 DNA by PCR. Primers PGB1 and
IA4 which encompass the whole PgBgpl50 cassette were used. Of the clones, six
produced a clear product and a further two had faint bands at the correct size. Figure
3.2.9 shows the results of a diagnostic PCR, clone A1 produced the most intense
product, clone A2 was one of two samples with a faint band, a product was not
observed for clones A3 and A4.
155










The structure of pBabe/PgBgpl50. The gpl50 gene is located downstream of the
putative gB promoter (PgB) to enable induction of gpl50 expression upon
infection of mammalian cells containing pBabe/PgBgpl50. The vector backbone
consists of pBabePuro a retroviral vector based on Moloney murine leukemia virus
(Morgenstern & Land, 1990) and contains the LTR - long terminal repeat, and gag
retrovirus sequences. The LTR shown to the left of the PgBgpl50 insert contains a
strong promoter from which some low level constitutive expression of gpl50 may
be directed. PSV4o ~ Simian virus 40 promoter, Puro - puromycin resistance, AmpR -
ampicillin resistance, ori - bacterial origin of replication.
Figure 3.2.9. Detection of gpl50 DNA in mammalian cells transfected with
pBabe/PgBgp!50
1 I 2 I 3 I 4 I 5 I 6 I 7 | 8 I 9 I 10
In order to test for the presence of gpl50 DNA within clones of CI27 cells
transfected with pBabe/PgBgpl50 polymerase chain reaction (PCR) analysis was
performed on lOOng ofDNA extracted from each cell line. Forty cycles were done
using primers PGB1 and IA4, which encompass the whole PgBgpl50 cassette of
~1.8kbp. Products were analysed on 0.7% agarose gels containing ethidium
bromide and visualised using a UV transilluminator. Lanes: 1- 1 kb DNA ladder
marker, size of pertinent bands are shown at the left, 2 - vector pPgBgpl50,
positive control, 3 - no DNA negative control, 4 - CI27 cells, negative control, 5 &
6 - cells transfected with pBabePuro (no insert) selected using puromycin, negative
control, 7,8,9 & 10 - Clones Al, A2, A3 & A4, respectively, - transfected with
pBabe/PgBgpl50 and selected using puromycin. Note: A faint band of ~1.8kbp
could be seen by eye in lane 8 however, it is difficult to see in the photograph of
the gel. The arrows indicates the position of the expected 1.8kbp product.
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Although the gpl50 gene had been positioned under the control of PgB the
possibility existed that low level expression of gpl50 may occur in the absence of
virus induction of gB due to transcription occurring via the strong promoter within
the LTR upstream of the PgBgpl50 cassette. Cell lysates of each clone were
separated by SDS-PAGE and transferred to an immobilon-P membrane which was
probed for the presence of gpl50 using rabbit anti-gpl50 antibody followed by a
swine anti-rabbit alkaline phosphatase conjugated antibody and the alkaline
phosphatase substrate NBT/BCIP. In addition immunofluorescence analysis was
done on acetone fixed cells using the rabbit-anti-gpl50 antibody followed by a swine
anti-rabbit FITC conjugated antibody. The presence of gpl50, using either method,
was not detected, pBabe/PgBgpl50 transfected cells did not appear significantly
different to the pBabePuro transfected and normal CI27 cells.
Next, cell lines were infected with equal amounts of MHV-68 and the level of gpl50
expression was analysed by probing western blots of cell lysates with anti-gpl50
antibody. Figure 3.3.1 shows a representative analysis. In previous studies using
virus induced expression the level of expression of the induced protein has been
much greater in the complementary cell lines compared to control cells when
infected with equal amount of virus (Forrester et al., 1992). However, in this case
the levels of gpl50 detected in gpl50 DNA positive cell lines were not significantly
different to the control cells.
In order to increase the sensitivity of protein detection cell lines were radiolabeled
using S methionine and radioimmunoprecipitated using anti-gpl50 antibody.
Gpl50 was successfully immunoprecipitated from MHV-68 infected CI27 cells,
used as a positive control, however no gpl50 expression was detected in the Al
clone of pBabe/PgBgpl50 transfected cells. Figure 3.3.2 shows a representative
analysis of radiolabeled immunoprecipitated proteins separated by SDS-PAGE and
exposed to autoradiographic film.
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Cell lysates were electrophoresed through a 5% acrylamide SDS-PAGE gel and
transferred to an immunobulon P membrane. To detect the presence of gpl50 the
membrane was probed with rabbit anti-gpl50 antiserum followed by a swine anti-
rabbit alkaline phosphatase conjugated antibody. The alkaline phosphatase
substrate nitro blue tetrazonium and 5-bromo-4-chloro-3-indoyl phosphate
(NBT/BCIP) was added to visualise detected protein. Equal amounts of samples
were added per well equivalent to 2.5 x 103 cells/well. An equal multiplicity of
infection of MHV-68 (5) was used to infect cells (+ MHV-68) 18 hours prior to
harvesting cells. D5 cells are CI27 cells transfected with pBabePuro, A1 cells are
C127 cells transfected with pBabe/PgBgpl50. The positon of molecular weight
markers (MW) are indicated on the left in kDa. The position of gpl50 and it's
precursor gpl30 are indicated. PI 10 is derived from the use of an alternative
translational initiation site in the gpl50 gene (Stewart et al., 1996).












































To test for expression of gpl50, cells were radiolabeled with [35S]-methionine.
Cells were then solubilised and immunoprecipitated with rabbit anti-gpl50
antiserum (a gpl50), rabbit anti-MHV-68 antiserum (a MHV-68) or normal rabbit
serum (NRS) using protein-A-sepharose. C127 cells were infected with MHV-68
at a multiplicity of infection (MOI) of 5, 18 hours prior to radiolabelling to be used
as a positive control for immunoprecipitation of gpl50. D5 is a cell line of CI27
cells transfected with pBabePuro used as a gpl50 negative control. The A1 cell
line consists ofCI 27 cells transfected with pBabe/PgBgpl50. Immunoprecipitated
proteins were electrophoresed through a 5% acrylamide SDS-PAGE gel, the gel
was dried and exposed to autoradiographic film. The numbers to the left indicate
the position of molecular weight standards (xlO3). The position of gpl50 is
indicated by the arrow. Panel shows appearance of film following a 3 hour
exposure, further exposures of 24 hours up to 5 days were also done, no further
significant bands were observed.
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RNA extraction was done to determine if there was low level expression of gpl50
mRNA in gpl50 DNA positive cells and if the level of gpl50 mRNA was greater in
these cells following infection with MHV-68 in comparison to control cells infected
with the same multiplicity of infection (MOI of 5) of MHV-68. Extracted
cytoplasmic RNA was separated by agarose gel electrophoresis and transferred to a
nylon membrane which was probed with a 32P radiolabeled gpl50 DNA probe. The
DNA target used to generate the probe by random primed labelling was the entire
gpl50 gene, generated as a PCR product using primers IElgpl50 and IE2gpl50. As
figure 3.3.3 shows one mRNA transcript of approximately 1.8 kb was detected in
MHV-68 infected cells 18 hours post infection however, the level of expression did
not differ significantly between the pBabe/PgBgpl50 cells in comparison to control
cell lines. In the absence ofMHV-68 infection no mRNA was detected by the gpl50
specific probe in any of the cell lines.
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Cells were infected with MHV-68 at a multiplicity of infection (MOI) of 5 (+
MHV-68) or left uninfected. At 18 hours post infection cells were harvested and
their cytoplasmic RNA extracted. Equal quantities of RNA extracted from each
sample, approximately 5pg, were electrophoresed through a 1.2% agarose gel and
transferred to a nylon membrane by capillary transfer. The membrane was probed
with a 32P radiolabeled probe generated by random primed labelling using target
DNA encoding the entire gpl50 gene. The membrane was then exposed to
autoradiographic film for 18 hours. The main image shows an autoradiogram of
the Northern blot. The numbers on the left indicate the position of RNA markers
in kilobases. The lower panel shows an ethidium bromide-stained image of 28S
rRNA as a control for RNA loading and integrity.
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3.2.1 Ecdvsone Inducible Mammalian Expression System
As an alternative method to express gpl50 in mammalian cells an ecdysone
inducible system for protein expression was employed. The advantage with this
system is that protein expression is inducible by external control i.e. the addition of
an induction agent - ecdysone or an ecdysone analogue. Inducible expression would
be valuable in the event that gpl50 proved toxic to cells. The ability to turn on
protein expression would also provide the opportunity to perform experiments
determining the susceptibility of the same cell line to MHV-68 infection in the
presence and absence of gpl50 expression. For example, a cell line engineered to
express HSV-1 gD is resistant to HSV-1 infection. HSV-1 can attach to cells
expressing gD but is not able to penetrate (Campadelli-Fiume et al., 1990) this is
likely to be due to the cellular gD sequestering the cell surface molecules which
HSV-1 requires to interact with via gD in order to infect the cell (Geraghty et al.,
2000).
Figure 3.3.4 shows an outline of the ecdysone-inducible mammalian system. The
gene for expression i.e. gpl50 is cloned into an expression plasmid under the control
of the minimal heat shock promoter, upstream of which is an
ecdysone/glucocorticoid hybrid responsive element (E/GRE). The hybrid response
element consists of one half site from the natural Drosophila ecdysone response
element and one half-site from the glucocorticoid response element. The expression
vector is co-transfected into mammalian cells with a plasmid encoding the ecdysone
receptor pVgRXR. In the presence of the sterioid hormone ecdysone analogue,
ponasterone A, expression of the gene of interest is activated. Activation is initiated
in the presence of ponasterone A as this enables the hybrid ecdysone receptor
(VgEcR/RXR) which is a heterodimer of the ecdysone receptor (VgEcR) and the
mammalian retinoid X receptor (RXR) encoded by pVgRXR to bind E/GRE on the
expression vector. The ecdysone receptor, derived from the natural Drosophila
ecdysone receptor, involved in induction of insect molting, has been modified to
contain the HSV VP 16 transactivation domain. Upon binding of the VgEcR/RXR
heterodimer to the E/GRE on the expression vector transcription of the inserted gene
is activated from the minimal heat shock promoter via the VP 16 transactivation
domain.
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Figure 3.3.4. The ecdysone inducible mammalian expression system for
expression of gp!50
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1. In order to express gp!50 in the ecdysone inducible expression system the gene encoding gpl 50 was
ligated into vector pIND/Hygro between restriction sites HindlU and Xhol to form pIND/IIygro/gpl 50.
2. pIND/Hygro/gpl50 was co-transfected with pVgRXR. using electroporation, into CI27, COS or
BI1K. cells. 3. pVgRXR encodes a heterodimer. consisting of the modified ecdysone receptor (VgEcR),
derived from Drosophila, and the mammalian retinoid X receptor, which binds the hybrid ecdysone
response element (E/GRE) in the presence of ponasterone A (a synthetic analogue of ccdysone). As the
heterodimer binds to E/GRE transcription of gpl 50 is activated from the minimal heat shock promoter
(Pahsp) via a HSV VP16 transactivation domain which the VgEcR has been modified to contain.
Abbreviations: BGHpA - bovine growth hormone polyadenylation signal, fl ori - fl origin of
replication, SV40 ori - simian virus 40 origin & promoter, SV40pA - simian virus 40 polyadenylation
signal, HygroR - hygromycin-B-phosphotransferase, ColEl - E. coli origin, AmpR - ^-lactamase, PC-MV~
CMV immediate early promoter, TKpA - thymidylate kinase polyadenylation signal, Zeocin - zeocin
resistance, EM-7 - EM-7 promoter, PRSV - Rous sarcoma virus promoter.
RESULTS
3.2.2 Introduction of gp!50 into the Ecdvsone System
The entire gpl50 gene was amplified by PCR using primers IElgpl50 and
IE2gpl50. In addition primers IElgpl50 and MA2stop were used to amplify the
gpl50 gene without the hydrophobic transmembrane domain and cytoplasmic tail
encoding region. This product, when expressed from an expression vector was
designed to produce secreted gpl50 due to the lack of the hydrophobic membrane
anchor. The expression of glycoproteins lacking their transmembrane hydrophobic
region is a common method used to produce soluble glycoproteins secreted into the
cell culture medium (Motz et al., 1987, Madej et al., 1992). Both the 148 lbp
product of primers IElgpl50 an IE2gpl50 and the 139lbp product of IElgpl50 and
MA2stop (named Xgpl50) were purified and then cut with Hindlll and Xhol. The
cut products were each ligated into the expression vector pIND/Hygro prepared by
digestion with Hindlll and Xhol (refer to figure 3.3.4 for map of pIND/Hygro).
Likewise, the whole gpl50 gene was also ligated into pIND(SPl)/Hygro. The
expression vector pIND(SPl)/Hygro is a modified version of pIND/Hygro differing
in that it contains three binding sites for the transcription factor SP1 positioned
between the E/GRE and minimal heat shock promoter designed to increase absolute
expression levels fivefold over those obtained with pIND/Hygro (Kadonaga et al.,
1987, No etal., 1996).
XL-1 blue E. coli were transformed with the ligation mixes using the heat shock
method. Transformants were selected using ampicillin, 16, 17 and 2 colonies grew
for the pIND/Hygro plus gpl50, pIND(SPl)/Hygro plus gpl50 and pIND/Hygro
plus Xgpl50 ligation mixes, respectively. Plasmid DNA was extracted from liquid
cultures of these clones and then digested using Hindlll and Xhol. All colonies for
each transformation contained plasmids with the insert. For each construct i.e.
pIND/Hygro/gpl50, pIND(SPl)/Hygro/gpl50 and pIND/Hygro/Xgpl50 a large
scale plasmid preparation was made using the CsCl method. In addition, large scale
DNA preparations were made of pVgRXR and pIND/Hygro//acZ. The vector
pIND/Hygro//acZ contains the p-galactosidase gene and was used as a positive
control for mammalian transfection and expression.
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Transfection of each expression construct in conjunction with an equal amount
(30pg) of pVgRXR into BHK cells was done using electroporation. The induction
agent ponasterone A (5pM) was added to cultures 24 hours post transfection. Cells
were harvested 22 hours post induction and analysed for expression of gpl50 using
immunofluorescence and western blotting. Using anti-gpl50 antibody to probe
western blots of cell lysates and in immunofluorescence analysis on both acetone or
paraformaldehyde fixed cells did not result in detection of gpl50. The supernatant of
cells transfected with pIND/Hygro/Xgpl50 + pVgRXR was retained for analysis by
western blotting however no gpl50 was detected. In contrast, expression of (3-
galactosidase was detected in cells co-transfected with pIND/Hygro//acZ and
pVgRXR as shown in figure 3.3.5. This confirmed that the large DNA preparation
of pVgRXR and the induction agent were functional. Repeat transfections were
performed however gpl50 was not detected. Transfection of COS and C127 cells
was also done. Analysis by immunofluorescence and western blotting did not result
in the detection of gpl50. Increasing the concentration of the induction agent
ponasterone A to 10pM did not alter the outcome. Sequence analysis of the gpl50
plasmid constructs using the gpl50 spanning primers and the ecdysone forward and
BGH reverse primers showed the gpl50 inserts to be 100% intact.
In addition to transient transfection analysis selection of COS and CI27 cell lines
containing pVgRXR and each expression construct was done using zeocin and
hygromycin. Prior to this the sensitivity of these parent cell lines to the selective
agents was established in order to determine the appropriate antibiotic concentration
that inhibits cell growth to use for selection of transformed cells. By monitoring
growth of cell lines in a range of concentrations (e.g. 0, 50, 125, 250, 500, 750 and
lOOOpg/ml) of each drug the minimum concentration of drug that inhibited cell
growth was determined to be 150pg/ml for both zeocin and hygromycin. After a
week post transfection of cells under these selection agents colonies of cells grew out
- approximately 5 per well of a six well plate. Clones were isolated by ring cloning
and grown up for induction and analysis of expression as before. No gpl50
expression was detected. Presence of gpl50 DNA was confirmed by PCR using
primers MAI and MA2. All clones, which were maintained under antibiotic
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To test the transfection efficiency and demonstrate P-galactosidase protein expression
using the ecdysone inducible system BHK cells (106) were transfected using
electroporation with various plasmids (30pg each). Twenty four hours post transfection
with pIND/Hygro/lacZ + pVgRXR 5pM ponasterone A was added to induce
expression. Forty eight hours post transfection cells expressing P-galactosidase were
stained blue by the application of the substrate X-gal. Cells stained for P-galactosidase
expression are shown - panel A: normal BHK cells, untransfected B: BHK cells
transfected with pMVIO; constitutive P-galactosidase expression, with lacZ under the
control of the CMV IE-1 promoter, C & D: BHK cells co-transfected with the ecdysone
receptor plasmid -pVgRXR and P-galactosidase expression plasmid pIND/Hygro//«cZ,
C - uninduced, D - 24 hours post induction; addition of ponasterone A (an analogue of
ecdysone). Original magnification: 50x.
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selection throughout, grew very slowly (approximately 82 times slower) in
comparison to standard COS cells.
BINDING & ANTISERA STUDIES
3.2.3 Generation of Gpl50-His
To generate purified gpl50 for functional studies a gpl50-His fusion protein was
made. The expression of the extracellular portion of gpl50 as a recombinant protein
fused to a hexahistidine tag provided an amenable method to purify the protein on
nickel charged resin. The extracellular domain of gpl50 as opposed to the whole
protein was selected as this was likely to facilitate any cellular binding or entry role
the protein may have and be more soluble in the absence of the hydrophobic
transmembrane domain. In addition the hexahistidine tag made up a relatively small
proportion of the protein and was therefore considered less likely to interfere with the
structure and function of gpl50 in comparison to other possible expression systems
that employ the attachment of larger protein molecules e.g. glutathione-S-transferase
to facilitate purification of the protein.
Bacterial expression of the gpl50 recombinant protein was used because of the ease
of manipulation and the ability to grow bacteria rapidly in bulk culture. Although
bacterial proteins do not undergo the same post translational modifications as those
of eukaryotic cells, bacterial expression was considered a worthwhile approach as
gpl50 has very limited glycosylation. Studies indicate that only one of the three
potential N-linked glycosylation sites are occupied (Stewart et al., 1996).
Investigations show that other viral glycoproteins lacking their oligosaccharide
modifications retain their function in binding and fusion. For example, gD of HSV





A 1.3kbp DNA sequence, encoding the extracellular domain of gpl50 (i.e. the region
between the signal peptide sequence and the transmembrane domain, see figure 1.8)
was cloned from pSP72/gpl50 (this vector contains the whole of the gpl50 gene) by
PCR using primers MAI and MA2 (for primers and conditions see section 2.1.8).
The resulting product was purified and the ends digested using Ncol and Xhol. The
cut DNA was then purified and ligated into the plasmid pET-22b upstream of and in
frame with a hexahistidine encoding region and downstream of a periplasmic leader
sequence (pel B) (see figures 3.3.6a, b & c). The periplasmic leader sequence directs
the fusion protein into the periplasm of the host bacteria and is cleaved on entry.
Figures 3.3.6a & b depict the pET-22b plasmid, the region upstream of the multiple
cloning site contains the T7 promoter which can be activated by T7 RNA
polymerase. For expression of the gene the presence of T7 RNA polymerase is
required therefore bacterial hosts that encode a chromosomal copy of the T7 RNA
polymerase gene are used such as BL21(DE3) selected in this case. The bacterial
strain BL21(DE3) is a lysogen of the bacteriophage DE3 from which a DNA
fragment encoding the lacUV5 promoter and the gene for T7 RNA polymerase is
inserted into the bacterial chromosome (Studier & Moffatt, 1986). The only
promoter known to direct transcription of the T7 RNA polymerase gene is the
lacUV5 promoter which is inducible by isopropyl-P-D-thiogalactopyranoside
(IPTG).
Prior to ligation pET-22b was cut with Ncol and Xhol and then treated with calf
alkaline phosphatase to prevent self ligation of the plasmid. Competent E.coli were
transformed with the ligation mix using the heat shock method. Transformed
bacteria were selected using ampicillin. From the 400 colonies that grew, 12 were
picked, grown up and minipreped. The resultant plasmids were cut with Ncol and
Xhol . Three of the 12 plasmids produced two bands of approximately 5.5kbp and
1.3kbp, indicating correct insertion of gpl50. These plasmids were named pET-
22b/gpl50. Plasmids from three clones were used to transform BL21(DE3) bacteria
by the colony transformation method. Successfully transformed bacteria were
selected for using carbenicillin. Of over 250 colonies that grew for each
169
Figure 3.3.6a & b. Expression vector pET-22b used for the expression of




T7 transcription start 360
pelB coding sequence 224-289
Multiple cloning site 158-225
Histidine coding sequence 140-127
T7 terminantor 26-72




B. pET-22b cloning/expression region
T7 promoter primer #69348-3
Bgl II T7 promoter lac operator Xba\ rbs
AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTQAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGA
Hdel ' palB leader Msc' Nco 1 BamHI fcoft I Sac I
TATACATATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGGCCATGGATATCGGAATTAATTCGGATCCGAATTCGAGCTCC
MetLys TyrLeuLeuProTrrAloAloA•oGIyLeuLeuLeuLeuAIoAIaGInProA!a^eiA IpMet Asp I IeG!y)IeAsnSerAspProAsnSerSerSc
Eag I Ava \* signal peptidase
5a/1 Hind III Not I Xho I His»Tag Bpu11021
GTCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCCCC7GCTAACAAAGCCCGAAAGGAAGCTGAGT 7GGC TGC 7 GCCACCGC1GAGCAA1 AAC
VqIAspLysLeuAIoAIoAIoLeuGIuHIsHisHisH t sHisH isEnd ^
17 terminator T7 terminator primer #69337-3
TAGCAT AACCCCTTGGGGCCrcrAAACGGGTCTIGAGGGGTTH I IG
A. The region upstream of the multiple cloning site (MCS) contains the T7 promoter which can be
activated by T7 RNA polymerase. For expression of the gene inserted in the MCS the presence of T7
RNA polymerase is required therefore bacterial hosts that encode a chromosomal copy of the T7 RNA
polymerase gene are used for example E.coli strain BL21(DE3). The bacterial strain BL21(DE3) is a
lysogen of the bacteriophage DE3 from which a DNA fragment encoding the lacUV5 promoter and the
gene for T7 RNA polymerase is inserted into the bacterial chromosome (Studier & Moffat, 1986).
lacUV5 is a promoter inducible by isopropyl-P-D-thiogalactopyranoside (IPTG) and is known to direct
transcription of the T7 RNA polymerase gene which in turn induces expression of the recombinant
fusion protein. B. Cloning region of pET-22b. For the generation of gpl50-His and GST-His fusion
proteins the extracellular domain of gpl50 was inserted into pET22b between the Ncol and Xhol
restriction sites, the glutathione-S-transferase (GST) gene was inserted between the Ncol and EcoRX
restriction sites, respectively. The fusion proteins have a pelB leader sequence which directs the fusion
proteins into the periplasm of the host bacteria, upon entry of the periplasmthe pelB leader domain is





















































To generate gpl50 and glutathione-S-transferase (GST) hexahistidine tagged fusion
proteins expression vector pET-22b was used. The extracellular encoding domain of
gpl50 was ligated into the multiple cloning site (MCS) of pET-22b between the Nco\
and Xhol restriction sites. The GST gene was ligated into the MCS between Ncul and
EcoRI. The number of amino acids of each fusion protein, following cleavage of the
pelB leader signal, is indicated in brackets.
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pET-22b/gpl50 used one colony was picked. The presence of the chosen plasmids
was checked by digestion ofminipreps of these clones as before.
Expression & Purification ofGpl50-His
By sequence analysis the gpl50-His fusion protein was predicted to have a molecular
weight of 45,515 and an isoelectric point of 3.84. Clones containing pET-22b/gpl50
were grown up in liquid culture using carbenicillin and induced to express the fusion
protein by addition of IPTG. To test for production of fusion protein the induced
bacteria were harvested three hours post induction, sonicated and analysed by SDS-
PAGE. A predominant band at 120 kDa was present for each of the transformants.
Subsequently, expression of the fusion protein in the periplasmic fraction was
confirmed by SDS-PAGE analysis of the periplasmic fraction of the induced
bacteria. Samples taken at increasing time points post induction of expression were
analysed by SDS-PAGE and an induction time of 2.5 hours was determined to be the
optimum time for protein production. One transformant was selected and induced to
express the fusion protein followed by small scale purification from the periplasmic
fraction using Ni2+ charged resin beads (lOOpl settled resin). The resultant purified
protein with an apparent molecular weight of 120 kDa was detected by gpl50
specific antiserum on a western blot, a faint band of approximately 1 lOkDa was also
detected. In addition, these bands were detected using anti-MHV-68 antiserum. The
apparent size of the gpl50-His fusion protein detected (120kDa) was much greater
than the predicted MW of 45,500 and this is thought to be due to the high proline
content (23%) of gpl50 which is known to increase the apparent MW of proline rich
proteins in SDS-PAGE gels (Stewart et al., 1996).
• • •2d"
Upon confirmation that it was possible to purify gpl50-His, using the Ni charged
resin, production of the protein was scaled up to 100ml and 500ml cultures,
purification was monitored by SDS-PAGE and western blot analysis (see figure
3.3.7a for purification steps and concentrated protein). Detection of the 120kDa
fusion protein using an anti-hexahistidine monoclonal antibody was also possible
(see figure 3.3.7b).
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1 2 3 4 5 6
A. A western blot of purified gpl50-His fusion protein and fractions generated during
the affinity purification process using Ni2+charged resin beads. The blot was probed
for gpl50-His fusion protein with rabbit anti-gpl50 antibody followed by a swine anti-
rabbit alkaline phosphatase conjugated secondary antibody. Lane: 1- molecular weight
(MW) marker, 2- periplasmic fraction (PF) of gpl50-His expressing bacteria, 3- PF in
binding buffer prior to application to beads, 4- binding buffer wash, 5- wash buffer, 6-
eluate, 7- Ni2+resin beads, 8- pooled waste from each purification step, 9 & 10 -
concentrated eluate (purified gpl50-His). Samples were separated on a 7.5%
acrylamide SDS-PAGE gel. B. Gpl50-His detected on a western blot of the
periplasmic fraction of induced bacteria probed with a range of dilutions of a mouse
anti-hexahistidine monoclonal antibody (1/100, 1/500, 1/1000, 1/2000 lanesl-4
respectively) followed by a goat anti-mouse alkaline phophatase conjugated secondary
antibody (lane 5 - secondary antibody alone, lane 6 - probed with anti-gpl50 antibody
as for blot A). Proteins were separated on a 10% acrylamide SDS-PAGE gel. The
arrow indicates the position of gpl50-His.
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The smaller band 11OkDa was not detected by the anti-hexahistidine monoclonal
antibody and is likely to be a C-terminus breakdown product of gpl50-His.
A sample of purified fusion protein was provided for analysis to SmithKline
Beecham Biologicals as part of a collaborative effort. Amino acid analysis
performed by them indicated that the protein preparation was highly pure. Using the
concentration determined by this analysis and the absorbance of the sample at 280nm
measured by spectrophotometry it was possible to calculate, using Beer-Lamberts
law (refer to section 2.4.6), the molar extinction coefficient of the gpl50-His protein
which was determined to be 70,000 NT'cm"1.
From 100ml culture 0.093 - 0.17mg of gpl50-His protein could be purified,
approximately 1.3mg per litre culture. Western blot analysis indicated that some
protein remained on the beads following one elution step. In order to improve
protein yield two separate elution steps were carried out. To limit protein eluting
from the beads during the wash step the level of imidazole in the wash buffer was
reduced from 60mM to 20mM. Purification of protein from a litre culture was done
however purification from smaller volumes (100ml and 500ml) proved more
efficient. Increasing the volume of Ni2+ resin used did not enhance the amount of
protein purified indicating that the protein yield was predominantly restricted by the
level ofprotein expressed by the bacteria.
3.2.4 Generation ofGST-His - Using Vector pET22b
In order to provide a control for the gpl50-His fusion protein a GST-His
recombinant fusion protein was generated. This consisted of the carboxy terminus of
the glutathione-S-transferase gene encoding a 27kDa protein attached to a
hexahistidine tag. GST is a common eukaryotic cytoplasmic protein in this case
derived from the parasite Schistosoma japonicum it belongs to a family of isozymes
that detoxify a variety of xenobiolics by catalysing the interaction of reduced
glutathione with these molecules (Smith et al., 1986, Smith & Johnson, 1988). This
was considered a feasible control protein because GST is known to be soluble in
solution and the serum available to gpl50 was generated against a GST-gpl50 fusion
protein and therefore could be used to identify GST-His. GST has been used as a
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control protein in other binding studies and was unlikely to display cell surface
specific binding (Xuan et al., 1995, Kitay et al., 1996).
The gene encoding GST was amplified from the plasmid pGEX-2T by PCR using
primers GSTln and GST2e (see section 2.1.8 for primers and conditions). The
resulting product of 689 bp was purified and then cut with Ncol and fscoRI. The cut
DNA was purified and ligated into the plasmid pET-22b upstream of and in frame
with a hexahistidine encoding region and downstream of a periplasmic leader
sequence (pel B) (see figures 3.3.6a, b & c). Prior to ligation pET-22b had been
prepared by digestion with Ncol and fscoRI followed by dephosphorylation to
prevent self ligation. Competent E. coli were transformed with the ligation mix
using the heat shock method. Transformed bacteria were selected using
carbenicillin. From the 45 colonies that grew, 12 were picked, grown up and their
plasmid DNA extracted. The resultant plasmids were cut with Ncol and EcoKl. All
of the plasmids produced the correct banding pattern, two bands of approximately
5.5kbp and 700bp, indicating that GST had been successfully ligated into pET-22b.
These plasmids were named pET-22b/GST. Four pET-22b/GST plasmid isolates
were used to transform BL21(DE3) bacteria by the colony transformation method.
Successfully transformed bacteria were selected for using carbenicillin.
Approximately 30 colonies grew for each pET-22b/GST clone, one colony was
picked from each. These colonies were grown up in liquid culture using carbenicillin
and induced to express the fusion protein by the addition of IPTG. To test for
production of fusion protein the induced bacteria were sonicated and analysed by
SDS-PAGE. Three out of the four clones, following induction expressed a protein
which resolved at approximately 27kDa by SDS-PAGE (see figure 3.3.8). To
check for the presence of the histidine tag a western blot of an SDS-PAGE gel of the
samples was probed with an anti-hexahistidine monoclonal antibody and the
approximately 27kDa band was detected.
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Clone: 1 | 2 | 3 | 4
Western blot of bacteria transformed with pET-22b/GST induced to express the fusion
protein GST-His by addition of isopropyl- (3-D-thiogalactopyranoside (IPTG). Samples
of bacterial culture prior to induction (U) and 3 hours post induction (IN) were
sonicated and the whole bacterial lysates separated on a 14% acrylamide SDS-PAGE
gel followed by western blotting. The western blot was probed with rabbit anti-gpl50
antibody followed by a swine anti-rabbit alkaline phosphatase conjugated secondary
antibody. The arrow indicates the location of the GST-His fusion protein. Numbers at
the left hand side indicate molecular weight in kDa.
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Unfortunately, the GST-His protein could not be detected in the purified periplasmic
fraction of induced bacteria. The GST-His protein for each clone appeared insoluble,
detectable in the pellet but not the supernatant of sonicated bacteria. The lack of
detectable protein in the periplasmic fraction may have been due to the pel B leader
signal undergoing mutation or the protein being translated from the GST AUG rather
than the pel B AUG. Alternatively, the GST-His may have been expressed at such
high levels that it formed aggregates and inclusion bodies and therefore was not
present in the periplasmic fraction. As it may have been possible that at early times
post induction there was more soluble GST-His and as it accumulated the protein
became insoluble and formed inclusion bodies a time course was carried out.
Following induction of bacteria, samples were harvested at increasing time intervals
post induction (15, 30, 60, 120 and 180 minutes) and the levels of soluble and
insoluble fusion protein assessed. Analysis of samples by SDS-PAGE showed the
majority of induced fusion protein to be insoluble from initial expression onwards
(see figure 3.3.9).
To investigate if expression at lower temperatures might enhance soluble protein
production cultures for each clone were grown and induced at three different
temperatures (20°C, 30°C and 37°C). Samples were collected at 60, 90, 120 and 180
minutes post induction, sonicated and the pellet and supernatant analysed by SDS-
PAGE. With increasing temperature higher levels of protein were expressed for each
time point post induction, the majority of protein was insoluble. At 2 hours post
induction, bacteria grown at 30°C did appear to have more GST-His in the soluble
fraction (see figure 3.4.1) therefore an attempt was made to purify GST-His, using
Ni2+ charged resin, from the supernatant of whole bacteria lysate following
production in these conditions. Unfortunately the purification was unsuccessful, no
significant band of purified protein was present in the elute buffer, and only a very
faint band when concentrated by centrifugal filtration could be seen by SDS-PAGE
analysis.
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Figure 3.3.9. Time course of expression of GST-His from bacteria transformed
with pET-22b/GST
M P SN P SN P SN P SN P SN P SN
Time post I I I I I
induction 0 15 30 60 120 180
(minutes)
BL21(DE3) bacteria containing the plasmid pET-22b/GST were induced by the
addition of isopropy-B-D-thiogalactopyranoside (IPTG) to express a GST-His
recombinant fusion protein. Lysates of bacteria harvested at the times indicated post
induction were subject to centrifugation, the pellet/insoluble fraction (P) and
supernatant/soluble fraction (SN) of each sample were separated in a 14% acrylamide
SDS-PAGE gel. The SDS-PAGE gel was stained with Coomasie blue dye to visualise
the proteins. The arrow indicates the position of GST-His. The numbers on the left
indicate molecular weight in kDa.
Figure 3.4.
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BL21(DE3) bacteria containing pET-22b/GST-His were grown at three different
temperatures as indicated. Samples were taken at increasing time intervals post
addition of isopropy-(3-D-thiogalactopyranoside (IPTG), for induction of fusion protein
expression, and subject to sonication. The bacterial lysates were centrifuged and the
pellet/insoluble fraction (P) and supernatant/soluble fraction (SN) were separated on
14% acrylamide SDS-PAGE gels as shown. The SDS-PAGE gels were stained with
Coomasie blue to visualise the proteins. The numbers on the left hand side indicate the
molecular weight in kDa. The arrow indicates the position ofGST-His.
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3.2.5 Generation of GST-His - Using Vector pGEX-2T
It was considered possible that the insolubility of GST-His expressed by bacteria
containing pET-22b/GST may be due to the system used for expression rather than
the GST-His protein structure itself therefore an alternative approach was adopted to
generate a GST-His fusion protein. A hexahistidine tag was cloned downstream of
the GST encoding gene in the pGEX-2T expression vector (see figure 3.4.2). This
was predicted to generate a protein of 232 amino acid residues with a molecular
weight of 27,133.
Sense and antisense DNA oligomers (Hisl and His2 refer to section 2.1.8) were
designed that encoded a hexahistidine sequence flanked by restriction sites BamHl
and EcoRI. Equimolar concentrations of the oligomers were mixed together at room
temperature and then subject to digestion with EcoRl and BamHl. The cut product
was phenol/chloroform extracted and precipitated at -70°C in the presence of 0.01M
MgCh which aids the precipitation of small (<100bp) DNA fragments. The DNA
fragment encoding the hexahistidine tag was then ligated into pGEX-2T (previously
cut with EcoKl and BamHl and treated with phosphatase) downstream of and in
frame with the GST protein encoding gene. The ligation mix was used to transform
competent E. coli by the heat shock method. Transformants were selected using
ampicillin, only three colonies grew. These colonies were picked, grown up in liquid
culture and their plasmid DNA extracted. The resultant plasmids were cut with Smal
alone and with BamHl and EcoKl simultaneously. Successful insertion of the
fragment should eliminate the Smal site. The Smal site appeared to be deleted and
the correct banding pattern following BamHl and EcoRI digestion (one band of
approximately 5 kbp and another of approximately 30bp) was produced by each of
the three clones however it was difficult to visualise the 30kbp fragment being so
small.
Expression ofGST-His
Cultures of each clone carrying pGEX-2T/His were induced for protein expression,
the lysates analysed by SDS-PAGE and western blotting. A protein of
approximately 27 kDa for each clone was detected on a western blot using an anti-
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Figure 3.4.2. Cloning strategy for generation of GST-His fusion protein using
vector pGEX-2T
Hexahistidine tag
Gly Ser His His His His His His Stop
CGC GGA TCC CAC CAC CAC CAC CAC CAC TGA ATT CGC C
V ) \ )
SamHI EcoRI
Hexahistidine tag inserted
between BamHI and EcoRI sites
Arg Gly Ser Pro Gly lie His Arg Asp Stop
CGT GGA TCC CCG GGA ATT CAT CGT GAC TGA
The vector pGEX-2T encodes the gene for glutathione-S-transferase (GST). A DNA
sequence encoding a hexahistidine tag was inserted into pGEX-2T between the BamHl
and EcoRI restriction sites to generate pGEX-2T/His. In bacteria carrying pGEX-
2T/His the lac repressor (product of the laclq gene) binds to the Ptac promoter repressing
the induction of GST fusion protein. Upon induction with isopropyl P-D-
thiogalactopyranoside derepression occurs and the GST-His fusion protein is expressed.
AmpR - ampicillin resistance gene, ori - origin of replication.
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hexahistidine monoclonal antibody confirming the presence of the hexahistidine tag
(see figure 3.4.3a) The protein was present in the soluble fraction of the bacterial
cell lysate and was successfully purified from bacteria 150 minutes post induction of
• • • "7-F • •
expression using the Ni charged resin method (see figure 3.4.3b). The protein was
also identified on western blots using the available anti-gpl50 serum which was
generated against a GST-gpl50 fusion protein.
From a 500ml culture of pGEX-2T/His containing bacteria it was possible to purify
0.35 - 0.665 mg of GST-His protein, approximately lmg/litre culture. Yields of
GST-His fusion protein were calculated from the absorbance at 280nm using the
relation 1 A280 = 0.5 mg/ml (Smith & Johnson, 1988).
3.2.6 BINDING STUDIES
As described in section 1.4.5 virus glycoproteins can have many different functions
including binding to cell surface molecules to facilitate virion attachment to cells.
Futhermore, virus glycoproteins that are involved in post attachment/entry events of
virus infection often display cell surface binding activity. The reported neutralisation
activity of anti-gpl50 antisera, the virion surface location and similarity with EBV
gp340/220 of gpl50 suggest that gpl50 may be involved in MHV-68 attachment
and/or entry of target cells. To test this possibility a series of binding experiments
was performed using gpl50-His.
3.2.7 Application of Gpl50-His in a 'Far-western blot'/VOPBA
To identify a cellular protein to which virus and gpl50 may bind gpl50-His, GST-
His, MHV-68 infected cell supernatant and concentrated virus preparations were
applied to western blots of different mammalian cell lysates. These included the
fibroblastoid BHK cell line and the CI27 mouse epithelial cell line which are known
to support productive MHV-68 replication. Also included were the transformed cell
lines of B cell origin NS0, SI 1, S31, and A20, since MHV-68 is B lymphotropic. A
transformed cell line of T cell origin, EL4, was also included. For each lane of a
7.5% SDS-PAGE gel cell lysate equivalent to 1 x 105 cells was loaded, proteins were
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Figure 3.4.3 Expression & purification of GST-His from bacteria carrying pGEX-
2T/His






Clones of bacteria transformed with pGEX-2T/His were induced to express the fusion
protein by addition of isopropyl-fi-D-thiogalactopyranoside (IPTG). A. Western blot
the whole bacterial lysate of clone 1 prior to induction (lane 1), 30, 90 and 150 minutes
post induction (lanes 2, 3 and 4 respectively) probed with an anti-hexahistidine mouse
monoclonal antibody followed by a goat anti-mouse alkaline phophatase conjugated
secondary antibody. Transferred from a 14% acrylamide SDS-PAGE gel B. Samples
were taken from each stage of affinity purification ofGST-His from bacteria using Ni2+
charged resin beads and analysed in a 14% acrylamide SDS-PAGE gel, lane: 1 -
uninduced, 2 - induced, 3 - pellet/insoluble fraction, 4 - supernatant/soluble fraction, 5 -
supernatant in binding buffer, 6 - binding buffer wash, 7 - wash buffer, 8 - eluate
(purified GST-His), 9 - strip buffer, 10 - Ni2+ resin beads. The SDS-PAGE gel was
stained with Coomassie blue to visualise proteins. Numbers at the left hand side
indicate the molecular weight in kDa.
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electrophoretically transferred to membranes, strips of which were used for binding
analysis. Incubations with the fusion proteins were performed at 4°C and room
temperature for times ranging from 1 hour to overnight. To detect binding, anti-
gpl50 antibody was used as the primary antibody followed by the secondary swine
anti-rabbit alkaline phosphatase conjugated antibody. Different cell lines gave rise to
different patterns of background staining but no specific bands for either virus or
gpl50-His were detected. Various concentrations of the gpl50 fusion protein (from
51.3ng/ml (1 lpM) to 51.3pg/ml (1 InM)) and of virus from infected cell supernatant
S- o
(5x10 pfu/ml) and also concentrated virus preparations (up to 3 x 10 pfu/ml) were
tested. In addition various concentrations (from 1/100 to 1/1000) of the primary
antibody were used however specific binding was not demonstrated.
A new strategy was adopted to eliminate the use of antibody in an attempt to reduce
background non-specific bands. This was considered a valid option as if there was
any specific binding it may have been masked by the non-specific staining.
Biotinylated fusion proteins were applied to western blots of cells and an avidin-
alkaline phosphatase conjugate was used for detection. The resultant bands were
determined to be non-specific. Efforts to eliminate the non-specific binding of the
avidin alkaline phophatase conjugate included varying the salt concentration of the
Tris-HCl buffer from 150-500mM NaCl, and changing the blocking buffer from milk
protein to bovine serum albumin. However, the non-specific binding was not
eliminated by these methods and no specific binding of MHV-68 or gpl50-His was
detected.
The use of a VOPBA (virus overlay protein binding assay) based method was
considered a valid approach in an effort to detect binding of virus and gpl50-His to
cellular proteins. Variations of this technique have proved effective for the
identification of putative cell receptors for a number of viruses including reovirus
type 3 (Co et al., 1985), mouse hepatitis virus (Boyle et al., 1987), CMV (Adlish et
al., 1990, Taylor & Cooper, 1990), lymphocytic choriomeningitis virus (LCMV)
(Borrow & Oldstone, 1992), Theiler's virus (Kilpatrick & Lipton, 1991), visna virus
(Dalziel et al., 1991, Crane et al., 1991) and encephalomyocarditis virus (Jin et al.,
1994). However VOPBAs are only useful in certain circumstances where binding is
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not dependent on protein conformation or affected by denaturation, a negative result
by VOPBA alone by no means rules out lack of binding function of a virus or
protein (Boyle et al., 1987).
3.2.8 Analysis of Gpl50-His Binding to Epithelial Cells - ELISA Binding Assay
To test the ability of gpl50-His to bind to C127 murine epithelial cells an enzyme
linked immunosorbent (ELISA) based assay was developed. CI27 cells were
selected as antibodies against gpl50 were reported to neutralise MHV-68 infection of
these rodent cells (Stewart et al., 1996). The use of this ELISA based system
avoided harvesting of cells eliminating mechanical disruption of cells and the use of
the protease trypsin which may destroy potential cell surface binding epitopes. The
receptors of some viruses such as rhinovirus (Mischak et al., 1988), B-lymphotropic
papovavirus (Haun et al., 1993) and papillomavirus (Qi et al., 1996) are destroyed by
trypsin.
Confluent monolayers of paraformaldehyde fixed CI27 cells (approximately 5 x 104
cells/well) in 96 well plates were incubated with equimolar concentrations of each
fusion protein, 50pl of 20pM protein solution (6xl014 molecules/well). In addition
107 pfu/well ofMHV-68 as a positive binding control and BHK cell lysate as a virus
negative binding control were applied. Incubations of protein and virus with the
cells were performed for 1.5 hours or overnight at 37°C and 4°C, respectively. The
primary antibody used was rabbit anti-gpl50 antiserum followed by swine anti-rabbit
alkaline conjugated antiserum. Alternatively, a mouse anti-hexahistidine monoclonal
antibody was used followed by a goat anti-mouse alkaline phophatase antibody.
Binding assays were repeated three times in triplicates.
As shown in figure 3.4.4 MHV-68 bound to fixed CI27 cell monolayers in the
ELISA assay. Greater binding was observed the longer the binding incubation time
and was greater at 37°C compared to 4°C. The readout for gpl50-His binding did
not differ significantly from the GST-His control fusion protein. Equivalent results
were observed for fusion protein binding levels whether mouse anti-hexahistidine
monoclonal antibody or anti-gpl50-GST antibody was used for detection. In relation
to the control protein any gpl50-His binding observed was deemed non-specific.
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The level of binding detected for gp 150-FIis applied to paraformaldehye fixed
monolayers of CI27 epithelial cells in an enzyme linked immunosorbent based assay.
Equimolar quantities of fusion proteins (50pl/well of 20pM protein solution), 107 pfu
of MHV-68/well (virus) or BHK cell lysate (BHK) as a virus negative control, were
applied to monolayers in a 96 well plate for either 1.5 hours at room temperature or
incubated overnight at 4°C. To detect binding the primary antibody used was rabbit
anti-gpl50 antibody (1') followed by swine anti-rabbit alkaline phosphatase conjugate
(2'). The optical density of wells was measured at 405nm following addition of the
alkaline phosphatase substrate. The experiment was performed in quadruplicates, bars
denote standard deviation. Chart represents one of three sets of experiments.
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The use of the ELISA based assay for analysis of the binding potential of gpl50-His
to lymphocytes was attempted. However, technical difficulties were experienced due
to the characteristic lack of adherence of lymphocytes which ultimately resulted in
loss of cells from the wells. In this case cells used included the A20 and NSO B cell
lines and primary splenic lymphocytes. Measures used to avoid the cell loss problem
included use of extreme care when washing wells by using slow hand pipetting,
precoating wells with anti-mouse immunoglobulin antibody (for purified splenic B
cells) and precoating wells with poly-L-lysine. These measures failed to resolve the
problem. The failure of the precoating techniques to prove effective was surprising
however, even new preparations of antibody applied by standard coating protocols
did not enable sufficient cell adherence for the assay. These measures could also
have adverse effects on the binding of virus and proteins to the cells as
reorganisation of molecules in the cell membrane may occur and the interaction of B
cell immunoglobulins with the antibody coating the wells may cause cell activation
and therefore upregulation of activation markers on the surface of the cells.
3.2.9 The Ability of Gpl50-His to Block Virus infection
The ability of gpl50-His to block MHV-68 infection of epithelial cells was tested by
plaque assay. CI27 monolayers were incubated with fusion protein (2pM) for one
hour at 4°C, 200 pfu of virus was applied to the monolayers and incubation was
continued for one hour at 4°C and then shifted to 37°C for one hour followed by
removal of the virus and washing of the monolayer with a low pH buffer to inactivate
and remove remaining extracellular virus. Repeat experiments consistently showed
no significant blocking of MHV-68 infection of mouse epithelial monolayers by
gpl50-His (refer to table 3.1.1). Incubation with gpl50-His fusion protein and virus
infection using the same quantities was also done with cells (106 cells per tube) in
suspension however, no blocking ofMHV-68 infection was detected.
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Well Number of Plat) ues





Mean 222.25 (+79.5) 222.5 (±39.8)
Table 3.1.1. Ability of gpl50-His to block MHV-68 infection of C127 epithelial
cells. Prior to MHV-68 infection (200pfu), CI27 cell monolayers in six well plates
were incubated, for one hour, with 500pl media in the presence (+ gpl50-His) or
absence (- gpl50-His) of 2pM gpl50-His to determine if gpl50-His could block
MHV-68 infection. After 5 days post infection monolayers were fixed with formal
saline and the number of plaques counted. A representative set of data is shown, the
figures in brackets show the standard deviation.
3.3.1 Ability of Antiserum to Block MHV-68 Binding to Epithelial Cells
To investigate if the anti-gpl50 antibody generated against a GST-gpl50 fusion
protein, previously reported to neutralise infection, blocked binding of virus to
epithelial cells the ELISA based assay was used. This was in order to elucidate the
mechanism of virus neutralisation i.e. to determine if the antibody blocked
attachment of virus to cells. Initially, the minimum virus concentration that could be
applied in the ELISA assay and detected as positive binding virus was tested. This
was done in order to be able to optimise the ratio of antibody to virus that may allow
even weak antibody block of virus binding to be detected. Virus was applied in a
series of dilutions to monolayers of C127 cells in 96 well plates. Anti-gpl50
antibody was used to detect binding of virus, followed by the swine anti-rabbit
alkaline phophatase conjugated secondary. As figures 3.4.5 shows the lowest virus
concentration applied to CI27 cells that could be detected above background was 1 x
105 pfu . It was decided that 107 pfu per well would be used, as this shows clear
binding, the lower concentrations that allowed detection of positive virus binding
would perhaps be too low to reasonably avoid the possibility of ambiguous results.
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Figure 3.4.5. Analysis of the minimum level of MHV-68 virus that results in
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MHV-68 was diluted in series and applied to paraformaldehyde fixed C127 mouse
epithelial monolayers in order to determine the minimum virus required to detect
positive binding above background in an enzyme linked immunosorbent based assay.
BHK cell lysate (BHK) was used as a virus negative control. The primary antibody
(1') used for the detection of binding was rabbit anti-gpl50 antibody followed by a
swine anti-rabbit alkaline phosphatase conjugate (2'). Following the addition of the
alkaline phosphatase substrate the optical density was measured at 405nm.
Quadruplicates were done, the bars denote standard deviation. The dotted line
indicates the cut off point for detection of significant binding above background.
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Next, virus (107pfu) was incubated with dilutions of anti-gpl50 antibody, anti-MHV-
68 antibody, as a positive antibody blocking control or anti-gB antibody as a
negative control. Following an hour incubation with antisera the virus was applied to
C127 monolayers in 96 well plates for one hour. As figures 3.4.6a & 3.4.6b show
anti-gpl50 antibody did not appear to specifically block binding of virus to cells
even at very low dilutions of 1/2 and 1/10. The anti-MHV-68 antibody (at 1/10)
consistently blocked MHV-68 binding, a feature which could be diluted out as figure
3.4.6b shows. At a dilution of 1/150 the MHV-68 antibody appeared to no longer
reduce virus binding. As a negative control the anti-gB antibody did not block
binding ofMHV-68. This was repeated three times with consistent results.
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Figure 3.4.6a. Analysis of the ability of anti-gpl50 antisera to block binding of












The relative amount ofMHV-68 binding to monolayers of paraformaldehye fixed C127
epithelial cells in a 96 well plate following virus incubation with antisera (final dilution
1/10) of different specificities for 1 hour. Virus preincubated with rabbit antisera of
different reactivities (anti-MHV-68, anti-gpl50 and anti-gB) was applied at 107 pfu per
well and incubated for 1.5 hours at room temperature. For detection of binding the
primary antibody used was rabbit anti-gpl50 antibody (1') followed by a swine anti-
rabbit alkaline phosphatase conjugated antibody (2'). The optical density of wells was
measured at 405nm following addition of the alkaline phosphatase substrate. BHK cell
lysate (BHK) was used as a virus negative control, BHK cell lysate preincubated with
the different antisera was also done however no difference from BHK lysate alone was
observed. MHV-68 +ve = virus alone (not incubated with antibody), as a positive
binding control. Bars denote standard deviation of quadruplicate samples. Chart
represents one of two experiments. The dotted line indicates the cut off point for
positive binding above background.
Figure 3.4.6b. Analysis of the level of anti-MHV-68 antibody necessary to block













Determination of the level of antibody required to block binding of MHV-68 to CI 27
mouse epithelial cells. MHV-68 virus (107pfu/well) was incubated with the sera
dilutions indicated for 1 hour prior to application of virus to monolayers of
paraformaldehye fixed CI27 cells in 96 well plates. An enzyme linked immunosorbent
based detection system was used, the primary antibody (1') was rabbit anti-gpl50
antiserum followed by a swine anti-rabbit alkaline phosphatase conjugated secondary
antibody (2'). The alkaline phophatase substrate BCIP/NBT was used and the optical
density read at 405nm. Bars denote standard deviation of quadruplicate wells. Chart
represents one of two experiments. Note: higher dilutions of anti-gpl50 and anti-gB
(i.e. 1/100, 1/500 & 1/1000, 10,000) were done however similar results to lower
dilutions were obtained therefore bars not shown. BHK cell lysate (BHK) was used as a











3.3.2 Virus Neutralisation By Antisera
Following the discovery that the anti-gpl50 serum did not block MHV-68 binding to
CI27 epithelial cells, neutralisation assays, in the form of a conventional plaque
reduction assay, were done. Prior to application to CI27 epithelial cell monolayers
lOOpfu of virus was incubated with dilutions (1/2, 1/10 and 1/100) of anti-gpl50
antisera. Polyclonal anti-MHV-68 was used as a positive control and anti-gB was
used as a negative control for neutralisation. In contrast to previously reported
findings (Stewart et al., 1996) the anti-gpl50 antibody did not exhibit significant
neutralising ability even at very low antibody dilutions of Vi and 1/10. The anti-
MHV-68 antibody consistently neutralised MHV-68 plaque formation 100% at a
dilution of 1/100 and the anti-gB antibody did not reduce plaque numbers as
predicted. Table 3.1.2. shows a representative set of data for antibody neutralisation
assays.
MHV-68 MHV-68 + MHV-68 + MHV-68 +
alone anti-MHV-68 anti-gpl50 anti-gB
Number of Plaques
112 0 117 115
105 0 130 118
98 0 120 92
120 0 107 120
109 (±9.43) 0 118.5 (±9.47) 111 (±13.0)
Table 3.1.2. Analysis of the virus neutralising ability of anti-gpl50 antibody by
plaque assay. MHV-68 (lOOpfu) was incubated with rabbit antisera (1/10 final
dilution) with different specificities for one hour prior to application to monolayers
of CI27 epithelial cells in 6 well plates. The sera was heat treated prior to use in
order to inactivate complement. After five days post infection cell monolayers were
fixed with formal saline and the number of plaques counted. The bottom row
indicates the mean number of plaques of quadruplicate wells with the standard
deviation in brackets.
3.3.3 Ability of Gpl50-His to Bind to Splenic Lymphocytes
In view of the B cell tropism and splenic site of latency displayed by MHV-68
investigations into the ability of gpl50-His to bind to splenic lymphocytes was
pursued by using fluorescence associated cell sorting (FACS) analysis. Equimolar
concentrations of fusion proteins (20pM), 107 pfu of MHV-68 as a positive binding
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control and BHK cell lysate as a negative virus control were each incubated with 106
freshly prepared live BALB/c splenocytes per well for 1.5 hours at 37°C in the
presence of sodium azide to inhibit capping. Binding was detected using anti-gpl50
antibody followed by a goat anti-rabbit FITC conjugated antibody or anti-
hexahistidine monoclonal antibody followed by a sheep anti-mouse FITC conjugated
antibody. Binding to splenic lymphocytes was analysed by FACS these cells were
discriminated by cell size and granularity. In conjunction to each cell binding assay
a proportion of the splenocytes used were analysed by FACS to determine the
lymphocyte cell make up of the population. Figure 3.4.9.a shows a representative set
of a splenocyte population profde.
The establishment of this assay was delayed by the great loss of cells experienced
during the washes between incubations. This technical difficulty was particularly
apparent due to the number of washes required in total i.e. 11 washes. The use of
standard FACS tubes and vacuum pump suction for removal of supernatant between
centrifugal pelleting of cells was abandoned. Ultimately, round bottom 96 well plates
were used, centrifugation was done for five minutes at 500 x g with the brake off and
the supernatant removed by careful hand pipetting to avoid dislodging cells.
As figure 3.4.7 shows significant binding of lymphocytes by gpl50-His at 20pM in
comparison to GST-His was detected, in contrast to the epithelial cell binding data.
A shift to the right was repeatedly seen on FACS graphs indicating cells with
increased FITC staining when gpl50-His was applied to splenocytes. Similar results
were obtained using either pair of antibodies for detection. MHV-68 was
consistently determined to bind approximately 10% of the lymphocytes. Gpl50-His
(at 20pM) repeatedly bound approximately 2 - 3% of lymphocytes a level which
was determined >95% significant in comparison to the control GST-His fusion
protein by Student's t test. This result could be diluted out, at 200nM of gpl50-His
protein no significant binding was detected and showed that the levels of protein
used were near the threshold between detection of binding and no detection.
Preferably, higher concentrations of proteins would have been tested however the
quantity of protein used was limited to a maximum of 20pM due to the restricted
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amount available. Protein concentrations used were at the upper limit of that which
was feasible from a bulk stock of protein that was generated with the intention of
maintaining the protein applied across assays consistently from the same stock.
The shape of the FACS graph in figure 3.4.7 for splenic lymhphocyte binding
suggests general binding of gpl50-His to the heterogeneous population of
lymphocytes rather than a specific subset of cells which might show as a second peak
rather than a shift in fluorescence of the whole population.
Binding of MHV-68 to primary splenic lymphocytes was also detected by FACS
analysis using the polyclonal rabbit anti-MFIV-68 antibody as the primary antibody
which gave results consistent with those realised using the anti-gpl50 antibody as
• 7 6
primary antibody i.e. when 10 pfu of virus was applied to 10 splenocytes
approximately 10% of the lymphocytes were bound by virus (see figure 3.4.8).
3.3.4 Ability of Gpl50-His to Bind to Purified Splenic B cells
In view of results indicating gpl50-His binding to splenic lymphocytes the fusion
proteins were applied to purified B cells. Of the subsets, B cells were selected for
analysis of potential gpl50-His binding on the basis that MHV-68 establishes latent
infection in B cells. In addition gpl50 may be functionally similar to gp340 of EBV
that specifically binds B cells. B cells were purified from freshly obtained
splenocytes by magnetic associated cell sorting (MACS) depletion, an anti-CD43
monoclonal antibody conjugated to metal beads was employed to specifically retain
cells expressing the CD43 epitope. The CD43 antigen is expressed on IL-7
responsive pro-B cells, plasma cells, peritoneal and splenic CD5+ B cells (B-l cells),
granulocytes, monocytes, macrophages, platelets, NK cells, thymocytes, peripheral
cytotoxic T cells and most helper T cells. CD43 is not expressed on resting
conventional peripheral B cells (Yedidia et al., 1998). This method routinely gave
preparations that were >90% pure as determined by FACS staining for lymphocyte
subsets (see figure 3.4.9). The FACS based splenic B cell binding assay was
performed as for the whole splenocyte binding assay. As figure 3.5.1 shows
significant binding of gpl50-His to approximately 8% of splenic B cells was
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Figure 3.4.7. Flow cytometric analysis of the ability of gpl50-His to bind to
BALB/c splenic lymphocytes
A. Freshly prepared live BALB/c splenocytes (106/well) were incubated, in suspension,
with equimolar concentrations (20 pM) of each fusion protein (gpl50-His or GST-His),
107 pfu ofMHV-68 or BHK cell lysate (BHK) as a negative virus control for 1.5 hours
at 37°C in the presence of 0.2% sodium azide. The primary antibody used for detection
of binding was rabbit anti-gpl50 antibody (T) followed by swine anti-rabbit
fluoresceine isothiocyanate (FITC) conjugated antibody (2'). Cells were formaldehyde
fixed and analysed by fluorescence associated cell sorting (FACS). Lymphocytes were
discriminated by cell size and granularity. The marker for positive staining was
positioned at 1% of staining with l',2' antibody alone. The bars denote standard
deviation of triplicate samples. Chart represents one of three sets of experiments. B.
Representative GST-His scatter profile of lymphocytes superimposed on top of a
gpl 50-His profile.
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A. Dilutions ofMHV-68 were incubated with 106 primary murine splenocytes per well
for 1.5 hours at 37°C in the presence of sodium azide. A baby hamster kidney cell
lysate preparation (BHK) was used as a virus negative control at a concentration
equivalent to the highest concentration ofMHV-68 applied, figures below MHV-68 on
x axis indicate the total pfu of virus applied per well. The primary antibody used was
polyclonal rabbit anti-MHV-68 antibody (1) followed by swine anti-rabbit flouresceine
isothiocyanate (FITC) conjugated antibody (2). Bars denote standard deviation from
triplicate samples. MHV-68 binding observed when a total pfu of 107 was applied in
comparison to the BHK control is 99.8% significant as determined by Student's t test.
Chart represents data from one of two experiments. B. Representative BHK FACS
scatter profile of splenocytes superimposed on top of a MHV-68 (107 pfu applied)
profile.
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Figure 3.5.1. FACS analysis of the ability of gpl50-His to bind to purified splenic
B cells
A. Primary B cells were purified from BALB/c splenocytes by magnetic cell sorting
(MACS) depletion of CD43* cells. Purified B cells (106/well) were incubated with an
equimolar concentration (20pM) of each fusion protein (GST-His or gpl50-His), 107
pfu MHV-68 and BHK cell lysate (BHK) as a negative virus control for 1.5 hours at
37°C in the presence of sodium azide. The primary antibody used for detection of
binding was rabbit anti-gpl50 antibody(l) followed by a swine anti-rabbit fluoresceine
isothiocyanate (FITC) conjugated secondary (2). Bars show standard deviation of
triplicates. Chart shows representative data from one of two experiments. B.
Representative FACS profiles of B cells incubated with each fusion protein, GST-His
profile superimposed on that of gpl50-His.
observed. Approximately 6% of purified B cells were bound by MHV-68 in
comparison to control BHK cell lysate staining.
3.3.5 CD19 Phenotvpe of Cells Bound hv Gp150-His & MHV-68
In order to further analyse the lymphocyte cell types bound by MHV-68 and gpl50-
His double FACS staining was done. Fusion proteins and virus were applied to
BALB/c splenocytes and then antibodies for detection of the fusion protein were
applied in conjunction with a primary rat antibody for CD19 and a secondary goat
anti-rat phytoerythrin conjugated antibody. CD 19 is a B cell specific marker
expressed throughout B cell development from the pro-B cell through to the mature
B cell stages (Krop et al., 1996, Krop et al., 1996b, Fearon, 1993, Tedder et al.,
1994). Terminally differentiated plasma cells do not express CD 19. On the surface
ofmature B cells the CD 19 molecule associates with CD21(CR2) and CD81 (TAPA-
1) and this multimolecular complex synergizes with surface immunoglobulin to
promote cellular activation (Krop et al., 1996b, Fearon, 1993, Tedder et al., 1994).
The FACS data indicate that both CD19+ and CD 19" subsets of cells bind virus and
gpl50-His (see figures 3.5.2a). Total cell binding of gpl50-His and MHV-68 in
comparison to the appropriate controls are significant by 95% and 99.9%
respectively by Student's t test. Of the splenocytes that gpl50-His binds
approximately 52% are CD19+ and 48% are CD 19". Of the splenocytes that stained
positive with incubation with MHV-68 approximately 15% are CD19+ and 85% are
CD19" (see figure 3.5.2b ).
3.3.6 FACS Analysis of Gpl50-His ability to Bind C127 Epithelial Cells
With the establishment of the FACS binding assay C127 epithelial cells were put
through the system using the same conditions as for splenocytes. Consistent with the
ELISA binding data gpl50-His failed to show significant binding from that of the
control protein. In contrast, MHV-68 demonstrated binding to approximately 58% of
the cells (refer to figure 3.5.3).
200
Figure 3.5.2a. CD19 phenotype of BALB/c splenic lymphocytes bound by
MHV-68 and gp!50-His determined by FACS analysis
MHV-68 gp150-His
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Primary BALB/c splenocytes (106/well) were incubated with an equimolar
concentration (20pM) of fusion proteins (GST-His or gpl50-His), 107 pfu of
MHV-68 and BHK cell lysate (BHK) as a negative virus control, for 1.5 hours at
37°C in the presence of sodium azide. Double staining was done, primary
antibodies used were rabbit anti-gpl50 antibody and rat anti-CD 19 antibody,
secondary antibodies used were swine anti-rabbit fluoresceine isothiocyanate
(FITC) conjugated antibody and goat anti-rat R-phytoerythrin. The markers for
positively stained cells were set at approximately 1% of anti-gpl50 antibody plus
anti-rabbit FITC on the x axis and at 1% of anti-Rat PE alone on the y axis.
Figures show representative FACS scatter profiles for splenic lymphocytes
incubated with the indicated reagent, numbers indicate the percentage of cells in
each quadrant. Labels in the bottom left panel indicate phenotype staining of cells
in each quadrant. Assays were done in triplicate.
















Primary BALB/c splenocytes (106/well) were incubated with an equimolar
concentration (20pM) of fusion proteins (GST-His and gpl50-His), 107 pfu ofMHV-68
and BHK cell lysate (BHK) as a negative virus control, for 1.5 hours at 37°C in the
presence of sodium azide. Double staining was done, primary antibodies used were
rabbit anti-gpl50 antibody and rat anti-CD19 antibody, secondary antibodies used were
swine anti-rabbit fluoresceine isothiocyanate (FITC) conjugated antibody and goat anti-
rat R-phytoerythrin (PE) conjugated antibody. Fluorescence associated cell sorting
(FACS) analysis was done, lymphocytes were discriminated for by cell size and
granularity. The markers for positively stained cells were set at approximately l% of
anti-gpl50 antibody plus anti-rabbit FITC and anti-Rat PE alone. A. The chart displays
the percentage of lymphocytes bound by gpl50-His and MHV-68 and the proportion of
CD19+ve and CD19-ve cells within the bound population. B. The overall CD 19
phenotype of the whole population of lymphocytes. The bars denote standard deviation
of triplicates. Representative data from one of two experiments.
Figure 3.5.3. FACS analysis of the ability of MHV-68 & gpl50-His to bind to
C127 murine epithelial cells
A. CI 27 murine epithelial cells (106/well) were incubated with equimolar
concentrations (20pM) of fusion protein (gpl50-His or GST-His), 107 pfu MHV-68 or
BHK cell lysate (BHK) as a virus negative control, for 1.5 hours at 37°C in the
presence of sodium azide. The primary antibody used for detection of binding was
rabbit anti-gpl50 antibody (1) followed by swine anti-rabbit fluoresceine
isothiocyanate (FITC) conjugated antibody (2). Cells were formaldehyde fixed and
analysed by fluorescence associated cell sorting (FACS). The marker for positive
staining was positioned at 1% of staining with 1,2 antibody alone. The bars denote
standard deviation of triplicate samples. B. Representative FACS profile of MHV-68
overlayed with a virus negative control BHK cell lysate profile.
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3.3.7 FACS Analysis of the Effect of Preincubation ofMHV-68 with Antisera on
Virus Binding to BALB/c Splenic Lymphocytes
The effect of preincubation of virus with antisera prior to application to splenic
lymphocytes was tested. MHV-68 (107 pfu) was incubated with increasing dilutions
of antisera with different specificities (anti-gpl50, anti-MHV-68 and anti-gB) for
one hour prior to incubation with primary BALB/c splenocytes (106/well) for 1.5
hours at 37°C in the presence of sodium azide. Antibodies used for detection of virus
binding were rabbit anti-gpl50 antibody followed by swine anti-rabbit FITC
conjugated antibody. FACS analysis was done, lymphocytes were discriminated by
cell size and granularity. As figure 3.5.4 shows, at antisera dilutions of 1/5 up to
1/100 and 1/500 increased numbers of cells were bound by virus over that observed
for virus alone, were detected with either anti-gpl50 and anti-MHV-68 antisera,
respectively. With higher dilutions of anti-gpl50 and anti-MHV-68 antibody
(<1/1000) the level of virus binding observed was similar to the level measured with
virus alone that had not been incubated with antibody. This phenomenon was seen in
repeat experiments and is thought to be due to antibody coated virus attaching to
lymphocytes via Fc receptors. The anti-gB antibody did not significantly alter virus
binding in comparison to MHV-68 alone as determined by Student's t test.
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Figure 3.5.4. FACS analysis on the effect of preincubation of MHV-68 with
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MHV-68 (107pfu) was incubated with dilutions of rabbit antisera with the
specificities indicated for one hour prior to incubation with BALB/c splenocytes
(106/well) for 1.5 hours at 37°C in the presence of sodium azide. The primary
antibody used for detection of binding was rabbit anti-gpl50 antibody (1')
followed by swine anti-rabbit fluoresceine isothiocyanate (FITC) conjugated
antibody (2'). Cells were formaldehyde fixed and analysed by fluorescence
associated cell sorting (FACS). Lymphocytes were discriminated by cell size and
granularity. The marker for positive staining was positioned at 1% of staining with
l',2' antibody alone. The bars denote standard deviation of duplicate samples.
BHK- BHK cell lysate as a virus negative control, anti-gB- anti-gB antibody at a
dilution of 1/10, MHV-68- MHV-68 alone, not incubated with antibody. The far
right column for both charts shows the indicated antisera (1/10) incubated with
cells in the absence of virus.
ri:si
3.3.8 GP150 BASED VACCINE
MHV-68 provides the opportunity to investigate the potential of a glycoprotein based
vaccine for gammaherpesviruses in an amenable animal model. As described in
sections 1.8.7 - 1.8.9 much emphasis has been put on the possible use of gp340/220
of EBV as a vaccine immunogen. A wide array of vaccine forms have been pursued
and there has been limited success in animal models and small human trials with a
recombinant vaccinia virus expressing gp340 (Morgan et al., 1988b, Mackett et al.,
1996, Gu et al., 1995). Gpl50 has been proposed as a candidate vaccine antigen for
immunisation against MHV-68 infection of mice. MHV-68 vaccination studies are
in their infancy however, at least three vaccination strategies have been reported. A
recombinant vaccinia virus expressing gpl50 (VV8p150) administered subcutaneously
to mice resulted in the production of gpl50 neutralising antibodies and upon
subsequent MHV-68 challenge splenomegaly and the peak level of latent virus in the
spleen was greatly reduced (Stewart et al., 1999a). In addition, mice immunised with
in vitro cultured dendritic cells pulsed with MHV-68 lytic cycle CD8+ and CD4+ T
cell epitopes (including one derived from gpl50) experienced significantly reduced
(10-100 fold) lung viral titres following MHV-68 infection (Liu et al., 1999). An
alternative strategy to prime CD8+ T cells against MHV-68 has been done using a
recombinant vaccinia virus and a recombinant influenza A virus both engineered to
express MHV-68 lytic phase CTL epitopes (Stevenson et al., 1999b). Only partial
protection against acute infection was achieved in these studies and none of these
vaccination approaches was able to prevent the long-term establishment ofMHV-68
latency.
In view of the potential of gpl50 to elicit neutralising antibodies and prime a T cell
mediated response against lytic antigens it was considered worthwhile to pursue a
vaccine based on this glycoprotein. The aim was to develop a strategy focusing on
limiting the acute infection and in turn prevent establishment of latency by blocking
spread of infectious virus. With consideration of the known immunological control
ofMHV-68 (refer to section 1.3.8), materials available and recent reports describing
the efficacy of DNA vaccination followed by vaccinia virus boost at eliciting high
levels of specific cell mediated and humoral immunity for HIV, a vaccine strategy
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was formulated (Hanke et al., 1998 & 1999). The aim was to immunise first with a
plasmid encoding gpl50 to prime animals and then boost the immune response with
a recombinant vaccinia virus expressing gpl50. The ultimate readout was to
determine whether this conferred protection against MHV-68 infection in the acute
stage and in the establishment of latency. This strategy was attractive due to the
potential to elicit cell-mediated as well as humoral immune responses against MHV-
68. In addition co-administration of a plasmid encoding type I interferon alpha with
a gpl50 encoding plasmid was proposed to see if expression of IFN-al would
enhance the protective effect of immunity generated to the viral antigen gpl50.
There is evidence to suggest that IFN I plays an important role in the generation and
survival of antigen specific CD8+ T cells during a primary immune response.
Furthermore, IFN I is thought to promote the survival of pre-existing memory CD8+
T cells (Tough et al., 1996a & b).
A source of recombinant vaccinia virus expressing gpl50 was available. Facilities
within the department offered the opportunity for gene gun mediated delivery of the
DNA vaccine into the dermis where many dendritic cells known as Langerhans cells
reside making the skin a particularly responsive site for vaccination. Following gene
gun immunisation dendritic cells resident in the skin are not only capable of taking
up, processing and presenting antigen to T cells but they have also been shown to
undergo direct transfection with the introduced DNA (Condon et al., 1996, Klinman
et al., 1998). Within lymph nodes draining the targetted skin directly transfected
cells have been shown to perform a predominant proportion of antigen presentation
over un-transfected dendritic cells that have taken up antigen, (Porgador et al., 1998).
Another benefit of this method of DNA administration is that 100 - 1000 fold less
DNA (levels of approximately 0.4- 2pg) is required in comparison to intramuscular
injection (Eisenbraun et al., 1993, Fuller & Haynes, 1994, Barry et al., 1995).
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3.3.9 Plasmid Construction for Gpl50 Expression
Prior to initiating the proposed vaccination strategy the generation of a plasmid
vector encoding gpl50 for expression in mammalian cells was required. There are a
number of vectors that have been employed for DNA vaccination studies including
pcDNA3 (see figure 3.5.5a). Within pcDNA3 the CMV major immediate early
promoter/enhancer region drives constitutive expression of inserted genes in
eukaryotic cells in vitro and in vivo. The entire gpl50 encoding gene was amplified
by PCR using primers IElgpl50 and IE2gpl50 (for primers & conditions see section
2.1.8). IElgpl50 includes a Kozak consensus sequence for proper expression of the
protein in eukaryotic cells (Cavener & Ray, 1991). The ~148lbp product of these
primers was cut with restriction enzymes Hindlll and Xhol. Purified cut PCR
product was ligated into pcDNA3 that had been prepared by digestion with Hindlll
and Xhol followed by dephosphorylation to prevent self ligation. The ligation mix
was used to transform competent XL1 blue E. coli by the heat shock method. All
five colonies that grew, selected using ampicillin, were grown up overnight in liquid
culture and their plasmid DNA extracted. Digestion of the isolated plasmid DNA
with Hindlll and Xhol showed one plasmid contained the gpl50 insert by the
appearance of two bands - one of ~5.4kbp and another of ~1.5kbp. This plasmid
was named pcDNA3/gpl50. This clone was grown up in bulk liquid culture and a
large DNA preparation was made using the CsCl gradient method.
Following confirmation of the identity of the large DNA plasmid preparation by the
same digestions used previously the plasmid was transfected into mammalian cell
lines by electroporation. BHK, CI27 and COS cell lines were used for transient
transfections of the plasmid. The transfection efficiency was monitored using a
plasmid encoding green fluorescent protein - pEGFP and also a plasmid encoding (3-
galactosidase - pMVlO. Transfected cells were subjected to immunofluorescence
and western blot analysis in conjunction with control cells that received pcDNA3
alone and cells that did not receive DNA as negative controls. For
immunofluorescence the primary antibody used was rabbit anti-gpl50 antibody
followed by swine anti-rabbit FITC conjugated secondary antibody.
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In order to generate a construct for expression of gpl50 in eukaryotic cells the
gene encoding gpl50 was inserted into the multiple cloning site (MCS) of (A)
pcDNA3 and (B) pcDNA3.1 between restriction sites Hindlll and Xhol and
Hindlll and EcoRl respectively, this positions the gpl50 gene under the control
of the constitutive CMV promoter (PCMV) ancl upstream of the bovine growth
hormone polyadenylation signal (BGHpA). Other features inculde the ampicillin
resistance gene (Ampicillin), fl origin of replication (fl ori), Simian virus 40
origin of replication (SV40 ori), neomycin resistance gene (Neomycin), SV40
polyadenylation signal (SV40pA), the bacterial origin of replication (ColEl) and
the T7 and Sp6 promoters for in vitro transcription. Note: pcDNA3.1 is an
updated version of pcDNA3 the main differences are the more extensive range of
restriction sites in the MCS and the absence of the Sp6 promoter (Sp6).
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By immunofluorescence no positive staining for gpl50 could be observed for the
pcDNA3/gpl50 transfected cells at 24 and 48 hours post transfection, in contrast to
MHV-68 infected cells used as a positive control for gpl50 expression. Likewise,
gpl50 expression was not detected by western blot analysis. The standard quantity
of plasmid DNA used for transfection was 30pg. In view of the absence of
expression, transfection with lOpg and lOOpg of plasmid DNA was tested however,
gpl50 protein detection was negative. In the event that the large DNA preparation of
pcDNA/gpl50 was in someway toxic to the cells a fresh DNA preparation was
generated by the alternative use of a commercial kit. Transfection of mammalian
cells with this fresh preparation did not result in detection of gpl50 expression. In
summary detection at the protein level was negative for gpl50. Sequencing analysis
of the entire gpl50 insert in the plasmid preparations using the sequencing primers
displayed in section 2.1.8 showed the gpl50 insert to be 100% intact therefore lack
of expression did not appear to be due to mutation of the plasmid insert.
3.4.1 PcDNA3.1/gpl50
In light of the lack of detectable protein expression, despite the inserted sequence
100% intact, efforts were made to generate a new construct using an updated version
ofpcDNA3 known as pcDNA3.1. PcDNA3.1 is essentially the same as pcDNA3 the
two main differences are the absence of the bacteriophage SP6 promoter site and the
presence of a multiple cloning region with a more extensive range of restriction
enzyme cleavage sites (refer to figures 3.5.5a & b). According to the manufacturers
(Invitrogen) the SP6 promoter site, which is positioned downstream of the site for
insertion of genes for expression, has been removed as it is thought to cause
secondary structures to occur in RNA transcripts which are detrimental to protein
expression.
In this instance gpl50 was amplified from the MHV-68 genome using primers IA3
and IA4 (refer to section 2.1.8 for primers and PCR conditions). At the time of
cloning the product of IA3 and IA4 - essentially the same as that of IElgpl50 and
IE2gpl50 but with alternative restriction sites, was immediately available so this was
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used instead. IA3 includes the translational start site of gpl50 and the nucleotides
directly upstream i.e. the Kozak sequence is that present in the viral genome. The
product of IA3 and IA4 was cut with Hindlll and £coRI, purified and ligated into
pcDNA3.1 (previously prepared by digestion with Hindlll and EcoBl followed by
dephoshorylation). The ligation mix was used to transform competent XL 1-Blue E.
coli by the heat shock method. Of the 18 colonies that grew, which were noticeably
smaller than bacteria transformed with pcDNA3.1 alone (no insert), 12 were grown
up in liquid culture and subjected to DNA extraction. Restriction digestion of the
plasmid DNA with Hindlll and fscoRI showed that all contained the gpl50 insert
with the appearance of two bands - one of approximately 1.5kbp and another of
5.4kbp. One bacterial clone was grown up and a large plasmid preparation prepared.
This pcDNA3.1/gpl50 construct was transfected into COS, BHK and C127 cells and
expression of gpl50 was assessed by immunofluorescence and western blotting of
cells. Protein expression of gpl50 was not detected at 24 or 48 hours post
transfection of cells.
Sequencing analysis (using the primers shown in section 2.1.8) showed the gpl50
gene insert in the pcDNA3.1/gpl50 construct to be 100% intact. In addition,
restriction digests of pcDNA3/gpl50 and pcDNA3.1/gpl50 were done to confirm the
identity of the plasmid backbone. At the time of cloning several other plasmids
produced by Invitrogen i.e. pIND/Hygro and pIND(SPl)/Hygro were in use, these
have a very similar size (less than 200bp difference) to pcDNA3 therefore
confirmation of the correct plasmid was of heightened importance. For diagnostic
restriction digestion Ncol was chosen due to differing site number between the
plasmids (2 sites in pcDNA3/gpl50 and pcDNA3.1/gpl50, three sites in
pIND/Hygro/gpl50 and pIND(SPl)/Hygro/gpl50). The backbone identity of




As part of a collaborative effort, Filippo Belardelli, Instituto Superiore di Sanita,
Rome, was supplied with pSP72/gpl50, this plasmid contains the entire cDNA for
gpl50. From pSP72/gpl50 his laboratory cloned the gpl50 gene and inserted this
into the mammalian expression vector pVR1255 (Hartikka et al., 1996), between
restriction sites Sail and BamHl, downstream of the CMV immediate early promoter
(refer to figure 3.5.6). The construct, named pVR1255/gpl50 was supplied to our
laboratory to be tested for expression of gpl50 when transfected into mammalian
cells. C127 murine epithelial cells were transfected with pVR1255/gpl50 by
electroporation. As figure 3.5.7 shows expression of gpl50 was successfully
detected 24 hours post transfection by immunofluorescence using anti-gpl50
antibody. Western blot analysis was also done and the characteristic gpl50 banding
pattern was seen with bands detected at 110, 130 and 150kDa when probed with anti-
gpl50 antibody corresponding with those detected by Stewart et al., 1996.
3.4.3 Generation of pVR1255/gpl50-coated Microparticles for DNA Vaccination
With confirmation of mammalian expression of gpl50 the pVR1255/gpl50 plasmid
was considered suitable for use in DNA vaccination studies. A large DNA
preparation of endotoxin free pVR1255/gpl50 was supplied by Filippo Belardelli,
Instituto Superiore di Sanita, Rome. This was used to coat 1.6 pm gold particles for
the generation of pVR1255/gpl50 charged bullets required for administration of
DNA to animals using the Helios gene gun system.
Production of the gene gun 'bullets' includes precipitating the chosen DNA onto
gold particles which are then used to coat the inside of a tube, sections of the tube
constitute the gene gun 'bullets'. Even coating of the tube is desired however, this
can be difficult to achieve. In regard to this the level of polyvinyl propylene (PVP)
in the DNA/gold particle preparation is of importance therefore different
concentrations were tested O.Olmg/ml, 0.05mg/m and a preparation with no PVP.
The best coating was achieved using O.Olmg/ml and therefore this level was used for
all further preparations.
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Figure 3.5.6. Vectors pVR1255/gp!50 & pVR1255/IFN-aI for mammalian
expression of gp!50 and interferon alpha I
For mammalian expression of gpl50 and interferon alpha 1 vectors pVR1255/gpl50
and pVR1255/IFNaI were used, respectively. The gpl50 and interferon alpha I (IFN-
al) genes for expression are under the control of the CMV immediate early promoter
(PCMv) w'th the CMV intron A (Int A) postioned between promoter and gene to
enhance expression. Downstream of the inserted genes is the minimal rabbit (3 globin
terminator (mRBG) and plasmid carries the kanamycin resistance gene (KanR). The
gpl50 gene for expression was inserted into pVR1255 between restriction sites Sal I and
BamHI these are indicated in brackets as the inserts had Xhol and BglU cut ends
therefore the restriction sites were eliminated upon ligation. These plasmids were
supplied by Dr. F. Belardelli.
Figure 3.5.7. Expression of gpl50 by C127 murine epithelial cells transfected
with pVR1255/gpl50
A. Immunofluorescence detection of gpl50 expression by CI27 murine epithelial
cells transfected with pVR1255/gpl50, 48 hours post transfection by
electroporation. Cells were acetone fixed and then probed with rabbit anti-gpl50
antibody, followed by a swine anti-rabbit fluoresceine isothiocyanate (FITC)
conjugated antibody. Fluorescence was visualised by ultra violet microscopy.
Size bar represents 10pm. B. Western blot ofCI 27 cells 48 hours post transfection
with pVR1255/gpl50 (lane 2). Cell lysates were electrophoresed through a 7.5%
acrylamide SDS-PAGE gel and transferred to an immobulin-P membrane. The
blot was probed with rabbit anti-gpl50 antibody followed by a swine anti-rabbit
alkaline phosphatase conjugated antibody and subsequent addition of the alkaline
phosphatase substrate NBT/BCIP (nitro blue tetrazonium/5-bromo-4-chloro-3-
indoyl phosphate). Lane 1 - MW marker, numbers to the left indicate the sizes in
thousands. Lane 3 - normal CI27 cells. Also indicated are the positions of the
predominant bands gpl50, gpl30 and pi 10 which correlate with Stewart et al.,
1996.
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Alongside pVR1255/gpl50 a large DNA plasmid preparation of endotoxin free
pVR1255/IFN-aI was used to prepare pVR1255/IFN-aI charged gene gun bullets.
pVR1255/IFN-aI consists of the mammalian expression vector pVR1255 with the
gene encoding murine interferon alpha I (IFN-al) inserted between sites Bamlil and
Ncol of the multiple cloning site (refer to figure 3.5.6). This plasmid was supplied
by Felippo Belardelli. Expression IFN-al from pVR1255/IFN-aI was confirmed by
the Belardelli laboratory using a vesicular stomatitis virus (VSV) growth inhibition
assay (Familletti et al., 1981,Vogel etal., 1991).
3.4.4 Testing Gpl50 Expression from pVR1255/gp!50 Gene Gun Bullets
The pVR1255/gpl50 gene gun bullets were tested for expression in vitro and in vivo,
to ensure the DNA, following incorporation into bullets, was functional. CI27
epithelial cell monolayers in six well plates were bombarded with the
pVR1255/gpl50 microparticles and the expression of gpl50 mRNA was analysed by
RT-PCR 24 hours post transfection. As figure 3.5.8 shows, at 24 hours post
transfection, a band of approximately 368bp was generated following nested RT-
PCR using primers PAG1 and PAG2 for 40 cycles and internal primers PAG11 and
12 for a subsequent 25 cycles (for primers and PCR conditions see section 2.1.8).
Gold particles coated with pVR1255/gpl50 were administered to the abdominal
region of C57BL/6 mice using the Helios gene gun system at a helium pressure of
500psi. Sectionsof 6pm thickness were cut from formalin fixed paraffin-embedded
abdominal skin biopsies taken 2, 4 and 24 hours post DNA administration. As figure
3.5.9 shows gpl50 expression was detected in the dermis at 24 hours post DNA
administration using anti-gpl50 antibody to immunostain sections. Gpl50
expression was not detected in sections of biopsies taken at earlier times post
transfection.
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Figure 3.5.8. Nested RT-PCR analysis of expression of gpl50 mRNA in cells
transfected with pVR1255/gp!50 using the Helios gene gun system
1st round PCR
pVR1255/gpl50 gene gun bullets were tested for expression of gpl50 in vitro, to
ensure the DNA, following incorporation into bullets, was functional. CI27 epithelial
cell monolayers in six well plates were bombarded with pVR1255/gpl50 coated gold
microparticles using the Helios gene gun at a helium pressure of 50psi. The expression
of gpl50 mRNA was analysed by nested RT-PCR 24 hours post transfection.
Following isolation of mRNA and reverse transcription (RT-) two rounds of
polymerase chain reaction (PCR) were done. The first round of PCR was done using
primers PAG1 & 2 for 40 cycles (expected product 501 bp). The second round of PCR
was done on 10pl of product from the first amplification using internal primers PAG 11
6 PAG12 for a subsequent 25 cycles (expected product 368bp). Products were
analysed on 0.7% agarose gels containing ethidium bromide and visualised using a UV
transilluminator. Lanes: 1- 1 kb DNA ladder marker, size of pertinent bands are shown
at the left 2 - MHV-68 DNA, positive PCR control 3 - mRNA from MHV-68 infected
cells 4 - untransfected cells, negative control, 5 & 6 - pVR1255/gpl50 transfected cells,
7 & 8 - pVR1255/gpl50 transfected cells not reverse transcribed, control for
contaminating DNA.
Figure 3.5.9. Expression of gpl50 in vivo following gene gun administration of
pVR1255/gp!50 into the abdominal dermis ofC57BL/6 mice
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To check for expression of gp 150 in vivo pVR1255/gpl50 was administered to the
abdomen of C57BL/6 mice by microparticle bombardment using the Helios gene
gun system. Sections of 6pm thickness were cut from formalin fixed paraffin-
embedded skin biopsies taken 24 hours post bombardment from the gene gun
targetted abdomen region (A & B). Negative control sections were derived from
unadministered abdominal skin (C). Positive control tissue for gpl50 detection by
immunostaining was derived from a Sll tumour biopsy from a BALB/c nude
mouse (D). Immunostaining was performed to detect the presence of gpl50,
rabbit anti-gpl50 antibody was used followed by a goat anti-rabbit biotinylated
antibody and DAB staining. Slides were negative as in (C) when use of normal
rabbit serum, in place of rabbit anti-gpl50 antibody to control for gp 150 specific
staining, was performed. Boxes in panels A(i) and B(ii) indicate the magnified
areas shown in A(ii) and B(ii) respectively. The black bars represent 10pm across.
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3.4.5 Optimum Pressure for Delivery of DNA Coated Gold Particles into the
Dermis
The optimum helium pressure for gene gun inoculation of the abdominal tissue of
mice was tested. The aim was to ensure gold particle DNA delivery into the dermis
of the skin as this is highly populated with the dendritic Langerhans cells making the
area highly immunologically responsive. Following administration of gold particles
at different pressures (400psi, 500psi and 600psi) biopsies of the targetted abdominal
skin were taken. Six pm sections of the biopsies embedded in paraffin were cut onto
slides and haematoxylin and eosin stained. Of the pressures tested 500psi was
selected for further use as examination of sections by microscopy showed this
pressure resulted in the delivery of substantial numbers of gold particles in the
desired region (refer to figure 3.6.1). In comparison, 400psi and 600psi produced
good levels of gold particles in the dermis but over all the sections studied (nine for
each pressure) 500psi more consistently produced location of particles in this area.
3.4.6 Vaccinia Recombinant Viruses - VVgp150 & yygpt
A recombinant vaccinia virus VVgp150 (Stewart et al., 1999a) containing the gpl50
encoding gene inserted into the thymidine kinase (tk) locus under the control of the
vaccinia 7.5K early/late promoter and the E. coli guanosine phosphoribosyl
transferase gene (gpt) as a selectable marker was supplied by Dr.J.P Stewart. A
control recombinant vaccinia virus VVgpt, with gpt alone (i.e. no additional foreign
gene) was also made available (Stewart et al., 1999a). These recombinant vaccinia
viruses were generated and used in a previous study which showed Wgpl5° to
specifically induce MHV-68 neutralising antibodies when introduced, at a dose of
107 pfu, into BALB/c mice sub-cutaneously. Stocks of these viruses were grown up
ready for use. Prior to use in the vaccination trial a preliminary in vivo assay was
done to ensure the virus preparations were not toxic and to test the lung viral titres
following intranasal infection. C57BL/6 mice were infected with 2 x 106 pfu by the
intranasal route, on days 3, 6 and 10 post infection the lungs were removed and the
virus titre analysed by conventional plaque assay. As figure 3.6.2 shows both
vaccinia recombinants were cleared from the lungs by day 10 post infection. A
higher titre of VVspt, (mean virus titre 181,200 pfu) approximately 3.5 times greater,
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Figure 3.6.1. Gold particle localisation in the abdominal dermis of C57BL/6
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A pressure of 500psi was used to bombard the abdomen of C57BL/6 mice with
1.6pm gold particles using the Helios gene gun system in order to obtain dermal
localisation of particles. Skin biopsies were taken immediately following
administration of particles and fixed in formaldehyde. Biopsies were embedded in
parrattin, cut into 6 pm sections and hematoxylin and eosin stained. Light
microscopy was used to examine the tissues sections. The gold particles are seen
here as black dots. The size bar represents 20pm across.
























3 4 5 6 7
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C57BL/6 mice, approximately six weeks old, were infected intranasally with 2 x 106
pfu (50pl) of either a vaccinia virus recombinant containing the E.coli gene for
guanosine phosphoribosyl transferase (VVgpt) or a vaccinia virus recombinant
containing the gene for gpl50 and gpt of MHV-68 (VVgpl5°). Lungs were taken from
three mice per group at each time point (days 3, 6 and 10 post infection). Virus titres of
lung homogenates were determined by conventional plaque assay on CI27 epithelial
cell monolayers in duplicates, pfu = plaque forming units.
CHAPTER 3 KKSl IIS
compared to VVgpl5° (mean virus titre 50, 466 pfu) was detected at day 3 post
infection. Wgp150 was cleared from the lungs by day 6 post infection whereas
approximately 500 pfu of VVgpt could be detected at this stage.
3.4.7 Gpl50 DNA & Vaccinia Virus Vaccination Trial
In order to determine the efficacy of a gp 150 DNA vaccine to protect against MHV-
68 infection individual groups of C57BL/6 mice were subject to different vaccine
regimens. Vaccine regimens included priming animals with plasmid
pVR1255/gpl50 (gpl50 DNA) alone or in conjunction with pVR1255/IFN-aI (IFN-
al DNA) followed by a booster three weeks later of either gpl50 DNA, Gpl50 DNA
plus IFN-al DNA or the gpl50 recombinant vaccinia virus VVgpl5°. The vaccine
schedule for each group is summarised in figure 3.6.3. Control groups included mice
that received no vaccine, gpl50 DNA in conjunction with the gpt recombinant
vaccinia virus (VVgpt) and mice that received IFN-al DNA alone. A control plasmid
lacking an insert i.e. pVR1255 was not available for inclusion in this experiment.
The C57BL/6 strain ofmice was selected due to the known susceptibility to MHV-68
and to maintain continuity with previous studies. These studies include the
immunisation of C57BL/6 mice using dendritic cells pulsed with MHV-68 lytic cycle
T cell epitopes (Liu et al., 1999) and the identification of MHC class I-restricted
epitopes that drive the primary CD8+ T cell response to MHV-68 infection in
C57BL/6 (Stevenson et al., 1999).
Plasmid DNA was administered to the abdomen of mice using the gene gun. One
shot (1 pg DNA) was used per plasmid for each vaccination. Three weeks following
the primary immunisation with DNA the second immunisation/boost with either
DNA or vaccinia virus was done. Recombinant vaccinia virus, 2 x 106 pfu, was
administered intranasally. This dose was selected on the basis of previous work
using a recombinant vaccinia virus to induce lung antibody against RSV glycoprotein
G (Stott et al., 1987). Intranasal challenge was used, as opposed to intramuscular
(i.m.) or intraperitoneal (i.p.) routes, in order to target mucosal immunity. Three
weeks after the second vaccination all groups were challenged with 1 x 104 pfu of
MHV-68 per animal by the intranasal route. This challenge dose is lower than the
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Time points (days post MHV-68 challenge)
59
Groups
Group 1 - MHV-68 Only
Group 2 - 2x [gp150 DNA] + MHV-68
Group 3 - 1x [gpl50 DNA], 1x \A/3P150(i.n.) + MHV-68
Group 4 - 1 x [gpl50 DNA], 1x Wsp' (i.n.) + MHV-68
Group 5 - 2x [gp150 DNA + IFN-a1 DNA] + MHV-68








Six groups of C57BL/6 mice, approximately 8 weeks of age, received combinations of vaccines as
indicated. Vaccine components were: pVR1255/gpl50 plasmid DNA (gpl50 DNA), pVR1255/IFN-aI
plasmid DNA (IFN al DNA), and recombinat vaccinia viruses VVepl5° and W^". VVgpl5° encodes
gpl50 and the E. coli guanosine phosphoribosyl transferase gene (gpt), the control recombinant virus -
VVgpt, contains gpt alone. Vaccine regimens included priming animals with gpl 50 DNA alone or in
conjunction with IFN-al DNA (group 5) followed by a booster three weeks later of either gpl 50 DNA
alone (group 2), Gpl50 DNA + IFN-al DNA (group 5) or one of two recombinant vaccinia viruses -
yygpi50 (group 3) and VVgpt (group 4). Group 1 were an unvaccinated control and group 6 received
IFN-al alone at both vaccine administrations. At each vaccine administration (vaccine 1 and vaccine 2)
the DNA was delivered to the abdominal dermis of mice using a Helios gene gun, one shot (lpg DNA)
per plasmid. Intranasal (i.n.) administration of 2 x 106 pfu of recombinant vaccinia virus per animal was
done. Three weeks after the second immunisation the mice were subject to intranasal challenge with 1 x
104 pfu of MHV-68. Four mice per group were taken at each time point for analysis of MHV-68
infectious lung titre, MHV-68 infectious centres of the spleen (latent MHV-68), extent of splenomegaly
and serological response to MHV-68.
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standard dose of 4 x 105 pfu routinely used by this laboratory and was selected in
order to promote the detection of immune control of the virus. Mice challenged with
1 x 104 pfu MHV-68 undergo the same course of infection resulting from the
standard challenge dose albeit peak lung virus titre and presence of latent virus in
the spleen is slightly delayed (unpublished observations, Phillipo/Allen).
Four mice per group were taken at each time point post MHV-68 challenge (days 3,
8, 15, 29 and 59) in order to analyse the MHV-68 infectious lung titre, infectious
centre titre of the spleen, extent of splenomegaly and the serological response to
MHV-68.
3.4.8 Effect of Vaccination on Viral Lung Titre
To assess the effect of the vaccine regimens on the acute phase ofMHV-68 infection
infectious lung titres were analysed by conventional plaque assay. For each group
infectious virus was detected in the lung at day 3 post infection alone, all later time
points were negative for infectious virus. As figure 3.6.4a shows at day 3 post
infection control mice, which did not receive any form of vaccination, had a mean
MHV-68 lung titre of approximately 700 pfu. In comparison, the other groups show
a trend towards a reduction in infectious lung titre (ranging from 25-350pfu/lung)
however, by the Student's t test only groups 5 and 6 (those that received gpl50 DNA
+ IFN-al DNA and IFN-al DNA alone) are statistically different by Student's t test
with P values of 0.046 and 0.03 respectively. Figure 3.6.4b shows the day 3 lung
titre data for each animal to provide an indication of the spread of the data.
3.4.9 Effect of Vaccination on Splenomegaly and Virus Latency in the Spleen
Following acute infection of the lung MHV-68 is known to establish latency in B
cells, lung epithelium and macrophages (Stewart et al., 1998, Sunil-Chandra et al.,
1992b, Week et al., 1999). The number of latently infected cells reaches a peak
level, of approximately 1:104 spleen cells, two weeks after infection and declines to a
stable level of approximately 1:106 spleen cells by day 21 (Sunil-Chandra et al.,
1992a, Cardin et al., 1996). The establishment of latency is characterised by transient
splenomegaly (Sunil-Chandra et al., 1992a). To assess the effect ofMHV-68 on the
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Figure 3.6.4a Lung virus titres on day 3 post MHV-68 infection in C57BL/6 mice













□ Gp150 DNA x 2
□ Gp150 DNA x 1 + VV9p15°
° Gp150 DNA x 1 + W9pt
■ Gp150 DNA + IFN-al DNA x 2
■ IFN-al DNA x 2
Group
day 3
❖ Statistically different P = 0.046
# Statistically different P = 0.03
C57BL/6 mice were vaccinated with the indicated regimens and challenged
intranasally with 1 x 104 pfu of MHV-68 21 days following the final administration of
vaccine. The MHV-68 lung titre was determined by conventional plaque assay. Only
day 3 post MHV-68 infection (time points tested included day 3, 8, 15, 29 and 59)
yielded virus for each group. Vaccine regimens included priming animals with plasmid
pVR1255/gpl50 (gpl50 DNA) alone or in conjunction with pVR1255/IFN-al (1FN- al
DNA) followed by a booster three weeks later of either gpl50 DNA, Gpl50 DNA +
IFN -al DNA or one of two recombinant vaccinia viruses - VVgpl5° and VVgpt. VVgpl5°
encodes gpl50 and the E.coli guanosine phosphoribosyl transferase gene (gpt), the
control, VVgpt, contains gpt alone. Plasmids were administered using gene gun delivery
to the abdomen ofmice, one shot (1 pg DNA) per plasmid. Intranasal administration of
2 x 106 pfu recombinant vaccinia virus was done. The data represent the mean values
from four mice, bars denote the standard deviation. The limit of detection was 10 pfu
(plaque forming units) per lung. Statistical difference was calculated using Student's t
test.
Figure 3.6.4b Lung virus titres on day 3 post MHV-68 infection in C57BL/6 mice
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C57BL/6 mice were vaccinated with the indicated regimens and challenged
intranasally with 1 x 104 pfu ofMHV-68 21 days following the final administration of
vaccine. The MHV-68 lung titre was determined by conventional plaque assay. Only
day 3 post MHV-68 infection (time points tested included day 3, 8, 15, 29 and 59)
yielded virus for each group. Vaccine regimens included priming animals with plasmid
pVR1255/gpl50 (gpl50 DNA) alone or in conjunction with pVR1255/IFN-aI (IFN- al
DNA) followed by a booster three weeks later of either gpl50 DNA, Gpl 50 DNA +
IFN -al DNA or one of two recombinant vaccinia viruses - VV^150 and VVgpt. VVgpl50
encodes gpl50 and the E.coli guanosine phosphoribosyl transferase gene (gpt), the
control, VVgpt, contains gpt alone. Plasmids were administered using gene gun delivery
to the abdomen ofmice, one shot (1 pg DNA) per plasmid. Intranasal administration of
2 x 106 pfu recombinant vaccinia virus was done. The limit of detection was 10 pfu
(plaque forming units) per lung. Statistical difference was calculated using Student's t
test. The reduction in virus titres in the gpl50 DNA + IFN- al DNA and IFN- al
DNA x 2 were significantly different from the unvaccinated control animals as
determined by a Student t test (P = 0.046 & 0.03, respectively).
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lymphoid system and the ability of the virus to establish a latent infection in mice
that had received different vaccination regimens spleen cell numbers were counted
and the number of infectious centres in the spleen were titred at day 3, 8, 15, 29 and
59 for each group. Spleen cell numbers provide a measure of splenomegaly and
infectious centre titres minus infectious virus titres determines the number of latently
infected cells in the spleen.
As figure 3.6.5 shows, in the unvaccinated control group peak spleen cell numbers
were detected at day 15 with levels approximately 1.8 times normal. At day 3, 8 and
15 spleen cell numbers in the other groups were not significantly different from the
control however there appeared to be a trend towards lower cell numbers. At day 29
spleen cell numbers were declining, all groups except the group which received
gpl50 DNA alone had significantly lower levels compared to the control group by
Student's t test (P<0.05). At day 59 spleen cell numbers had returned to
approximately normal levels in all groups except the group which received IFN-al
DNA alone. This group was significantly different with approximately 10 times less
spleen cells compared to the unvaccinated control.
Infectious centre assays provided an indication of the level ofMHV-68 latency in the
spleen. As figure 3.6.6 shows the unvaccinated control followed the common pattern
for MHV-68 infection with peak infectious centres, approximately 3:104 spleen cells,
detected at day 15. The mean number of infectious centres per spleen was
approximately 56000. By day 59 infectious centre titre per spleen had resolved to a
basal level (mean 230 infectious centres per spleen). All groups followed a similar
trend infectious centre titres peaking at day 15 and then declining to a basal level by
day 59. The groups which received gpl50 DNA followed by a booster of either
Vvgpl5° or VVgpthad significantly lower peak infectious centre titres at day 15 post
infection (by Student's t test gpl50 + Wgp150 P = 0.039 and gpl50 + VVgpt P =
0.035). All the other groups were not significantly different from the control group
at each time point. At day 29 and 59 the infectious centre levels of the groups which
received recombinant vaccinia virus were not significantly different from the control
group. Thus, although two groups had lower peak numbers of infectious centres
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■ Gp150 x 2
a Gp150 x 1 VVGp150
x-Gp150 x 1 VVgpt
*^Gp150 x 2 IFN alpha 1 x 2
• IFN alpha x 2
10 20 30 40
Number of days post infection
50 60
C57BL/6 mice were vaccinated with different regimens and challenged intranasally
with 1 x 104 pfu of MHV-68 21 days following the final administration of vaccine.
Data represent mean spleen cell numbers per spleen for four mice per group for each
given time post intranasal challenge with MHV-68. Vaccine regimens included
priming animals with plasmid pVR1255/gpl50 (gpl50 DNA) alone or in conjunction
with pVR1255/IFN-aI (IFN- al DNA) followed by a booster three weeks later of either
gpl50 DNA, Gpl50 DNA + IFN -al DNA or one of two recombinant vaccinia viruses
- VVgpl5° and VVgpt. VVgpl50 encodes gpl50 and the E.coli guanosine phosphoribosyl
transferase gene (gpt), the control, VVgpt, contains gpt alone. Plasmids were
administered using gene gun delivery to the abdomen of mice, one shot (1 pg DNA) per
plasmid. Intranasal administration of 2 x 106 pfu recombinant vaccinia virus was done.
The control group received MHV-68 alone. The bars denote standard deviation.
Figure 3.6.6. Infectious centres in spleen post MHV-68 infection of C57BL/6 mice
subject to different vaccine regimens
6000 MHV-68 only
—■—Gp150 DNA x 2
Gp150 x 1 VVgp150
Days post infection
# Statistically different P = 0.039
* Statistically different P = 0.035
C57BL/6 mice were vaccinated with different regimens and challenged intranasally
with 1 x 104 pfu of MHV-68 21 days following the final administration of vaccine.
Data represent mean infectious centres (IC) per 107 splenocytes for four mice from
each group. Vaccine regimens included priming animals with plasmid pVR1255/gpl50
(gpl50 DNA) alone or in conjunction with pVR 1255/IFN-aI (IFN- al DNA) followed
by a booster three weeks later of either gpl50 DNA, Gpl50 DNA + IFN -al DNA or
one of two recombinant vaccinia viruses - VVgp,5° and VVgpt. VV8P150 encodes gpl50
and the E.coli guanosine phosphoribosyl transferase gene (gpt), the control, VVgpt,
contains gpt alone. Plasmids were administered using gene gun delivery to the
abdomen of mice, one shot (lpg DNA) per plasmid. Intranasal administration of 2 x
106 pfu recombinant vaccinia virus was done. The control group were unvaccinated
and received MHV-68 alone. Bars denote standard deviation. Statistical significance
was calculated using Student's t test.
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ultimately the basal levels of latent virus in all groups at day 59 were not
significantly different from the unvaccinated control. Infectious virus was detected
only sporadically in the spleen of mice from each group at levels below lOOpfu.
3.5.1 Effect of Vaccination on the Serological Response to MHV-68 Infection
Sera obtained from blood taken from mice prior to MHV-68 infection and day 3, 8,
15, 29 and 59 post MHV-68 challenge were analysed by ELISA to determine relative
levels of MHV-68 specific antibody. Groups tested included the unvaccinated
control, the recipients of gpl50 DNA alone and gpl50 DNA plus either VV8p150 or
VVgpt. As figure 3.6.7 shows MHV-68 specific antibody was not detected until day
15 post MHV-68 infection in the control group as was the case for those animals
which received gpl50 DNA followed by a booster of VV81". In contrast, MHV-68
specific antibody was detected prior to infection in recipients of gpl50 DNA plus
yygpiso an(j at (jay g p0St infection in recipients of gpl 50 DNA alone. By day 15 all
groups tested had detectable MHV-68 specific antibody which continued to increase
at day 29. By day 59 MHV-68 antibody levels appeared to be leveling off for the
groups which received gpl50 DNA alone or in conjunction with a recombinant
vaccinia virus boost. The MHV-68 specific antibody levels for the unvaccinated
control and the group receiving gpl50 DNA in conjunction with the control vaccinia
virus appeared to be on the incline upwards at day 59. From day 15 onwards the
antibody levels of each group were not statistically different from the control group
by the Student's t test.
Following on from the determination of the levels ofMHV-68 specific antibody the
immunoglobulin isotypes within the anti-MHV-68 antibody population were
analysed from groups at selected time points. Time points for analysis were selected
between day 3 and day 15 post infection (illustrated in figure 3.6.7 by red dotted
lines) on the basis that MHV-68 specific antibody had been detected. Antibodies
used for detection of different mouse immunoglobulin subclasses included anti
IgG/A/M antibody, anti-IgG2a, anti-IgG2b, and an anti-IgGl antibody. An anti-IgA
antibody was not available. Figure 3.6.8 shows that the anti-MHV-68 antibody
response detected in all groups was predominantly IgG2a and IgG2b - indicating a T
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helper 1 (Thl) response. No antibody to MHV-68 was detected in the IgGl or IgM
subclass.
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Figure 3.6.7. Titration of MHV-68 specific antibody reponse of C57BL/6 mice,
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Sera was prepared from blood taken from C57BL/6 mice that had been vaccinated with
different gpl50 based regimens pre and post infection with MHV-68 (days 3, 8, 15, 29
and 59). An enzyme linked immunorbent assay was used to determine the levels of
MHV-68 specific antibody in samples relative to a standard curve generated using
dilutions of mouse anti-MHV-68 hyperimmune antiserum. Vaccine regimens included
priming animals with plasmid pVR1255/gpl50 (gpl50 DNA) followed by a booster
three weeks later of either gpl50 DNA, or one of two recombinant vaccinia viruses -
VVgpl5° and VVgpt. VVgpl5° encodes gpl50 and the E.coli guanosine phosphoribosyl
transferase gene (gpt), the control virus VVgpt contains gpt alone. Plasmid was
administered using gene gun delivery to the abdomen of mice, one shot (1 pg DNA) per
plasmid. Intranasal administration of 2 x 106 pfu recombinant vaccinia virus was done.
The unvaccinated control group received MHV-68 alone. Data represent mean values
from four mice, bars indicate standard deviation. The data points positive for anti-
MHV-68 specific antibody within the red dotted lines were selected for analysis of
immunoglobulin isotype populations.
Figure 3.6.8. Analysis of immunoglobulin subclass of the MHV-68 specific antibody
response post MHV-68 challenge in C57BL/6 mice vaccinated with different regimens







































































































Figure 3.6.8. Analysis of immunoglobulin subclass of the MHV-68 specific
antibody response post MHV-68 challenge in C57BL/6 mice vaccinated with
different regimens. Sera was prepared from blood taken from C57BL/6 mice that had
been vaccinated with different gpl50 based regimens pre and post infection with
MHV-68 (days 3, 8, 15, 29 and 59). An enzyme linked immunorbent assay was used to
determine the levels of different immunoglobulin subclasses of MHV-68 specific
antibody in samples relative to a standard curve generated using dilutions of mouse
anti-MHV-68 hyperimmune antiserum. Vaccine regimens included priming animals
with plasmid pVR1255/gpl50 (gpl50 DNA) followed by a booster three weeks later of
either gpl50 DNA, or one of two recombinant vaccinia viruses - VVgpl5° and VVgpt.
VVgpiso enco(jes gpl50 and the E.coli guanosine phosphoribosyl transferase gene (gpt),
the control, VVgpt, contains gpt alone. Plasmid was administered using gene gun
delivery to the abdomen of mice, one shot (lpg DNA) per plasmid. Intranasal
administration of 2 x 106 pfu recombinant vaccinia virus was done. The unvaccinated
control group received MHV-68 alone. Data represent mean values from four mice,
bars indicate standard deviation. The data points positive for anti-MHV-68 specific




Gpl50 is a potential virus to cell attachment facilitating protein for MHV-68 due to
its virion surface localisation, induction of neutralising antibodies and similarities to
gp340/220 of EBV. In order to investigate the function of gpl50 two main
approaches were taken. The generation of a gpl50 negative recombinant virus and
functional analysis of isolated gpl50 in binding studies. Furthermore, a preliminary
investigation into the practical application of gpl50 as a DNA vaccine combined
with a recombinant vaccinia virus expressing gpl50 has been performed to determine
if protection against MHV-68 infection can be achieved.
4.1.2 Generation of a Gpl50 Negative Recombinant Virus
Generation of recombinant herpesviruses dysfunctional in a specific gene by
homologous recombination in mammalian cells has been used successfully to
determine the function of a broad range of herpesvirus genes including
glycoproteins. Here, the green fluorescent protein (GFP) encoding gene was targeted
for homologous recombination into the gpl50 locus of the MHV-68 genome. This
would result in a recombinant virus unable to express gpl50 and identifiable by the
expression of GFP. The' first plasmid construct used, when co-transfected with
MHV-68 DNA, successfully resulted in the generation of recombinant viruses
expressing GFP. However, DNA analysis of virus cultures which appeared pure
following sequential plaque picking i.e. wild type plaques were absent, indicated that
the entire plasmid had recombined into the MHV-68 genome. Southern blot analysis
indicated that the plasmid had integrated into the genome directly to the left of the
gpl50 gene via a single crossover event. This was similar to the experience of Lee et
ah, in their generation of EBV recombinant viruses (Lee et ah, 1992). Although not
useful in terms of a gpl50 knock out virus this was promising from the point of view
that the single recombination event appeared specific, targeting gpl50.
If gpl50 is essential for virus replication a virus unable to express gpl50 would be at
a growth disadvantage and therefore, during plaque picking and limiting dilution
used to purify recombinant virus this would be selected against. To adapt to this
possibility a second recombinant virus vector construct for homologous
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recombination was generated specifically to be compatible for recombinant virus
growth in a gpl50 complementary cell line. The level of sequence in the
recombinant construct homologous to gpl50 sequence carried by the cell line was
minimised. Recombinant viruses grown in complementary cell lines have been
known to revert to wild type following recombination with the intact gene carried by
the cell line, as was experienced by Prichard et al., 1999, when producing a HCMV
recombinant negative for an essential gene (UL84). Cultivation of recombinant
viruses on a cell line expressing gpl50 should enhance the selection of gpl50
negative viruses. Recombinant viruses expressing GFP were successfully generated
using this new construct, sequential plaque picking and limiting dilutions of virus on
normal cells resulted in enrichment of green virus however wild type virus persisted.
Southern blot analysis of DNA from virus cultures indicated that the recombinant
gene cassette containing gfp had not integrated into the virus genome at the targeted
site. The data shown here suggests the recombinant cassette had inserted to the right
of the centre of the genome in the region of ORF58. The function of ORF58 is not
known. The adjacent ORF57 is an immediate early gene, although not directly
characterised it is likely to encode a transcriptional activator considering the known
function of the EBV and HVS ORF57 homologues (Virgin et al., 1997). Why the
recombinant construct has inserted here is open to speculation. This area may be
transcriptionally active during lytic viral replication and so accessible for
recombination. The generation of a complementary cell line expressing gpl50, to
aid isolation of a gpl50 knock out virus, was unsuccessful and therefore was not
available for use in recombinant virus purification.
4.1.3 Modifications for the Generation of Recombinant Viruses
From the process used here to generate recombinant viruses several aspects require
attention for improvement. Enhancement of the probability of targeted
recombination occurring may be achieved by increasing the size of flanking
sequences. The production of a new recombinant construct with flanking sequences
for homologous recombination each of approximately 5 kilobase pairs was underway
towards the end of the project but not completed. Equally important to homologous
recombination is the efficiency of recombinant virus purification and analysis. In
235
HAP 1ER4 DISCUSSION
order to accurately characterise the phenotype resulting from the absence of a
particular gene product the virus must be clonal and free from wild type virus
contamination. GFP serves as an excellent marker tool to identify the presence of
recombinant viruses. However, using physical isolation of recombinant virus by
sequential plaque picks and limiting dilutions was not fully successful at eliminating
the presence of wild type virus. Unstable insertion of the recombinant cassette
resulting in loss of the cassette from the genome could also cause the presence of
wild type virus to be detected. In this regard the use of a drug resistance encoding
gene for positive selection of recombinant viruses could prove very valuable. In fact,
initial work was performed to construct a vector for homologous recombination
containing both gfp and the gene encoding the E. coli guanosine phosphoribosyl
transferase gene (gpt) flanked by the genomic targeting sequences. Gpt has been
used successfully to select Marek's disease virus and HCMY recombinants
(Marshall et al., 1993, Greaves et al., 1995). Unfortunately incorporation of both
genes into vector pSP72/gpl50 proved incompatible. Introduction of the
hygromycin phosphotransferase gene would allow positive selection of hygromycin
resistant viruses (Wang et al., 1991, Marchini et al., 1992). Other selectable markers
that have been used for selection of herpesvirus recombinants include the HSV-1
thymidine kinase gene (Post et al., 1981) and the neomycin resistance gene
(Neidhardt et al., 1987, Wang et al., 1998). In summary large flanking sequences
(in the kilobase range) and use of a positive selection marker such as the hygromycin
resistance gene are strong recommendations for the generation of recombinant
viruses in the manner used here.
The isolation of a recombinant virus resulting from the desired homologous
recombination crossover event may have been hindered by the process of plaque
purification selecting against viruses with debilitated growth. More rapid
identification of the required recombinant is needed that would eliminate time
consumed purifying incorrect recombinants prior to analysis of their DNA. A PCR
assay was designed in this vein in order to identify from the initial transfection
whether the required recombination event had occurred using a primer from within
the GFP gene and one located in the MHV-68 genome, out with the region of
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recombination. Unfortunately, in analysis of transfections using the second
recombination construct no product was detected suggesting the required
recombination had not occurred. This detection method does have potential,
detection of the desired recombination in the total DNA extracted from an initial
transfection would allow one to pursue isolation of the sought after recombinant with
confidence. Many clones could be screened early on by PCR rather than growing
clones up for southern blot analysis. Ultimately, isolation of the correct recombinant
is a numbers 'game' i.e. the more virus clones analysed the more chance of
identifying the correct recombinant. Better targeting of recombination using larger
flanking sequences and the use of a marker for selection should improve the
probability of success.
Infection of B cell lines with recombinant virus mixes and cloning the cells could be
a more effective method at isolating recombinant viruses. An advantage of using B
cells is that lytic replication of the virus is not essential i.e a virus genome negative
for an essential lytic gene can be propagated as a latent episome in dividing B cells.
The transfection efficiency of B cells is low in comparison to adherent cell lines (a
well known phenomenon) therefore the initial transfection may have to be performed
in adherent cells lines with subsequent infection of B cells. In addition the detectable
marker GFP, under the control of the CMV promoter may be subject to shut down in
B cells due to the establishment of the latent form of the viral genome. Incorporation
of a selectable marker such as hygromycin resistance into recombinants would allow
selection of recombinants in this system. In vitro the majority of MHV-68 infected
cells in a B cell line are latently infected however there is a low level, approximately
5%, of lytic virus replcation (Sunil Chandra et al., 1993). Chemical agents such as
the phorbol esters e.g. 12-0-tetradecanoyl-phorbol-13-acetate can be used to activate
lytic replication and therefore produce progeny virions from the recombinant virus
genome. EBV recombinants engineered with resistance to selective agents have




4.1.4 Alternative Strategies for Generating Recombinant Viruses
A major drawback of the method used here for the generation of recombinant viruses
was the contamination by wild type virus. The use of cosmids is an alternative
method to generate recombinant herpesviruses in the absence of wild type virus
(Cunningham & Davison, 1993, van Zijl et al., 1988, de Wind et al., 1990). For this
a cosmid library of the viral genome is used which usually consists of approximately
5 cosmids that each contain large stretches ofDNA, in the region of 30 - 40 kb, from
the viral genome. The gene of interest can be modified i.e. mutated in the particular
cosmid it is located within and cloned in bacteria. The genomic insert of this cosmid
is excised and in conjunction with excised inserts from cosmids containing sections
of the rest of the viral genome in overlapping stretches (overlapping from 5 to 20 kb)
is transfected into mammalian cells. Virus is produced following recombination of
the lengths of genomic DNA at homologous sequences resulting in the generation of
an intact virus genome. The gene of interest must also be a unique sequence in the
cosmid library and not in a stretch repeated in several cosmids. This method of
recombinant virus generation requires a cosmid library of the virus genome which
takes time to generate however a comprehensive library could be extremely valuable
in the long-term. Another advantage with the cosmid system is that a marker is not
required and therefore discrete mutations of the target gene i.e. a few base pairs can
be done rather than inserting additional DNA which may be more disruptive.
Correct recombination of the fragments needs to be verified by Southern blot
analysis. Most systems have their inherent difficulties, one of which is the instability
and subsequent loss of repeat sequences, common to herpesvirus genomes, as they
are cloned in bacteria (Gray & Kaerner, 1984, Quinn & McGeoch 1985, Weller et
al., 1985). In addition the restriction site used to excise the DNA inserts from the
cosmids must not be present in the viral genome.
The use of the bacterial artificial chromosome (BAC) system to generate
recombinant viruses is another alternative method which avoids the problem of
contamination of recombinant virus with wild type virus. In the BAC system the
entire intact viral genome is manipulated in bacteria in the absence of viral gene
expression and generation of virions. To engineer the viral genome into a bacterial
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artificial chromosome the genome is cloned onto a F (fertility) factor based plasmid
which can encompass large foreign DNA fragments (up to 300kbp) (Shizuya et al.,
1992). This is done by conventional homologous recombination of the F factor
plasmid flanked by viral genomic sequences with viral DNA following their co-
transfection into eukaryotic cells. Recombinant viral DNA containing the F factor is
purified from these cells and introduced into E. coli by electroporation. Genetic
manipulation of the viral genome can be done in bacteria The structure of the
manipulated genome i.e. successful elimination of a particular gene and insertion of
marker genes if desired can be analysed and confirmed prior to introduction of clonal
recombinant virus DNA into mammalian cells for the production of infectious
progeny. In this way virus produced is of known genotype. This is a major
advantage of the BAC system in comparison to using cosmids where the correct
recombination of the genomic fragments needs to be verified. Furthermore, isolated
viral genome DNA with essential genes made dysfunctional can be achieved and
cloned in bulk in E. coli without the need for a complementary cell line. That is to
say, construction and isolation of the recombinant genome is independent of the
biological fitness of the mutant virus.
The use of the BAC system for production of herpesvirus recombinants is increasing,
viral genomes which have been incorporated into BACs include MCMV, HSV and
EBV (Delecluse et al., 1998, Messerle et al., 1997, Horsburgh et al., 1999). The as
yet limited use of the BAC system stems from the time taken to generate a BAC
genome and the unfamiliarity of this new technology. The greater stability of HSV
sequences in BACS in comparison to HSV sequences in cosmids is attributed to the
low copy number of BACs per cell (i.e. one copy). The availability of a BAC
incorporating the MHV-68 is the restricting factor at present for the use of the BAC
system. In this laboratory, work is underway to produce such a tool which once
established may be adopted for the efficient generation ofMHV-68 recombinants in
future. Koszinowski et al. report they have a MHV-68 BAC (Adler et al., 1999).
Successful use of the BAC system would eliminate the lengthy rounds of selection
and analysis of recombinant clones inherent with conventional recombinant
techniques. It remains to be seen if the BAC system will live up to the promise and
239
CHAPTER 4 DISCUSSION
prove to be the solution for efficient generation of MHV-68 recombinant viruses.
The stability of the genome in bacteria needs to be monitored.
4.1.5 Mammalian Expression of Gpl50 - pBabe/PgBgp!50
A plasmid construct, pBabe/PgBgpl50, was made consisting of the gene encoding
gpl50 positioned downstream of the putative gB promoter (PgB) to be used for the
generation of a complementary cell line inducible for the expression of gpl50
following virus infection. The intention was to use this cell line in conjunction with
the generation of a gpl50 negative recombinant virus. In the event that gpl50 is
essential for virus replication the cell line would allow culture of gpl50 negative
viruses. Inducible expression of gpl50 was chosen to avoid possible problems of
toxicity known to occur following constitutive expression of some viral
glycoproteins. Although a CI27 cell line containing pBabe/PgBgpl50 was selected
using puromycin and the presence of gpl50 DNA confirmed by PCR the expression
of gpl50 was not detected. In the absence of viral infection low level expression of
gpl50 could have occurred via the strong promoter in the long terminal repeat
derived from the murine Moloney leukemia retrovirus upon which the plasmid
backbone was based (Morgenstern & Land, 1990). Following infection of the cell
line with MHV-68 the levels of gpl50 mRNA and protein did not differ in
comparison to control cells. Higher levels of gpl50 in the complementary cell line
following infection with MHV-68 DNA compared to MHV-68 infected control cells
would have indicated that gpl50 expression via the gene encoded by the cell line had
occurred. In the absence of this it appeared that the cell line generated did not
express gpl50.
The design of the pBabe/PgBgpl50 plasmid was based on knowledge of a successful
complementary cell line, in which the HSV-1 gH gene was under the control of the
gD promoter, generated for propagation of a gH negative recombinant HSV-1
(Forrester et al., 1992). Following infection of these cells with HSV a much greater
level, at least 10 fold, of gH was detected by western analysis, in comparison to
normal cells infected with HSV-1. With the availability of the closely related HSV-2
they were able to induce expression of gH by infection of the complementary cell
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line with HSV-2 and distinguish the expression of the cellular encoded HSV-1 gH
from the viral HSV-2 gH using monoclonal antibodies specific to gH of HSV-1.
Unfortunately a similar method for testing the expression of gpl50 from the cell line
- other than assessment of increased level of gpl50, was not available. Other
gammaherpesviruses such as acelaphine herpesvirus 1 or KSHV may be closely
related enough to transactivate MHV-68 promoters, however this has not been tested
and the availability of other gammaherpesviruses such as a AHV 1 is limited by their
restricted growth in vitro. The putative gB promoter consisted of a 264bp region
directly upstream from the translational start site of the gB gene (Stewart et al.,
1994), although not experimentally confirmed as the promoter it was likely that this
region was the gB promoter. A TATA box is present 67bp upstream from gB and
viral promoters in herpesvirus genomes are commonly located directly before genes
for glycoprotein expression. In the case of the HSV-1 gD promoter all the signals
necessary for full regulated expression lie within 83bp of the RNA start site and
some promoter activation is still detectable when only 55bp upstream are present
(Everett, 1983). Uncertainty does however remain as to whether this putative PgB
promoter is functional. Insertion of a reporter gene such as gfp downstream of PgB
could be used to determine if expression via this promoter occurs upon infection of a
cell line containing this construct. An alternative approach would be to design a
primer from the transcritional start site of the putative gB promoter and pair this with
a primer from within gpl50 in an RT-PCR to detect gpl50 mRNA transcripts
derived from the vector. However, analysis of RNA expression following infection
with MHV-68 showed the presence of one transcript, if expression from the cell line
occurred another gpl50 positive transcript of at least a slightly different size might
be expected to be present. A tag engineered to the C terminus of gpl50 such as a
hexahistine tag would allow identification of cellular encoded gpl50 to be
distinguished from that of viral gpl50.
Possible reasons for lack of gpl50 expression from pBabe/PgBgpl50 could include
mutation of the plasmid backbone or integration of the vector into the host cell
genome into a site inaccessible for expression. The PgBgpl50 insert was sequenced
and shown to be intact. Of the clones generated that were positive for gpl50 DNA
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the clone that provided the greatest signal by PCR for the presence of gpl50 DNA
was selected for further analysis of gpl50 expression (i.e. Northern blotting and
radioimmunoprecipitation). By immunofluorescence and western blotting all clones
were negative for gpl50 expression. Further analysis of other clones might prove
fruitful. In the absence of a gpl50 negative recombinant virus and the uncertainty as
to whether a complementary cell line would be essential this system was not pursued
further. Of course, a functionally confirmed complementary cell line may be used
successfully to isolate gpl50 negative viruses that may have debilitated growth on
normal cells. That is to say, existence of a gpl50 negative virus might come after the
generation of a complementary cell line required as a tool to isolate gpl50 null
mutants.
4.1.6 Ecdvsone Inducible System for Mammalian Expression of Gpl50
In order to express gpl50 in mammalian cells an alternative system was adopted in
the form of the ecdysone inducible system. The advantage of this system is that
expression of the inserted gene i.e. gpl50 can be controlled externally by the addition
of the induction agent Ponasterone A (an analogue of ecdysone). This therefore
avoids constitutive expression of gpl50 which could prove toxic, a feature of
glycoproteins that has hindered generation of cell lines for their expression (Whang
et al., 1987, Conway et al., 1989, Motz et al., 1987, Gompels & Minson, 1989) and
in addition induction of gpl50 is independent of viral infection. Not only could such
a cell line be used to complement a gpl50 negative virus but comparison of the
susceptibility of the same cell line to MHV-68 infection in the absence and presence
of gpl50 expression may provide indications as to the role of gpl50. For example
reduced ability of MFIV-68 to bind to or enter cells expressing gpl50 may indicate
that the cellular expressed gpl50 interacts with and sequesters cell surface molecules
which virion gpl50 requires to interact with for infection to occur. This scenario has
been shown for gD ofHSV-1 (Campadelli-Fiume et al., 1990, Geraghty et al., 2000).
A construct was also engineered containing the region encoding the extracellular
domain of gpl50 in order to produce soluble gpl50 which should be secreted into the
culture media in the absence of the hydrophobic transmembrane anchoring domain.
242
CHAPTER 4 DISCUSSION
This was intended as a source of soluble gpl50 to be used in functional studies such
as determining the proposed binding function of gpl50.
Expression of P-galactosidase from a control plasmid using the ecdysone system was
achieved confirming that the plasmid peparations and the induction agent were
functional. However, gpl50 expression was not detected from any of the three
constructs generated. Use of different cell types and levels of induction agent did not
have any detectable effect. Selection of cells containing both the expression and
ecdycone receptor encoding vectors was done to enhance the number of potential
cells expressing gpl50 over that of a transient transfection. No gpl50 expression
was detected. The sequences of the gpl50 inserts were determined to be correct
therefore mutation of the insert was ruled out as the cause of lack of detectable
expression. The inserted sequences included their own ATG and Kozak translation
initiation sequence. The expression plasmid backbone may have undergone mutation
inhibiting expression of the insert. Perhaps something inherent within the gpl50
gene is incompatible for expression from this vector. Although a ready made control
expression vector is provided, encoding p-galactosidase, it would be worth cloning a
reporter gene, and other genes in general for that matter, into the expression vector
used to determine if expression of genes other than gpl50 is successful. Analysis of
RNA expression would provide an indication of whether gpl50 encoding mRNA is
generated and so suggest if lack of detectable protein expression was due to the lack
of transcription or efficient translation. The expression vector provides the SV40 pA
downstream of the gpl50 insert which is designed to increase stability of the mRNA
transcript. Although glycoproteins can be toxic to cells, short term expression of
gpl50 during transient transfection i.e 24- 48 post transfection is unlikely to be long
enough to cause cell decline and lack of detection gpl50. The reason for lack of
expression of gpl50 using the ecdysone system is unclear.
4.1.7 PcDNA3 & PcDNA3.1 for Expression ofGpl50
The gene encoding gpl50 was cloned into pcDNA3, downstream of the constitutive
CMV immediate early promoter, for mammalian expression of gpl50 with the aim of
using this vector as a DNA vaccine to induce immunity against MHV-68. In
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addition the vector could be used to generate a cell line constitutively expressing
gpl50. The CMV immediate early promoter is one of the strongest
enhancer/promoters known (Boshart et al., 1985, Thomsen et al., 1984, Ghazal et al.,
1987). Expression of gpl50 from pcDNA3/gpl50 and pcDNA3.1/gpl50 was not
detected. PcDNA3.1 is an updated version of pcDNA3 with a more extensive
multiple cloning site (MCS) and lacks the bacteriophage SP6 promoter site present in
pcDNA3 positioned just downstream of the MCS into which genes for expression are
inserted. The production of an updated version of pcDNA3 is perhaps a testament to
the inefficient expression of this vector. The manufacturers indicated that the SP6
promoter site has been removed as it is thought to cause secondary structures in RNA
transcripts that are detrimental to protein expression (personal communication,
Invitrogen) presumably due to inefficient association of transcripts with ribosomes.
From discussions with other workers within and out with this laboratory the failure
of pcDNA3 to yield expression of the inserted gene is not an isolated event. It is
possible that there is low level expression of gpl50 below the level of detection. In a
pcDNA3 construct containing the M2 ORF ofMHV-68 no expression was detectable
by conventional immunofluorescence and western blot analysis however it appears
that a cell line containing this vector could act as a target for M2 specific cytotoxic T
cells (A McCrae & E Usherwood, personal communication) suggesting that a very
low level of M2 protein expression was present, enough to result in processing and
presentation of M2 via the MHC I pathway. None the less, with regards to
vaccination it would be preferable to use a vector that provides efficient expression
of gpl50 and leaves no doubt over the generation of the protein. Such a vector exists
in the form of pVR1255/gpl50.
4.1.8 PVR1255/gp150 Expression of Gp150
It must be stressed that the vector pVR1255/gpl50 was acquired at a late stage in the
project. Confirmation of expression of gpl50 in eukaryotic cells from this vector
was achieved rapidly by conventional immunofluorescence and western blot analysis
of transfected cells. This vector was deemed suitable for use as a gpl50 DNA
vaccine. The successful expression of gpl50 using vector pVR1255 begs the
question as to how this construct differs from the other vectors engineered here for
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the expression of gpl50. This vector confirms that it is possible to express gpl50, at
least transiently, from a mammalian expression vector. Within pVR1255/gpl50 the
entire gpl50 encoding region, from the translational start codon to the stop codon, is
inserted downstream of the constitutive CMV promoter. Of note is the presence of
the CMV immediate early intron A sequence positioned between the CMV promoter
and the gpl50 gene (for a map of the plasmid refer to figure 3.3.2). The intron A
sequence contains binding motifs for transcription factors such as nuclear factor 1
and is known to enhance expression of inserted genes (Chapman et al., 1991,
Hartikka et al., 1996). The intron A element is not present in pcDNA3 and pcDN3.1.
The pcDNA3 vectors differ from pVR1255 in that they have a bovine growth
hormone polyadenylation signal (BGHpA) positioned downstream of the inserted
gene whereas pVR1255 has a minimal transcriptional terminator derived from the
rabbit p globin gene (mRBGpA) (Levitt et al., 1989). The expression of a luciferase
insert from pVR1255 was reported to be two fold greater when compared to an
earlier version of the vector which differs only in that it contains a BGHpA as
opposed to the mRBGpA (Hartikka et al., 1996). In a range of vectors studied by
Hartikka et al., to determine plasmid elements required for optimum gene expression
they unexpectedly found replacement of the ampicillin gene with the kanamycin
resistance gene resulted in an over two fold increase in expression of luciferase
(Hartikka et al., 1996). Whether this effect depends upon the context of the
resistance gene or if specific features of the kanamycin gene result in better
expression of the inserted gene in expression vectors in general (i.e. not just the ones
tested by Hartikka et al.) in comparison to vectors encoding ampicillin resistance is
not known. It is worth noting however that pcDNA3 encodes ampicillin resistance in
contrast to the kanamycin resistance carried by pVR1255. Another difference in the
plasmid backbone is that the pcDNA3 vectors used here encode the neomycin
resistance gene whereas pVR1255 does not encode any marker for drug selection in
eukaryotic cells.
The work of Hartikka et al. 1996, systematically adding or replacing elements of
plasmid expression vectors, demonstrates that introduction of new DNA sequences
can have dramatic and unexpected effects on expression of the target gene. There
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may be unidentified features of the gpl50 gene that make it incompatible for
expression in certain vectors such as pcDNA3.
As well as use as a DNA vaccine pVR1255/gpl50 offers much promise particularly
in the light of failure to express gpl50 using other vectors. PVR1255/gpl50 could
be used to generate a mammalian cell line expressing gpl50 for complementation of
a gpl50 negaitve virus. Deletion of the hydrophobic transmembrane encoding
domain of gpl50 within the vector would in theory result in secretion of gpl50 from
cells transfected of the modified pVR1255/gpl50 plasmid. This could be used as a
source of eukaryotic derived gpl50 for binding studies. One disadvantage with
pVR1255/gpl50 in terms of generation of a mammalian cell line expressing gpl50 is
that the vector lacks a eukaryotic selectable marker. Modification of the vector by
insertion of a eukaryotic selectable marker is feasible but of course alterations in the
vectors backbone could have adverse effects on protein expression. Alternatively co-
transfection of pVR1255/gpl50 with a vector containing a eukaryotic selectable
marker and selection of double transfectants could be done. Due to the efficient
expression displayed by this vector many workers in the laboratory have adopted
pVR1255 for expression of a range of viral genes.
There are no definitive reasons why several different plasmid constructs failed to
express gpl50 in mammalian cells. Speculation includes any one of a number of
general reasons why protein expression is not detected. Sequence analysis has ruled
out the lack of expression due to corruption of the insert. Unstable or structurally
deformed mRNA, insertion of the plasmid into areas of the host cell genome that
are inaccessible for transcription may result in shut off of gene expression. Although
the inserts for all expression constructs generated were shown to be intact by
sequence analysis it is possible that the vector backbone had mutated. However, this
seems unlikely to be the reason for lack of expression for all the different vectors
used. To establish this it would be necessary to sequence each entire plasmid
backbone (>5kbp) which would be expensive in both time and money.
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The gpl50 gene may be incompatible for expression in certain vector contexts. An
interesting feature to note is that growth of E. coli transformed with pVR1255/gpl50
was restricted in comparison to growth of E. coli transformed with pVR1255
containing other inserts such as the interferon alpha type 1 encoding gene (personal
communication, Elenora Arico). In addition, low yields (approximately 20 fold) of
pSP72/gpl50 DNA in comparison to that of pSP72 were produced following large
plasmid preparations. The colonies formed by bacteria transformed with
pcDNA3/gpl50 were noticeably smaller than those produced from bacteria
transformed with pcDNA3 alone. Furthermore, in the generation of a cosmid library
of the MHV-68 genome the isolation of a cosmid clone containing a ~2kb stretch of
the genome which includes the gpl50 ORF is proving difficult. The rest of the
genome has been isolated in cosmid clones apart from this elusive stretch (A.
Davison, personal communication). These observations suggest some property of
gpl50 is not highly compatible with standard cloning. This may be due to the high
AT content or the proline rich repeat sequences of the gpl50 encoding gene.
4.1.9 Binding Analysis of Gpl50
For the source of isolated gpl50 for functional studies bacterial expression and
purification of the extracellular portion of gpl50 as a fusion protein attached to a
hexahistidine tag was achieved. The gpl50-His fusion protein was sufficiently
similar to eukaryotic gpl50 for identification by rabbit MHV-68 specific antiserum.
In addition a GST-His fusion protein was generated as a control protein for
functional studies of gpl50-His.
The ability of gpl50-His to bind to different cell types was analysed in order to
determine if gpl50 is involved in virion attachment and entry of target cells.
Significant binding of gpl50-His (at 20pM) to approximately 3% of 106 splenic
lymphocytes was observed. The shape of the FACS graphs showed the whole
lymphocyte population shifted in fluorescence following incubation with gpl50-His
suggesting gpl50-His bound the heterogeneous lymphocyte population as a whole.
As opposed to the appearance of a second peak with greater fluorescence intensity
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which would suggest a particular subset of cells present with a high affinity for
gpl50-His. In further analysis gpl50-His exhibited binding to purified splenic B
cells, approximately 6% of cells were bound. Double staining of splenic
lymphocytes to determine the CD 19 phenotype of bound cells showed gpl50-His
bound to approximately equal numbers of CD19+ and CD 19" cells in a
heterogeneous population of splenic lymphocytes. Indicating that gpl50-His binds
both B lymphocytes and non B lymphocytes. In contrast no significant binding of
gpl50-His to CI27 murine epithelial cells or inhibition of MHV-68 infection by
gpl50-His was detected. These observations suggest that gpl50-His binds a
lymphocyte cell surface marker absent from or in insufficient levels in CI27
epithelial cells.
From this data it is not possible to rule out gpl50-His binding to epithelial cells in
general as lack of binding may be due to a feature specific to CI27 epithelial cells.
Airway epithelial cells which MHV-68 encounters following intranasal infection of
mice may differ in their binding potential for gpl50-His. Binding to primary splenic
lymphocytes is shown. It would be advisable to test a wider variety of epithelial
cells to determine if lack of binding to CI27 cells is a feature specific to this
particular cell line or if gpl50-His is unable to bind to adherent cells in general.
Gpl50-His may bind a lymphocyte specific marker however, the testing of further
epithelial cell lines is required to establish a clearer picture.
The number of splenic lymphocytes bound by gpl50-His appears low considering
the relatively high concentration of protein applied (20pM) which is equivalent to 5
o
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x 10 molecules per cell. The level of protein used here is towards the high end, of
protein concentrations used in similar binding studies (Hedrick et al., 1994, Johnson
et al., 1990, Tanner et al., 1987). This may suggest that there is a low percentage of
cells able to bind gpl50-His in the splenic lymphocyte population. The affinity of
the interaction is not known. It may be that the cells bound express a high level of
the gpl50-His binding molecule/molecules, the affinity may be low and so cells




Using the FACS assay MHV-68 was shown to bind to approximately 10% of splenic
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lymphocytes when 10 pfu was added to 10 splenocytes. Double staining FACS
data shows MHV-68 binds both CD19+ and CD 19" lymphocytes. Of total
lymphocytes bound by MHV-68 in the assay reported here, only 20% were CD19+.
This could be considered surprising for a B cell tropic virus where 80% of the cells
bound from the heterogeneous lymphocyte population are not B lymphocytes.
However, attachment to cells does not necessarily equate to infection of the cell and
tropism of MHV-68 may not be determined by the receptor MHV-68 uses for
attachment. In addition, MHV-68 can infect a wide range of cells including
epithelial, fibroblastoid, neuronal and T cells which suggest MHV-68 may use a
rather more ubiquitous cellular receptor in comparison to EBV. Dutia et al., detected
non B lymphocytes that were readily susceptible to MHV-68 infection (Dutia et al.,
1999a).
Using FACS analysis approximately 60% of the CI 27 epithelial cells were bound by
7 f\
MHV-68 when 10 pfu was incubated with 10 cells. This represents a much greater
proportion of the population of the cells bound by MHV-68 in comparison to the
proportion of cells bound in the hetereogeneous splenic lymphocyte population or
purified B cells. This may be due to more receptors present on CI27 epithelial cells
and the greater surface area of epithelial cells increasing probability that virion
comes into contact with cells. The affinity of interactions of MHV-68 with
splenocytes in comparison to epithelial cells has not been determined. A quantitative
study of the cell types bound by MHV-68 and the level ofMHV-68 binding could be
valuable in providing a key as to what MHV-68 specifically binds to on the surface
of cells. As yet a cell type which is not susceptible to infection by MHV-68 has not
been identified - many different cell lines have been tested but the list is by no
means comprehensive and does not include cell lines with specific defects such as
heparan sulphate negative murine L cells (Gruenheid et al., 1993).
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The FACS analysis used here allows the proportion of cells bound by gpl50-His or
virus to be determined however, the proportion of gpl50-His or virus bound from the
total added is unknown. That is to say, the FACS assay is not quantitative and so
information such as the number gpl50-His molecules or virions bound or the affinity
of binding is not determined. In order to determine such information fusion protein
molecules and virions need to be directly labelled to allow quantitative detection of
levels bound. Radiolabelling fusion protein molecules/virions with isotopes such as
I can be done and the level of radioactivity associated with cells following
incubation with different concentrations of the fusion protein molecules or virions
measured. Quantitative analysis of binding would allow the protein and virion
concentration causing saturation to be determined and used to calculate the number
of receptor sites per cell for the protein or virus. Radioiodination can have adverse
affects on protein or virus for example Hedrick et al., 1994, found tyrosine iodination
compromised binding ability of recombinant gp350/220.
The particle to pfu ratio of the virus preparations used was not known. At 107 pfu of
virus there may be a log more virions capable of binding depending on the particle:
pfu ratio. Therefore caution must be used to avoid making assumptions about the
level of virus bound in the absence of quantitative data.
Although use of radiolabelled protein and virions would provide a quantitative
handle on the level protein or virus of binding the FACS analysis used here enables
the number and type of cells bound to be determined. Further use of double staining
for other cell surface markers besides CD 19 might provide information on the type of
cells within the heterogeneous lymphocyte population bound by gpl50-His and
MHV-68. MHV-68 may favour attachment to and infection of cells at a particular
stage in development which can be detected by surface markers that are present
during specific stages of B and T lymphocyte maturation. The virus receptor may be
a common molecule that needs to be present at a certain level to enable efficient
attachment of the virus.
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Analysis of the effect of incubation of gpl50-His with splenic lymphocytes may
indirectly indicate the receptor to which it binds. That is to say, binding of cells by
gpl50-His may result in changes in the cell such as activation and/or proliferation if
it binds to a cell surface molecule involved in signal transduction. Gp340/220
binding to CD21 of B lymphocytes pushes resting B cells into the cell cycle (Sinclair
et al., 1994). Analysis of levels of cell surface markers upregulated on activated
lymphocytes and the level of proliferation of cells could be tested in the presence and
absence of gpl50-His.
Whether gpl50-His is binding to the same site on splenic lymphocytes as virus has
not been determined. The ability of gpl50-His to block virus binding to
lymphocytes would provide an insight into this. If virus binding was blocked by
gpl50-His it would suggest that gpl50-His binds the same receptor as MHV-68. In
the absence of blocking there are a number of scenarios that could be correct. For
example if gpl50-His binds to the same receptor but with a lower affinity the virus
expressed gpl50 may dislodge the gpl50-His. The concentration of the protein is
too weak and/or the binding affinity too low. Even if one molecule of gpl50-His and
one molecule of gpl50 at the virion surface have the same affinity for a receptor due
to the multiple number of molecules at the virion surface for interaction with the cell
surface the virion may have a higher binding avidity in comparison to a single
molecule of gpl50-His. Blocking of virus binding to splenocytes by gpl50-His was
not tested using the FACS analysis system because an antibody that would
distinguish MHV-68 binding from that of gpl50-His was not available. Further
work could include testing if virus can block gpl50-His binding to cells by using the
anti-His monoclonal antibody.
Binding of gpl50-His to splenocytes has been shown indicating that gpl50 can bind
to lymphocyte surface molecules. Demonstration of binding alone does not
necessarily mean that a protein is required for the initial attachment of the virus to
cells, the protein may have a post binding entry role. This is the case for gD which is
involved in cell penetration by HSV-1, gD binds to the cell surface but is not
essential for virion attachment to cells (Ligas & Johnson, 1988, Johnson et al., 1990).
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That is to say, although gpl50-His has been shown to bind to cells the exact function
of this binding property for gpl50 could be for the proposed attachment ofMHV-68
to cells but alternatively it could have a post attachment entry role.
In order to substantiate the observed lymphocyte binding ability of gpl50-His
identification of the molecule bound by gpl50-His is strongly recommended. To
identify the receptor gpl50-His is binding to a range of approaches could be taken.
Analysis of common features of the cells bound by gpl50-His could provide an
insight e.g. pan-lymphocyte specific markers. A more direct and recommended
approach is that of 'receptor pull down' analysis using cross-linking agents to
covalently link gpl50-His to the cellular molecule/molecules it interacts with and
subsequently immunoprecipitate gpl50-His plus the attached cellular receptor using
gpl50 specific antiserum. Indeed, a preliminary assay using 125I labelled splenocytes
was performed in this manner however, due to the number of parameters involved
limitations of time inhibited establishment of the assay and full analysis by this
method.
Another method that could allow identification into what gpl50-His binds to on the
cell surface is the use of surface plasmon resonance (SPR). SPR allows the detection
of very subtle interactions between molecules. Gpl50-His could be coupled to the
surface of a SPR biosensor chip. Solubilised lymphocyte membrane preparations
passed over the immobilised gpl50-His protein may allow the cell surface molecule
or molecules which gpl50 interacts with to associate with gpl50. Molecular
interactions with the immobilised protein result in changes in the surface of the chip
and changes in diffraction of light directed to the underside of the chip are measured.
Measurements are taken in real time and so allow on/off rates and the affinity of
protein interactions to be calculated. The captured protein which has bound to
immobilised protein can be eluted and then characterised. SPR is proving an
extremely powerful tool to identify and analyse molecular interactions. Influenza
haemagglutinin binding to sialic acid receptors (Takemoto et al., 1996), soluble
intercellular cell adhesion molecule binding to human rhinovirus (Casasnovas et al.,
1995) and HSV gB binding to glycosaminoglycans (Williams & Straus, 1997) have
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been analysed using SPR. The binding ability of truncated forms of gD to the
herpesvirus entry mediator has been analysed in detail using SPR also (Willis et al.,
1998). If the molecule to which gpl50-His binds is identified experiments to test the
importance of this molecule in the context of the virus lifecycle could be done. For
example antibodies against the molecule could be tested to see if they inhibit virus
binding and/or infection of cell.
A virus overlay protein assay (VOPBA) failed to detect a cellular protein to which
MHV-68 virions or gpl50-His bound. As described in section 3.2.7 VOPBAs are
only useful in certain circumstances where binding is not dependent on protein
conformation or affected by denaturation, a negative result by VOPBA alone by no
means rules out lack of binding function of a virus or protein (Boyle et al., 1987).
As mentioned a cell line which cannot be infected or bound by MHV-68 has not been
identified therefore experiments in which a wide range of different molecules are
each expressed in cells from a mouse cDNA library in an attempt to identify one
which facilitates virus binding are not feasible as yet.
From here the use of gpl50-His in quantitative cell binding studies and identification
of the cellular molecule to which gpl50 interacts is suggested. The bacterial
expression of gpl50 has been advantageous in ease of expression and purification
and has provided valuable indications on the ability of gpl50 to bind to splenic
lymphocytes. It must be remembered that differences in gpl50-His due to the
expression in a heterologous host may cause the function of gpl50 to be altered or
diminished compared to gpl50 expressed in eukaryotic cells. It is recognised that
caution must therefore be taken when interpreting the function of virion gpl50 from
data that has been generated using a protein that has been produced artificially. Lack
of significant binding of gpl50-His to CI27 cells does not rule out the possibility
that gpl50 in the virion does bind to CI27 cells. Lymphocytes may have a higher
level in general of the gpl50-His binding molecule i.e. some may be present on
epithelial cells but to a lesser degree. If gpl50-His has a lower affinity compared to
native gpl50 the level of the receptor on lymphocytes may facilitate binding at a
significant level in contrast to that on epithelial cells. With the fortuitous acquisition
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of pVR1255/gpl50 it is highly recommended that the generation of eukaryotic
expressed secreted gpl50 for binding studies be pursued by modification of the
pVR1255/gpl50 vector in addition to further work suggested with gpl50-His.
4.2.1 Neutralisation Activity of Gpl50 Specific Antiserum
In order to determine the mechanism of neutralisation by the gpl50 specific serum
reported to neutralise MHV-68 infection, the ability of antibody to block binding of
MHV-68 to cells was assessed. The anti-gpl50 serum did not show inhibition of
virus attachment in contrast to the anti-MHV-68 antiserum. This initial observation
suggested that gpl50 may be involved in a post attachment entry event e.g. fusion.
For example antibodies to gH, a glycoprotein required for fusion, do not block
attachment of HSV-1 to cells however they are neutralising by inhibiting fusion
(Fuller et al., 1989). Similarly, a monoclonal antibody to gH of EBV inhibits fusion
but not attachment of virus to cells (Miller & Hutt-Fletcher, 1988). In order to
pursue this neutralisation assays were set up with the intention of setting up a system
to see if neutralisation could be overridden by the addition of the fusion induction
agent poly ethylene glycol (Forrester et al., 1992).
Neutralisation ofMHV-68 infection using the anti-gpl50 antibody was not observed
in contrast to previous studies (Stewart et al., 1996). The reported neutralising
activity was described as weak with a 50% reduction in plaque number occurring at a
1/30 dilution and 84% reduction at a 1/10 dilution. It may be argued that the
antiserum preparation had perhaps degraded over time however, with regards to
detection of gpl50 in western analysis, immunofluorescence and immunostaining the
antiserum was effective. Several aliquots from the frozen stock of gpl50 specific
antiserum were tested. Perhaps differences in the passage number of cells used and
different virus stocks influenced the outcome of these neutralisation assays.




It should be noted that the anti-gpl50 antibody was generated against a GST-gpl50
fusion protein (Stewart et al., 1996) consisting of a portion of i.e. not the whole
extracellular domain of gpl50. Failure to demonstrate neutralising activity in this
circumstance does not mean gpl50 is not a neutralising determinant because the
antibody is against only a portion of the protein which possibly has limited
neutralising epitopes and the region not included in the portion of gpl50 used for the
generation of the antisera may contain important neutralising epitopes.
Glycoproteins that are described as neutralising determinants commonly have a
limited number of neutralising epitopes, e.g. for the influenza haemagglutinin
glycoprotein five main neutralising epitopes have been identified in the knob region
(Wiley et al., 1981). The attachment of antibodies to other regions of the molecule
does not necessarily result in neutralisation. The portion of gpl50 used for the
generation of GST-gpl50 corresponds to nucleotides 69716 to 70199 on the MHV-
68 genome within gpl50 (see figure 1.8 for location), a total of 161 amino acids (the
entire extracellular portion is predicted to be 435 amino acids and therefore the
region used in the GST-gpl50 fusion protein represents approximately one third of
the extracellular portion). A stretch of 66 amino acids at the N terminal and 208 at
the carboxyl end of the extracellular portion are not included.
It must also be remembered that antibody effected neutralisation in vitro differs from
that of in vivo where not only physical blocking of virus from adhering to cells and
virus aggregation occurs but activation of complement and targeting of cells for
phagocytosis is in effect to clear virus therefore weak neutralising activity in vitro
may equate to a much stronger effect in vivo. The vaccination study by Stewart et
al., using the VV8pI50 supports the description of gpl50 as a neutralising epitope as
neutralising antibodies were detected prior to MHV-68 challenge in animals
vaccinated with vvgp150 jn contrast to those which received the control VVgpt
(Stewart et al., 1999a).
Due to the inability to detect neutralisation using the anti-gpl50 antibody described
here the generation of a new anti-gpl50 antiserum, using the entire extracellular
portion of gpl50 is advisable. This could be done using the gpl50-His protein as an
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antigen or alternatively the recombinant vaccinia virus engineered to express gpl50,
yygpi50 Use of VV8p150 for the generation of antiserum would be preferable due to
the eukaryotic nature of the protein expressed. This antiserum could subsequently be
used to definitively determine the ability of gpl50 to induce MHV-68 neutralising
antibodies. Followed by studies, in the likely event of neutralisation, into the
mechanism of neutralisation e.g. whether the antibody blocks virus attachment to
cells, in order to determine the role of gpl50.
The effect of preincubation of virus with antisera prior to application to splenic
lymphocytes was tested. Following incubation of MHV-68 with dilutions (ranging
from Vi to 1/100) of either anti-MHV-68 antibody or anti-gpl50 antibody increased
levels of binding MHV-68 were observed. Up to 50% of lymphocytes were detected
to have bound MHV-68 in contrast to the normal level of approximately 10% . This
is likely to be due to the attachment of antibody coated MHV-68 virions to cells via
Fc receptors expressed by lymphocytes. From a dilution of 1/500 of anti-gpl50
antibody the enhanced binding was no longer seen whereas the anti-MHV-68
antibody needed to be diluted further (1/1000 onwards) for the enhanced binding
effect to cease. This difference may be due to a greater number of virion epitopes
recognised by the anti-MHV-68 antibody in comparison to the anti-gpl50 antibody.
In order to test the importance of epitopes recognised by the anti-gpl50 antiserum in
virus attachment to splenic lymphocytes a preparation of the Fab fragments alone is
required to avoid the antibody enhancement of attachment. The results here show
that high concentrations of antibody can enhance binding of MHV-68 to splenic
lymphocytes. Whether this would subsequently result in enhanced infection is not
known. With regards to virus infection in vivo physiological levels of antibody are




4.2.2 Gpl50 Based Vaccination
The work described here forms a preliminary study into the potential of gpl50 as a
DNA vaccine encoded immunogen against MHV-68 infection. The use of gpl50
was intended as a model to determine the potential of a virion membrane
glycoprotein in a DNA vaccine to induce protection against a gammaherpesvirus
infection. In addition, the investigation provided an opportunity for familiarisation
with the relatively new gene gun technology for vaccination. The feasibility of this
method of vaccination in terms of the preparation and materials required could also
be considered.
The main strategy was to prime animals with gpl50 DNA and boost with a
recombinant vaccinia virus, Wgpl5° which expresses gpl50. This strategy of DNA
priming-recombinant vaccinia boosting has been shown to be highly effective at
inducing specific CTL cells for HIV (Hanke et al., 1999). Here, this method was
used with the intention of inducing both cellular and humoral immunity against
MHV-68 in order to control the primary infection and prevent the establishment of
virus latency. Levels of lytic and latent virus were measured as a readout for success
of protection against MHV-68. Subcutaneous administration of the recombinant
vaccinia virus VV8p150 had previously been shown to induce MHV-68 neutralising
antibodies in mice (Stewart et al., 1999a). The ability of co-administration of a
plasmid encoding type I alpha interferon (IFNal) to enhance the protective effect of
immunity induced by the gpl50 DNA vaccine was also tested. During viral
infections type I interferon is detected at high levels and evidence exists which
indicates this promotes generation of CD8+ T cells and in addition the survival of
pre-existing memory CTLs (Tough et al., 1996a & b).
Immunisation of mice with gpl50 DNA followed by a boost of either gpl50 DNA or
either of the recombinant vaccinia viruses - VVgpl5° or the control VVgpt, resulted in
a trend, although not significant, towards reduced lung titres upon subsequent
challenge with MHV-68. From the data obtained here it is concluded that these
vaccination strategies are not effective at limiting the acute MHV-68 infection.
Significantly reduced MHV-68 lung titres (approximately 10 fold less) were detected
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in groups that had been immunised with gpl50 DNA + IFNal DNA or IFNal DNA
alone. This suggests that IFNal can promote protection non specifically. The
duration of expression from the administered DNA is not known however, following
intramuscular administration of vector pVR1255/IFNaI expression has been detected
at least a month after introduction into animals (K Robertson, personal
communication). The presence of IFNal was determined to be systemic.
Considering this and the data here, increased levels of IFNal present during primary
infection ofMHV-68 may improve the efficacy of the naive hosts immune response
at controlling the acute infection. High levels of IFNal in the blood may have a
direct antiviral effect and stimulate components of the innate immune response such
as NK cells (Vilcek & Sen, 1996, Biron, 1998, Diefenbach et al., 1998). As an
adjuvant this could be unsuitable when the aim is to generate CD8+ memory T cells.
It is known that MHV-68 is sensitive to type I interferon (Dutia et al., 1999b).
Promisingly immunisation with gpl50 DNA followed by W8p150 stimulated the
production of MHV-68 specific antibodies prior to MHV-68. Furthermore, anti-
MHV-68 antibodies were present earlier post MHV-68 challenge in recipients of two
doses of gpl50 DNA alone in comparison to control mice. This shows that gpl50
DNA is effective at priming a specific humoral reponse and is specifically enhanced
when used in conjunction with the recombinant vaccinia virus expressing gpl50. A
specific priming and boost are required for early generation of the MHV-68 specific
antibody response i.e. the use of gpl50 DNA followed by the control VVgpt did not
result in appearance of MHV-68 antibodies any earlier than the control mice.
Antibody data for the groups receiving IFNal DNA is not available and was not
generated owing to limited materials for analysis.
The antibody response detected in all groups tested predominantly consisted of
IgG2a and IgG2b isotypes indicating a T helper 1 response which does not differ
from the normal response to MHV-68 infection of mice. Unfortunately an anti-IgA
antibody was not available for detection of the IgA isotype population. Ideally this
would have been done and is strongly recommended to be performed in repeat and
further trials. Intranasal administration of the recombinant vaccinia virus aimed to
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induce mucosal immunity, where IgA is the predominant isotype of antibody
(Mazanec et al., 1996), which could neutralise MHV-68 at the site of primary
infection.
None of the vaccine regimes prevented the transient splenomegaly which occurs
following MHV-68 infection. This contrasts to the marked reduction in
splenomegaly observed previously in animals that were immunised subcutaneously
with VVgpl5° (Stewart et al., 1999). Of note was the group that received IFNal DNA
alone which at day 59 post MHV-68 challenge had 10 times less spleen cells present
compared to all other groups in which levels had returned to normal. The reason for
this is not known, it may be due to the migration of splenocytes from the spleen due
to prolonged expression of the introduced IFNal DNA. IFNal can regulate
lymphocyte trafficking by inducing the expression of the L-selectin receptor (Evans
et al., 1993). It would be interesting to see if this phenomenon occurs in the absence
of virus infection. This effect needs further investigation with regards to use of
IFNal in DNA vaccination. It suggests prolonged expression of IFNal is
undesirable. The prolonged presence of IFNal may subdue the immune response as
it is anti-proliferative.
None of the vaccination regimes prevented establishment of latency in the spleen.
However, a promising result was seen at day 15 where groups which received gpl50
DNA followed by a booster of either VVgpl5° or VVgpt had significantly lower
(approximately 6 fold) amounts of latent virus in the spleen in comparison to the
control group. The reduction in peak latent virus titre in the spleen for these groups
suggests that vaccinia virus efficiently boosts the immune response to the DNA
prime. The fact that either vaccinia virus produces a similar reduction in peak latent
virus titre indicates that this is a non specific boost possibly accountable by a
bystander effect induced by the vaccinia viral infection in general (Tough et al.,
1996a &b).
The reduction in peak latent viral titres in recipients of gpl50 DNA + either
recombinant vaccinia virus may be due to reduced virus reaching the spleen due to
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enhanced antiviral response in the lung. However, no significant reduction of
infectious virus in the lung was seen for these groups. Unfortunately no evidence
provided here shows that the reduction in peak latent virus titres is due to a gpl50
specific response. An essential component of any further studies would be the
inclusion of a DNA control i.e. pVR1255 alone without the gpl50 insert. This was
not available for the investigation described here.
Considering the viral titre data alone it could be concluded that the gpl50 based
vaccine does not have a significant effect on the acute lung infection but rather
produces an immune response that acts against infection of splenocytes. If due to a
specific humoral response to gpl50, this would tie in with the binding data showing
that the recombinant gpl50 protein does not bind epithelial cells whereas it displays
binding activity to splenic lymphocytes. However, the level of neutralising ability of
anti-gpl50 antibody against MHV-68 infection of epithelial cells in comparison to B
cells is not known. The mechanism of the reduction in peak splenic latency is not
clear.
Although occurring earlier the overall level of MHV-68 specific antibody does not
differ in the recipients of gpl50 DNA and VVgpl5° compared to control mice. The
proportion of antibodies generated against gpl50 is not known or the neutralising
activity of the humoral response. Further investigations should include neutralisation
analysis of the antibody response and the determination of the level of gpl50 specific
antibody. The gpl50-His protein could be used in an ELISA assay to detect gpl50
specific antibodies in the sera. The lack of reduction in viral lung titres detected here
may be due to inadequate levels of MHV-68 neutralising antibody. During the
normal course of MHV-68 infection CD8+ T cells are the main component of the
immune response which effects control of the acute infection. In the absence of
antibody, clearance of the acute lung infection is slightly delayed (Ehtisham et al.,
1993). It is not known whether increased levels of antibody against MHV-68 in
general and gpl50 specifically would provide complete protection or at least a
significant decrease in infectious lung titres. To test this passive transfer of MHV-68
or gpl50 specific antisera to nai've mice could be done prior to challenge.
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This preliminary vaccination experiment needs to be repeated to confirm the effects
seen. It would be worth concentrating on the lung at early times post infection e.g.
days 1, 3, 5, 6 and 8. This is suggested as there may be significant differences
between the groups in the acute infection not detected in the study described here due
to the limited time points analysed. It would also be worth comparing the efficacy
of gpl50 DNA vaccination administered using the gene gun in comparison to an
alternative route such as intramuscular injection. Although with intramuscular
vaccination more plasmid (over 100 fold) is required generation of gene gun bullets
is time consuming and expensive. The production of the gene gun bullets takes time
to master and the coating process (where the gold microparticles onto which DNA
has been precipitated are coated onto the inside of a tube) is inefficient and can result
in much wastage.
Analysis of the CTL response generated by this method of vaccination ought to be
addressed. In the case of this pilot study this was not done due to lack of a
comprehensive CTL analysis system, preferably further investigations should include
the analysis of MHV-68 specific CTLs, identification of the major epitopes they
recognise, their activity and the overall activation ofmemory T cells.
A notable feature of MHV-68 is that no matter what level of infectious virus titre
occurs in the lung, splenic latency is established. Whatever the level of peak latent
virus titre in the spleen long term latency settles at a common low level. The
inclusion of latency associated antigens in addition to lytic antigens into a vaccine is
likely to be pursued due to the difficulty in preventing the initial infection and the
establishment of latency.
Control of the acute lung infection in order to prevent spread of virus may demand a
level of neutralising antibody not elicited by the vaccination strategy used here.
Infection of a B cell in the lung may result in rapid trafficking of the virus from the
lung to other sites such as the spleen. It seems logical that if a huge reduction in
virus titre in the lung could be achieved via neutralisation by antibody and
elimination of lytically infected cells by CD8+ T cells the amount of virus available
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to encounter trafficking B cells would be reduced reducing the probability of
establishment of latency. Whether an additional vaccine boost of gpl50 DNA or
yygpi5o jHjght effect protection remains to be tested. As sterilising immunity for the
acute infection seems unlikely addition of vaccine components to generate specific
immunity to latency associated antigens may prove effective. The lack of significant
reduction in the lung viral titres using the vaccination strategy described here may be
due to the induction of insufficient levels of neutralising antibodies and MHV-68
CD8+ T cells. Use of a protein vaccine in combination with an adjuvant might prove
more effective at eliciting protection against MHV-68 infection. However, a
preliminary study using gpl50-His as an immunogen suggests this is not the case (K
Robertson, personal communication). In addition the use of a protein immunogen
does not efficiently target the cell mediated immunity in contrast to DNA vaccination
and the use of vaccinia virus recombinants both of which target the immunogen to
the MHCI pathway for presentation to CTLs.
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